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 Abstract 
 
This thesis aims to assess the human health impact of exposure to estrogenic compounds 
from the diet.  A multi-disciplinary approach is taken to address various aspects of this 
issue.  An introduction to xenoestrogens, including international research priorities, 
wildlife and human health effects, mechanisms of action, structure activity relationships 
and additivity of estrogenic effects is provided as background information. 
 
An assessment of exposure to a range of naturally occurring and synthetic estrogenic 
compounds found in food is derived in Chapter 2.  The assessment combines new and 
existing data on food concentration, food consumption and serum levels for each 
xenoestrogen.  Exposure is combined with relative estrogenic potency data from 
published bioassasy data to estimate risk relative to normal circulating levels of estradiol. 
Assuming additivity of xenoestrogens, for an average New Zealand male and for post-
menopausal women, xenoestrogens in the diet contribute an additional 12-90% of 
estrogenicity above normal circulating levels.  For a pre-menopausal female, the 
contribution from the diet represents in the order of an additional 2%.  The level of 
exposure determined in this thesis would seem to be of pharmacological relevance, 
especially for men with low levels of estrogen and for post-menopausal women.  
 
Bisphenol A (BPA) is an important monomer used in the manufacture of epoxy resins for 
internal food can linings.  A survey of the BPA content of a range of 80 canned foods 
available to the New Zealand consumer was undertaken and the results used in the 
exposure and risk assessments.  BPA was detected in all foods analysed except soft 
drinks, at concentrations ranging from <10-29 µg/kg, except for individual samples of 
tuna, corned beef and coconut cream that were 109, 98 and 191 µg/kg respectively.  None, 
of over 4000 individual exposure scenarios, exceeded the temporary Tolerable Daily 
Intake (TDI) of 10 µg/kg body weight per day set by the Scientific Committee on Food in 
2002. 
 
Intestinal microflora influence the bioavailability of the naturally occurring xenoestrogens 
genistein and daidzein that contribute significantly to total estrogenicity from the diet. The 
  
  
iv
degradation of genistein and daidzein by the faecal microfloral of 5 human subjects was 
variable and unpredictable between individuals and within an individual.  These findings 
have important implications for the promotion and prescription of soy foods and 
supplements for disease prevention and health benefits. 
 
The “yeast assay” is one of a number of methods available to measure estrogenicity.  This 
assay was established and validated.  In utero exposure to estrogenic compounds at 
critical periods of sexual differentiation and endocrine development may imprint for 
health effects observed later in life.  Placental transfer of estrogenicity, from 17β-estradiol 
was studied using the human placental perfusion model and the yeast assay.  The placenta 
provides a protective barrier to the transfer of estrogenicity.  Experiments with genistein 
showed that 5-15% placental transfer occurred, suggesting that in utero exposure might be 
in the order of 10% of maternal exposure.  
 
The thesis concludes with consideration of a genomic approach to substantiate, or refute, 
the mechanistic link between exposure to xenoestrogens and claimed human health effect.  
Such an approach offers exciting opportunity to clarify the mode of action of the synthetic 
versus the naturally occurring xenoestrogens, to confirm or dispute additivity of effect 
that is an important premise of the exposure assessment, to identify key genes involved in 
the many possible health effects and thence risk to the individual from dietary exposure to 
xenoestrogens.   
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Chapter 1 
 
 
 
Introduction to xenoestrogens and their 
actions 
 
 
1.1 Background and history of xenoestrogens 
 
The endocrine systems of the body regulate metabolic processes including nutritional, 
behavioural, reproductive, growth, gut cardiovascular and kidney function (WHO, 2002a).  
The fundamental role of all endocrine systems is to enable a regulated response of target 
tissue to a signal originating elsewhere and to maintain homeostasis, avoiding big 
fluctuations in response.  This is mediated by feedback signals from target organs to the 
regulating cells.  All the endocrine systems of the body are integrated via cross-talk.  For 
example, reproductive function needs to account for age and nutritional status.  The result 
is that an environmental compound may affect several endocrine systems such as 
reproductive tissue, bone growth and cardiovascular function.  For many endocrine 
systems, homeostatis programming is established during fetal/neonatal development so 
that an imbalance at this stage of life, perhaps from an environmental compound, may 
result in permanent misprogramming (Seckl and Meaney, 2004, Owen et al., 2005). 
 
Hormones are the chemical messengers of the endocrine system. Hormones are released 
into the bloodstream from numerous glands and tissues (Figure 1.1).   
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Figure 1.1:  Hormone producing glands and tissues of the endocrine system  
  (Norris, 1996) with example hormones (in colour). 
 
 
The endocrine system is integrated and complex with interactions between different 
components. For example, production of testosterone from Leydig cells in the testis is 
stimulated by luteinizing hormone produced in the pituitary gland that in turn is controlled 
by the peptide gonadotropin-releasing hormone (GnRH) secreted from the hypothalamus 
(WHO, 2002a). Both the male and female sex hormones (androgens and estrogens) are 
synthesized from a common precursor, cholesterol, via the intermediate pregnenolone.  
Interestingly, mammalian estrogen biosynthesis requires prior synthesis of an androgen, 
or an external source of androgen.  In addition the androgen, testosterone, may be 
converted to estrogen in the brain (Norris, 1996).   
 
A cell may be exposed to both endogenous and exogenous sex hormones, or hormone 
mimicking compounds, the level of which is influenced by various enzymes such as P450 
Phase I,  α-reductase and aromatase for example.  The complexity of contributing 
sex hormones at a cellular level is illustrated in Figure 1.2.  Whilst recognising that no 
one hormone functions in isolation from other hormones of the endocrine system, this 
thesis focuses solely on the estrogens. 
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Figure 1.2: The complex interactions of sex hormones in a cellular context. 
 
Estrogens are a family of hormones that promote the development and maintenance of 
female sex characteristics.  The prefix ‘xeno’ derives from the Greek ‘xenos’ meaning 
foreign or strange.  Hence ‘xenoestrogens’ are compounds that are foreign to the body and 
that mimic the action, at least in part, of estrogens.  Xenoestrogens may be synthetic such 
as the plasticizer bisphenol A (BPA), or naturally occurring compounds, for example 
genistein that occurs in soy. 
 
The history of xenoestrogens dates back at least to 1938 when Dodds and colleagues 
synthesized diethylstilbestrol (DES) (Figure 1.3) a chemical with potent estrogenic 
properties (Dodds et al., 1938).  DES has subsequently been used to castrate chickens, 
increase weight gain in cattle, treat prostate cancer in men, suppress lactation and prevent 
miscarriage in women (McLauglan et al., 2001).   
 
OH CH3
CH3 OH 
 
 
 
 
 
Figure 1.3: Chemical structure of diethylstilbestrol 
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Plant derived estrogenic compounds (phytoestrogens) were first associated with adverse 
effects on mammalian development and fertility from observations of animals consuming 
phytoestrogen-rich plants in the 1940s.  Ewes feeding on clover in Western Australia 
developed abnormal plasma concentrations of endogenous hormones with subsequent loss 
of fertility (Bennett et al., 1946, Moersch et al., 1967, Obst and Seamark, 1975).  This 
syndrome was termed “Clover Disease”.  Subsequent effects on fertility by a known 
estrogen led to the identification of the naturally occurring xenoestrogens; formononetin, 
biochanin A and genistein in 3 clover species (Shutt, 1976).  Modified farming practices 
have since prevented further cases of “Clover Disease” (Little, 1996).   
 
The ability of some pesticides to induce estrogen-like responses in the reproductive 
tissues of rats, chickens and quail has been known since 1968 (Bitman et al., 1968).  
Later, in 1993, Krishnan and colleagues, raised awareness of the potential environmental 
impact of another synthetic estrogenic chemical used in manufactured products (Krishnan 
et al., 1993).  They observed that water autoclaved in polycarbonate flasks exhibited 
estrogenic activity.  The active compound was isolated and identified as BPA (BPA).  
This work was significant because it showed that compounds could leach from 
manufactured products into the environment. 
 
Rachel Carson’s book Silent Spring  (Carson 1962) did much to raise the awareness that 
chemicals in the environment can exert profound and deleterious effects on wildlife 
populations and that human health is inextricably linked to the health of the environment.  
This awareness coupled with the publication by Herbst and colleagues (Herbst et al., 
1971) a decade later, that linked maternal ingestion of an estrogenic drug, DES, during 
early pregnancy with an increased risk of cervical and vaginal cancers in the daughters of 
exposed mothers, fuelled concern, research and debate over chemicals with hormonal 
effects -endocrine disrupting chemicals (EDC)s.  Xenoestrogens are a major subset of this 
group of compounds.  
Public interest was heightened in the 1990s with: 
• the publication in 1992 of a scientific paper by Carlsen et al., (1992) concerning 
apparent declines in human sperm count. 
• publication of “Our stolen future”  by Theo Colborn in 1996 and 
•  the broadcast of the 1993 BBC Horizon documentary “Assault on the male” . 
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1.2 International efforts  
 
The growing concern from different groups around the world lead to a major international 
effort culminating in 2002 with the publication of a “Global assessment of the state of the 
science of endocrine disruptors”.  This assessment, beginning in 1997, was lead by the 
International Programme on Chemical Safety (IPCS) that is a collaboration of the United 
Nations Environment Programme (UNEP), the International Labour Organization (ILO) 
and the World Health Organisation (WHO).  The steering group was truly international 
with scientific experts from the USA, United Kingdom, Sweden, The Netherlands, 
Mexico, Canada, Germany, Japan, France, Italy, and Switzerland.  They concluded that 
analysis of the human data, while generating concerns, does not provide firm evidence of 
direct causal associations between low–level (as found in the general population) 
exposure to EDCs and adverse human health effects (WHO, 2002a).  The identification of 
life stages that are most vulnerable to the effects of EDCs and an understanding of how 
EDC toxicity may affect individual populations were highlighted as research priorities. 
 
A second global project jointly undertaken by SCOPE (Scientific Committee of Problems 
of the Environment) and IUPAC (International Union of Pure and Applied Chemistry) 
culminated in a symposium on “Implications of endocrine active substances for humans 
and wildlife” in Yokohama, Japan in November 2002a.  Scientists (408), managers and 
public policy-makers from 31 countries met together to share papers on (1) human effects, 
(2) wildlife effects, (3) exposure assessment, and (4) testing for endocrine active 
substances and effects.  These papers, plus discussion from 6 workshops, provide a view 
of current research efforts and have been published in a special issue of Pure and Applied 
Chemistry (SCOPE/IUPAC,2003).  
 
In April 2003, the European Union launched a 4-year, $23 million programme for a new 
Cluster of Research on Endocrine Disruption (CREDO) (Lorenz, 2003).  CREDO 
involves 60 laboratories across Europe.  In line with the findings of the Global 
Assessment (WHO, 2002a), two areas of interest for CREDO focus on: how hormone-
mimicking chemicals interact with each other, particularly at low doses, and to what 
extent these compounds influence gene expression in non-reproductive organs.  The latter 
approach is a step towards substantiating cause and effect. 
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In 1996, the US Environmental Protection Agency’s (EPA) Office of Research and 
Development (ORD) identified endocrine disruption as one of its top-six research 
priorities and developed a risk-based research approach to address some of these 
uncertainties (USEPA, 2003).  The EPA Federal Research Project Inventory includes 
projects in three categories:  
• Methods research that identifies human health and ecological hazards and 
biomarker research 
• Model research that develops risk models, supports basic research that may lead to 
model development 
• Measurement research to quantify exposure or effect (USEPA, 2004).  
In 2003, the EPA called for proposals to research high-throughput screening systems to 
enable the prioritization of chemicals for their potential as endocrine disruptors.  This call 
for proposals was driven by the Food Quality Protection Act of 1996 and the Safe 
Drinking Water Act Amendments of 1996 that both contain provisions related to 
determining whether pesticides or chemical substances found in or on food or in drinking 
water sources may have estrogenic or other endocrine effects.  Candidate chemicals 
number in the order of 87,000 (EPA, 2003). 
In the US, research into human health effects of EDCs is funded by the National Institutes 
of Health (NIH) incorporating 27 institutes and centres.  Both the National Institute of 
Environmental Health Sciences (NIEHS) and the US National Cancer Institute are 
currently funding research into the role of environmental exposures, on birth and 
developmental defects, sterility, breast and testicular cancers.  With more of a food focus, 
the NIH is funding a 5-year, $8 million project, to study the safety of phytoestrogens in 
response to a proliferation of dietary supplements and food additives containing 
phytoestrogen extracts (IFT, 2004).   
 
The New Zealand Ministry of Research Science and Technology commissioned a report 
“Environmental oestrogens: sources and possible health effects in New Zealand (MoRST, 
1998).  The NZ Ministry of Health and subsequently New Zealand Food Safety Authority 
have funded several projects of xenoestrogens in food (Lauren and Veitch, 1996, Taylor 
and Burlingame, 1998, Thomson et al., 2003, Thomson, 2005) including the significant 
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study of human exposure to xenoestrogens (Chapter 2) and BPA (Chapter 3) within this 
thesis. 
 
 
1.3 Health effects of xenoestrogens 
 
1.3.1 Wildlife effects 
 
Concern about the effects of xenoestrogens on human health has arisen from the 
accumulating body of evidence of endocrine disrupting effects in wildlife.   These effects 
vary from subtle changes in the physiology and sexual behaviour of species to 
permanently altered sexual differentiation.  Most of the data come from Europe and North 
America and include effects on invertebrates, fish, amphibians, reptiles, birds and 
mammals.  Effects on wildlife, globally, have been most usefully reviewed in both the 
WHO (2002a) and  SCOPE/IUPAC, (2003) documents.  Examples of potential effects in 
wildlife include: 
 
• Invertebrates:  The masculinization of female marine gastropods exposed to 
tributyl tin oxide (TBTO) in antifouling paints is the most convincing example of 
an endocrine disrupting effect on an invertebrate.  At the molecular level, TBTO 
interferes with hormone metabolism, most probably by inhibition of aromatase, 
thereby increasing levels of androgens (Oehlmann J and Schulte-Oehlmann U, 
2003).  Thus this effect is likely to be via an androgenic rather than an estrogenic 
pathway. 
• Fish:  Reproductive abnormalities in freshwater fish living downstream of pulp 
and paper mill effluents and sewage treatment effluents.  A multiplicity of 
causative agents have been suggested, including estrogenic compounds (Jobling 
and Tyler, 2003). Most recently, in a national survey of 51 river sites in England 
over one third of the male population of roach (Rutilus rutilus ) were feminized.  
(Taylor et al., 2004).  Histological analysis of 654 male roach showed that 218 of 
them were intersex, as defined by the simultaneous presence of both testicular and 
ovarian tissue within the gonads, demonstrating that sexual disruption in roach is 
widespread in English rivers.  Trudeau and colleagues (2005) have shown that 
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waterborne BPA can modulate transcription of estrogen responsive genes 
transfected into tadpoles and fish. 
• Amphibians:  Population declines and deformities in amphibians in both pristine 
and polluted habitats worldwide. Gardiner et al., (2003) demonstrated that 
deformities in frogs is via a retinoid signalling pathway. The conclusion of the 
WHO review (2002a) is that there is insufficient data to implicate EDCs, and 
therefore xenoestrogens, as causative agents for these effects.   
• Reptiles:  One of the most publicized examples of wildlife effects has been the 
developmental abnormalites observed in alligators (Alligator mississippiensis) in 
Lake Apopka, Florida, USA.  In 1980, a stream that feeds Lake Apopka was 
contaminated with high concentrations of the organochlorine pesticide, dicofol, its 
metabolites and other compounds after a chemical spill.  A 90% decline in 
alligator numbers followed (Guillette et al., 1994).  Further elegant studies at 
polluted and unpolluted sites, and in the laboratory, have associated a variety of 
developmental abnormalities in endocrine and reproductive systems including 
shortened penises, depressed testosterone and elevated estrogen levels with 
exposure to organochlorine pesticides (Guillette et al., 1999, Guillette and Iguchi, 
2003).   
• Birds:  Eggshell thinning and altered gonadal development in birds of prey 
exposed to DDT, resulting in severe population decline.  Currently, the most 
favoured mechanism to explain egg shell thinning in some bird species involves 
the inhibition of prostaglandins but this remains conjectural (Giesy et al., 2003). 
• Mammals:  Exposure to OC contaminants (PCBs, DDE) has been shown to 
adversely impact the reproductive and immune function in Baltic seals, resulting 
in population declines (Reijnders, 1980, Roos et al.,1998).  Whether this is due to 
immune effects resulting in higher disease rates or declining reproduction is 
unclear.  Sperm concentrations and sperm motility were reduced in adult rats that 
had been exposed to xenoestrogen contaminated fish during lactation 
(Aravindakshan et al., 2004). 
 
Overall, the current scientific knowledge provides evidence that some effects observed in 
wildlife can be attributed to chemicals that disrupt the endocrine system.  However, in 
nearly all cases the causal link between exposure and endocrine disruption is implied but 
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not established – there is no clear cause-effect relationship.  The dearth of causal links 
more likely reflects the difficulty in establishing rather than the absence of such links, one 
of the factors being the very large number (around 100,000) of man-made chemicals in 
everyday use (Sumpter, 2003). 
 
Endocrine disruption can be via a number of mechanisms (see Chapter 1.4), including 
estrogenic pathways.  For wildlife, an estrogenic mechanism, which might be caused by 
exposure to a xenoestrogen, is implicated in the effects seen in fish, reptiles and 
mammals.  At the present level of knowledge it is either not known, or is unlikely, that 
exposure to xenoestrogens would account for effects observed in invertebrates, 
amphibians and birds.   
 
1.3.2 Human health 
 
The evidence of adverse outcomes in wildlife combined with studies in laboratory animals 
substantiates our concerns about human health effects. Since the sex and thyroid 
hormones are major determinants of development and function of the reproductive, 
central nervous, and immune systems, much of the experimental research to date has 
focused on the effects of EDCs on these key hormone systems and target tissues. The 
main areas of: reproduction, neurobehaviour, immune function, and cancer were globally 
reviewed by WHO (2002a). In addition, a compilation of publications has been published 
by SCOPE/IUPAC (2003). The area is extensive and a synopsis of the current state of 
evidence, drawn from these and subsequent publications, is provided below. 
 
1.3.2.1 Reproductive effects  
 
Estrogen has profound effects on the development and function of reproductive organs.  
For example it stimulates proliferation of epithelial cells in the reproductive tract and 
mammary gland of females and in the prostate of males (Kushner et al., 2003).  Hence the 
potential for estrogenic compounds to interfere with the reproductive system.  
Xenoestrogens have been implicated in declining human sperm count and quality, fertility 
impairment, an increase in spontaneous abortions, a decline in the proportion of male 
babies and in abnormalities of the male reproductive tract.  
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A number of studies show variations in sperm count within and between countries (e.g. 
Carlsen et al., 1992) but there are limitations in the study designs that may bias the data.  
Most of the studies are retrospective, using subjects recruited for other purposes (eg 
infertility diagnosis) and may not truly reflect the population status.  More recently, it has 
been shown that exposure to persistent organochlorine pollutants (e.g. PCBs and p,p’ –
DDE) may have a slight negative impact on human sperm chromatin integrity (Rignell-
Hydbom et al., 2005). The issue remains controversial and the causal association weak  
with exposure to xenoestrogens or other EDCs, (WHO, 2002a, Fisch and Golden, 2003).   
 
Human studies have shown a possible link between maternal exposure to contaminated 
Great Lakes fish and reduced fertility (Buck et al., 1999) and an increased risk of 
infertility for women working in the agricultural industry (Fuortes et al., 1997). The 
inference is that PCBs and pesticides might account for this reduced fertility.  In separate 
studies, analysis of blood or serum samples from 2000 American and 50 Southeast Asian 
women showed a link between PCBs and DDE levels and altered human menstrual 
cycles, with the implication that this alteration may influence other end points such as 
fertility, pregnancy and reproductive cancers (Windham et al., 2005, Cooper et al., 2005).  
In a case-control study, Takeuchi and colleagues (2004) reported a positive correlation 
between BPA concentration in serum and ovarian disease.  Women with ovarian disease 
had mean serum concentrations of 1ng/ml compared with 0.7 ng/ml  for normal women 
(p<0.05).   
 
An increased rate of spontaneous abortion has been reported for subjects exposed to a 
range of pesticides (Rupta et al., 1991).  Although a causal link has not been established, 
compounds that affect levels of progesterone (a precursor to testosterone and estrogen) are 
of most interest as a mechanistic explanation (WHO, 2002a).  It is unlikely that 
environmental doses would be sufficient to cause spontaneous abortions. 
 
Increased frequency of abnormalities of the male reproductive tract development, namely 
cryptochidism and hypospadias have been associated with exposure to EDCs, including 
xenoestrogens.  A notable finding was the increased incidence of hypospadias in sons of 
women consuming vegetarian diets during pregnancy (North et al., 2000).  A suggested 
explanation is increased exposure to phytoestrogens for the vegetarian mothers although 
this has not yet been substantiated with blood levels of phytoestrogens for vegetarian 
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versus non-vegetarian mothers.  In a recently published case-control study utilizing 
historical samples (1959-1967) taken at a time when DDT was used, maternal serum 
levels showed no association of DDT or DDE and hypospadias or cryptorchidism (Bhatia 
et al., 2005).  Neither of these independent studies substantiates a causal link between 
xenoestrogen exposure and hypospadias or cryptorchidism. 
 
A number of male reproductive disorders (cryptorchidism, hypospadias, testis cancer and 
low sperm counts) have been linked as interconnected disorders, collectively known as 
testicular dysgenesis syndrome, with a common origin in fetal life (Sharpe and 
Skakkebaek, 1993, 2003).  In 1993, these authors hypothesized that decreasing sperm 
counts and increasing incidence of testis cancer, cryptorchidism and hypospadias might be 
related to increased exposure to estrogenic compounds in utero (Sharpe and Skakkebaek, 
1993).  Ten years on, results from animal studies suggest that the low estrogenic activity 
of environmental estrogens would be insufficient to lead to the observed effects and that 
attention should be redirected to chemicals that alter endogenous androgen production/ 
action or on factors that can elevate endogenous estrogens in the fetus (Sharpe and 
Skakkebaek, 2003).   
 
The onset of puberty is regulated by gonadotrophins that stimulate an increase in estrogen 
levels in both boys and girls, resulting in the pubertal growth spurt (MacGillvray, 2004).  
The age of puberty has decreased over the last century, presumably due to improved 
nutrition but perhaps also due to exposure to EDCs (Teilmann et al., 2002).  
Environmental chemicals including phthalate plasticizers, p,p’-DDE and polybrominated 
biphenyls, have been suggested as potential causative agents for precocious puberty 
(Colon et al., 2000, Krstevska-Konstantinova et al., 2001, Blanck et al.,2000) although 
there is not yet any clear cause-effect relationships in humans.  Giampietro and colleagues 
(2004) found no evidence of precocious puberty in 3 year children who had been fed soy 
for more than 6 months.   
 
1.3.2.2 Neurobehaviour 
 
The brain contains steroid receptors that make it a potential target for xenoestrogens.  
Data from human and experimental animal studies indicate that exposure (particularly in 
utero) to a number of environmental chemicals including DES, organochlorine pesticides, 
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some fungicides (methoxychlor, fenarimol), polychlorinated dibenzyodioxins, PCBs, 
dibenzofurans can have adverse effects on neurological development (such as growth 
retardation, impairment of intelligence and emotional instability), neuroendocrine 
function and behaviour (WHO, 2002a, Shirai and Asamoto, 2003, O’Connor and Chapin, 
2003).  But the mechanisms of these effects remain to be elucidated. The development of 
neural sex differences is initiated by estradiol, which activates two processes in male 
neonates; masculinization, the development of male-type behaviours, and defeminization, 
the loss of the ability to display female-type behaviours.  Most recently, Kudwa and 
colleagues (2005) have demonstrated that one estrogen receptor sub-type, namely ERβ, is 
involved in defeminization of neonatal mice and they hypothesize that ERβ plays an 
essential role in sexual differentiation of the brain and behaviour.  Assuming an 
extrapolation to humans, it follows that environmental chemicals that bind to ERβ, could 
potentially have a modulating effect on defeminization .   
 
1.3.2.3 Immune function 
 
The immune system is a target for many compounds, including drugs and environmental 
chemicals.  Of a large number of compounds with immunotoxic properties, only a few 
have been shown to cause immunotoxicity that is mediated through an endocrine-
disrupting mechanism.  These include the potent estrogenic DES, which has been shown 
to cause a weak immunological change following in utero exposure and the AhR binding 
PCBs, PCDFs and PCDDs (WHO, 2002a).  DES but not the estrogenic pesticide 
methoxyclor (at doses of 0.5 and 50 mg/kg/day respectively), reduced the level of 
circulating lymphocytes in pubertal rhesus monkeys (Golub et al., 2004).  Currently, there 
is little evidence of xenoestrogens impacting on human immune function.  
 
1.3.2.4 Cancer 
 
Increasing trends of cancer in hormonally sensitive tissues such as breast, endometrial, 
testicular, prostate and thyroid have been attributed, in part, to widespread exposure of the 
general population to xenoestrogens.  
Breast 
 
The unknown etiology of the majority of breast cancer cases, along with large 
geographical differences in incidence rates, has heightened concerns to the potential role 
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of environmental exposures, including xenoestrogens, in breast cancer risk. One group of 
dietary compounds that have received much attention is the phytoestrogens.  In vitro 
studies with phytoestrogens have shown both proliferative and antiproliferative effects 
depending on the tumour cell type, dose, timing of exposure and the phytoestrogen given 
(Aldercreutz and Mazur, 1997).  Phytoestrogens can act via multiple mechanisms of 
action, both ER mediated and non-receptor mediated and may be estrogenic and 
antiestrogenic.  The indirect evidence that high consumption of soy products, a rich 
source of phytoestrogens, is associated with a lower risk of breast cancer, is inconsistent. 
A meta-analysis (Trock et al., 2000) indicated that high soy intake might reduce the risk 
of developing premenopausal breast cancer but has no effect on post menopausal breast 
cancer risk.  Of nearly 30 studies critiqued by the WHO (2002a) that have considered the 
potential relationship between non-occupational exposure to DDT and female breast 
cancer, the great majority of these studies (26) showed no relationship between DDT and 
breast cancer risk.  Two studies showed a positive association (WHO, 2002a).  In studies 
on general populations exposed to low levels of PCBs, none have detected a statistically 
significant increase in breast cancer risk, although interpretation of the data is difficult 
because PCBs are a mixture of congeners, containing both estrogenic and antiestrogenic 
compounds.  Overall, the data do not support an association between PCB exposure and 
increased breast cancer risk. 
 
There are limited data on the association between breast cancer and exposure to dieldrin.  
A study by Hoyer et al., (1998) including 268 cases from a cohort of 7,712 Danish 
women found a two fold increase in the risk of breast cancer associated with the highest 
plasma concentration of dieldrin.  This is an association only with no evidence of an 
endocrine mechanism. 
 
Since development of the mammary gland occurs at distinct stages including perinatal, 
puberty and pregnancy, the timing of exposure may be critical to defining the dose-
response relationships of xenoestrogens for breast cancer.  The importance of timing of 
exposure is supported by human data on radiation and smoking and from animal studies 
(Tokunaga et al., 1987, Palmer et al., 1991, Colerangle and Roy, 1997) .  Adult women 
currently at risk for breast cancer may have been exposed to exogenous xenoestrogens 
(such as DDT) in utero or during infancy, childhood and adolescence when contaminant 
levels of organochlorines were higher.   
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Overall, the current scientific evidence, from both human and animal studies do not 
support a direct association between exposure to xenoestrogens and increased risk of 
breast cancer (WHO, 2002a).  However, all these studies have measured xenoestrogen 
exposure in adult women and have considered exposure to individual xenoestrogens.  
Breast cancer is most likely multifactorial, including genetics, lifestyle, diet, endogenous 
hormone status and environmental factors, including timing of exposure.  The interaction 
between these factors is unexplored and the role of xenoestrogens in breast cancer 
remains controversial.   
 
Endometrial 
 
Because endometrial tissue is very responsive to the actions of antiestrogenic and 
estrogenic compounds, it is a candidate target tissue for xenoestrogens.  Epidemiologic 
data on the effects of environmental EDCs on endometrial cancer are limited.  Sturgeon et 
al., (1998) found no association between endometrial cancer and PCBs and 
organochlorine compounds.  Hiroi et al., (2004) reported lower levels of estrogenic BPA 
in the serum of patients with complex endometrial hyperplasia and endometrial cancer 
compared with healthy controls or patients with simple endometrial hyperplasia.  This 
result does not support estrogenic compounds as causative agents for endometrial cancer. 
The lower prevalence of endometrial cancer in Japanese and US (Hawaiian) women 
consuming isoflavone rich diets supports a protective role of phytoestrogens in 
endometrial cancer (WHO, 2002a). Thus, there is currently no evidence to support an 
association between exposure to xenoestrogens and risk of endometrial cancer.  
 
Prostate 
 
A comparison of prostate cancer incidence rates between migrants and residents of the 
country of origin supports a role of environmental or lifestyle factors in prostate cancer 
incidence (Doll and Peto, 1981).  Little is known about the causes of prostate cancer but it 
is both hormone dependent and able to be modulated by hormone treatment (WHO, 2002 
a, Ho, 2004).  Epidemiological studies undertaken in the USA (Settimi et al., 2003) and 
Italy (Alavanja et al., 2003) show an increased risk of prostate cancer with exposure to 
organochlorine pesticides.  Animal studies are limited by the lack of suitable models 
(Bosland, 1992).  Human prostate cells contain ERs such that cancer may be the result of 
cell proliferation via an ER response (Ho, 2004).  It seems highly probable that estrogenic 
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compounds have some role in prostate cancer since it is known that expression of one ER 
subtype changes as prostate cancer progresses (Latil et al., 2001, Lau et al., 2000).  
Further detail is provided in Chapter 7.1.1.   
 
Testicular 
Cryptorchidism is a known risk factor for testicular cancer, suggestive of a possible 
prenatal etiology for this cancer (Moss et al., 1986).  The implication is that if 
environmental compounds are causative agents then timing of exposure (i.e. in utero ) 
may be important.  Limited data suggests that the incidence of cryptorchidism and 
hypospadias may show similar geographical differences to the incidence of testicular 
cancer, suggesting that these conditions may be linked (WHO, 2002a).  Altered 
expression of ERs between human normal and testicular tissue, implicates a role for ERs, 
and hence estrogenic compounds, in testicular cancer (see Chapter 7.1.2) (Hirvonen-Santti 
et al., 2003, Pais et al.,2003).  Studies of germ cell testicular cancer are hampered by the 
lack of suitable animal models. Overall, estrogenic compounds cannot be eliminated as 
having a role in testicular cancer but the supporting evidence is currently weak. 
 
Thyroid 
 
The thyroid gland has a key role in endocrine, metabolic and physiological functions.  
Thyroid hormones are important for growth and development  and are involved in the 
carcinogenesis process by affecting tumor formation, growth and metastasis (Guernsey 
and Fisher, 1990).  Thyroid cancer is uncommon, relative to other forms of cancer 
(NZHIS, 2004) and the etiology is largely unknown.  A direct association between 
exposure to specific xenoestrogens and thyroid cancer is not supported by human 
experimental data.  However, environmental chemicals including pesticides and PCBs can 
affect the hypothalamic-pituitary-thyroid axis.  The link between this and thyroid cancer 
needs clarification (WHO, 2002a). 
 
In addition to reproductive, central nervous, immune system and hormone responsive 
cancers, interference with steroid biosynthesis and metabolism is another source of 
estrogen-mediated adverse health effects (Sanderson and van den Berg (2003). Of 
particular interest is the inhibition of aromatase, the enzyme that catalyzes the conversion 
of androgens to estrogens.  Possible aromatase inhibitors are some pesticides (including 
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DDT and its metabolites), organotin compounds, dioxins and PCBs. The consequences of 
such inhibition are largely unknown at this time.  
 
Both the global WHO (2002a) and IUPAC/SCOPE (2003) reviews conclude that after 
substantial research in the past decade, there have been no conclusive findings of low-
level environmental exposures to xenoestrogens causing human disease i.e. no proven 
cause and effect relationships.  There is little evidence to link xenoestrogen exposure with 
spontaneous abortion, cryptorchidism, hypospadias and immune function.  However there 
is more experimental and epidemiological evidence together with biological plausibility 
(i.e. via a possible estrogen receptor mechanism) for xenoestrogens to have a potentially 
causative role in sperm quality, infertility, spontaneous abortion, sex ratios, precocious 
puberty, neurobehaviour, breast, endometrial, prostate and testicular cancer.  Food is a 
major route of exposure to environmental chemicals and humans are exposed to complex 
mixtures from the diet as a whole rather than to single compounds.  Surely the total 
burden of xenoestrogens needs to be considered in the study of links between human 
exposure and health.   
 
1.3.2.5 Positive effects 
 
Some naturally occurring xenoestrogens (e.g. phytoestrogens) are actively promoted in 
functional foods, sold as dietary supplements, and as an alternative to hormone 
replacement therapy because of their claimed health benefits.  They have been claimed to 
be beneficial in (COT, 2003): 
• Cardiovascular disease   
• Hormone-dependent cancers, particularly breast cancer   
• Cholesterol-related disorders  
• Postmenopausal conditions such as osteroporosis 
• Stomach disorders   
• Cognitive functions 
 
A good example is a brand of bread sold in Australasia that proudly advertises its soy and 
linseed content (soy and linseed are rich in the phytoestrogens genistein and coumestrol 
respectively) and its positive effects on women’s health.  Whether this and related claims 
are true is uncertain because there are no good, controlled clinical studies that substantiate 
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the claim.  Despite this it is important to remember that xenoestrogens (i.e. 
phytoestrogens) in food might be beneficial in some circumstances. 
 
1.4 Mechanisms of action of xenoestrogens 
 
EDCs can mitigate adverse effects by a number of different mechanisms (WHO, 2002a, 
SCOPE/IUPAC, 2003). One xenoestrogen may affect multiple target cells by multiple 
mechanisms.  The mode of action may be by :  
• Activating or suppressing expression of the androgen receptor  
• Activating or suppressing expression of the ER, via a genomic or non-
genomic pathway 
• Activating the aryl receptor  
• Inhibition of steroid hormone synthesis, transport or metabolism 
• Modulation of neurotransmitter receptors 
• Other less defined mechanisms 
 
The selection of xenoestrogens for consideration in this thesis is restricted to chemicals in 
the diet that are known to mediate a potential effect via activating or suppressing 
expression of the ER. 
 
ERs are nuclear receptors present in many cell types.  They are large protein molecules 
with a specific binding site that has conformational specificity for the estrogen molecule 
(i.e. in a natural context 17β-estradiol).  Despite the specificity of the binding site, it is 
sufficiently generic to allow binding by a wide range of natural and synthetic compounds.  
Once an estrogenic compound has diffused into a cell nucleus, it may bind to the ligand-
binding domain of the receptor, whence the ER-ligand undergoes a conformational 
change, and dimerizes.  The dimers, with cofactors, form a complex that binds to specific 
sequences of DNA, known as estrogen-response elements (ERE), of estrogen responsive 
genes.  Binding to the ERE stimulates transcription and mRNA synthesis leading to 
increased or decreased expression of estrogen responsive genes that code specific protein 
syntheses (Gruber et al., 2002, WHO 2002a).  This is the classic pathway of estrogenicity 
resulting in an overall effect of feminisation at a cellular and whole body level and is 
shown schematically in Figure 1.4. 
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Figure 1.4: Schematic of (xeno)estrogen nuclear receptor mediated mechanism 
(modified from WHO, 2002a) 
 
1. Endogenous estrogen or xenoestrogens circulating in the plasma, may be bound to 
SHBG. 2. Estrogenic compound diffuses into the cell and binds to ER located in the 
nucleus (3). 4. Occupied receptor undergoes conformational change, dimerises and binds 
with cofactors (Tf) to specific sequences on estrogen responsive genes. 5. mRNA is 
transcribed. 6. mRNA is transported from the nucleus to the cytoplasm. 7. Proteins are 
synthesized from the mRNA template. 
 
There are alternative mechanisms for estrogenicity.  The ERs can be also be activated 
independently of ligand binding (e.g. by growth factors) and estrogens can stimulate a 
rapid nonnuclear effect (e.g. via the mitogen-activated protein kinase pathway) (Gruber et 
al., 2002a).  However, this thesis focuses on the classic pathway of ligand-dependent 
activation of the nuclear ERs. 
 
There are at least two subtypes of ER, namely α and β.  Although most xenoestrogens 
tested bind with similar affinity to both subtypes, differences in the amino acid sequences 
means that some ligands bind with different affinities to the two receptor subtypes (Table 
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1.1).  Notably, the phytoestrogens have been shown to have a greater binding affinity for 
ERβ. 
 
Table 1.1: Relative binding affinities (the higher the number the greater the 
binding affinity) of different estrogens and xenoestrogens for the α- 
and β-ERs (Gruber et al., 2002). 
 
ER Estrogen/Xenoestrogen 
α β 
17β-Estradiol 100 100 
Estriol 14 21 
Estrone 60 37 
4-Hydroxyestradiol 13 7 
2-Hydroxyestrone 2 0.2 
Genistein 4 87 
Coumestrol 20 140 
Daidzein 0.1 0.5 
4-Octylphenol 0.02 0.07 
Nonylphenol 0.05 0.09 
 
Tissue distributions or expressions of ER α and β differ although there is some overlap.  
Granulosa, developing spermatids, intestinal mucosa, lung parenchyma, bone, brain 
endothelial, prostate, bladder and cells contain mostly receptor β. Endometrium, kidney, 
pituitary, epididymis, adrenal, breast-cancer and avrian stroma contain, or express,  
mostly ER α (Kuiper et al.,1997, Gruber et al., 2002).  In contrast testis, uterus and ovary 
cells express both α and β receptors. 
 
For both ER α and ERβ, the conformation of the ligand binding domain changes in 
different ways for different ligands and therefore a ligand binding to an ER α may elicit a 
different response than when the same ligand binds to ERβ, thus resulting in tissue 
specific responses (Gruber et al., 2002).   
 
 
1.5 Structure activity 
 
Xenoestrogens include a number of classes of compounds that look structurally different 
(Figure 1.5) yet can bind to the ER and elicit an estrogen-like response.  
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Figure 1.5: Chemical structures of a selection of estrogenic compounds including, 
for comparison, the endogenous hormone 17β-estradiol. 
 
The ligand-binding domain of the ER contains amino acids that interact on a 
conformationally specific basis with particular chemical groups on the estrogen molecule 
(Figure 1.6).  For example, there is a requirement for two electronegative groups a 
specific distance apart (they probably hydrogen bond to amino acid residues in the 
binding site) and a hydrophobic region between the electronegative groups (which is 
likely to interact with hydrophobic amino acids in the binding site by Van der Waals 
forces).  17β-Estradiol is the best fit for the ER and therefore results in a maximum 
response.  Other molecules that have structural similarities to 17β-estradiol will also fit 
the site, but less well and so illicit a diminished ER-mediated response.  
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Figure 1.6: Interaction between ER amino acids and 17 β-estradiol in the ER 
active site 
 
Structure activity relationships (SARs) have been elegantly explored by Fang et al., 
(2001).  They considered 230 chemicals including both naturally occurring and synthetic 
xenoestrogens.  Activity was based on a validated ER competitive binding assay over a 
106-fold range.  They identified the following five distinguishing criteria as being 
essential for xenoestrogen activity: 
• H-bonding ability  
• the distance between the 3-and 17β-OH 
• a rigid structure 
• steric moieties at 7α and 11β-positions 
• satisfactory hydrophobicity 
If a chemical contains a phenolic ring and any additional key structural features it tends to 
be an ER ligand.  Whilst it is useful to explore SARs as a basis for predicting 
estrogenicity (e.g. for drug design), the SARs proposed by Fang and co-workers leave 
some thoughts to ponder.  For example, why is the o,p’- isomer of DDT more estrogenic 
than the p,p’-DDT isomer? 
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1.6 Assays for estrogenicity 
 
Xenoestrogens have different degrees of estrogenicity.  For example, DDT has 10-6 of the 
activity of 17β-estradiol (the natural ER agonist) (Soto et al., 1995) which must be taken 
into account when determining exposure levels, since it is estrogenicity not concentration 
that is important in pharmacological effect (Shaw and McCully, 2002). 
 
A range of in vivo and in vitro assays are available to measure estrogenicity.   
 
1.6.1 In vivo assays  
 
The best assays for assessing estrogenic effects are those that use target species responses 
because they allow for interactions between cells and between different components of the 
endocrine system and thence the whole animal.  In addition, they take account of 
absorption, disposition, metabolism and excretion of test chemicals.  Assays usually 
employ immature, ovariectomised adult or male animals to minimise contributions from 
endogenous estrogens. A diverse array of assays have been reported in the literature, 
including: 
• Measures of cell proliferation in the rodent female genital tract. Examples include;  
measurement of uterine epithelial height and vaginal epithelial thickness in 
ovariectomised mice (Ulrich et al, 2000), measurement of uterine weight in weanling 
mice (Shelby et al, 1996).  
• Measures of other estrogen related effects on the female genital tract, including 
increases in uterine vascular permeability (Milligan et al, 1998), increases in glycogen 
production in immature rat uteri (Bitman and Cecil, 1970). 
• Measures of testicular changes or sperm quality in male rodents, including reduction in 
testicular size, reduction in ventral prostate weight, and reduction in sperm production 
in male rats (Sharpe et al, 1995). 
• Induction of vitellogenin in fish. Induction of the protein, vitellogenin, in male and 
female fish after exposure to estrogenic compounds has been carried out for a number 
of fish species, including; rainbow trout (Sumpter, 1985), carp (Tyler and Sumpter, 
1990), and winter flounder (Pereira et al, 1992). 
• Sex determination in turtles. The sex of offspring of the red-eared slider turtle, as for 
other reptiles, is determined by the temperature of incubation. The ability of 
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xenoestrogens applied to the eggshell to overcome this effect was used as an assay of 
estrogenic activity (Bergeron et al, 1994). 
For most human dietary xenoestrogens, this data is lacking. 
1.6.2 In vitro assays 
 
In vitro estrogen assays fall into three groups corresponding to steps in the ER-dependent 
metabolic pathway that they assay (see Figure 1.4). The groups are: 
• Receptor binding assays, which measure the strength of the interaction between 
the ER and the estrogenic compound. 
• Receptor-dependent gene expression assays, which measure the ability of the 
estrogenic compound to activate cells’ biochemical responses, via the ER and 
hence to produce a protein or proteins. 
• Cell proliferation assays, which measure an estrogen-dependent cellular response. 
 
1.6.2.1 Receptor binding assays 
 
These assays measure the strength of the interaction between the ER and the test 
xenoestrogen in a competitive binding assay with 17β-estradiol.  Assays utilise ERs from 
mouse uteri (Korach et al., 1988, Krishnan et al., 1993), spotted seatrout liver (Thomas 
and Smith, 1993), rainbow trout liver (White et al., 1994), cultured MCF-7 human breast 
cancer cells (Nagle et al., 1997) and cultured ECC-1 human endometrial carcinoma cell 
lines (Bergeron et al., 1999). 
 
 
1.6.2.2  Receptor-dependent gene expression assays 
 
Receptor-dependent gene expression assays measure the ability of the estrogenic 
compound to cause a conformational change in the receptor leading to DNA transcription 
and gene expression.  Examples of assays of this type include: 
• the yeast estrogen screen (YES), created by transfecting yeast cells with the 
human ER and two estrogen response elements linked to the lacZ reporter gene, 
coding for β-galactosidase (Arnold et al., 1996) which is upregulated and leads to 
the conversion of a yellow galactoside dye to red chromophore (plus galactose) 
that can be measured spectrophotometrically. 
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• HeLa cells, which do not contain an ER, co-transfected with an estrogen 
responsive reporter vector (ERET81CAT) and a mouse ER vector (pRSV). 
Estrogenic activation results in production of chloramphenicol acetyltransferase 
which is detected by ELISA (Shelby et al., 1996). 
• the production of cathepsin-D and pS2 from MCF-7 human breast cancer cell line 
can be monitored with the ELSA-CATH-D and ELSA-PS2 immunoradiometric 
assays following exposure to estrogenic compounds (Olea et al., 1996). 
• production of complement C3, a well known estradiol-regulated protein from a 
cultured rat endometrial adenocarcinoma cell line (RUCA-I). Proteins are labelled 
with [35S]-methionine and determined by autoradiography after electrophoretic 
separation (Hopert et al., 1998). 
• production of zona radiata proteins and vitellogenin in primary hepatocytes from 
Atlantic salmon exposed to xenoestrogens in vitro. Protein products are 
determined by ELISA (Celius et al., 1999). 
 
1.6.2.3 Cell proliferation assays 
 
Cell proliferation assays measure an estrogen-dependent physiological response resulting 
from the production of functional proteins.  The ability of chemicals to induce ER positive 
cell proliferation is an indicator of estrogenic activity (Soto et al., 1995). Assays of this 
sort can be carried out in vitro by utilising established cell lines derived from estrogen 
responsive target organs, such as rat pituitary cells and human breast cancer cell lines 
(T47-D and MCF-7).  MCF-7 is by far the most commonly used cell line for assays of 
estrogenicity and is the basis for the so-called E-Screen assay (Soto et al., 1995). 
1.6.3 Choice of assay and comparative results from different assays using EQ 
 
The yeast (YES) and E-Screen assays are the most widely used.  Whilst the majority of 
assays have employed purified individual test chemicals and the response compared to a 
reference compound (generally 17β-estradiol), the yeast assay has been used to study the 
effect of mixtures and to measure estrogenicity of foodstuffs (Silvia et al., 2002, 
Takamura-Enya et al., 2003).   
 
Results from the different assay methods cannot be compared directly.  However it is 
arguable that relative estrogenicity (i.e. relative to 17β-estradiol) can be compared 
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between assays.  The 17β-estradiol equivalence factor (XEQ) is the ratio of the 
concentration of the xenoestrogen to the concentration of 17β-estradiol that produced the 
same response in an estrogenicity assay.  Rudel (1997) has reviewed the use of XEQs 
(that he termed ‘TEFs’ (Toxic Equivalent Factor)) in assessing risk from xenoestrogens 
and states that the use of XEQs is reliant on two assumptions: 
• that the relative xenoestrogenic potency in in vitro assays for all compounds is 
predictive of the relative potency for the most sensitive in vivo xenoestrogenic 
effect, and  
• that all xenoestrogens act via the same mechanism.  
He provides significant evidence that different xenoestrogens may act by different 
mechanisms to produce a multitude of different effects, and that the use of XEQs 
represents a significant simplification of this complex and poorly understood system.   
The TEF approach is adopted for assessing overall effect of exposure to dioxins (van den 
Berg et al., 2000) and it is the author’s view that this simplification is a reasonable basis 
for relative potency for xenoestrogens that act by the same mechanism (such as via the 
nuclear receptor pathway) to provide an estimate of risk and to suggest priorities for 
further risk analysis.  
 
 
1.7 Additivity of xenoestrogens 
  
A significance component of this thesis is to assess the cumulative risk to public health 
due to the exposure of the population to a diverse array of xenoestrogenic compounds 
through the diet.  The assessment of chemical mixtures is a complex topic for 
toxicologists, regulators and the public (Monosson, 2005).  Such a cumulative approach 
can only be undertaken if a reasonable model can be applied to combine the 
xenoestrogenic effects of different groups of xenoestrogenic compounds. The effect of 
mixtures can be classified as synergistic (greater than expected), antagonistic (less than 
expected), or additive (as expected).  In the absence of evidence of chemical interaction, 
assumption of no interaction is the default approach (USEPA, 2000).  
 
While some studies have suggested that xenoestrogenic compounds may combine their 
effects in a synergistic manner (Arnold et al., 1996), this finding has not been reproduced 
in subsequent studies (Gaido et al., 1997; Kortenkamp and Altenburger, 1999; Payne et 
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al., 2000). Gaido et al., (1997) reported additivity of effect for combinations of 
organochlorine compounds. Payne et al., (2000) demonstrated that the effect of four 
xenoestrogens (o,p-DDT, genistein, 4-nonylphenol, and 4-n-octylphenol) in a yeast 
estrogen screen (YES) could be predicted using a model of concentration addition, when 
due consideration was given to the characteristics of the individual dose-response curves. 
 
Clear evidence of additivity of effect has been demonstrated by Kortenkamp and 
colleagues (Payne et al., 2000, Silva et al., 2002, Rajapakse et al., 2002 ) who tested the 
estrogenicity of  xenoestrogen mixtures including alkyl phenols, hydroxylated PCBs, 
benzophenones, parabenes, BPA and genistein using the yeast assay.  Compounds were 
combined at concentrations below individual No Observable Effect Levels in proportion 
to their individual potencies.  When combined, an estrogenic response was measureable.  
The response of the compounds in combination showed good agreement with the 
estimated response of the individual xenoestrogens, demonstrating that the combined 
effect was additive. In subsequent work, additivity was less than estimated when a similar 
experiment was undertaken using the MCF-7 cell proliferation assay (Rajapakse et al., 
2004).  A different suite of estrogenic compounds were used than for the yeast assay 
experiments.  The lack of additivity in this case was ascribed to two alkyl phenols that 
were estrogen antagonists when present in a mixture. Possible interactions between 
components of a mixture resulting in deviation from additivity must be kept in mind when 
assessing the effect of combinations of  xenoestrogens in the diet. 
 
Using molecular techniques to measure gene expression Gaido et al., (2003) found that  
endocrine effects of a selected chemical were tissue and mixture dependent meaning that 
EDCs could be additive for one response and antagonist for another response. When 
estradiol and HPTE (an hydroxylated analogue of DDT) were added individually to the 
reproductive tissue of male and female mice, they were found to act similarly on  
expression of most genes in the ovaries, uterus, testes and prostate. However, for each 
tissue type there were subsets of genes differentially regulated by the 2 compounds.  
When added in combination, the effect was often, but not always additive (e.g. expression 
of IGF binding protein in the testis).  Similarly genistein and methoxychlor showed an 
additive effect on vaginal opening and altered estrous cyclicity in female Sprague-Dawley 
rats but genistein enhanced the effects of  methoxychlor on preputial separation in male 
rats.  
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For the purpose of the current risk assessment a concentration addition model is applied 
as a basis for assessing a maximum possible effect.  While this is clearly a simplification, 
it represents the most pragmatic approach based on the current state of knowledge, is 
generally supported by research on this topic and errs on the side of safety for deciding 
whether these compounds might be of concern for human health.  
 
 
1.8 Risk assessment 
 
If a person (or wildlife species) is not exposed to a hazard, then they will suffer no 
adverse effects as a result of that hazard, there is no risk to them.  Risk assessment is a 
scientifically based process, invaluable for defining the importance of any particular 
hazard.  The model of risk assessment described by the National Research Council of the 
National Academy of Sciences (NAS-NRC, 1983), and used by government agencies 
including the Environment Protection Agency (EPA), consists of : 
• hazard identification 
• dose-response 
• exposure assessment and 
• risk characterization. 
 
Hazard identification 
Hazard identification relates to whether a specified chemical causes a particular health 
effect.  In the context of this thesis, hazard identification relates to the selection of dietary 
constituents that might contribute to total estrogenicity from the diet.  Ideally, all 
chemicals in food with estrogenic activity would be included.  However, since different 
xenoestrogens have different estrogenic potencies, a XEQ approach is necessary to allow 
for the differences in potency between xenoestrogens.  A XEQ approach requires a 
common mechanism of action.  Given that the main (or classical) action of xenoestrogens 
is via the nuclear ER, it is appropriate to base hazard selection on xenoestrogens that have 
been shown to act via this pathway.  On this basis, compounds that activate or suppress 
expression of the androgen receptor, inhibit steroid hormone synthesis, activate the aryl 
receptor,  or modulate neurotransmitter receptors would not be included.  Thus genistein 
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would be included but phthalates and dioxins that act via binding to the aryl receptor, 
would not. 
Dose-response 
Dose-response is a measure of the relationship between the magnitude of exposure and 
the probability of health effects (NAS-NRC, 1983).  For xenoestrogens in the diet this 
translates to how much xenoestrogen gives a measureable estrogenic effect, where effect 
can be measured in a variety of ways including human epidemiological studies, animal 
studies, in vivo or in vitro assays (see 1.6).  Ideally, a whole organism effect would be the 
basis for dose –response data but in the absence of this, a common in vitro assay basis is 
preferred because different assays can give different relative responses to different 
xenoestrogens (for example see Chapter 2.7.1 relating to DDT).  For xenoestrogens, effect 
based on in vitro cell proliferation assays is considered the best option for two reasons.  
Firstly, this assay represents a higher level of biological complexity than either 
competitive binding or gene expression assays.  Secondly, cell proliferation assays based 
on the MCF-7 breast cancer cell line are one of the most widely employed asssays of 
estrogenicity providing a common basis for diverse xenoestrogens (Soto et al.,1995, 
Breinholt and Larsen, 1998). 
 
Exposure assessment 
Exposure assessment is the measure of the amount of hazard to which a person or 
organism is exposed, or the likelihood of being exposed.  For a foodborne hazard, 
exposure is equivalent to intake where intake is the product of the concentration of the 
hazard in the food and consumption of that food item. For example, the dietary intake of a 
pesticide residue in a given food is obtained by multiplying the residue level in the food 
by the amount of that food consumed (WHO, 1997).  Food consumption may be 
determined in a number of ways (WHO, 1997): 
i. Per capita consumption from food balance sheets that estimate average food 
consumption from national data of food production, less exports, plus imports, 
minus wastage.  Food balance sheets are thought to overestimate consumption of 
most commodities and therefore represent high percentile consumers.  
i. Household budget data, that is often a refinement of (i) above as they reflect food 
purchased for human consumption. 
ii. Food diary records, where respondents record all food consumed over a specified 
period.   
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iii. 24-hour diet recalls, where a sample of respondents recall all food consumed in a 
defined 24 hour period. 
iv. Food frequency questionnaires where respondents recall how often a food is 
consumed. 
 
Risk characterization 
Risk characterization brings together dose-response and exposure to estimate the nature 
and magnitude of human risk, including uncertainty.  For example, if a person does not 
consume canned food, their risk of feminizing effects from BPA that might be present in 
the canned food, will be zero.  For xenoestrogens, if dose-response is based on cell 
proliferation effects, then the derived risk characterization would describe the magnitude 
of cell proliferation for the derived level of exposure.  But in terms of human health, this 
is not very descriptive because cell proliferation is not the only likely (adverse) outcome 
of exposure.  The pharmacological impact of xenoestrogens is dependent on the blood 
level attained relative to normal levels of endogenous estrogens. Therefore if a combined 
blood concentration of exogenous estrogenicity was either a significant proportion of, or 
greater than, the endogenous estrogenicity, it is highly plausible that a pharmacological 
effect will result.  Since in a XEQ approach, xenoestrogen effects are standardized 
relative to the endogenous hormone 17β-estradiol, it is reasonable to assess risk from 
exposure to xenoestrogens as a proportion of normal circulating levels of 17β-estradiol, as 
followed by Shaw and McCully (2002).  This approach assumes that the transfer from 
blood across cell membranes to target receptors is the same for endogenous estrogen as 
for xenoestrogens. 
 
 
1.9 Work described in this thesis 
 
The background information provided in the introductory Sections 1.1 through 1.7 
demonstrates an international interest in estrogenic compounds.  Evidence for the effects 
on wildlife are more convincing than the array of associated human health effects, both 
positive and negative.  Causal links between estrogenic hazards and human health need to 
be substantiated.  This is difficult given the usually long latency between exposure and 
observed effect. In assessing the hypothesis that dietary xenoestrogens may contribute to 
adverse endocrine effects, the thesis addresses the overarching question: 
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“Is the level of exposure to estrogenicity from dietary constituents in combination 
sufficient (in the context of normal body levels of estrogens) to have a 
pharmacological effect?” 
A comprehensive risk assessment of naturally occurring and synthetic estrogenic 
compounds found in food is presented (Chapter 2).  Several contributing questions are 
subsequently addressed from data gaps identified from this risk assessment: 
• What is the level of exposure to BPA in the New Zealand diet? 
• Do microflora account for low plasma levels of isoflavones compared with intake 
levels? 
• What is the maternal to fetal transfer of xenoestrogens?  
 
This exposure assessment combines new and existing data on food concentration, food 
consumption and serum levels for each xenoestrogen.  Exposure is combined with relative 
estrogenic potency information, from published bioassay data, to estimate risk relative to 
normal circulating levels.  Four areas that are identified from the risk assessment are then 
pursued from a multidisciplinary approach.   
 
A priority data gap, namely the quantitation of BPA in canned food and subsequent 
population exposures are described in Chapter 3, drawing on quantitative analytical 
chemistry using gas chromatography mass spectrometry with an isotopic internal 
standard.  
 
Human intestinal microflora are reviewed and microbiological techniques applied in 
combination with high-pressure liquid chromatography to study the role of gut microflora 
on the bioavailability of the phytoestrogens genistein and daidzein in Chapter 4. 
 
A “gene expression” biological assay for measuring estrogenic potency is validated in 
Chapter 5.  The assay, utilising a yeast strain incorporating the human ER is used in 
experiments to explore in utero exposure to estrogenic compounds.  The dual perfusion 
placental model is further applied to measure the transfer of xenoestrogens across the 
human placenta in Chapter 6.  
 
The thesis concludes with preliminary experiments towards a genomic approach to 
investigate exposure to xenoestrogens with a biochemical response in human cell lines, 
Chapter 7. 
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Chapter 2 
 
 
 
Risk assessment of dietary exposure to 
xenoestrogens 
 
 
2.0 Introduction 
 
Food is a major source of exposure to xenoestrogens.  A number of investigators have 
assessed the exposure of selected populations to individual groups of xenoestrogens (eg 
Maskarinec et al., 1998, Arai et al., 2000a,b, Hertog and Hollman 1996, CAC 2000, 
Hardy 1998, Gunderson 1995, Howe et al., 1998, Botterweck et al.,2000).  However, 
there are only two reports describing the relative contribution of different groups of 
xenoestrogens to total estrogenic intake from the diet (Safe 1995, Shaw and McCully, 
2002).  Safe et al., compared the estrogenic intake of flavonoids in foods with the 
estrogenicity of four combined pesticides using a combination of binding affinity and cell 
proliferation respectively.  No evaluation was attempted of the pharmacological 
significance of this level of dietary exposure to xenoestrogens.  Shaw and McCully (2002) 
estimated the estrogenic intake of several dietary xenoestrogens in terms of 17β-estradiol 
equivalents as determined by a cell proliferation assay.  Included in the comparison were 
coumesterol, genistein, bisphenol-A, phthalates, DDT, dicofol, endosulphan, dieldrin and 
β-HCH.  A theoretical blood serum concentration was calculated, assuming 100 percent 
absorption, and compared with circulating levels of 17β-estradiol.  This is a simplification 
since 100% absorption does not occur (Xu et al., 1995, Arai et al., 2000a).  Both the Safe 
and Shaw studies showed that the contribution of synthetic compounds to the intake of 
estrogenicity was low relative to the estrogenicity from naturally occurring xenoestrogens. 
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However, a more comprehensive estimate is now possible compared to those reported by 
Safe (1995) and Shaw and McCully (2002). A wider range of xenoestrogens, more robust 
concentration and estrogenicity data, and allowance for factors influencing serum levels 
can be considered.  In this chapter, dietary exposures to a total of 13 groups of estrogenic 
compounds are assessed from food concentration, and food consumption information for 
a sample of New Zealand adults.   
 
2.1 Rationale for risk assessment  
2.1.1 Selection of chemicals 
 
Chemical compounds for the exposure assessment were included on the basis of 
consideration of the scientific literature. Compounds, or closely related groups of 
compounds, were included in the current assessment if: 
• There was consistent evidence of the chemical having xenoestrogenic activity, either 
in vitro or in vivo and that the chemical’s mechanism of action was via the ER. 
Evidence of a common mode of action was considered to be a necessary criterion for 
xenoestrogenicity for validity of an XEQ approach for different chemicals to be 
considered in aggregation (Rudel, 1997, van den Berg et al, 2000). 
• There was evidence for their presence in the New Zealand diet. For instance, 
pesticides that have never been registered for use in New Zealand and have never been 
reported to be detected in foods in New Zealand were not included in the intake 
assessment. 
Assessment based on the above criteria resulted in inclusion of the four specific 
compounds and nine chemical classes (Table 2.1.1). 
 
Table 2.1.1 Xenoestrogens included for dietary assessment 
Natural compounds Synthetic compounds 
Isoflavones 
Lignans 
Coumestans 
Flavonoids 
Resorcylic lactones 
 
 
 
DDT and its metabolites 
Aldrin and Dieldrin 
Endosulfan 
Synthetic pyrethroid pesticides 
PCBs 
Alkyl phenols 
Bisphenol-A 
Butylated Hydroxyanisole (BHA) 
Chapter 2 32 
  
 2.1.2 Concentration data 
 
New Zealand data were used whenever they were available for population consistency 
with consumption data. Median concentration is desirable for intake estimates, to reflect 
the intake of the majority of consumers, but in the absence of this data, mean levels of 
chemicals in foods were used for exposure estimates  (WHO, 2000).  Where concentration 
data was available only as a range (for the isoflavones, coumestrol, quercetin and 
phloretin), both upper and lower intake estimates were determined. Where New Zealand 
data were not available or do not exist (such as nonyl phenol), data from the world 
scientific literature were employed.  
2.1.3 Food consumption 
 
The two primary sources of food consumption information used to derive exposure 
estimates for xenoestrogens in the New Zealand diet were: 
• 1997/98 New Zealand Total Diet Survey simulated typical diets (Cressey et al., 2000). 
These diets were based largely on national consumption data (Horwath et al., 1991) 
with input from other sources of information (e.g. fish industry data). The vegetarian 
simulated diet was based on two New Zealand studies (Alexander et al., 1994, Harman 
and Parnell, 1998).  Simulated diet information was used as much as possible as it is 
designed for population sub-group dietary intake estimates.  However, the number of 
foods included limits the usefulness.  Food consumption for the simulated diets are 
included in Appendix 2. 
• The 1997 National Nutrition Survey (NNS) (Russell et al., 1999) was used for specific 
foods not included in simulated diets (for example, isoliquiritigen in licorice, and  
BPA in canned food).  Further detail is given in 8.2.1.  
 
For the foods not reported in the National Nutrition Survey (and therefore not consumed 
by any of the 4636 respondents), an assumption was made that one person in 5000 would 
consume 50 g of these foods on a daily basis. This equates to a daily level of 
consumption for the average New Zealand resident of 0.01 g/day. This approach was 
used to estimate intake of coumestrol from split peas, kala chana seeds, lima and pinto 
beans and soyabean sprouts. 
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2.1.4 Population sub-groups 
 
Exposure assessments were undertaken for the following sub-populations; 
• an average adult male (≥ 25 years), mean body weight 80kg 
• an average adult female (≥ 25 years), mean body weight 65kg 
• a 19-24 year old male, mean body weight 70kg 
• a lacto-ovo vegetarian (19-40 years) (no animal products other than dairy and 
eggs), mean body weight 65kg 
 
as representative of the majority of the population and because food consumption data for 
these groups could be accessed from both the simulated model diets and the NNS.  The 
19-24 latter group was included because this is the population sub-group with the highest 
average level of food consumption, thence a high potential exposure. The lacto-ovo 
vegetarian female was included as a group potentially at risk because of dependence on a 
narrower range of foods than the general population.  Exposure to younger people was 
excluded because of the lack of rigour in consumption information and not because of a 
low risk for this sub-population group.  Food consumption data for vegetarian females, 
that may be an at risk sub-group, was available from the simulated diets but not NNS 
data.  Where consumption information was not available (coumestrol, isoliquiritegenin 
and bisphenol A), exposure for this sub population was assumed to be the same as for 
adult females. 
 
2.1.5 Relative estrogenic potency data 
 
In the absence of sufficient data on in vivo effects, relative estrogenicity based on in vitro 
cell proliferation assays is considered the best option as a measure of dose-response for 
two reasons.  Firstly, this assay represents a higher level of biological complexity than 
either competitive binding or gene expression assays.  Secondly, cell proliferation assays 
based on the MCF-7 breast cancer cell line are one of the most widely employed asssays 
of estrogenicity providing a common basis for diverse xenoestrogens (Soto et al.,1995, 
Breinholt and Larsen, 1998).  For internal consistency, results from Breinholt and Larsen 
(1998) were used.  Where these data were not available, and where different studies 
derived different estimates of estrogenic potency for the same xenoestrogen, the highest 
estimate (worst case) was used for the risk assessment. In the absence of cell proliferation 
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data, the estrogenic potency of isoliquiritigenin was based on structure activity 
relationship to the most estrogenic flavonoid (apigenin). These worst case assumptions 
follow the “precautionary principle” (Burger, 2003), in recognition of the uncertainty of 
the potential endocrine effect. 
 
2.1.6 Circulating concentrations of xenoestrogens 
 
Any potential pharmacological effect of a xenoestrogen depends not on intake, but rather 
on the circulating concentration in the blood.  A blood level, accounting for absorption, 
distribution, metabolism and excretion, was extrapolated from the intake estimate by 
adjusting for the ratio of actual (A) serum (or plasma) level to theoretical (T) serum level 
from published data.  Information on actual serum levels used, in order of priority was: 
• Studies relating dietary intake of xenoestrogens to actual steady-state levels of the 
xenoestrogens in serum for the same study group. 
• Studies reporting serum levels of xenoestrogens for the general New Zealand 
population. 
• Studies reporting serum levels of xenoestrogens from a region of similar diet to New 
Zealand. 
Hence an A:T ratio was determined (see 8.2.2 for further detail).  This adjustment 
assumes the same ratio of actual to theoretical concentrations across population groups 
which is undoubtedly a simplification.  Nevertheless, this conversion to an internal dose is 
considered an improvement over previous exposure estimates.  
2.1.7 Uncertainty 
 
Quantitative or qualitative uncertainty analysis is an integral component of risk 
characterization or risk estimation (NAS-NRC, 1983, Covello and Merkhofer, 1996), and 
allows a ranking of key factors and data gaps to be prioritised.  In the risk assessments 
that follow, there are uncertainties that are equivalent across each xenoestrogen, for 
example the uncertainty associated with extrapolating from a cell proliferative effect to a 
whole organism.  In addition there are uncertainties that vary for each xenoestrogen. The 
following uncertainties are recognized for each component of the individual assessments 
that  comprise the aggregated risk from dietary xenoestrogens: 
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• Food concentration: uncertainty arising from analytical variability, 
representativeness of sampling, data gaps. 
•  Food consumption: misreporting, errors in assigning foods, variability 
from combining individual consumption to population groups, data gaps.  
• Estrogenic potency: analytical variability in assays, extrapolation from cell 
proliferation to other in vitro assays, extrapolation of effect from one 
compound to another based on structural similarity 
• A:T ratio: analytical variability in plasma determinations, extrapolation 
from one population to another, extrapolation from NZ serum levels to NZ 
intake data from a different study, extrapolation from serum levels of non 
NZ  population, no data. 
 
Data for some xenoestrogens are more robust (less uncertain) than for other 
xenoestrogens. An assessment of the significance of differences between various 
contributing factors is guided by the following qualitative uncertainty assignments (Table 
2.1.2.), where * represents least uncertainty (more robust) and *** represents the greatest 
uncertainty (least robust). This approach is consistent with the format proposed by 
Covello and Merkhofer (1996, Table 23) for qualitative uncertainty analysis where * 
represents minor significance and *** represents major significance. 
 
For the current assessment, concentration data from New Zealand was rated to be more 
certain (*) than data from overseas (**) as it better reflects useage of industrial chemicals 
and food growing patterns that may influence natural chemicals for the consuming 
populations for which the risk assessment is being undertaken.  
 
In nearly all cases, consumption was available for the population groups under study and 
an uncertainty of * was assigned.  Where it was not available (e.g. alfalfa sprouts) it was 
assigned an uncertainty of ** to reflect the estimation. 
 
The uncertainty of data on estrogenic potency between different xenoestrogens was 
ranked for analytical variability in assays from primary operator (*) to another (**), 
extrapolation from cell proliferation to other in vitro assays (***) and extrapolation of 
effect from one compound to another based on structural similarity (***) based on the 
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variabilites of potency data available for each xenoestrogen and across different 
xenoestrogens. 
 
Qualitative uncertainty assignments for the A:T were ranked from the most certain 
scenario where intakes and serum levels were available for the same population group (*) 
to extrapolation of serum levels from one population to another population from the same 
country, and therefore assumed similar intake (**) or extrapolation from NZ serum levels 
to NZ intake data from a different study (**), to the extrapolation from serum levels of 
non NZ  population (***) being the most uncertain (Table 2.1.2). 
 
Table 2.1.2: Assignments of qualitative uncertainties 
 
Contributing 
factor 
Description of data source Uncertainty
 assignment 
Food concentration New Zealand  * 
 Overseas ** 
Food consumption New Zealand * 
 No New Zealand data ** 
Estrogenic activity Cell proliferation, Breinholt and Larsen, 1998 * 
 Other cell proliferation data ** 
 Other in vitro data *** 
 Extrapolation from structure/activity relationships *** 
A:T ratio Intake and serum levels, same population, same study * 
 Intake and serum levels, same population but not the 
same study 
** 
 New Zealand serum data ** 
 Other serum data *** 
 Extrapolated from structure/activity relationship *** 
 
An overall uncertainty equivalent to the maximum contributing uncertainty of any one 
component was assigned such that an overall uncertainty of “*” represented a less 
uncertain (more robust) risk assessment than an overall uncertainty of “***” in an attempt 
to convey what is missing, hence confidence in the risk assessment (USEPA, 2000).  
These assignments do not distinguish between the relative importance of estrogenic 
activity and A:T ratio but do mean that these components dominate over food 
concentration and food consumption data that have only 2 levels of uncertainty.  This is a 
limitation of the model.   
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2.2 Isoflavones 
 
Included in this group are the compounds genistein, daidzein, biochanin A and 
formononetin (COT, 2003).  Isoflavones are often present as glucoside conjugates in 
plants and foods (e.g.genistin and daidzin).  The glucose group may be esterified with an 
acetyl- or malonyl group to form acetyl- or malonylglucosides (acetylgenistin, 
acetyldaidzin, malonylgenistin and malonyldaidzin).  Although found in many plant 
tissues, highest levels are observed in legumes (particularly soybeans), with more variable 
levels in oilseeds and nuts. 
 
The structures of genistein, genistin, daidzein, daidzein, biochanin A and formononetin 
are shown below (Figure 2.1). The structural similarity of the non-conjugated (aglucone) 
isoflavones, to 17β-estradiol is clear with distally located hydroxyl group separated by a 
multiple ring structure. 
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Figure 2.1: Chemical structures of the isoflavones genistein, daidzein biochanin A 
and formononetin and the glucoside conjugates genistin and daidzein. 
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2.2.1 Estrogenic activity 
 
The relative estrogenic potencies of phytoestrogens has been reviewed (IEH, 2000) 
including very limited in vivo, and more numerous in vitro, assays.  The estrogenic 
potency data for the isoflavones is summarised in Table 2.2.1. 
 
Table 2.2.1  Relative estrogenic potencies of isoflavones  
 
 In vitro assays In vivo assays 
 Receptor 
binding 
Gene expression Cell 
proliferation 
 
17β-estradiol 1 1 1 1 
genistein 0.021 
0.0012 
0.93 
0.000844 
0.00016 
0.0000458 
0.00085 
0.00038 
0.000017 
genistin  0.0000486   
daidzein 0.0053 0.000134 
0.000026 
0.00000288 
0.00000715 
0.00018 
0.00000757 
daidzin  0.0000126   
biochanin-A <0.00013 <0.000064 
0.0000126 
0.00000258 
0.0000485 
0.00018 
 
formononetin <0.00011 
<0.00013 
0.0000064 0.00000465 0.00000267 
1 = IEH, 2000    2 = Zava et al., 1997  3 = Kuiper et al., 1998. 
4 = Markiewicz et al., 1993 5 = Welshons et al., 1990  6 = Mayr et al., 1992 
7 = Bickoff et al., 1962  8 = Breinholt and Larsen, 1998. 
 
The values given are the highest reported where estrogenicity varied between the α and β 
estrogen receptor subtypes. 
 
Relative estrogenic potencies of EQ= 0.0003 (300 x 10 –6 ) for genistein and 0.0001 (100 
x 10-6 ) for daidzein will be used for the current assessment of estrogenicity. 
2.2.2 Occurrence in foods 
 
The isoflavones genistein and its glucoside, genistin, (the sum of which is referred to as 
total genistein), daidzein and its glucoside, daidzin, (the sum of which is referred to as 
total daidzein), biochanin A and formononetin have been analysed in a range of selected 
foods available to the New Zealand consumer (Taylor and Burlingame, 1998).  A 
summary of concentrations is shown in Table 2.2.2.  The concentration of the glucoside 
conjugates, genistin and daidzin, is much higher than the aglucone forms.  Since the 
glucosides are readily converted to the aglucone by gut microflora, intake of both the 
glycoside and aglucone must be considered for a realistic exposure assessment.  
Concentrations of individual isoflavones greater than 15 mg/kg were limited to soy 
products with the exception of formononetin in red clover tablets. The concentration of 
the glucosides, genistin and daidzin, were higher than the parent isoflavones by factors 
ranging from two to two hundred. Biochanin A and formononetin were not detected in 
any of the New Zealand foods, with the exception of red clover tablets, which are not a 
food so much as a supplement.  
 
Table 2.2.2 Concentration of isoflavones in selected New Zealand foods (mg/kg) 
(Taylor and Burlingame, 1998) 
 
Food type Genistein + 
Genistin 
Genistein 
 
Daidzein+ 
Daidzin 
Daidzein 
 
Biochanin 
 
Formononetin 
 
Australian soy 
beans 
1334-1559 <2.4- 8.4 795-1059 <1.3- 7.6 <3.7 <2.0 
New Zealand 
soybeans  
611-1891 <2.4- 41 913-1419 <1.3- 29 <3.7 <2.0 
Soy based infant 
formulas 
121-201 4.6- 7.7 83.8-153.7 1.9- 24.2 <3.7 <2.0 
Farex infant food 134-170 2.3- 7.1 211-394 1.3- 10.2 <3.7 <2.0 
Dairy based infant 
formulas 
<2.4-11.4 <2.4 1.5-10.8 0.2- 3.5 <3.7 <2.0 
Soy flour 1765- 1801 31- 160 1151- 1281 24.1-85.4 <3.7 <2.0 
Soy protein isolate 942 159 369 60.7 <3.7 <2.0 
Soy chunks 916- 1570 15.5- 23.7 375- 858 17.3- 48.5 <3.7 <2.0 
Soy mince 977 160 1266 175 <3.7 <2.0 
Soy/TVP bacon bits 957-1613 20.9- 29.6 656- 1120 13.0- 233 <3.7 <2.0 
Tofu luncheon 140 19.5 71.4 11.4 <3.7 <2.0 
Soysage 50.0 9.0 4.9 4.9 <3.7 <2.0 
Tempeh1 165 77.5 136 44.3 <3.7 <2.0 
Soy yoghurt 19.7 0.7 11.9 0.8 <3.7 <2.0 
Tofu 197-401 9.8-159 81.1-213 5.3-135 <3.7 <2.0 
Soy milk 39.0-110 0.4-3.9 62.2-84.8 0.8-2.7 <3.7 <2.0 
Miso2 320-671 90.0-389 184-1855 76.7-273 <3.7 <2.0 
Milk <0.5 <0.5 0.25-0.33 0.25-0.33 <3.7 <2.0 
Yoghurt <0.5-0.8 <0.5-0.8 <0.3 <0.3 <3.7 <2.0 
Red clover tablets 6123 812 2162 302 <3.7 4000 
1=fermented soy beans 
2=soy based soup 
 
Formononetin (0.05-4.02 mg/kg), daidzein (0.02-0.63 mg/kg), genistein (0.045-1.82 
mg/kg) and biochanin A (0.23-1.38) have been measured at low levels in beer (Lapcik et 
al., 1998).  Beer was not included in the foods analysed in the New Zealand study and 
therefore upper and lower concentrations reported in the literature were used in the 
exposure assessment. 
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A survey of the use of soy protein in New Zealand meat products was conducted in 1993 
(Lake et al., 1993). Assuming upper and lower levels of soy protein content and mean 
concentrations of isoflavones in soy protein isolate reported by Taylor and Burlingame 
(1998), upper and lower estimates of isoflavones in these meat products can be derived. 
Not all of the meat products analysed contained soy protein and if it is assumed that the 
proportion of positives found in 1993 is representative of currently available meat 
products, average concentrations for each meat category may be derived as shown in 
Table 2.2.3.   
 
Similarly, bread might contain soy flour as a component of bread improvers 
(approximately 0.5% of the flour mix). Correcting for moisture content differences 
between flour and bread (Athar et al., 1999), the soy flour content of bread would be 
approximately 0.35% by weight. Using the upper and lower concentrations of isoflavones 
in soy flour reported by Taylor and Burlingame (1998), the maximum and minimum 
concentrations of total genistein in bread are 6.3 and 6.2 mg/kg and total daidzein 
concentrations are 4.5 and 4.0 mg/kg. 
 
Table 2.2.3  Estimated average upper concentration of isoflavones in New Zealand 
meat products1 
 
Product 
category 
Proportion 
of positive 
samples2 
Range of soy 
protein levels  
Genistein + 
Genistin 
Upper 
Genistein 
+ Genistin 
Lower 
Daidzein+ 
Daidzin 
Upper 
Daidzein+ 
Daidzin 
Lower 
  (%)2 (mg/kg) (mg/kg) (mg/kg) (mg/kg) 
Pies (fillings) 14/34 0.5-4.5 17.5 1.9 6.8 0.8 
Hams 3/10 1.5 4.2 4.2 1.7 1.7 
Saveloys 4/14 0.5-2.0 5.4 1.3 2.1 0.5 
Sausages 11/24 0.5-2.5 10.8 2.2 4.2 0.8 
Luncheons 3/7 1.5-2.0 8.1 6.1 3.2 2.4 
 
1 Calculated from concentration in soy protein isolate x maximum % soya protein in that food x 
proportion of positive samples 
2 Lake et al., 1993 
 
 
2.2.3 Exposure assessment 
 
Tofu, tempeh and miso are each derived from soy beans: tofu is curdled soy milk in the 
same way that cheese is made from milk, tempeh is made from cooked soybeans 
fermented with a Rhizopus mold and miso is made from fermented, salted soybeans aged 
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for 1-3 years.  Very little tofu, tempeh, miso, soy yoghurt or soy milk is consumed by the 
average New Zealander.  Intake of soy is therefore low compared with people who 
frequently eat these soy foods.  Documentation of the complete range of New Zealand 
foods in which soy occurs as an ingredient is not known but soy protein is used in 
processed meat and soy flour is a minor constituent in bread.  Apart from individuals who 
may consume red clover tablets (as an alternative to hormone replacement therapy), New 
Zealanders appear not to be exposed to dietary sources of biochanin A or formononetin.  
 
Using consumption information from the model diets used in the New Zealand Total Diet 
Survey (NZTDS), where available (Cressey et al., 2000), or from the 1997 National 
Nutrition Survey (Russell et al.,1999), where available, and both upper and lower 
concentration data in Tables 2.2.2 and 2.2.3, the maximum and minimum intake for a 
young male, adult males and adult female New Zealanders can be estimated (Table 2.2.4a 
and b).  For details see Appendix 1. 
 
Table 2.2.4a:  Estimated maximum daily dietary intake of genistein (G) and daidzein 
(D) by age-sex group (mg/day)  
 
Food Young male Adult male Adult female Vegetarian F 
 G D G D G D G D 
Ham 0.015 0.006 0.025 0.010 0.013 0.005 0.000 0.000 
Saveloys 0.038 0.015 0.012 0.005 0.004 0.002 0.000 0.000 
Sausages 0.303 0.118 0.208 0.081 0.103 0.040 0.000 0.000 
Luncheon 0.009 0.004 0.023 0.009 0.010 0.004 0.000 0.000 
Pies, 
savoury 0.236 0.092 0.236 0.092 0.098 0.038 0.000 0.000 
Milk, soy 0.097 0.075 0.279 0.215 0.234 0.181 5.808 4.477 
Milk, cow 0.000 0.120 0.000 0.078 0.000 0.057 0.000 0.053 
Bread 1.191 0.847 1.242 0.883 0.882 0.628 0.882 0.628 
Beer 0.562 0.197 0.637 0.223 0.063 0.022 0.063 0.022 
Total 2.5 1.5 2.7 1.6 1.4 1.0 6.7 5.2 
 
Table 2.2.4b  Estimated lower daily dietary intake of genistein (G) and daidzein (D) 
by age-sex group (mg/day)  
 
Food Young male Adult male Adult female Vegetarian F 
 G D G D G D G D 
Ham 0.015 0.006 0.025 0.010 0.013 0.005 0.000 0.000 
Saveloys 0.038 0.004 0.012 0.001 0.004 0.000 0.000 0.000 
Sausages 0.303 0.022 0.208 0.015 0.103 0.008 0.000 0.000 
Luncheon 0.009 0.003 0.023 0.007 0.010 0.003 0.000 0.000 
Pies, 
savoury 0.236 0.031 0.236 0.031 0.098 0.013 0.000 0.000 
Milk, soy 0.097 0.055 0.279 0.158 0.234 0.132 5.808 3.284 
Milk, cow 0.000 0.091 0.000 0.059 0.000 0.043 0.000 0.040 
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Bread 1.191 0.761 1.242 0.794 0.882 0.564 0.882 0.564 
Beer 0.562 0.006 0.637 0.007 0.063 0.001 0.063 0.001 
Total 1.4 1.0 1.5 1.1 1.0 0.8 2.9 3.9 
 
 
The major contributor of exposure to genistein and daidzein, for the omnivorous diets is 
bread and for the vegetarian diet is soy milk. 
 
2.2.4 Actual versus theoretical serum levels 
 
Uehar et al., (2000) determined mean serum levels of 406.8 nmol/L (110µg/L) of 
genistein and 118.4 nmol/l (32 µg/l) of daidzein for 111 healthy Japanese women.  From 
dietary records, the mean daily intake for these women was 86.5 µmol/day (23400 
µg/day) of genistein and 57.4 µmol/day (15500 µg/day) of daidzein.  Assuming serum 
volume of 2.5l for a woman (Lentner, 1984) and 100% absorption, the theoretical serum 
level would be dietary intake/serum volume, i.e.: 
 Genistein: 23400/2.5 =9350 µg/l 
 Daidzein: 15500/2.5 = 6200 µg/l 
 
The ratio of measured (or actual) :theoretical (A:T) serum levels is: 
 Genistein: 110/9350 ≈0.01 
 Daidzein: 32/6200 ≈ 0.005 
 
In another study, mean serum concentrations of 307.5 nmol/l genistein and 111.7 nmol/l 
daidzein were measured for mean intakes of 111.6 µmol/day genistein and 64.6 µmol/day 
of daidzein (Arai et al., 2000a) with resulting A:T ratios of 0.007 for genistein and 0.004 
for daidzein.  Wiseman et al., (2004) found mean plasma levels of 187µg/l for genistein 
and 94µg/l for 13 subjects each consuming 56 mg/day genistein and 43 mg/day daidzein.  
The sex of these subjects was not specified but for an average plasma volume of 2.9l, 
these values equate to A:T ratios of 0.01 for genistein and 0.006 for daidzein, in good 
agreement with the former estimates. 
 
It is apparent from these studies that only a small proportion of ingested isoflavone is 
actually found in the serum, consistent with efficient 1st pass metabolism in the liver to 
glucuronides or sulphates that are excreted in the urine (COT, 2003).  A:T serum ratios of 
0.01 for genistein and 0.005 for daidzein will be used in this assessment of serum 
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estrogenicity to allow for factors that affect serum levels, such as absorption and 
metabolism. 
2.2.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume, and the difference in molecular weight compared with estradiol, the 
derived serum estrogenicity of genistein and daidzein for the four New Zealand 
population subgroups is shown in Table 2.2.5.  
 
Table 2.2.5 Derived maximum and minimum serum XEQ of genistein and 
daidzein for young males, adult males, females and vegetarian females 
(µg/l). 
 
 XEQ (genistein) XEQ (daidzein) 
Age-sex 
group 
Maximum 
(µg/l) 
Minimum 
(µg/l) 
Maximum 
(µg/l) 
Minimum 
(µg/l) 
Young male 2.5 x 10 -3 1.4 x 10 -3 2.1 x 10 -4 2.7 x 10 -4 
Adult male 2.4 x 10-3 1.4 x 10-3 2.6 x 10 -4 1.7 x 10 -4 
Adult female 1.7 x 10 -3 1.2 x 10 -3 2.1 x 10 -4 1.7 x 10 -4 
Vegetarian F 8.2 x 10 -3 3.5 x 10 -3 11.1 x 10 -4 8.3 x 10 -4 
 
2.2.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration =*, food consumption = *, estrogenic activity = *, A:T = *, Overall 
uncertainty = *.  See Table 2.1.2 for a description of uncertainty assignments.  
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 2.3 Lignans 
 
 
The diphenolic mammalian lignans enterolactone and enterodiol are formed from the 
plant precursors matairesinol and secoisolariciresinol by gut microflora (Adlercreutz and 
Mazur, 1997).   
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Figure  2.2: Chemical structures of the lignans matairesinol and 
secoisolariciresinol and the metabolites enterolactone and enterodiol 
 
2.3.1 Estrogenic activity 
 
Enterolactone and enterodiol have shown weak estrogenic activity. Enterolactone was 
approximately one million times less estrogenic than 17β-estradiol (EQ =1 x 10-6) at 
inducing cell proliferation and enterodiol was approximately 10% as potent as 
enterolactone (EQ = 10-7) in MCF-7 breast cancer cells (Welshons et al., 1987).  These 
values will be used for the assessment of estrogenicity. 
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2.3.2 Occurrence in foods 
 
Levels of the plant lignans, matairesinol (an immediate precursor of enterolactone) and 
secoisolariciresinol (an immediate precursor of enterodiol), have been reported in some 
pulses, grains, fruits, vegetables and other foods (Adlercreutz and Mazur, 1997, Liggins et 
al., 2000). However balance studies in humans following the consumption of rye bread, 
have indicated that most of the mammalian lignan precursors remain unidentified 
(Adlercreutz and Mazur, 1997).  
 
Thus levels of enterolactone and enterodiol produced from food precursors was 
considered a more realistic measure of dietary exposure to lignans than estimates based on 
individual plant lignans. The concentrations of enterolactone and enterodiol produced 
from lignan precursors in a range of 68 plant foodstuffs have been determined by 
simulated colonic fermentation (Table 2.3.1) (Thompson, 1991).  This work showed that 
by far the richest source was linseed meal from flax (Linum usitatissimum), which is 
currently marketed in various forms as dietary supplements.  
Table 2.3.1 Levels of enterolactone and enterodiol produced from simulated 
colonic fermentation of various foods  (Thompson, 1991). 
 
Food Enterolactone (mg/kg) Enterodiol (mg/kg)
Apples 0.34 0.01 
Asparagus 1.36 2.38 
Bananas 0.55 0.14 
Bean, broad 0.452 0.308 
Bean, kidney 1.155 0.812 
Bean, navy 1.232 0.378 
Beans, refried or pinto 0.539 0.165 
Beef stew 0.264 0.203 
Beets 1.09 0.26 
Bok choy 0.44 0.14 
Bread or rolls, dark 0.648 0.23 
Broccoli 1.61 0.65 
Cabbage, red 0.3 0.34 
Cantaloupe 0.21 0.16 
Carrots 2.84 0.62 
Cauliflower, brussels sprouts 0.68 0.77 
Celery 0.17 0.14 
Rolled oats 0.351 0.125 
Coleslaw 0.249 0.282 
Cornbread 0.617 0.096 
Cucumber 0.18 0.11 
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Food Enterolactone (mg/kg) Enterodiol (mg/kg)
Flaxseed (Linum usitatissimum), flaxseed bread 31.91 110.32 
Garlic 0.81 3.26 
Green beans 0.4 0.56 
Green pepper 1.62 0.33 
Mushrooms 0.43 0.13 
Onions 0.11 1.01 
Oranges 0.27 0.12 
Peanuts, peanut butter 1.05 0.56 
Pears 1.12 0.69 
Pizza 0.038 0.035 
Plums 0.47 0.98 
Potatoes, fried 0.33 0.5 
Potato, other 0.33 0.5 
Potato, sweet (Ipomoca batata) 2.4 0.55 
Salad, lettuce 0.425 0.55 
Snowpeas (Pisum sativum var, macrocarpon) 0.6 0.62 
Soup, vegetable 0.264 0.203 
Soybeans 6.9 1.7 
Spaghetti and pasta with tomato sauce 0.039 0.036 
Squash (Cucurbita spp.) 2.71 1.1 
Strawberries 0.41 0.38 
Tomatoes 0.11 0.1 
 
2.3.3 Exposure assessment 
 
Dietary intakes for four adult sub-populations were estimated by combining consumption 
of foods containing lignan precursors from the simulated diets with the levels of 
enterolactone and enterodiol produced from those foods as detailed in Table 2.3.1.  The 
resulting intake estimates are shown in Table 2.3.2.  For details see Appendix 1. 
 
Table 2.3.2 Estimated dietary intakes for the mammalian lignans, enterolactone 
and enterodiol for population subgroups 
 
Age-sex group Enterolactone intake 
(mg/day) 
Enterodiol intake 
(mg/day) 
Young male 
Adult male 
0.26 
0.28 
0.16 
0.15 
Adult female 0.19 0.10 
Vegetarian female 0.45 0.23 
2.3.4 Actual versus theoretical serum levels 
 
Serum concentrations of enterolactone have been reported in a number of studies and are 
summarized in Table 2.3.3. 
Table 2.3.3 Serum concentrations of enterolactone (nmol/l) 
 
Country gender Number 
of 
subjects 
Enterolactone 
concentration nmol/l 
Enterodiol 
concentration 
nmol/l 
Finland men 2380 13.8 1 na 
 women  16.01 na 
USA women 60 20.22 1.52 
USA women 115 13.3 3 na 
 men 78 11.0 3 na 
Finland men 488 15.5 4 na 
Sweden men 342 13.8 4 na 
Norway men 1720 6.64 na 
 
na =  not available, 1 = Kilkkinen et al., 2001 2 = Zeleniuch-Jacquotte et al ., 1998,  
3 = Horner et al., 2002 4 = Stattin et al., 2002. 
 
Although serum concentrations of enterolactone have been correlated with the intake of 
vegetables, fruits, berries, whole grains, caffeine containing drinks and alcohol 
(Kilkennan et al., 2001,2003 Horner et al., 2002) neither of these studies report intake of 
enterolactone precursors with serum concentrations.  However, in one Finnish study, 75 
non-smoking men were given rye bread containing variable amounts of lignan precursors 
(Vanharanta et al., 2002).  Intake and serum levels are shown in Table 2.3.4 with derived 
theoretical serum concentrations assuming 100% absorption and no metabolism.   
Table 2.3.4 Dietary intake, serum concentration (Vanharanta et al., 2002) and 
derived theoretical serum concentration of enterolactone  
 
Intake of lignan 
precursors 
(nmol/day) 
Actual serum (A) 
concentration 
(nmol/l) 
Theoretical (T) 
serum concentration 
(nmol/l)  
A:T 
998 1.9 302 0.006 
12331 25.3 34040 0.0007 
20773 27.1 6295 0.004 
 
For this assessment of serum estrogenicity, a worst case A:T ratio of 0.005 will be 
assumed for both enterolactone and enterodiol. 
2.3.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume, the derived serum estrogenicity of enterolactone and enterodiol for the 
four New Zealand population subgroups is shown in Table 2.3.5.: 
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Table 2.3.5 Derived serum XEQ of enterolactone and enterodiol for adult males, 
females and young males (µg/l). 
 
Age-sex group Enterolactone 
intake 
(mg/day) 
XEQ 
(µg/l) 
Enterodiol 
intake 
(mg/day) 
XEQ 
(µg/l) 
Young male 0.26 4.1 x 10 -7 0.16 2.7 x 10-8 
Adult male 0.28 4.2 x10-7 0.15 2.3 x 10 -8 
Adult female 0.19 3.5 x 10-7 0.10 2.0 x 10-8 
Vegetarian female 0.45 8.2 x 10-7 0.23 4.1 x 10-8 
 
2.3.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration =**, food consumption = *, estrogenic activity = **, A:T = *, Overall 
uncertainty = **.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.4 Coumestans 
 
Coumestans are phytoestrogens structurally similar and biosynthetically related to 
isoflavones.  A large number of coumestans have been isolated from plants, but relatively 
few have been shown to have estrogenic activity.  The only coumestan for which 
estrogenic and dietary information is available is coumestrol (Figure 2.3), present in soya 
beans, alfalfa, clover and other fodder crops. 
 O O
O
OH
HO
 
 
 
 
 
 
Figure 2.3: Chemical structure of the phytoestrogen coumestrol 
 
Coumestrol is structurally similar to 17β-estradiol with two distal hydroxyl groups 
attached to a four fused ring structure. There are also close structural similarities to the 
other phytoestrogens (chalcones, flavones, and flavonols).  
2.4.1 Estrogenic activity 
 
The limited data for the estrogenicity of coumestrol relative to estradiol has been 
summarised in Table 2.4.1.  The estrogenic potency of coumestrol is extremely variable.  
The greatest reported estrogenicity relative to estradiol, using a cell proliferation assay is 
EQ= 0.0003 (300 x 10 –6 ).  This value will be used for the current risk assessment. 
 
Table 2.4.1  Estrogenic potencies of coumestrol relative to estradiol 
 
 In vitro assays In vivo 
assays 
 Receptor 
binding 
Gene expression Cell 
proliferation 
 
17β-estradiol 1 1 1 1 
Coumestrol 0.11 
0.0212 
0.0023 0.00034 
0.000015 
0.000351 
0.0000016 
1=IEH, 2000 2=Hopert et al., 1998 3=Markiewicz et al., 1993  4=Mayr et al., 
1992 
5=Soto et al.,1995 6= Milligan et al., 1998 
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2.4.2 Occurrence in foods 
 
Coumestrol is infrequently found in foods but it has been reported in alfalfa sprouts, kala 
chana seeds, split peas, lima beans, pinto beans, and soyabean sprouts.  Analysis of 
coumestans in New Zealand foods has been limited to six herbal supplements with the 
concentration of coumestrol ranging from <7 to 1285 mg/kg (Taylor and Burlingame, 
1998).  The limited data on occurrence of coumestrol in foods and dietary supplements is 
shown in Table 2.4.2.  
 
 Table 2.4.2: Average concentration of coumestrol in foods. 
 
Food type Coumestrol content 
(mg/kg) 
Alfalfa sprouts1 (Medicago sativa) 46.8 
Alfalfa tablets2 48.9-1285 
Alfalfa and kelp2 847 
kala chana seeds1, (chickpea)(Cicer arietinum) 61.3 
split peas1 (Pisum sativum) 81.1 
lima beans1 (Phaseolus limensis) ND-14.8 
soyabean sprouts1  4.5-12.1 
1=IEH, 2000  2=Taylor and Burlingame, 1998 
 
2.4.3 Exposure assessment 
 
The foods in which coumestrol has been shown to occur are generally foods which are not 
frequently consumed by the wider New Zealand population. Consumption of kala chana 
seeds, lima beans, pinto beans and soyabean sprouts was not reported by any of 4636 
subjects who completed 24 hour dietary recall questionnaire as part of the National 
Nutrition Survey (NNS) (Russell et al., 1999).  Certain assumptions are required in order 
to make an estimate of exposure of New Zealanders to coumestrol. For the foods not 
reported in the NNS an assumption was made that one person in 5000 would consume 50 
g of these foods on a daily basis. This equates to a daily level of consumption for the 
average New Zealander of 0.01 g/day. Both maximum and minimum intakes were 
calculated using the concentration range data in Table 2.4.2 but since consumption of 
these foods is very low, the maximum and minimum intakes were equivalent.  The 
estimated coumestrol exposures were 0.033, 0.019, 0.027 and 0.027 mg/day for young 
males, adult males, adult females and vegetarian females respectively. Consumption 
estimates for alfalfa sprouts and split peas were based on actual NNS data.  Since NNS 
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data does not distinguish vegetarian females, exposure of this group to coumestrol was 
assumed to be the same as for adult females.  For details see Appendix 1. 
 
Those individuals who choose to consume alfalfa tablets are likely to be exposed to 
highly elevated amounts of coumestrol compared with the majority of the population for 
whom any risk is most unlikely. 
 
2.4.4 Actual versus theoretical serum levels 
 
There are no reports of human serum levels of coumestrol. 
 
2.4.5 Serum estrogenicity XEQ 
 
Given the structural similarity between coumestrol and the isoflavones, especially 
daidzein, the worst case (higher) A:T ratio of these two isoflavones i.e. 0.01 will be used 
in the current assessment.  Combining exposure with A:T ratio, relative estrogenic 
potency and adjusting for total serum volume, the derived serum estrogenicity of 
coumestrol is 1.7, 3.3 and 3.5 x 10 -5  for adult males, females and young men 
respectively. 
 
2.4.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration =**, food consumption = **, estrogenic activity = **, A:T = ***, 
Overall uncertainty = ***.  See Table 2.1.2 for a description of uncertainty assignments.  
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2.5 Flavonoids 
 
Flavonoids are a broad group of compounds including chalcones, flavones, flavonols and 
flavanones, which includes many of the most common plant pigments. Isoflavones are a 
subgroup of the flavonoids, but have been covered separately (Chapter 2.2). Of the wide 
range of compounds in this category, the three most commonly reported in food are the 
flavonols quercetin, kaempferol and myricetin.  Important dietary sources of flavonoids 
are vegetables, fruits and beverages. 
 
Varying numbers and positions of hydroxyl groups leads to a wide range of chemically 
related compounds.  Hydroxylation in the 4’ position is a common feature of the 
estrogenic flavonoids.  The structure of example flavanonoids are shown below.   
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Isoliquiritegenin (a chalcone)  Apigenin (a flavone) 
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     Quercetin  (a flavonol) 
 
 
 
Figure 2.4: Chemical structures of isoliquiritigenin, apigenin and quercetin, 
representing examples of flavonoids found in food. 
 
 
 
Chapter 2 53 
  
Chapter 2 54 
  
2.5.1 Estrogenic activity 
 
A summary of literature reports of estrogenicity of seven flavonoids relative to 17β-
estradiol, in receptor binding, gene expression and cell proliferation assays, are shown in 
Table 2.5.1. 
Table 2.5.1 Relative estrogenic potencies of flavonoids  
 
 In vitro assays 
 Receptor binding Gene expression Cell proliferation 
17β-estradiol 1 1 1 
Quercetin 0.000011 
0.00042 
0.032 
<0.00051 
<0.0000014 
Kaempferol 0.000121 
0.032 
0.0051 
0.52 
0.0043 
0.0000015 
0.000014 
0.000075 
Apigenin 0.062 0.52 
0.033 
0.0000025 
0.000054 
0.000155 
Luteolin  0.00093 0.000014 
0.000065 
Isoliquiritigenin  0.0053  
Naringenin  0.00112 0.52 
0.0033 
0.000085 
0.00014 
0.000085 
Phloretin 0.0072 0.52 
0.0023 
0.00000095 
0.0000255 
1=Zava et al., 1997  2=Kuiper et al., 1998.  The values given are the highest reported where 
estrogenicity varied between the α and β estrogen receptor subtypes. 
3=Miksicek, 1995  4=Le Bail et al.,1998  5=Breinholt and Larsen,1998 
 
Estrogenic potency of flavonoids will be based on the cell proliferation assay results 
reported by Le Bail et al., (1998) and Breinholt and Larsen (1998).  Results from the two 
studies are generally in good agreement. Where they differed the higher potency value 
will be adopted, in line with the conservative approach taken in this study. Thus apigenin 
= 150 x 10 –6, luteolin = 60 x 10 –6, kaempferol = 70 x 10 –6, naringenin = 100 x 10 –6  and 
phloretin = 25 x 10 –6.  Where no results are available (isoliquiritigenin), a relative 
estrogenic potency equal to the most estrogenic flavonoid (apeginin, EQ= 0.00015) (150 x 
10 –6 ) will be assigned, therefore this represents the worst case scenario from a risk 
perspective. An EQ value of 0.000001 (1 x 10 –6 ) is assigned for quercetin. 
2.5.2 Occurrence in foods 
 
There are no data available on the level of chalcones, flavones, flavanols or flavanones in 
New Zealand foods.  However, extensive work has been carried out overseas on the 
analysis of flavonoids in foods by Hertog and co-workers (Hertog et al., 1992; 1993).  In 
these studies the three major flavonols, quercetin, kaempferol and myricetin, and two 
major flavones, luteolin and apigenin were selected for analysis. The reason for selection 
of these constituents was not because of estrogenic potential, but rather, because of the 
anticarcinogenic properties of these compounds.  Losses of 50 to 100% were observed for 
processed compared with unprocessed food (ie there were higher concentrations in raw 
than cooked food). Two compilations of literature values for the concentration of five 
flavanols and flavones in human foods have been published (IEH, 2000; Pillow et al., 
1999). A summary of available relevant analytical data is shown (Table 2.5.2). 
Table 2.5.2: Literature values for the concentration of flavonoids in human foods 
(mg/kg).  
 Quercetin Kaempferol Myricetin Apigenin Luteolin 
Apples 36 <2 <1 <2 <1 
Apple juice1 2.8 <1 <0.5 <1 <0.5 
Apricot 25 <2 <1 <1 <1 
Broad beans 20 <2 26 <2 <1 
Broccoli 30 72 <1 <1 <1 
Celery <1 <2 <1 108 22 
Endive <1 46 <1 <2 <1 
Grape 12-15 <2 4.5 <1 <1 
Green beans 29-39 <12 <1 <1 <1 
Green pepper 18 <1 <1 <1 <1 
Kale 110 211 <1 <1 <1 
Leek <1 30 <1 <1 <1 
Lettuce 14 <2 <1 <1 <1 
Onion 347 <2 <1 <2 <1 
Orange juice 3.4-5.7 <1 <1 <1 <1 
Pear 6.4 <2 <1 <1 <1 
Plum 9 <2 <1 <1 <1 
Red cabbage 4.6 <2 <1 <1 <1 
Red currant 13 <2 <1 <1 <1 
Red pepper <1 <1 <1 <1 11 
Red wine 11 <1 9 <1 <0.5 
Strawberry 8.6 12 <1 <1 <1 
Sweet cherry 15 <2 <1 <1 <1 
Tea1 20 14 2.5 <1 <0.5 
Tomato 8.0 <2 <1 <1 <1 
Tomato juice1 13 <1 <0.5 <1 <1 
1=Reported in mg/l ≈mg/kg 
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Isoliquiritigenin occurs in liquorice and soybeans but concentrations were not available. 
This flavonoid occurs mainly in the plant root and, consequently, is unlikely to enter the 
diet in any food except liquorice. Weinberg et al., (1993) reported isoliquiritigenin at 
levels of 9600 mg/kg in liquorice-root extract powder. 
 
Naringenin is the aglycone of naringin and is a constituent of grapefruit, tangerines and 
bitter oranges (Widmer, 2000). The concentration of total naringin in grapefruit is 
generally in the range 290-480 mg/kg (Gray and Olson, 1981; Hsu et al., 1998; Widmer, 
2000), while grapefruit juice has been reported to have slightly lower levels (115-384 
mg/kg; Ho et al., 2000).   
 
Phloretin occurs solely in apples and is used as a marker for contamination of fruit juices 
and jams by apple products (Fernández de Simón et al., 1992; Andrade et al., 1998). 
Phloretin is principally found in apples in the form of the xyloglucoside and the glucoside 
(phloridzin) (Burda et al., 1990; Spanos et al., 1990; Andrade et al., 1998) and occur at 
levels 6-8 times higher in the skin than the flesh of the apple (Burda et al., 1990). Levels 
of total phloretin in apples are typically 20-40 mg/kg (Burda et al., 1990; Andrade et al., 
1998) and in apple juice typically 10-75 mg/kg (Burda et al., 1990; Spanos et al., 1990; 
Spanos and Wrolstad, 1992; Andrade et al., 1998). 
 
 
2.5.3 Exposure assessment 
 
Both maximum and minimum flavonoid exposures were calculated from the 
concentration data presented in Table 2.5.2 and the range data for phloretin concentrations 
in apples and apple juice.  For the purpose of calculating a dietary exposure to 
isoliquiritigenin it is assumed that the level in confectionery liquorice is the same as that 
found in liquorice-root extract powder. Estimates of dietary exposure to seven estrogenic 
flavonoids, largely based on consumption figures from the model diets of the NZTDS, are 
given in Table 2.5.2. Consumption of liquorice was based on data from the 1997 National 
Nutrition Survey (Russell et al., 1999) and was assumed to be the same for all population 
subgroups.  For details see Appendix 1. 
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Table 2.5.3: Estimated dietary exposure to six flavonoids for four population 
subgroups (mg/day) 
 
 Young male Adult male Adult female Vegetarian 
female 
Quercetin 6.7-6.9 8.6-8.8 9.6-9.8 9.4-9.5 
Kaempferol 1.8 3.5 5.0 3.0 
Luteolin 0.10 0.10 0.14 0.10 
Apigenin 0.31 0.31 0.54 0.31 
Naringenin 2.9 2.9 1.8 1.8 
Phloretin 1.6-6.8 1.1-3.7 0.9-3.2 1.0-4.7 
Isoliquiritigenin 2.3 2.3 2.3 2.3 
Total 15.7-21.1 18.8-21.4 20.3-22.78 17.9-21.7 
 
2.5.4 Actual versus theoretical serum levels 
 
In a Dutch study, 8 male and 7 female subjects were given strong black tea, providing 49 
mg quercetin and 27 mg kaempferol, or fried onions, providing 13 mg quercetin (de Vries 
et al, 1998).  The mean serum concentration of quercetin, was 29µg/l from the 
consumption of tea, and 22µg/l from the onions (compared with a baseline level of 7 
µg/l).  The mean serum level of kaempferol was 15 µg/l.  Intake and serum levels are 
shown in Table 2.5.3 with theoretical serum concentrations assuming 100% absorption, 
no metabolism and a serum volume of 2.7l (the average of 3.3 and 2.5l for males and 
females respectively).   
 
Thirty seven female subjects fed a high vegetable diet contributing 29 mg/day of 
naringenin were found to have a mean serum concentration of 29.4 µg/l above a baseline 
level (Erlund et al., 2002).  The theoretical serum level from 29 mg/day is 11600 (29 x 
1000/2.5) µg/l, therefore A:T = 0.003.  Phloretin was not detected (<9.9 µg/l) in serum 
samples from six subjects (4 male and 2 female) who had consumed 4.8 mg of phloretin 
precursors from the consumption of apple cider (DuPont et al., 2002).  Assuming a serum 
level at the limit of detection, and a mean serum volume of 3.0l, for 4 males and 2 
females, a maximum A:T ratio of 0.006 is derived.  No data on serum levels of apigenin, 
isoliquiritigenin or luteolin is available. 
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Table 2.5.4 Dietary intake versus serum concentration of flavonoids  
 
Flavanoid Intake of 
flavanoid 
(mg/day) 
Actual serum 
(A) 
concentration 
(µg/l) 
Theoretical (T) 
serum 
concentration 
(µg/l)  
A:T 
quercetin 491 22 18148 0.001 
 131 15 4815 0.003 
kaempferol 271 15 10000 0.0015 
naringenin 292 29.4 11600 0.0025 
phloretin 4.83 <9.9 1584 0.006 
1=de Vries et al., 1998 2=Erlund et al., 2002. 3= DuPont et al., 2002. 
 
The A:T ratios of all the flavonoids considered, including genistein (0.01) and daidzein 
(0.005), are within one order of magnitude.  For the assessment of serum estrogenicity the 
assumed A:T ratios have been highlighted in bold font in Table 2.5.4.  Where A:T ratios 
cannot be derived because there is insufficient information (apigenin, luteolin and 
isoliquiritigenin), an A:T ratio of 0.01 is assumed , as this reflects the worst case scenario 
for serum estrogenicity. 
 
2.5.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume and molecular weight relative to estradiol, the derived serum estrogenicity 
of the various flavonoids for the three New Zealand populations are shown in Table 2.5.5. 
 
Table 2.5.5 Derived serum XEQ of flavonoids for a young male, adult males, 
females and a vegetarian female (µg/l). 
Flavanoid Young male Adult male Adult female Vegetarian 
female 
Quercetin 6.2-6.4 x 10 -6 7.0-7.2 x 10 -6 1.0-1.1 x 10 -5 1.0 x 10 -5 
Kaempferol 6.2 x 10 -5 1.1 x 10 -4 2.0 x 10 -4 1.2 x 10 -4 
Luteolin 2.0 x 10 -5 1.7 x 10 -4 3.2 x 10 -5 2.2 x 10 -5 
Apigenin 1.6 x 10-4 1.4 x 10-4 3.3 x 10-4 1.9 x 10-4 
Naringenin 3.0 x 10 -4 2.6 x 10 -4 2.2 x 10 -4 2.2 x 10 -4 
Phloretin 0.8-3.5 x 10 -4 0.5-1.7 x 10 -4 0.5-1.9 x 10 -4 0.6-2.8 x 10 -4 
Isoliquiritigenin 1.3 x 10 -3 1.1 x 10 -3 1.5 x 10 -3 1.5 x 10 -3 
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 2.5.6 Uncertainty 
 
The qualitative uncertainty assignments associated with each of the flavonoids of this 
assessment are shown in Table 2.5.6.  
Table 2.5.6:  Qualitative uncertainties associated with the exposure estimate for 
flavonoids. 
 
 
Flavanoid 
Food 
concentration 
Food 
consumption 
Estrogenic 
 activity 
A:T ratio Overall 
uncertainty 
Quercetin ** * ** * ** 
Kaempferol ** * * * ** 
Luteolin ** * ** *** *** 
Apigenin ** * * *** *** 
Naringenin ** * ** * ** 
Phloretin ** * * * ** 
Isoliquiritigenin ** * *** *** *** 
 
A definition of uncertainty assignments is given in Table 2.1.2.   
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2.6 Resorcyclic lactones 
 
These compounds are secondary fungal metabolites, produced by several Fusarium 
species that proliferate in poorly stored grains, oilseeds and hay.  Fusarium infection 
tends to develop during prolonged cool, wet, growing and harvest seasons (FAO, 1999).  
The most important resorcyclic lactone, zearalenone, occurs worldwide with the highest 
incidence rates occurring in North America, and central and northern Europe.  But the 
occurrence of zearalenone has also been reported in Egypt, South Africa, Italy South 
America and New Zealand (FAO, 1999).  In mammals, zearalenone is metabolized to the 
stereoisomers, α and β zearalenol (Figure 2.5). Some structural similarities to 17β-
estradiol are apparent, with two distally located oxygen-containing groups.   
 
O
CH3OOH
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zearalenone     (α, β)-zearalenol 
 
Figure 2.5: Chemical structure of zearalenone and its metabolies α and β-
zearalenol 
 
2.6.1 Estrogenic activity  
 
Zearalenone and zearalenol are two of the most potent xenoestrogens.  A summary of 
available estrogenic potency data is shown in Table 2.6.1.  There is fairly good agreement 
around various estimates of the estrogenic potency of zearalenone and the commonly 
derived estimate of 1% of the activity of 17β-estradiol (EQ = 0.01) will be used for the 
current study. Although there is some evidence to suggest that the relative activity of 
zearalenol may be greater, the current risk assessment will deal only with zearalenone as 
this is the form of the lactone for which most information is available and the form in 
which it is mainly ingested. 
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Table 2.6.1: Summary of estrogenic potencies (EQ) determined for zearalenone 
and zearalenol 
 
 In vitro assays In vivo assays 
 Receptor 
binding 
Gene 
expression 
Cell 
proliferation 
 
17β-estradiol 1  1 1 
Zearalenone 0.011 
0.033-0.0342 
 0.013 
0.014 
0.006-0.0135 
Zearalenol   0.013 
0.564 
 
1=Kiang et al., 1978  2= IEH, 2000   3= Soto et al., 1995  
4= Welshons et al., 1990  5= Hobson et al., 1977 
 
A relative estrogenic potency of EQ = 0.01 (10,000 x 10–6 ) will be used in the current risk 
assessment. 
2.6.2 Occurrence in foods 
 
In New Zealand, the climate is generally favourable for the growth of Fusarium species 
and zearalenone (and trichothecene mycotoxins) were found in a preliminary investigation 
of wheat (Agnew et al., 1986) and in a small study of maize (Hussein et al., 1989). In a 
large survey of the occurrence of Fusarium mycotoxins in cereals grown in New Zealand 
in 1986-1989, Lauren et al., (1991) reported the common finding of zearalenone in maize 
samples (75%) but at relatively low levels, none greater than 500 µg/kg.  Wheat, barley 
and oats from 6 regions in New Zealand showed contamination rates of 32%, 18% and 
34% respectively with maximum concentrations of 460, 170 and 90 µg/kg. Samples of 
commercially grown hybrids of maize taken at harvest from several North Island sites 
from 1992 to 1994 were analysed for Fusarium mycotoxins including zearalenone 
(Lauren et al., 1996).  Results are summarised in Table 2.6.2.  Two factors contributing to 
higher contamination levels were the late harvesting of crops and the use of hybrids that 
were more susceptible to accumulation of zearalenone.   
Table 2.6.2:  Distribution of zearalenone contamination of New Zealand maize 
 
Year No. samples % of samples with zearalenone (mg/kg) 
 
  <0.4 0.4 – 1.0 1.0 – 2.0 >2.0 Max. level 
1992 178 67 17 8 7 10.5 
1993 162 81 14 3 2 2.7 
1994 176 93 3 2 2 6.1 
 
Internationally, there have been many reports of contamination of foods (Price and 
Fenwick, 1985 and Pohland and Wood,1987). 
 
A preliminary survey of maize-based foods, mainly cornflakes, was conducted by 
HortResearch (The Horticulture and Food Research Institute of New Zealand Ltd.) for 
samples collected in 1993.  The range in 7 samples (5 positives) was from 0.16 to 0.30 
mg/kg with a mean concentration of 0.22 mg/kg.  An extensive survey in 1995 examined 
124 foods and found a much lower incidence of contamination (7.2%)  (Lauren and 
Veitch, 1996).  Results are presented in Table 2.6.3. 
 
Table 2.6.3 Zearalenone concentrations (mg/kg) of maize-based foods in New 
Zealand (Lauren and Veitch, 1996) 
 
Food category No. samples No. positives Range (mg/kg) 
Breakfast Foods 20 5 0.05 – 0.12 
Extruded snack foods 20 1 0.14 
Flours; grits 17 2 0.12 – 0.30 
Breads 16 2 0.06 – 0.14 
Masa flour products 24 0 < 0.05 
Corn (maize) oils & snack bars 21 0 < 0.05 
Corn syrups & liquid brewing sugar 6 0 < 0.05 
 
2.6.3 Exposure assessment 
 
In New Zealand exposure to zearalenone is likely to be principally through consumption 
of corn-based foods with breakfast cereals, mixed grain breads and extruded corn-based 
snack foods likely to be the major contributors 
 
Table 2.6.4 combines food consumption information from simulated diets formulated for 
the 1997/98 NZTDS with average zearalenone concentrations for mixed grain breads, 
corn-based breakfast cereals and corn-based snack foods from the study of Lauren and 
Veitch (1996). Average zearalenone concentrations were calculated by assuming that 
some level of zearalenone was present in all samples and assuming that the level in 
samples reported as ‘not detected’ was equal to half of the limit of detection. 
 
 
Chapter 2 62 
  
Table 2.6.4: Estimated dietary exposure to zearalenone for four population age-sex 
groups 
 
Age-sex group Food Consumption 
(g/day) 
Zearalenone 
concentration 
(mg/kg) 
Exposure 
(mg/day) 
Adult male Mixed grain bread 25 0.034 0.00085 
 Breakfast cereal 2.9 0.04 0.00012 
 Total   0.00097 
Adult female Mixed grain bread 17 0.034 0.00058 
 Breakfast cereal 4.3 0.04 0.00017 
 Total   0.00075 
Young male Mixed grain bread 29 0.034 0.00099 
 Breakfast cereal 4.4 0.04 0.00018 
 Total   0.00117 
Vegetarian Mixed grain bread 62 0.034 0.00211 
female Breakfast cereal 4.3 0.04 0.00017 
 Total   0.00228 
  
2.6.4 Actual versus theoretical serum levels 
 
There are very few reports of human serum levels of zearalenone.  In a study undertaken 
in South Africa, the mean serum level of zearalenone for 132 female subjects was 0.36 
µg/ml (360 µg/l) (Pillay et al., 2002).  This level included glucuronides and is therefore an 
overestimate of free (estrogenic zearalenone) but does not include the estrogenic 
derivatives α- and β-zearalenol that were also detected.  The study made no assessment of 
dietary intake of zearalenone.  An intake of 0.00075 mg/day (as estimated for a New 
Zealand female) would equate to a theoretical serum level of 0.3µg/l.  This is 1000 times 
lower than what was measured in the South African study.  The intake in South Africa 
might be in the order of 10-100 times higher because of a higher concentration of 
zearalenone in South African corn (Pillay et al., 2002, Price and Fenwick, 1985, Pohland 
and Wood,1987) and a greater consumption of corn in South Africa compared with New 
Zealand where it is less of a staple food.  However, this does not completely account for 
the higher serum levels measured than might be expected.  It may be that zearalenone 
accumulates in the body.  In the absence of better data, an A:T ratio of 1 is assumed for 
the purposes of this assessment of estrogenicity. 
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2.6.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume, the derived serum estrogenicity of zearalenone for the four New Zealand 
population subgroups is shown in Table 2.6.5. 
 
Table 2.6.5: Derived serum XEQ of zearalenone for young males, adult males, 
females and vegetarian females (µg/l). 
 
Age-sex group Zearalenone intake 
(mg/day) 
XEQ 
(µg/l) 
Young male 0.00117 3.5 x 10 -3 
Adult male 0.00097 2.5 x 10 -3 
Adult female 0.00075 2.6 x 10 -3 
Vegetarian female 0.00228 7.8 x 10 -3 
 
2.6.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = **, A:T = ***, 
Overall uncertainty = ***.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.7 DDT and metabolites 
 
The insecticide, p,p’-DDT, was used in New Zealand, primarily for the control of grass 
grub, from the late 1940s.  Use of DDT on farmland in New Zealand has been prohibited 
since the 1970s when it became apparent that it was accumulating in the environment and 
the foodchain.  Commercial DDT comprised a mixture of isomers, the main component 
being p,p’-DDT, and up to 30% o,p’ DDT.  In the environment and in vivo, DDT breaks 
down, or is metabolised to p,p’ DDE and p,p’ DDD (also known as TDE).  The structure 
of p,p’-DDT, o,p’ DDT and metabolites, p,p’-DDE and p,p’-TDE are shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure 2.6: Chemical structures of p,p’-DDT, o,p’ DDT and metabolites, p,p’-DDE 
and p,p’-TDE 
 
2.7.1 Estrogenic activity 
 
There is consistent evidence of the estrogenicity of o,p’ DDT and some evidence for 
estrogenicity of o,p’ TDE, o,p’ DDE and p,p’ DDT.  There is more limited evidence for 
the estrogenicity of p,p’ TDE.  There is no evidence of estrogenic effects from the major 
metabolite found in foods (p,p’ DDE).  A summary of estrogenic potency of DDT and its 
metabolites, relative to 17β-estradiol, is shown in Table 2.7.1. 
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 Table 2.7.1: Relative estrogenic potencies of DDT and metabolites  
 
 In vitro assays In vivo assays 
 Receptor 
binding 
Gene expression Cell 
proliferation 
 
17β-estradiol 1 1 1 1 
p,p’ DDT 0.0011 0.000033 0.0000012  
o,p’DDT 0.0011 
0.0000012 
0.0014-0.0031 
0.000113 
0.0000012 0.0001-0.0014 
o,p’ DDE 0.0011 0.000043   
p,p’ TDE 0.000015    
o,p’ TDE 0.0011    
1=Chen et al., 1997   2=Soto et al., 1995 
3=Coldham et al., 1997   4=IEH, 1995  5=Klotz et al., 1996 
 
A relative potency of EQ=0.000001 (1 x 10–6 ) will be used to assess estrogenicity from 
DDT and its metabolites, but excluding the non estrogenic p,p DDE. 
2.7.2 Occurrence in foods 
 
The parent compound, p,p’-DDT, and its metabolites, p,p’-DDE and p,p’-TDE have been 
found in decreasing concentrations in the five NZTDSs from 1974/75 to 1997/98 (Cressey 
et al., 2000). p,p’-DDT was found at a mean concentration of 0.003 mg/kg in a composite 
egg sample and p,p’-DDE was found in 22 foods of the 1997/98 NZTDS, primarily in 
foods of animal origin, as shown in Table 2.7.3. The isomer o,p’- DDT and the 
metabolites o,p’- DDE, p,p’-TDE and o,p’-TDE were not detected in any food samples in 
the 1997/98 NZTDS (Vannoort et al., 1997, 1998a,b,c). 
2.7.3 Exposure assessment 
 
The following assumptions were made to estimate dietary exposure to DDT and its 
metabolites (excluding the non estrogenic, but more prevalent p,p’-DDE).  For those food 
items which were found to contain p,p’-DDE in the 1997/98 NZTDS (listed in Table 
2.7.3), it is assumed that these foods also contained some level of o,p’-DDT, p,p’-DDT, 
o,p’-TDE, p,p’-TDE and/or o,p’-DDE at levels below the limit of detection (0.003 mg/kg 
for each analyte; Cressey et al., 2000). Since the relative estrogenic potency of p,p’-TDE 
appears to be about 10 times less than the other analytes the risk from this analyte would 
be less (by a factor of 10 times) and therefore it is not included in the exposure estimate 
for combined DDT analytes.  Assuming the remaining DDT analytes are present at the 
limit of detection (0.003 mg/kg), an assumed combined concentration of 0.012 mg/kg for 
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these four DDT analytes will be used to derive exposure estimates. This is a conservative 
approach and will lead to a considerable overestimation of exposure to estrogenic DDT 
metabolites. Estimated dietary exposures to estrogenic DDT for adult males, adult 
females, young males and vegetarian females are 0.0055, 0.0036, 0.0073 and 0.0019 
mg/day respectively (Table 2.7.3).  This estimate includes the low level (0.003 mg/kg) of 
p,p’-DDT found in eggs (Cressey et al., 2000). 
 
Table 2.7.3: Estimated daily exposure to estrogenic DDT analytes (o,p’-DDT, p,p’- 
DDT, o,p’-TDE and o,p’-DDE) for three sub populations (µg/day). 
ND = not detected 
Food  Adult male Adult female Young male Vegetarian 
female 
 Eaten 
g/day 
Intake 
µg/day 
Eaten 
g/day 
Intake 
µg/day 
Eaten 
g/day 
Intake 
µg/day 
Eaten 
g/day 
Intake 
µg/day 
Bacon 5.0 0.06 3.6 0.04 4.3 0.05 0.0 0.00 
Beef, mince 12.9 0.15 7.9 0.09 13.6 0.16 0.0 0.00 
Beef, rump 12.9 0.15 7.9 0.09 12.9 0.15 0.0 0.00 
Biscuits, chocolate 17.9 0.21 12.5 0.15 20.0 0.24 12.0 0.14 
Butter 15.9 0.19 10.3 0.12 18.9 0.23 32.9 0.39 
Cheese 20.0 0.24 18.9 0.23 29.9 0.36 0.0 0.00 
Chicken 12.9 0.15 10.0 0.12 12.1 0.15 0.0 0.00 
Chicken nuggets 7.1 0.09 4.3 0.05 7.9 0.09 7.7 0.09 
Egg 21.8 0.26 13.9 0.17 16.5 0.20 22.7 0.27 
Fish in batter 12.9 0.15 4.3 0.05 10.4 0.12 0.0 0.00 
Fish, terakihi 8.6 0.10 4.3 0.05 5.0 0.06 0.0 0.00 
Hamburger, plain 16.1 0.19 16.1 0.19 19.3 0.23 0.0 0.00 
Lamb/mutton, leg 12.9 0.15 9.3 0.11 13.6 0.16 0.0 0.00 
Lamb/mutton, 
shoulder 
 
25.7 
 
0.31 
 
14.3 
 
0.17 
 
26.4 
 
0.32 0.0 0.00 
Lamb’s liver 2.1  1.8 0.02 2.5 0.03 0.0 0.00 
Luncheon sausage 10.0 0.12 7.5 0.09 10.7 0.13 0.0 0.00 
Milk, whole 186.4 2.24 116.4 1.40 327.9 2.24 77.9 0.93 
Pie, meat 11.4 0.14 8.6 0.10 11.4 0.14 0.0 0.00 
Pizza 16.1 0.19 14.3 0.17 17.9 0.21 0.0 0.00 
Pork pieces 11.4 0.14 8.6 0.10 14.3 0.17 0.0 0.00 
Raisins/Sultanas 1.1 0.01 1.4 0.02 1.8 0.02 3.6 0.04 
Sausages, beef 12.9 0.15 6.1 0.07 12.9 0.15 0.0 0.00 
Total µg/day  
mg/day 
 5.45 
0.0055 
 3.62 
0.0036 
 7.32 
0.0073  
1.88 
0.0019 
2.7.4 Actual versus theoretical serum levels 
 
The level of DDT and its metabolites have been measured in the serum of non 
occupationally exposed New Zealanders (Buckland et al., 2001).  Serum from 1834 
subjects was pooled into 60 samples. Serum concentrations of p,p’ DDT and o,p’ DDT, 
and the serum lipid levels from which these values were derived, are shown in Table 
2.7.4.  The major metabolite p,p’ DDE was detected, but is not included because it is not 
estrogenic.  
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 Table 2.7.3: Maximum serum concentrations of estrogenic DDT analytes in non- 
occupationally exposed New Zealanders (µg/l) (from Buckland et al., 
2001). 
 
 15-24 
years 
25-34 
years 
35-49 
years 
50-64 
years 
65+ years 
Female      
o,p’ DDT   0.14 0.14 0.16 0.18 
p,p’ DDT  0.20 0.18 0.35 0.43 
Serum lipid 
(%w/v) 
 0.68 0.68 0.79 0.88 
Male      
o,p’ DDT  0.15 0.08 0.17 0.09 0.08 
p,p’ DDT 0.11 0.19 0.28 0.21 0.17 
Serum lipid 
(%w/v) 
0.77 0.79 0.86 0.87 0.83 
 
Combining the maximum serum values for the two DDT analytes, representing upper 
exposure, and intakes from Table 2.7.3, the following A:T ratios are derived: 
 
 
Table 2.7.4: Dietary intake versus serum concentration and derived serum 
concentration of estrogenic DDT analytes.  
 
Sub population Intake of DDT 
analytes 
(mg/day) 
Actual serum 
(A) 
concentration 
(µg/l) 
Theoretical (T) 
serum 
concentration 
(µg/l)  
A:T 
Adult male 0.0055 0.45 1.7 0.26 
Adult female 0.0036 0.61 1.4 0.44 
Young male 0.0073 0.26 2.5 0.10 
2.7.5 Serum estrogenicity XEQ 
 
Combining exposure with a conservative A:T ratio of 0.44, relative estrogenic potency (1 
x 10-6) and adjusting for total serum volume and molecular weight relative to estradiol, 
the derived serum estrogenicity of DDT analytes for the three New Zealand populations is 
5.6, 4.9, 8.5 and 2.6 x 10-7 µg/l for adult males, females, young males and vegetarian 
females respectively. 
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 2.7.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = **, A:T = **, Overall 
uncertainty = **.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.8 Aldrin and dieldrin 
 
Aldrin and dieldrin (Figure 2.7) were formerly used as insecticides and are included in the 
group of chemicals known as persistent organic pollutants.  Aldrin was voluntarily 
withdrawn from sale in New Zealand in 1985 on the basis of its toxicity and persistence in 
the environment.  Dieldrin was deregistered in 1990 for similar reasons (C Alsford, 
personal communication, 1996). Aldrin is readily converted to dieldrin by plants and 
animals. Therefore, mainly dieldrin residues are detected in food.  The structures of aldrin 
and dieldrin do not immediately suggest a basis for their estrogenic potential. It appears 
that the electronegative chlorine atoms must perform a similar role to the hydroxyl groups 
in 17β-estradiol. 
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Figure 2.7: Chemical structures of  insecticides dieldrin and aldrin 
2.8.1 Estrogenic activity 
 
The estrogenicity of aldrin and dieldrin appears to be questionable with some studies 
reporting no estrogenic activity (Tully et al., 2000), while others report only very low 
estrogenic potency for these compounds.  Based on cell proliferation assay results the EQ 
of dieldrin is 0.000001 (1 x 10 –6) (Soto et al., 1995) and this value will be used in the 
current risk assessment, again taking a worst case scenario for risk assessment purposes. 
2.8.2 Occurrence in foods 
 
Dieldrin has been detected in one of two cooked composite pumpkin samples of the 
1990/1991 NZTDS at a trace concentration (0.0025 mg/kg; Vannoort et al., 1995).  
Dieldrin has also been detected in two cucumber samples collected from New Zealand 
auction, gate sale or supermarket sites in 1990-91 (MAF/DoH, 1992).  However, dieldrin 
was not detected in any food analysed in the 1987/88 and 1997/98 NZTDSs.  In addition, 
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aldrin was not detected in any food analysed in the 1990/91 and 1997/98 NZTDSs 
(Vannoort et al., 1995, Cressey et al., 2000). 
2.8.3 Exposure assessment 
 
Given the very sporadic detection of dieldrin in New Zealand foods in the past, and the 
absence of any detectable amounts of dieldrin or aldrin in the 1997/98 NZTDS, the 
estimated daily exposures for New Zealand population groups are likely to be negligible. 
2.8.4 Serum level and derived estrogenicity 
 
Dieldrin was detected in 95 % of seurum samples from non-occupationally exposed New 
Zealanders, reflecting exposure at some time (Buckland et al., 2001).  Serum 
concentration ranges for three population groups of interest are shown in Table 2.8.1.  
This serum level, combined with relative estrogenic potency, equates to maximum 
estrogenicities of 2.3, 2.5 and 1.0 x 10 –7 for adult males, females and young men as 
shown.  In the absence of serum data for vegetarian females, their exposure is assumed to 
be the same as for females.  With negligible current dietary intake, this estrogenicity is 
predicted to be a result of past exposure and would be expected to decrease over time.  
 
Table 2.8.1: Range of dieldrin serum concentrations in non occupationally exposed 
New Zealanders (µg/l) (from Buckland et al., 2001) and derived 
estrogenicity.  
 
 Adult male Adult female Young male 
dieldrin 0.07-0.23 0.05-0.25 0.07-0.10 
Max XEQ 2.3 x 10 -7 2.5 x 10 -7 1.0 x 10 -7 
 
2.8.5 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = **, A:T = **, Overall 
uncertainty = **.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.9 Endosulphan 
 
Endosulfan is a broad spectrum organochlorine insecticide currently registered for use in 
New Zealand (MAF, 2000).  It is used to control chewing and sucking insect pests on 
berryfruit (blackberries, boysenberries, raspberries, blackcurrants, gooseberries and 
strawberries), turnips, swedes, choumoellier, rape, fodder beet, mangolds, brassicas, 
maize, sweetcorn, onions potatoes and tomatoes (Novachem, 1996).  The structure of 
endosulfan (Figure 2.8) does not immediately suggest a basis for its observed estrogenic 
potential as there is little structural similarity to 17β-estradiol. It is likely that the 
electronegative chlorine atoms in endosulfan perform the role of the hydroxyl groups in 
17β-estradiol. 
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Figure 2.8: Chemical structure of the insecticide, endosulphan 
 
2.9.1 Estrogenic activity 
 
Technical grade endosulfan showed an estrogenic potency of 0.0001% of the potency of 
estradiol in the cell proliferation E-SCREEN assay using MCF-7 human breast cancer 
cells (EQ = 0.000001).  In addition, endosulfan competed with estradiol for binding to the 
estrogen receptor and increased the levels of progesterone receptor and pS2 levels in 
MCF-7 cells (Soto et al., 1995).   A potency of 0.0001-0.00001% relative to estradiol was 
confirmed for endosulfan by Jorgensen et al., (2000) by measuring the induction of the 
‘marker gene’ pS2 in human breast cancer MCF-7 cells (EQ = 0.0000001-0.000001). 
An EQ=0.000001 (1 x 10-6 ) will be used for the current assessment of serum 
estrogenicity. 
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2.9.2 Occurrence in foods 
 
Endosulfan was detected in lettuce, tomato, oil, pears, currants and raisins in the 1990/91 
NZTDS.  Daily intakes of 0.0541, 0.0304 and 0.0295 µg/kg bw/day were estimated for 
young males, adult males and children (4-6 years) respectively (Vannoort et al., 1995). 
 
Endosulfan was found in one of eight samples of tomatoes analysed in the more recent 
1997/98 NZTDS at a concentration of 0.0038 mg/kg and in one of two samples of 
cucumbers at a concentration of 0.01 mg/kg (Cressey et al., 2000).  
 
Exposure estimates from both the 1990/91 and 1997/98 NZTDS results, and consumption 
of the appropriate foods, (Table 2.9.1) are indicative of a decline in exposure to 
endosulphan from 1990 to 1997. 
 
2.9.3 Exposure assessment 
 
Table 2.9.1  Estimated daily exposure to endosulfan by age–sex group (mg/day) 
 
Year  Young male Adult male Adult female Vegetarian 
female 
1990/911 0.0038 0.0024 0.0024 NR 
1997/982 0.00011 0.00011 0.00013 0.00019 
1 Vannoort et al., 1995 2 Cressey et al., 2000,   NR = no result 
 
2.9.4 Actual versus theoretical serum levels 
 
In a small Spanish study including 9 agricultural workers and two non occupationally 
exposed subjects, (Arrebola et al., 2001) the concentration of total endosulphan isomers in 
the non-occupationally exposed male was 7.2 µg/l and for the female was 6.6µg/l.  
Assuming New Zealand 1997/98 dietary intakes, the A:T ratio is approximately 170, 
indicative of bioaccumulation.  
 
2.9.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume and molecular weight relative to estradiol, the derived serum estrogenicity 
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of endosulphan for the four New Zealand populations is 4.3, 3.8, 5.9 and 8.6 x 10-6 µg/l 
for young males, adult males, females and vegetarian females respectively. 
2.9.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = **, A:T = ***, 
Overall uncertainty = ***.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.10 Synthetic pyrethroids 
 
Pyrethroids are a group of synthetic derivatives of pyrethrin, the active insecticidal 
ingredient of the natural chrysanthemum (Chrysanthemum cinerariaefolium) extract 
known as pyrethrum. The following pyrethroids are registered for use in New Zealand : 
bifenthrin, cyfluthrin, cypermethrin, deltamethrin, esfenvalerate (the S- stereoisomer of 
fenvalerate which is a racemic mixture), lambda-cyhalothrin, permethrin, pyrethrins and 
taufluvalinate (NZFSA, 2004).  For the year ending 30 June 1998, 5,300 kg of synthetic 
pyrethroids were used for agricultural purposes in New Zealand (Holland and Rahman, 
1999). Usage has increased seven-fold in the period 1986 to 1998 (Holland and Rahman, 
1999).   
 
Pyrethroids appear to act by inhibiting neurotransmission and there is evidence to suggest 
some similarities to DDT in their mode of action, although they are structurally dissimilar 
(Miller and Salgado, 1985).  The variety of synthetic routes starting from natural 
pyrethrins have resulted in a wide range of different structures.  The structure-activity 
relationships in pyrethroids are based mainly on considerations of shape and 
stereochemistry rather than electronic properties (Davies, 1985). 
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Figure 2.9: Chemical structures of three synthetic pyrethroid insecticides 
While structural analogies to 17β-estradiol are not immediately obvious, the first step in 
their metabolism in mammals involves ester cleavage to give carboxylic acid and alcohol 
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fragments (Davies, 1985) (Figure 2.10). The alcohols produced have some structural 
similarities to 17β-estradiol  However, it is noted that these alcohols are only intermediate 
species in the metabolic pathway. 
 
O
CNO
O
Cl
Cl
O
Cl
Cl
OH
O
O
H O
OH
OH
O
OH
Ester hydrolysis
+ +
+
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Ester hydrolysis of cypermethrin showing estrogenic metabolites 
(Anna McCarthy, personal communication, 2005) 
 
2.10.1 Estrogenic activity 
 
Measurements of the estrogenic potency of synthetic pyrethroids vary with the type of 
assay used (Table 2.10.1). 
 
Table 2.10.1 Relative estrogenic potencies of synthetic pyrethroids  
 
 In vitro assays 
 Receptor binding Gene expression Cell proliferation 
17β-estradiol 1 1 1 
Pyrethrum  NE1  
Fenvalerate NE4 NE1, 0.00012,0.0013 0.0013 
Sumithrin  0.000012, 0.0013 0.0013 
Permethrin NE4 NE2,3,4 NE3 
d-trans allethrin NE4 NE2,3,4 0.0013 
NE= not estrogenic,  1= Soto et al., 1995,  2= Garey and Wolff, 1998 (relative to 17α-
ethynlestradiol),  3= Go et al., 1999,  4= Saito et al., 2000. 
Pyrethrum was reported to not be estrogenic when tested by the E-screen method (Soto et 
al., 1995). Fenvalerate and sumithrin demonstrated significant estrogenicity in gene 
expression assays whereas d-trans allethrin and permethrin did not (Garey and Wolff , 
1998, Go et al., 1999 ).  Fenvalerate and sumithrin also induced MCF-7 cell proliferation 
in a dose-dependent manner (Go et al., 1999).  
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 Saito et al., (2000) tested the estrogenic activity of a range of pyrethroids (d-trans 
allethrin, cypermethrin, empenthrin, fenvalerate, imiprthrin, permethrin, d-phenothrin, and 
prallethrin) using three in vitro assays (competitive ligand-binding, luciferase reporter 
gene and yeast two-hybrid assays).  No significant activity was observed for any 
pyrethroid tested using these assays. 
 
Shaw and Chadwick (1998) demonstrated estrogenic activity for permethrin using a 
recombinant yeast assay. Its potency relative to 17β-estradiol was not reported. 
 
For the purposes of the current risk assessment the estrogenic potency values determined 
by Go et al., (1999) will be utilised for synthetic pyrethroids.  An upper limit EQ of 0.001 
(1000 x 10 –6) will be used and applied to all synthetic pyrethroids as a conservative worst 
case approach.  This is a simplification as obviously not all synthetic pyrethroids are 
equally estrogenic and emerging evidence indicates that estrogenicity of metabolites is 
probably more relevant from a human health perspective than estrogenicity of the parent 
compound (McCarthy, personal communication, 2004). 
 
2.10.2 Occurrence in foods 
 
The increased usage of pyrethroid pesticides in New Zealand from 1986 to 1998 is not 
reflected in levels reported in foods.  The 1990/91 NZTDS reported detection of 
permethrin in one of sixteen tomato samples (Vannoort et al., 1995).  No residues of 
synthetic pyrethroids were detected in any foods analysed in the 1997/98 NZTDS 
(Cressey et al., 2000).  This does not mean that estrogenic metabolites were not present.  
Piperonyl butoxide is registered for use in New Zealand as a synergist (in this case, a 
compound that improves the performance of a co-applied pesticide) for pyrethrin or 
pyrethroid pesticides (NZFSA, 2004, Tomlin, 1994).  A number of residues of piperonyl 
butoxide have been found in food, indicative of pyrethroid use.  The ratio of pyrethroid to 
piperonyl butoxide ranges from 1:1 to 1:11 for formulations currently registered in New 
Zealand (NZFSA, 2004).   
 
In 1990/91 the then Department of Health and the Ministry of Agriculture and Fisheries 
(now the Ministry of Agriculture and Forestry) carried out a survey of pesticide residues 
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in retail fruit and vegetables (MAF/DoH, 1992). The pyrethroid residues detected in this 
survey are summarised in Table 2.10.2. 
 
Table 2.10.2: Pyrethroid residues in New Zealand fruit and vegetables, 1990/91  
  (Vanoort et al.,1995). 
 
Crop Number of 
samples tested 
Number 
containing 
residues 
Maximum 
(mg/kg) 
Mean 
(mg/kg) 
Fenvalerate 
Tomatoes 97 1 0.05 0.0005 
Permethrin 
Tomatoes 97 9 0.08 0.006 
Celery 60 2 0.11 0.003 
Beans 26 1 0.19 0.007 
 
2.10.3 Exposure assessment 
 
Table 2.10.3 shows estimates of pyrethroid exposure for four population age-sex groups 
based on either of two assumptions: 
1. That pyrethroids are present in foods at the levels observed in 1990/91 (MAF/DoH, 
1992), 
2. That pyrethroids are present in foods at the level found for piperonyl butoxide in 
1997/98 (Cressey et al., 2000). 
 
Table 2.10.3: Dietary exposure to synthetic pyrethroids for four population age-
sex groups 
Age-sex group Intake (mg/day; assumption 1) Intake (mg/day; assumption 2) 
Young male 0.00017 0.00546 
Adult male 0.00021 0.0048 
Adult female 0.00021 0.00344 
Vegetarian female 0.00020 0.00572 
 
For the purposes of the current estrogenic assessment it will be assumed that all 
pyrethroids are estrogenic and the higher estimate for exposure will be applied. 
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2.10.4 Actual versus theoretical serum levels 
 
In humans, pyrethroids are rapidly metabolized by esterases and eliminated by the 
kidneys (Leahey, 1985).  This may account for the lack of data on human serum 
concentrations.  In a study of 30 pest control workers in Germany, concentrations of 
cyfluthrin, cypermethrin and permethrin were <5µg/l (Leng et al., 1997).  In a second 
study of 199 urban minority American females, trans-permethrin was detected in 14 (7%) 
of subjects at levels of <1 to 27.0 ng/l with a median of 1 ng/l.  Cis-Permethrin was 
detected in 20 (10 %) of subjects at concentrations ranging from <1 to 11.4 ng/l, median = 
<1 ng/l (Whyatt et al., 2003).  Assuming a worst case serum concentration of 27 ng/l for 
all pyrethroids combined, and a New Zealand female dietary intake, a maximum A:T ratio 
of 0.02 is estimated (0.027/[0.0034x 1000/2.5]).  A low A:T ratio is consistent with rapid 
metabolism and elimination and this value will be used for the current assessment.  
 
2.10.5 Serum estrogenicity XEQ 
 
Combining exposure with A:T ratio, relative estrogenic potency and adjusting for total 
serum volume and molecular weight relative to estradiol, the derived serum estrogenicity 
of pyrethroids for the three New Zealand populations is 2.6, 2.0, 1.9 and 3.2 x 10-5 µg/l 
for young males, adult males, females and vegetarian females respectively. 
2.10.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = ***, A:T = ***, 
Overall uncertainty = ***.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.11 PCBs 
 
Polychlorinated biphenyls (PCBs) are chlorinated aromatic compounds that occur as 
widely distributed persistent contaminants in the environment.  They were formerly used 
in industry as electrical transformer fluids, solvent extenders, flame retardants and 
plasticisers, and in printing inks, paints, immersion oils and sealing liquids.  Because of 
their persistence and accumulation in the environment, the use of PCBs in New Zealand 
has been prohibited, apart from under specific exemptions, since 1994.  In common with 
most countries, New Zealand now controls disposal of these materials to ensure they are 
not released into the environment.  PCB’s have been implicated in chronic effects on 
reproduction, immune status, hormonal function and behaviour. 
 
The metabolism of PCBs, mediated by cytochrome P450 in humans results in the 
formation of hydroxylated PCBs and several hydroxylated PCBs have estrogenic activity. 
Studies in laboratory animals have shown that these hydroxylated metabolites are 
persistent and show specific retention in blood and tissues of laboratory animals 
(Haraguchi et al., 1999). 
 
PCBs comprise a class of 209 congeners with varying numbers of chlorine atoms attached 
to the basic ring structure shown below. 
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Figure 2.11: Basic PCB structure above, and the most prevalent PCBs found in  
food, below 
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 2.11.1 Estrogenic activity 
 
Kuiper and co-workers (1998) tested estrogenicity of hydroxylated PCBs by measuring 
receptor binding affinity relative to estradiol and gene expression using enhanced enzyme 
activity as an endpoint.  They reported that in general only minimal (EQ=0.001) if any 
competition was detected except for 2’,4’,6’-trichloro-4-biphenylol and 2’,3’,4’,5’-
tetrachloro-4-biphenylol (EQ = 0.05-0.07).  These same two OH-PCB compounds showed 
relatively strong gene expression activity relative to estradiol (EQ = 0.4-0.7) compared 
with the other hydroxylated PCBs (EQ=0.01). 
 
The estrogenicity of 18 PCB congeners and 10 hydroxylated PCBs has been tested using 
the E-Screen assay of cell proliferation by Soto and co-workers (Soto et al., 1995).  Four 
hydroxylated PCBs (where the hydroxylation occurred in the 4 position) were more 
estrogenic (EQ=0.0001-0.00001) than the remaining hydroxylated or non hydroxylated 
PCBs (EQ=0.000001).   
 
Table 2.11.1:  Relative potencies of PCBs 
 
In vitro assays PCB 
congener Receptor 
binding 
Gene expression Cell proliferation 
17β-estradiol 1 1 1 
2’,4’,6’-trichloro-4-
hydroxybiphenyl 
0.051 0.6-0.71 0.00012 
2’,3’,4’,5’-tetrachloro-
4-hydroxybiphenyl 
0.071 
0.002284 
0.4-0.71 0.000012 
2’2’,5-trichloro-4-
hydroxybiphenyl 
  0.000012 
2’,5’-dichloro-4-
hydroxybiphenyl 
0.000364  0.000012 
Other PCBs3 0.002-0.00011 
0.000074 
0.01-0.031 0.0000012 
1=Kuiper et al., 1998 2=Soto et al., 1995 3=May include hydroxylated and non-
hydroxylated PCBs. 4=Fang et al.,2001 
 
Only the less estrogenic PCBs have been measured in New Zealand foods. For those 
PCBs, a relative estrogenicity of EQ = 0.000001 (1 x 10 –6 ), from cell proliferation 
studies, will be used for the current risk assessment.  For the hydroxylated PCBs an EQ of 
0.0001 is applied. 
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2.11.2 Occurrence in foods 
 
PCBs are widely distributed in foods, particular high-fat foods such as meat, fish, dairy 
products and oils.  A limited dietary survey of PCBs in New Zealand foods was carried 
out by the New Zealand Ministry for the Environment (MfE) (Buckland et al., 1998). 
None of the four non hydroxylated congeners of the more estrogenic congeners identified 
in Table 2.11.1 were analysed in the MfE and therefore an intake estimate of these 
congeners is derived from the PCBs.  The sum of those PCBs which were detected for 
each food category, has been summarised in Table 2.11.2. 
 
Table 2.11.2:  Concentrations of PCBs in New Zealand foods (Buckland et al., 1998). 
 
Food type PCB concentration (ng /kg) 
Beef Meat 58.7 
Sheep meat 67.6 
Pork meat 535.9 
Beef fat 638.6 
Sheep fat 198.4 
Pork fat 194.9 
Liver 104.1 
Processed meats 117.5 
Milk 14.9 
Butter 514.1 
Cheese 237.5 
Ice cream/yoghurt 83.6 
New Zealand fish 552.8 
Imported tinned fish 2371.4 
Shellfish 231.7 
Poultry 27.0 
Eggs 142.0 
Bread 43.2 
Cereals 70.1 
Potatoes 52.1 
Snack foods 161.9 
Vegetable fats/oils 37.9 
 
2.11.3 Exposure assessment 
 
The MfE study for which data are reproduced in Table 2.11.2 carried out dietary exposure 
estimates for an average male adult (10.8 MJ/day) and a high consumer (21.5 MJ/day) 
adolescent male. For consistency with other dietary exposure estimates carried out as part 
of this chapter, the MfE data on levels of PCBs in foods has been combined with 
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simulated typical diets from the 1997/98 NZTDS (Cressey et al., 2000) to give dietary 
exposure estimates for young males (19-24 years), adult males, females and vegetarian 
females.  Estimated exposure levels, expressed in terms of ng PCB/day were 90, 84, 58 
and 44 ng/day for a young male, adult males, females and vegetarian females respectively.  
For details see Appendix 1. 
 
2.11.4 Actual versus theoretical serum levels 
 
The levels of non hydroxylated PCBs have been measured in the serum of non 
occupationally exposed New Zealanders (Buckland et al., 2001).  Serum from 1834 
subjects was pooled into 60 samples. Serum concentrations of total PCB congeners, 
including non detect levels at half the limit of detection, and the serum lipid levels from 
which these values were derived, are shown in Table 2.11.4.   
 
Table 2.11.3: Range of serum concentrations of total PCB congeners in non- 
occupationally exposed New Zealanders (µg/l) (from MfE, 2001). 
 
Sub-population 
group 
15-24 
years 
25-34 
years 
35-49 
years 
50-64 
years 
65+ years 
Female      
Sum PCBs  1.10-1.21 1.20-1.94 1.45-2.19 1.69-2.14 
Serum lipid 
(%w/v)1 
 0.68 0.68 0.79 0.88 
Male      
Sum PCBs 0.98-1.96 1.14-1.53 1.56-1.93 1.82-2.43 2.03-2.32 
Serum lipid 
(%w/v)1 
0.77 0.79 0.86 0.87 0.83 
 
Combining the intake estimates and maximum serum values from Table 2.11.4, the 
following A:T ratios are derived: 
Table 2.11.4: Dietary intake versus serum concentration and derived serum 
concentration of non hydroxylated PCBs.  
 
Sub 
population 
Intake of total 
PCBs  
(mg/day) 
Actual serum 
concentration- 
max (A) 
(µg/l) 
Theoretical (T) 
serum 
concentration 
(µg/l)  
A:T 
Adult male 84 x 10 -6 2.43 0.025 97 
Adult female 58 x 10 -6 2.19 0.023 95 
Young male 90 x 10 -6 1.96 0.031 63 
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For the purpose of estimating estrogenicity of PCBs, a rounded A:T ratio of 100 will be 
assumed. 
 
2.11.5 Serum estrogenicity XEQ 
 
Only the less estrogenic non-hydroxylated PCBs have been determined in food and 
serum. Combining exposure with an A:T ratio of 100, relative estrogenic potency (1 x 10-
6) and adjusting for total serum volume and molecular weight relative to estradiol, the 
derived serum estrogenicity of non hydroxylated PCBs for the four New Zealand 
populations is 3.2, 2.7, 2.4 and 1.8 x 10-6 µg/l for young males, adult males, females and 
vegetarian females respectively.  PCBs are metabolized in the mammalian system to OH-
PCBs (Haraguchi et al., 1999)  The ratio of OH-PCB in human serum has been measured 
in several studies with results ranging from 0.10 (Fängström et al.,2002), 0.11 (Sandau et 
al., 2000) and 0.4 (Sandanger et al., 2004) for subjects living in the Faroe Islands in the 
North Atlantic and Quebec.  Assuming a worst case scenario of 0.4 for the ratio of OH-
PCB to PCB, and assuming a relative estrogenic potency of 0.0001 for all OH-PCB, the 
contribution of estrogenicity from OH-PCB for a young male, for example, is 3.2 x 10-6 x 
0.4 x 0.0001/0.000001 = 1.3 x 10-4 µg/l.  Similarly the estimated contribution of OH-PCB 
to serum estrogenicity for adult males,  females and vegetarian females is 1.1 x 10-4, 1.0 x 
10-4 and 0.7 x 10-4 µg/l respectively.  Clearly, the estrogenicity from PCBs is potentially 
dominated by the hydroxylated PCBs. 
 
 
2.11.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with the exposure 
assessment for PCBs and thence the OH-PCBs: food concentration = **, food 
consumption = *, estrogenic activity = **, A:T = **, Overall uncertainty = **.  See Table 
2.1.2 for a description of uncertainty assignments. 
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2.12 Alkyl phenols 
 
Alkyl phenols are a group of degradation products derived from alkylphenol ethoxylates, 
that are non-ionic surfactants used widely in industrial detergents, paints, herbicides, 
household products, plastics and as process aids in pulp and paper production and textile 
manufacturing. Most of the ethoxylate groups are readily biodegradable, but the phenolic 
backbone is resistant to further breakdown. The two moieties most commonly implicated 
as xenoestrogens are 4-octylphenol and p-nonylphenol. 
 
 
 
 
 
 
 
p-nonylphenol      4-octylphenol 
OH
 
OH
CH3
 
Figure 2.12: Chemical structures of the alkylphenols,  p-nonylphenol and 4-
octylphenol 
2.12.1 Estrogenic activity 
 
Estrogenicity of octyl- and nonylphenol has been well studied by all assay systems.  
Potency values are summarised in Table 2.12.1. The maximum estrogenic potency 
determined for octyl- and nonylphenol by cell proliferation assay is approximately 0.1% 
(EQ = 0.001) of the potency of 17β-estradiol.  
 
Table 2.12.1 Summary of estrogenic potencies determined for octylphenol and 
nonylphenol. 
 
 In vitro assays In vivo assays 
 Receptor binding Gene 
expression 
Cell 
proliferation 
 
17β-estradiol 1 1 1 1 
octylphenol 0.0000036-0.000033  
0.000029-0.000725 
0.0011 
0.0012 
0.0003-0.00147 
0.0011 
0.00038 
0.000016 
nonylphenol 0.000022-0.000053 
0.0014 
0.000039-0.000265 
0.00014 0.000003-
0.000038 
0.00000363 
0.000014 
0.000016 
1= White et al., 1994  2= Arnold et al., 1996  3= Coldham et al., 1997  
4= Shelby et al., 1996  5= Nagle et al., 1997  6= Milligan et al., 1998  
7= Sheeler et al., 2000  8=Soto et al., 1995. 
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The maximum estrogenic potency determined for octylphenol by cell proliferation assays 
is approximately 0.1% (EQ = 0.001) and for nonylphenol is EQ = 0.00003 (30 x 10 –6) of 
the potency of 17β-estradiol.  
 
2.12.2 Occurrence in foods 
 
No data are available (2005) for concentrations of octyl- or nonylphenol in New Zealand 
waters or foods.  Levels of total 4-nonylphenol congeners ranging from <3.8 to 25 µg/kg 
were found in UK duplicate diet samples, with octylphenol detected in just one from the 
total of fifty duplicate diet samples (Fernandes et al., 2003),.  Concentrations of 
alkylphenols in individual foods are not available from the UK study.  However 
nonylphenol concentrations have been determined in 60 different foodstuffs commercially 
available in Germany (Guenther et al., 2002).  Mean concentrations are shown in Table 
2.12.2,  along with consumption of those foods by NZ males, young males and females 
(Cressey et al., 2000, Russell et al.,1999). 
 
Table 2.12.2: Mean concentration of all nonylphenol(NP) congeners in German 
foods (µg/kg fresh weight) (Guenther et al., 2002) and NZ consumption 
(Cressey et al., 2000, Russell et al.,1999). 
 
Food  Mean NP 
conc. 
(µg/kg) 
Consumption (g/day) 
YM  Male  Female Vegetarian 
      female 
Mayonnaise 5 0.44 0.44 0.44 0.44 
Sugar 6.8 13.7 13.7 13.7 13.7 
Tuna 8.1 0.7 0.7 0.7 0 
Butter 14.4 15.9 18.9 10.3 12.0 
Lard 10.2 5.2 5.2 5.2 5.2 
Spinach 1.3 1.3 1.3 1.3 1.3 
Milk chocolate 14.1 2.9 2.9 1.8 2.8 
Egg 1.5 21.8 16.5 13.8 22.7 
Pineapple 2.6 3.6 2.1 3.6 4.3 
Fresh cheese 7.5 20 29.9 18.9 32.9 
Pasta 1 11.4 11.4 8.6 27.9 
Apples 19.4 67.1 114.3 57.1 75 
Chicken meat 3.8 35.4 35.4 27.5 0 
Tea 0.1 194 80.7 255 158 
Potatoes 0.6 93.2 130 51.1 111.1 
Tomatoes 18.5 37.5 37.1 37.5 40 
Whole milk 1.1 256 399 190 200 
Wholemeal bread 1.6 30 52.5 105 126 
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Food  Mean NP 
conc. 
(µg/kg) 
Consumption (g/day) 
YM  Male  Female Vegetarian 
      female 
Beer 0.5 271 186 19.3 28.6 
Coffee (brewed) 0.3 241 128 278 220 
Orange juice 0.1 35 50 25.7 21.4 
Freshwater fish 2020 0.08 0.08 0.08 0 
Water 0.029 541 547 877 886 
 
 
2.12.3 Exposure assessment 
 
Using the concentration data reported by Guenther et al., (2002) and consumption of 
those foods by New Zealanders, from the TDS simulated diets, exposure to nonyl 
alkylphenols is estimated to be 4.7, 3.6, 3.0 and 3.5 µg/day for young males, adult males, 
females and vegetarian females respectively, with the greatest contributors to intake being 
apples and tomatoes.  For details see Appendix 1.  This is suggestive of alkylphenol 
ethoxylates used as emulsifiers in pesticide formulations. 
2.12.4 Actual versus theoretical serum levels 
 
There are no data on the levels of alkylphenols in the serum of New Zealanders.  In a 
publication of methodology for the analysis of 4-nonylphenol and 4-octylphenol in human 
blood samples (Inoue et al., 2000) trace levels of alkyl phenols in the range 0.5-1.0 µg/l 
nonylphenol and <0.24 µg/l octylphenol were reported.  Subjects are presumably 
Japanese, details of sample numbers are not provided. Nonyl phenol was detected in the 
serum of 155 (86%) umbilical cord blood samples collected from Malaysian women, with 
concentrations reported from <0.05 to 15 μg/l (Tan and Mohd 2003).  These levels are 
considered high on the basis of the reported recovery information and therefore may be 
overestimated.  Combining the intake estimates and a maximum serum value of 15 μg/l, 
for each population group, the following A:T ratios are derived: 
 
 
 
 
 
 
 
 
 
Table 2.12.3: Dietary intake versus serum concentration and derived serum 
concentration of nonyl phenols.  
 
Sub population Intake of total 
NP  
(mg/day) 
Actual serum 
concentration- 
max (A) 
(µg/l) 
Theoretical (T) 
serum 
concentration 
(µg/l)  
A:T 
Young male 0.0047 15 1.42 10.7 
Adult male 0.0036 15 1.09 13.9 
Adult female 0.0030 15 1.20 12.6 
Vegetarian female 0.0035 15 1.40 10.8 
 
For the purpose of estimating estrogenicity of PCBs, a rounded A:T ratio of 10 will be 
assumed. 
2.12.5 Serum estrogenicity XEQ 
 
Since the biodegradation metabolite nonylphenol is prevalent in food and serum, whereas 
the octylphenol metabolite is only infrequently reported, estrogenicity from alkylphenols 
is best represented by data for nonylphenol (Table 2.12.2).  Combining exposure with an 
A:T ratio of 10, relative estrogenic potency (30 x 10-6) and adjusting for total serum 
volume and molecular weight relative to estradiol, the derived serum estrogenicity of 
nonylphenol for the four New Zealand populations is 6.2, 4.1, 4.6 and 5.3 x 10-4 µg/l for 
young males, adult males, females and vegetarian females respectively. 
 
2.12.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = **, food consumption = *, estrogenic activity = **, A:T = ***, 
Overall uncertainty = ***.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.13 Bisphenols 
 
Bisphenol is a generic term for a family of diphenylalkanes, which are currently among 
the leading chemicals used in the manufacture of plastics. Considerable attention with 
respect to estrogenicity has focused on Bisphenol A (BPA) (Figure 2.13), a primary raw 
material for the production of polycarbonates, epoxy resins, phenolic resins, polyesters, 
and polyacrylates.  Epoxy-based coating are used in lacquer coatings in cans and other 
vessels used for foodstuffs, amongst other uses (Perez et al., 1998). 
 
 
 
OH
CH3 CH3
OH
 
 
 
 
 
 
Figure 2.13: Chemical structure of bisphenol A 
 
 
Structural similarities to 17β-estradiol are clear, with two distal hydroxyl groups attached 
to a ring structure.  
2.13.1 Estrogenic activity 
 
The estrogenic activity of BPA was first reported by Krishnan et al., (1993), who 
observed that water autoclaved in polycarbonate flasks exhibited estrogenic activity. 
Since that time, estrogenic activity of bisphenol A has been demonstrated in all assay 
types by a number of investigators.  A wide range of estrogenic equivalence ranging from 
EQ = 0.0018 (Fang et al., 2000) to 0.0000001 (Jørgensen et al., 2000) has been reported 
and is summarized in Table 2.13.1. 
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 Table 2.13.1 Summary of estrogenic potencies determined for bisphenol-A (BPA) 
 
 In vitro assays In vivo assays
 Receptor 
binding 
Gene expression Cell 
proliferation 
 
17β-estradiol 1 1 1 1 
Bisphenol A 0.00051 
0.00006-0.00013 
0.00187 
0.000568 
0.0002-0.0012 
0.00003-0.00055 
0.0000001-0.000016 
0.00005-0.0000667 
0.00021 
0.0002-0.0012 
0.000027 
0.00018 
0.00014 
1= Krishnan et al., 1993  2= Steinmetz et al., 1997  3= Nagle et al., 1997 
4= Milligan et al., 1998  5= Sheeler et al., 2000  6= Jørgensen et al., 2000 
7= Fang et al., 2000  8=Perez et al., 1998 
 
For the purposes of the current risk assessment the top end (worst case) cell proliferation 
potency of EQ = 0.001 (1000 x 10 -6) will be used. 
2.13.2 Occurrence in foods 
 
There is limited data on the concentration of BPA in canned foods from the UK (Goodson 
et al, 2002) and Japan (Yoshida et al, 2001, Kang and Kondo, 2003).  A survey of BPA 
concentration in canned foods has been undertaken as part of this thesis and is described 
in Chapter 3.  Eighty different canned foods purchased from retail outlets in Christchurch, 
New Zealand between November 2003 and February 2004 were analysed for BPA 
concentration by gas chromatography/mass spectrometry.  BPA was detected in all foods 
analysed except soft drinks.  Range and mean concentrations are shown in Table 2.13.2. 
Table 2.13.2: Concentration of bisphenol A measured in New Zealand canned foods 
(µg/kg) 
 
Food type Mean concentration BPA 
(µg/kg) 
Concentration range 
Tomatoes 12 <10-21 
Corn 13 <10-20 
Beetroot 20 13-29 
Peas 8 <10-17 
Apricots 5 <10 
Peqches 5 <10 
Pineapple 5 <10 
Fruit salad 5 <10 
Salmon 13 <20-24 
Tuna 43 <20-109 
Chicken soup 10 <20 
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Food type Mean concentration BPA 
(µg/kg) 
Concentration range 
Tomato soup 11 2-16 
Sauces 13 <10-21 
Corned beef 46 <20-98 
Other meat 10 <20 
Spaghetti 5 <10 
Baked beans 5 <10 
Coconut cream 77 <20-192 
Dessert &dairy 10 <20 
Infant foods-vegetable 5 <10 
Infant foods-dessert 5 <10 
Soft drink 0 ND 
Eurpoean olives 14 9-23 
  
2.13.3 Exposure assessment 
 
A slightly different approach was taken to assess exposure to BPA.  Because of the 
aggregation of foods in the simulated diets, it is difficult to distinguish consumption of 
canned versus non- canned foods.  Therefore, consumption data from the 1997 NNS 
(Russell et al., 1999) that includes a much wider range of foods, was used for exposure 
assessments.  Aggregated food descriptors were assigned a BPA concentration based on 
the mean concentration results determined.  These foods and concentrations were 
combined with the 24 hour dietary recall information of the NNS survey data for each 
respondent for whom body weight information was available.  Exposure scenarios for 
4399 individuals were determined.  Mean (and range) daily intakes for adult males, adult 
females and young males were 0.64 (0-25.4), 0.46 (0-17.9) and 0.80 (0-10.3) µg/day 
respectively. However, this approach does not allow for the vegetarian sub-population.  
For the overall assessment of estrogenicity, it is assumed the exposure for this population 
sub-group is the same as for adult females. 
2.13.4 Actual versus theoretical serum levels 
 
There is no data on the levels of BPA in the serum of New Zealanders.  However, there 
have been remarkably consistent concentrations of BPA reported in four Japanese studies 
including normal healthy males and female subjects (Table 2.13.3).  
 
 
 
Table 2.13.3: Serum levels of BPA reported in the literature (µg/l). 
Gender number Concentration BPA 
Mean (range) µg/l 
Reference 
Female 12 0.33 (0-1.6) Sajiki et al.,1999 
Male 9 0.59 (0.38-1.0) Sajiki et al.,1999 
Female (pregnant) 9 0.46 (0.21-0.79) Kuroda et al.,2003 
Not specified (sterility 
patients) 
21 0.46 (0.22-0.87) Kuroda et al.,2003 
Female 14 0.64 Takeuchi et al.,2002 
Male 11 1.49 Takeuchi et al.,2002 
 
None of these four studies cite dietary intake information but quite recently there has been 
an estimate of a daily intake of <0.3–7.9µg/day (median<2.0 µg/day) for Japanese 
pregnant women (Fujimaki et al., 2004).   When this intake estimate is combined with the 
serum data for a similar Japanese sub-population (Kuroda et al.,2003), A:T ratios of 3.8-
0.1 are derived (Table 2.13.4).  An A:T ratio of 1, reflecting a median value, is assumed 
for the assessment of estrogenicity. 
 
Table 2.13.4: Dietary intake versus serum concentration of BPA for Japanese 
pregnant women and derived A:T ratios.  
Pregnant 
female 
Intake of BPA1 
(mg/day) 
Actual serum 
concentration- 
Mean2 (A) 
(µg/l) 
Theoretical (T) 
serum 
concentration3 
(µg/l)  
A:T 
Minimum 0.0003 0.46 0.12 3.8 
Maximum 0.0079 0.46 3.2 0.1 
Median-approx 0.0015 0.46 0.6 0.8 
1= data from Fujimaki et al., 2004,   2= Kuroda et al.,2003,   3=intake/2.5l 
 
2.13.5 Serum estrogenicity XEQ 
 
Combining exposure with an A:T ratio of 1, relative estrogenic potency (1000 x 10-6) and 
adjusting for total serum volume and molecular weight relative to estradiol, the derived 
serum estrogenicity of BPA for the three New Zealand populations is 2.8, 2.3 and 2.2 x 
10-4 µg/l for young males, adult males and females and respectively. 
2.13.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = *, food consumption = *, estrogenic activity = **, A:T = **, Overall 
uncertainty = **.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.14 Butylated hydoxyanisole (BHA) 
 
BHA is an approved antioxidant used in many countries in fats and oils and foods 
containing fats and oils. Use of BHA in New Zealand appears to be diminishing in favour 
of TBHQ (tertiary-butyl hydroquinone). 
 
 OH
OCH3
C(CH3)3
 
 
 
 
 
 
 
 
Figure 2.14: Chemical structure of the antioxidant, BHA 
 
2.14.1 Estrogenic activity 
 
BHA has been measured to be weakly estrogenic in both gene expression and cell 
proliferation assays.  Soto et al., (1995) determined the relative proliferative potency 
(RPP) of BHA using MCF-7 human mammary cancer cell lines (E-Screen) as 0.00006% 
of the potency of estradiol (EQ = 0.0000006). This was the weakest positive response of 
any compound reported by Soto et al., (1995). 
 
Jobling et al., (1995) utilised fish and human estrogen receptors to assess the estrogenicity 
of a range of environmentally persistent chemicals and concluded that BHA was six or 
more orders of magnitude less potent than estradiol (EQ = 0.000001). 
 
The cell proliferation based EQ of 0.0000006 (0.6 x 10-6) will be used for the current 
assessment. 
2.14.2 Occurrence in foods 
 
No systematic information is available on the levels of BHA in New Zealand foods, 
although its usage is reported to be diminishing (Stanton, 1996). 
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BHA is a permitted antioxidant under the New Zealand Food Regulations 1984. BHA 
may be legally present in foods to a level of 100 mg/kg. If a combination of antioxidants 
is used the total level of antioxidants is not allowed to exceed 100 mg/kg. The Draft 
Australia New Zealand Food Standards Code has a more detailed list of allowed levels of 
BHA addition to foods, with the major relevant categories being: 
• Edible oils and oil emulsions  200 mg/kg 
• Instant dried mashed potato  100 mg/kg 
• Chewing gum/bubble gum  200 mg/kg 
• Walnut and pecan nut kernels    70 mg/kg 
• Flavourings    1000 mg/kg 
• Preparations of food additives  200 mg/kg 
 
2.14.3 Exposure assessment 
 
Addis and Hassel (1992) reported mean daily consumption of BHA to be 0.13 mg/kg 
body weight/day. A Dutch study reported a lower level of intake of 0.105 mg/day (0.0015 
mg/kg body weight/day for a 70 kg adult; Botterweck et al., 2000). Intake of BHA in New 
Zealand is likely to be at or lower than the level reported in the Dutch Cohort Study. For 
the purpose of the current risk assessment a daily intake of BHA of 0.105 mg/day will be 
assumed for all population age sex groups. 
 
2.14.4 Actual versus theoretical serum levels 
 
In an Italian study, BHA was detected in 30 out of 45 human plasma samples with a mean 
level of 1.02 µg/l for the 30 positive samples (Bianchi et al., 1997).  In an earlier study, 
nine healthy Dutch men (mean weight 74 kg) given 37mg of BHA (as a solution in corn 
oil) had a mean peak serum concentration of 117µg/l for BHA (Verhagen et al., 1989).  
Two scenarios for the calculation of A:T ratios for BHA from the above data are shown 
below (Table 2.14.1). 
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Table 2.14.1: Dietary intake versus serum concentration and derived A:T ratios for 
BHA.  
 
Sub population Intake of 
BHA  
(mg/day) 
Actual serum 
concentration- 
max (A) 
(µg/l) 
Theoretical (T) 
serum 
concentration 
(µg/l)  
A:T 
Dutch adult male 37 117 11212 0.01 
Mixed adults 0.1051 1.022 39 0.03 
1= Botterweck et al., 2000  2= Bianchi et al., 1997 
 
Continuing a conservative (worst case approach), an A:T ratio of 0.03 is assumed for the 
assessment of estrogenicity from BHA. 
2.14.5 Serum estrogenicity XEQ 
 
Combining exposure with an A:T ratio of 0.03, relative estrogenic potency (0.6 x 10-6) 
and adjusting for total serum volume and molecular weight relative to estradiol, the 
derived serum estrogenicity of BPA for the four New Zealand populations is 0.98, 0.86, 
1.1 and 1.1 x 10-6 µg/l for young males, adult males, females and vegetarian females 
respectively. 
 
2.14.6 Uncertainty 
 
The following qualitative uncertainty assignments are associated with this assessment: 
food concentration = **, food consumption = *, estrogenic activity = **, A:T = *, Overall 
uncertainty = **.  See Table 2.1.2 for a description of uncertainty assignments. 
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2.15 Total serum estrogenicity 
 
A summary of data for each xenoestrogen is shown in Tables 2.15.1 and 2.15.2 along with 
a summation of individual contributions to give an estimate of total estrogenicity from the 
diet for each population subgroup. 
 
Table 2.15.1: Summary information on molecular weight (MW), estrogenic potency 
relative to 17β-estradiol, actual versus theoretical plasma 
concentration (A:T) and qualitative uncertainty of risk assessment for 
a range of xenoestrogens.  
 
Xenoestrogen MW Estrogenic 
potency x 10 6 
A:T ratio Overall 
uncertainty 
Genistein 270.2 300 0.01 * 
Daidzein 254.2 100 0.005 * 
Enterolactone 298.3 1 0.005 ** 
Enterodiol 302.4 0.1 0.005 ** 
Coumestrol 268.2 300 0.01 *** 
Quercetin 302.2 1 0.003 ** 
Kaempferol 286.2 70 0.001 ** 
Luteolin 286.2 60 0.01 *** 
Apigenin 270.2 150 0.01 *** 
Naringenin 272.3 100 0.003 ** 
Phloretin 274.3 25 0.006 ** 
Isoliquiritigenin 256.3 150 0.01 *** 
Zearalenone 318.4 10000 1 *** 
Dieldrin 380.9 1 na ** 
DDT and    metabolites 354.5 1 0.44 ** 
Endosulfan 406.9 1 170 *** 
Synthetic pyrethroids 391.3 1000 0.02 *** 
PCBs 260.0 1 100 ** 
OH-PCBs  100  ** 
Alkyl phenols 215 30 10 *** 
Bisphenol A 228.3 1000 1 ** 
BHA 180.3 0.6 0.03 ** 
*= least uncertain (more robust), *** = most uncertain (least robust).  See Table 2.1.2 for uncertainty 
assignments) 
 
The low A:T ratios of the naturally occurring xenoestrogens (of the order of 1%) are 
indicative of extensive metabolism by gut microflora and/or in the liver, excretion and 
elimination (COT, 2003).  A similarly low A:T ratio is observed for the pyrethroids that 
are rapidly metabolized by esterases and eliminated by the kidneys (Leahey, 1985).  By 
contrast, the synthetic estrogenic compounds show variable A:T ratios, most probably 
reflective of the limited serum data but also perhaps indicative of less extensive 
metabolism and bioaccumulation.  Bioaccumulation is a feature of lipid soluble PCBs 
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(van Leeuwen and Younes, 2000) and explains the high A:T ratio for this group of 
xenoestrogens. 
 
Where the overall uncertainty is high (***), in each case this reflects the data gaps in 
serum levels for that xenoestrogen, resulting in uncertainty around the corresponding A:T 
ratios. 
 
Table 2.15.2: Summary information on intake and estrogenicity for a range of 
xenoestrogens 
 
 Young male 
19-24 yrs 
Adult male 
25+ yrs 
Adult female 
25+ yrs 
Vegetarian female 
19-40 yrs 
Xenoestrogen Intake1 
mg/day 
XEQ 
µg/l 
Intake 
mg/day 
XEQ 
µg/l 
Intake 
mg/day 
XEQ 
µg/l 
Intake 
mg/day 
XEQ 
µg/l 
Genistein 1.4-2.5 1.4-2.5 
E-03 
1.5-2.7 1.4-2.4 
E-03 
1.0-1.4 1.2-1.7 
E-03 
2.9-6.7 3.5-8.2 
E-03 
Daidzein 1.0-1.5 1.8-2.7 
E-04 
1.1-1.6 1.8-2.6 
 E-04 
0.8-0.9 1.7-2.1 
E-04 
3.9-5.2 8.3-11.1 
E-04 
Enterolactone 0.3 4.2 E-07 0.3 3.9 E-07 0.2 3.5 E-07 0.5 8.2 E-07 
Enterodiol 0.2 2.5 E-08 0.1 2.0 E-08 0.1 1.8 E-08 0.2 4.1 E-08 
Coumestrol 0.03 3.5 E-05 0.02 1.7 E-05 0.03 3.3 E-05 0.03 3.3 E-05 
Quercetin 6.7-6.9 0.6 E-05 8.6-8.8 0.7 E-05 9.6-9.8 1.0-1.1 
E-05 
9.4-9.5 1.0 E-05 
Kaempferol 1.8 6.2 E-05 3.5 1.1 E-04 5.0 2.0 E-04 3.0 1.2 E-04 
Luteolin 0.1 2.0 E-05 0.1 1.7 E-05 0.1 3.2 E-05 0.1 2.2 E-05 
Apigenin 0.3 1.6 E-04 0.3 1.4 E-04 0.5 3.3 E-04 0.3 1.9 E-04 
Naringenin 2.9 2.9 E-04 2.9 2.6 E-04 1.8 2.2 E-04 1.8 2.2 E-04 
Phloretin 1.6-6.8 0.8-3.5 
E-04 
1.1-3.7 0.5-1.7 
E-04 
3.1 0.5-1.9 
E-04 
1.0-4.7 0.6-2.8 
E-04 
Isoliquiritigenin  2.3 1.3 E-03 2.3 1.1 E-03 2.3 1.5 E-03 2.3 1.5 E-03 
Zearalenone 0.001 3.5 E-03 0.001 2.5 E-03 0.0007 2.6 E-03 0.002 7.8 E-03 
Dieldrin  1.0 E-07 - 2.3 E-07 - 2.5 E-07 - 2.5 E-07 
DDT and    
metabolites 
0.007 8.5 E-07 0.005 5.6 E-07 0.004 4.9 E-07 0.002 2.6 E-07 
Endosulfan 0.0001 4.3 E-06 0.0001 3.8 E-06 0.0001 5.9 E-06 0.0002 8.7 E-06 
Synthetic 
pyrethroids 
0.005 2.6 E-05 0.005 2.0 E-05 0.003 1.9 E-05 0.006 3.2 E-05 
PCBs 0.00009 3.2 E-06 0.00008 2.7 E-06 0.00006 2.4 E-06 0.00004 1.8 E-06 
OH-PCBs NA 1.3 E-04 NA 1.1 E-04 NA 1.0 E-04 NA 0.7 E-04 
Alkyl phenols 0.005 6.2 E-04 0.003 4.1 E-04 0.003 4.6 E-04 0.003 5.3 E-04 
Bisphenol A 0.0007 2.8 E-04 0.0006 2.3 E-04 0.0005 2.2 E-04 0.0005 2.2 E-04 
BHA 0.1 9.9 E-07 0.1 8.7 E-07 0.1 1.1 E-06 0.1 1.1 E-06 
Total (µg/l) 
  
 (ng/l) 
 8.1-9.5 
E-03  
8-9 
 
 
6.5-7.8 
E-03 
7-8 
 7.1-7.8 
E-03 
7-8 
 
 
15.2-20.3 
E-03 
15-20 
1= a range is shown where intake is based on a range of concentration in the food.  All other intakes are 
based on mean concentration data. 
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The total daily serum level of estrogenicity from food is estimated to be 8-9, 6-8, 7-8 and 
15-20 ng/l for young males, adult males, females and vegetarian females respectively 
(Table 2.15.2).  
 
Comparison of the total serum XEQ activity with normal serum levels of 17β-estradiol for 
each group gives an indication of potential pharmacological impact.  The normal serum 
level of 17β-estradiol in human males and postmenopausal women is 10-50 ng/l 
(Greenspan and Gardner, 2001) and therefore it is possible that an additional contribution 
of 6-8 ng/l for males, 8-9 ng/l for young males, 7-8 or 15-20 ng/l for postmenopausal 
women might have a pharmacological effect for these sub-populations.  The contribution 
of estrogenicity from dietary xenoestrogens for omnivorous females (7-8 ng/l) is a small 
proportion of natural circulating levels for a non-pregnant female (20-350 during the 
menstrual cycle) and therefore it is difficult to see how this level of exposure could be of 
health significance for this population group. (Table 2.15.3) assuming comparable transfer 
of xenoestrogens and 17β-estradiol across the cell membrane of target cells. 
 
Table 2.15.3 Serum estrogenicity from the diet compared with normal circulating 
levels of 17 β-estradiol (ng/l) (Greenspan and Gardner, 2001, Beard 
and Nathanielsz, 1984). 
 
 Adult male Young male 
(>17 yr) 
Adult female Vegetarian 
female (19-40y)
Normal serum 
levels (ng/l) 
10-50 10-50 Premenopausal 20-350 
Postmenopausal 10-30 
Pregnant 100-30000 
Contribution 
from diet (ng/l) 
 
6-8 
 
8-9 
 
7-8 
 
15-20 
% extra from the 
diet 
 
12-80% 
 
16-90% 
 
Pre: 2% 
Post.: 23-80% 
 
4-6% 
 
 
In order to assess which foods are likely to contribute most to xenoestrogen exposure 
from the diet, the serum estrogenicity of each xenoestrogen was assessed as a percentage 
of the total estrogenicity for each population group (Figure 2.15).  The total estrogenicity 
and relative contributions of different xenoestrogens are very similar for adult males, 
females and young males but different for the vegetarian females. 
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Young male 
Adult male 
Adult female 
Vegetarian 
female 
 
 
Figure 2.15: Distribution of estrogenicity from dietary sources for adult males 
(over 25 years), young males(over 25 years), adult women (over 25 
years) and vegetarian women (25-40 years). 
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The xenoestrogens accounting for the greatest contribution to estrogenic exposure in the 
New Zealand diet are the contaminant mycotoxin, zearalenone (representing 33-39%), 
because of its very high estrogenic potency and occasional occurrence in corn based 
foods; the naturally occurring isoflavones (24-46%) and flavonoids (11-32%), and the 
synthetic compounds bisphenol A and alkylphenols (representing 1-3 and 3-7% 
respectively). 
 
For the average New Zealander, the naturally occurring isoflavones, genistein and 
daidzein come largely from foods containing soy ingredients, and for males, from beer 
(Figure 2.16). The differences between absolute amount and relative contributions of 
estrogenicity for a vegetarian female compared with an omnivorous female are 
attributable to vegetarian females consuming 53 g/day of soy milk compared with no 
consumption for the average omnivorous female (Appendix 2).  Exposure to flavonoids is 
dependent on consumption of specific foods; quercetin- tea and onions, phloretin – 
apples, kaempferol – tea and broccoli, apigenin – celery, isoliquiritigenin – licorice, and 
narningenin – grapefruit.  Bisphenol A exposure is based on leaching from the lacquer in 
non acidic canned foods.   Alkyl phenols are used in the manufacture of non-ionic 
surfactants, as additives for plastics and as pesticide excipients.  However, the prevalence 
of use in New Zealand is unknown.   
 
 
 
 
 
 
 
 
 
Figure 2.16: Dietary intake of geneistein for a young male and a vegetarian female 
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The relative contributions to dietary xenoestrogenicity calculated in this study are at 
variance with the findings of Shaw and McCully (2002) where the contribution from 
synthetic xenoestrogens was less than 1% of the contribution from phytoestrogens.  This 
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reflects several important issues.  Primarily, the model used by Shaw and McCully did not 
account for absorption, metabolism and excretion: the A:T modification adopted by the 
author, introduces these variables into the assessment and makes the model more realistic.  
Secondly, the current assessment draws on analytical data published since the Shaw and 
McCully assessment. The serum levels suggested by the current model are substantiated 
by literature values for ‘real’ serum levels of selected xenoestrogens in humans which 
means that the data and conclusions have in vivo validity.   
 
The present assessment is still simplistic and limited by data gaps and uncertainties.  For 
example, there is a wide range in some of the potency results, such as the synthetic 
pyrethroids.  From the qualitative uncertainties applied, it is clearly apparent that gaps in 
serum data is a limitation.  The most significant of these is for zearalenone because of the 
major contribution this mycotoxin contributes to total estrogenicity.  The assumption that 
serum exposure levels of endosulphan in 2 Spanish subjects, is relevant to exposure in 
New Zealand may be debated.  The resulting high A:T ratio (170) means that the 
contribution of endosulphan to total estrogenicity may be overestimated.  Even so, 
endosulphan makes a very small contribution to total estrogenicity from xenoestrogens, 
ranking 15 /21 for contribution of individual compounds.  Similarly, the serum level of 15 
µg/l for nonyl phenol is for Malaysian women who will have a different exposure given 
the likely difference in use of this synthetic compound between Malaysia and New 
Zealand.  Exclusion of an A:T factor (i.e.A:T =1) would reduce the contribution of alkyl 
phenols.  In the absence of better data, a precautionary approach is justifiable (Burger, 
2003). The serum concentrations applied may not reflect exposure at target cells (and 
therefore pharmacological effect).  Indeed, Borgert et al., (2003) argued that the science is 
insufficiently developed to allow a credible assessment of health risks to infants based on 
estrogenic potency or toxic effects mediated by estrogenic mechanisms.  Their conclusion 
stems largely from the difficulty of extrapolating from estrogenic potency to possible 
health effects.  In this current risk assessment the interpretation of risk has been calculated 
more simply on a comparison of cumulated estrogen equivalents for a common effect, 
namely cell proliferation in MCF-7 cells with circulating levels of estradiol.  It is possible 
that the contribution from phytoestrogens is overestimated because the actual serum levels 
include both conjugated and parent flavonoids, but only the parent compound is 
estrogenic.  Any contribution from estrogenic metabolites is limited to PCBs as this 
information is not yet available  (Van de Wiele et al.,2005).   
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Despite the limitations, by taking a TEF type approach, and using the best available data, 
contributions from components of mixtures can be ranked and priorities for moving the 
science forward are identified. 
 
It is suggestive from the model for assessing intake of xenoestrogens in food that XEQ 
levels in serum of New Zealanders are sufficient to have a pharmacological effect on 
males and postmenopausal women, but are unlikely to affect pre-menopausal females. 
The lack of potential impact upon premenopausal females is because of their high and 
incredibly variable 17β-estradiol levels during the menstrual cycle and the relatively 
minor contribution from xenoestrogens in the diet.   
 
 
2.16 Summary` 
 
An assessment of serum estrogenicity from the daily exposure to 21 compounds (or 
groups of compounds) in the diet that have hormone mimicking properties has been 
undertaken.  The total daily serum level of estrogenicity from food is estimated to be 8-9, 
6-8, 7-8 and 15-20 ng/l for young males, adult males, adult females and vegetarian 
females respectively.  Comparison with normal serum levels of 17β-estradiol is 
suggestive of potential pharmacological effects for males and post-menopausal women 
but such effects seem unlikely for premenopausal women. 
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Chapter 3 
 
 
 
Exposure to bisphenol A from New 
Zealand canned foods. 
 
 
3.1 Introduction 
 
Bisphenol A (BPA) (Figure 3.1) is a synthetic chemical manufactured from phenol and 
acetone and is used in the plastics industry especially for the production of polycarbonate 
and epoxy resins (EC, 2003).   
 
OH
CH3
OH
OH
CH3 CH3
OH
 
Bisphenol A  17β-estradiol  
 
Figure 3.1: Chemical structures of bisphenol A and 17β-estradiol 
 
BPA has been shown to be estrogenic in receptor binding, gene expression, cell 
proliferation and in vivo assays.  It is one of the most potent xenoestrogens that occur in 
the diet (Table 2.15.1) with a potency in the order of 1000 less than 17β-estradiol.  BPA 
can enter the food chain from its use as epoxy-based lacquers of food cans and 
polycarbonate food containers.  Food and beverage cans often have an internal polymeric 
coating to protect the food and prevent undesirable interactions between the metal from 
the can and the food.  The coatings are usually resins that can withstand typical processing 
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 conditions (e.g. 1.5h at 121°C).  BPA is a starting substance used in the manufacture of 
epoxyphenolic resins that are the most prevalent type of can coating.  BPA is also used in 
the manufacture of polycarbonate plastics that may be used to make baby feeding bottles, 
water jugs, jugs, beakers and microwave ovenware.  Levels of up to about 50 µg/L BPA 
have been reported from migration studies using food simulants in used, but not new, 
polycarbonate infant feeding bottles.  Migration of BPA into food from polycarbonate 
tableware and food storage containers is thought to be negligible (EC, 2003).   
 
Inspection of selected canned foods showed that a variety of lacquers are used for canned 
foods that are available to the consumer being either white, gold, grey or clear (Figure 
3.2).  White, gold and grey lacquers are all epoxy based (Bill Tzimos, Technical Manager, 
Valspar Australia, personal communication, October 2003) and therefore potentially leach 
BPA into the can contents.  A number of factors including pH, salt, oil and glucose have 
been shown to influence the migration of BPA from the lacquer to the can contents 
(Brotons et al.1995, Kang et al.2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Photograph showing variation of lacquers inside food cans 
 
Regulatory limits of 3mg/kg and 2.5 mg/kg for BPA in canned foods have been specified 
by the (EU) and the Japanese government (EC, 2002, in Kang and Kondo, 2003, source 
reference in Japanese).  The US EPA reference dose for non-carcinogenic effects from 
oral exposure to BPA is 0.05 mg/kg bw/day (EPA, 1993).  The reference dose is an 
estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to 
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 the human population (including sensitive subgroups) that is likely to be without an 
appreciable risk of deleterious effects during a lifetime. In 2002, the European 
Commission Scientific Committee on Food gave a temporary Tolerable Daily Intake 
(TDI) of 0.01mg/kg bw/day for BPA based on a three-generation dietary rat study that 
showed significant reductions in adult body weight and pup body and organ weights 
(SCF, 2002).  The TDI remains temporary because of uncertainties with the 
appropriateness of the rodent model and the need for more data.  
 
There are limited data on the concentration of BPA in canned foods from the UK 
(Goodson et al, 2002) and Japan (Yoshida et al,2001, Kang and Kondo, 2003).  Exposure 
estimates have been published for the UK (SCF, 2002) and US (NAP, 1999).  In this 
chapter results for a survey of BPA in foods available to the New Zealand consumer are 
combined with 24-hour diet recall information to estimate over 4000 individual exposure 
scenarios.  
 
3.2 Sampling 
 
This survey was limited to BPA in canned foods and did not include possible migration 
from polycarbonate plasticware.  The following food groups were targeted for 
surveillance on the basis of international results and NZ canned food consumption, from 
the simulated diets employed for the 1997/98 NZTDS: 
 
Table 3.1: Canned foods targeted for analysis of BPA 
 
Food group Sample description 
Vegetables tomatoes, corn, beetroot, peas 
Fruit apricots, peaches, pineapple, fruit salad 
Fish  salmon, tuna 
Soups  chicken, tomato 
Sauces  tomato, pasta sauce 
Meat based on availability 
Desserts based on availability 
Canned dairy foods condensed milk 
Infant foods based on availability 
Beverages canned soft drinks 
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In addition, the following factors were considered in the selection of samples for analysis:  
o From observation, different brands of the same foods have different lacquers on 
the cans, hence brand may impact on BPA content of the food. 
o From observation, different foods of the same brand come in differing lacquered 
cans, hence food type is a potential factor. 
o High pH gives higher BPA, hence non acidic foods are more likely to have higher 
BPA than acidic foods (Brotons et al., 1995). 
o Salt, vegetable oils and glucose give higher BPA levels (Kang et al., 2003). 
 
The derived food list is shown in Table 3.1 
 
Table 3.1: Food list for the analysis of BPA in canned foods 
 
Food group No. brands No. food types No. samples 
Vegetables (tomato, 
corn, beetroot, peas) 
4 4 16 
Fruit 2 4 sweetened 
4 unsweetened 
8 
Fish 4 2 8 
Meat 4 2 8 
Sauces 2 2 4 
Soups 2 2 4 
Spaghetti 4 1 4 
Baked beans 4 1 4 
Canned dairy foods 4 2 8 
Infant foods 2 4 8 
Soft drinks-canned 2  2 
Soft drinks-bottled 2  2 
Total   76 
 
 
3.2.1 Purchase of samples 
 
Single cans of food were purchased from major supermarkets in Christchurch in 
November 2003 and February 2004.  Details of batch number and label information on fat 
and sugar content were recorded.  Samples were stored at room temperature until analysis.   
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 3.2.2 Analytical Methods 
 
Details of the physical appearance, and area of lacquered surface of each can was 
recorded.  Sample extraction and analysis for BPA was based on the methodology of 
Goodson et al., (2002) and is described in Chapter 8.3.  One modification was made to the 
published methodology.  For samples claiming to contain more than 1% fat (based on 
label claims), heptane was substituted for trimethylpentane that was found, in our hands, 
to be more effective at removing interfering compounds.    
 
3.3 Quality control  
 
The following quality assurance procedures were undertaken to assure robust results:  
• Each sample was spiked with deuterated BPA.  The amount of internal standard 
measured in the final extract provides an estimate of the extraction and cleanup 
losses.  All results were corrected for the recovery of internal standard. 
• A laboratory control sample of homogenized beetroot was analysed repeatedly 
during the project as a replicate to assess method variability (Table 3.2).  The 
coefficient of variation was 8%. 
• A laboratory blank was analysed with each batch of 5-8 samples to check for 
laboratory contamination.  BPA was not detected in any of the blank samples. 
• A number of samples were spiked with BPA at concentrations ranging from 6-
80.4 µg/kg (Table 3.3).  Spike recovery ranged from 47-112%.  Despite the 
correction for recovery of the internal standard the reported concentrations of BPA 
are likely to be conservative of the actual amount.   
• A number of samples were analysed in duplicate.  A limit of detection (LOD) of 
10µg/kg was derived for samples with less than1% fat and a LOD of 20µg/kg was 
derived for those samples containing greater than 1% fat (Table 3.4). 
 
For single results, LOD ≅ 5SR  (Telarc, 1987) 
Where SR = standard deviation of the method and for a series of duplicates: 
 
SR = Σ (Y1-Y2)2 
  2p 
   
√
p = number of duplicates 
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Table 3.3: Individual data showing within sample variability.  
 
Replicate 
 
Concentration 
BPA (µg/kg) 
1 27.8 
2 27.8 
3 26.6 
4 33.1 
5 29.6 
6 26.6 
7 26.8 
8 30.7 
Mean 28.6 
Stdev 2.33 
 
 
 
Table 3.4: Recovery of BPA from samples spiked with BPA.  
 
Food type % fat in sample1 Spike level (µg/kg) % Recovery 
vegetable 0.2 25.1 72 
fruit 0.1 25.1 67 
 0.1 40.2 54,57 
 0.1 80.4 89 
sauce 0.2 25.1 71 
spaghetti 0.1 6 60 
 0.1 25.1 42 
baked beans 0.3 80.4 95 
meat 12.2 10 47 
 20.4 80.4 112 
fish 5 25.1 87 
1=based on label claim 
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 Table 3.5: Individual results for duplicate analyses of selected samples. 
 
Food type % fat in sample1 Replicate  1 
(µg/kg) 
Replicate 2 
 (µg/kg) 
vegetable 0.2 21.7 18.2 
 0.5 7.7 9.6 
 0.5 10.8 4.1 
 0.1 17.2 14.7 
fruit 0.1 5.2 5.1 
 0 1.7 2.1 
sauce 0.2 15 13.4 
spaghetti 0.1 2.1 3.5 
infant food 0.3 <0.3 <0.3 
fish 7 15.1 10.5 
 5 0.9 0.3 
 1.9 108.5 109.8 
condensed milk 8.1 3 0.3 
pasta sauce 2.9 17.7 23.5 
meat NA 19.1 7.6 
 20.4 92.2 103.3 
1=based on label claim, NA = not available 
For some food matrices, especially condensed milk, meat and fish, extracts were prone to 
interfering compounds that resulted in more variability and a higher limit of detection. 
 
3.4  Concentration of BPA in NZ foods 
 
3.4.1 Food origin 
 
Eighty seven samples of canned foods originated from 13 different countries with the 
majority being products of New Zealand (34) and Australia (23). Other samples were 
from Thailand (6), Italy (3), USA (3), Philippines (2), Spain (2), Canada, China, Samoa, 
Singapore, Sth Africa and Sri Lanka (1).   
 
3.4.2 Lacquers 
 
All cans included at least one lacquered surface.  The use of lacquers for different food 
types is mostly consistent.  Generally, canned vegetables, sauces and vegetable based 
infant foods come in cans with lacquered ends and sides whereas fruits, spaghetti, baked 
beans, and fruit based infant foods are sold in cans with lacquered ends and tinned sides.  
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 Meats and fish are routinely sold in grey, white or gold lacquered cans, often of a 2 piece 
construction. There were a few exceptions.  For example three varieties of canned 
tomatoes came in cans with lacquered sides whilst two varieties were in cans with tinned 
sides.  Similarly one sample of tomato sauce was in a can with lacquered sides and one 
sample was in a tinned can with only the ends lacquered. 
3.4.3 Concentration of BPA measured in canned foods. 
 
The application of gas chromatography- mass spectrometry (GCMS), with a deuterated 
internal standard, for the detection and quantification of BPA provided good selectivity.  
An example chromatograph is shown in Figure 3.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BPA, 
m/e 
d 14 BPA 
m/e224, 242 
 
Figure 3.3: GCMS trace of an extract of beetroot showing  BPA diacetyl ions m/z  
  228, 213 and the ions of the deuterated internal standard BPA-d14  
  diacetyl, m/z 224 and 242  
 
A full set of analytical results for the concentration of BPA in individual samples, and 
mean concentrations for each food type, are listed in Table 3.5.  Since all cans had at least 
one lacquered surface and BPA was detected in at least one sample of each food, except 
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 the soft drinks, it is highly likely that BPA is present at some level.  For this reason, “less 
than” values have been recorded.  The limits of detection are robust and conservative 
being based on the variability of duplicate analyses rather than a signal: noise ratio.  BPA 
was detected in all foods except soft drinks in which there was none detected.  
 
Table 3.6:  Concentration of BPA, area of lacqured surface, pH, % fat and %  
  sugar in New Zealand canned foods 
 
Food type Country 
of origin 
Lacquer 
area mm2 
pH
 
% fat1 % sugar1 Conc BPA 
µg/kg 
tomatoes NZ 30561 NR 0 2.7 16 
 Australia 7695 4.2 0.1 3.8 <10 
 NZ 30561 4.4 0 2.7 21 
 Italy 7695 NR 0.5 3.4 <10 
 NZ 30561 4.2 0.1 3.3 15 
mean      12 
corn NZ 30561 6.5 1.8 3.3 12 
 NZ 30561 6.3 1.8 3.3 14 
 NZ 30561 6.3 0.2 3.5 20 
 Thailand 31001 6.3 <1 3 <10 
mean      13 
beetroot NZ 30561 4.1 0.2 10 23 
 NZ 30561  0.2 10 24 
 NZ 30561 4.3 0.2 8 22 
 Australia 32195 4.2 0.1 11.9 13 
mean      20 
peas NZ 30561 6.4 0.5 3 <10 
 NZ 30561 6.3 0.5 3 <10 
 NZ 30561 6.4 0.5 3 <10 
 Australia 5280 6 0.5 4.7 17 
mean      8 
apricots NZ 7695  <1 12.5 <10 
 Australia 7695 4 0.1 12.5 <10 
 NZ 7695 3.5 <1 8.2 <10 
 Sth Africa 7695 3.5 0 10.1 <10 
mean      5 
peaches Australia 7695 3.9 0.1 12.7 <10 
 Australia 7695 3.8 0 12.4 <10 
 Australia 7695 nr 0.1 8.7 <10 
 Australia 7695 4.2 0.1 8.7 <10 
mean      5 
pineapple Australia 5280 3.9 0.6 17.4 <10 
 Philippines 5280 3.7 0 14.6 <10 
 Australia 5280 3.5 0.1 12.2 <10 
 Philippines 5280 NR 0 12 <10 
mean      5 
fruit salad China 7695 3.9 0.1 15.8 <10 
 Australia 7695 4.0 0 13.1 <10 
 NZ 7695 3.9 0.1 10.5 <10 
 Australia 7695 3.8 0.1 9.4 <10 
mean      5 
salmon Canada 22518 6.4 7.4 <1 24 
 Alaska 22518 6.4 NR <1 <20 
 NR 21378 6.4 7 0 <20 
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Food type Country 
of origin 
Lacquer 
area mm2 
pH
 
% fat1 % sugar1 Conc BPA 
µg/kg 
 Alaska 22518 6.5 5 0 <20 
mean      13 
tuna Thailand 20605 5.8 14 <1 27 
 Thailand 20605 5.6 10 0 26 
 Thailand 15177 5.9 6.5 11.3 <20 
 Thailand 20605 5.8 1.9 <1 109 
mean      43 
chicken soup Australia 30561 6.3 2.6 2 <20 
 NZ 30561 5.6 2.1 3.9 <20 
mean      10 
tomato soup Australia 7695 4.5 1 6.5 <10 
 NZ 30561 4.5 0.4 4.6 16 
mean      11 
sauces NZ 26743 3.9 0.2 21.3 14 
 NZ 36719 3.8 0.2 23.6 <10 
 NZ 36719 NR 0.1 20.5 11 
 NZ 30561 5.2 2.9 1.9 21 
mean      13 
corned beef Australia 28409 6 18 0 29 
 Australia 28646 6 20 NR 98 
 NZ 28409 6 12 <1 <20 
mean      46 
other meat USA 23420 6.6 21 1.9 <20 
 Australia 15163 6.2 12 0 <20 
 NZ 28646 6.6 NA NR <20 
mean      10 
spaghetti NZ 7695 4.7 0.3 3.8 <10 
 NZ 7695 4.7 0.3 3.8 <10 
 NZ 7695 4.6 0.1 6.8 <10 
 Italy 7695 4.5 0.2 4 <10 
mean      5 
baked beans NZ 7695 5.2 0.3 6.8 <10 
 NZ 7695 5.3 0.3 6.8 <10 
 NZ 7695 5.4 0.4 8.2 <10 
 Italy 7695 5.6 0.4 4 <10 
mean      5 
dessert/dairy NZ 30561 6.3 2.7 11.0 <20 
 Singapore 24185 6.4 8.1 56.5 <20 
mean      10 
coconut cream Thailand 30561 6.1 17 1.7 192 
 Samoa 30561 6.2 25 1.8 <20 
 Sri Lanka 30561 6 17 0 29 
mean      77 
infant food- Australia 16183 5.4 1.9 2.2 <10 
Vegetable Australia 16183 5.5 0.3 5.7 <10 
 Australia 16183 5.7 1.4 0.1 <10 
 Australia 16183 5.3 0.2 3.7 <10 
mean      5 
infant food- Australia 4926 3.9 0.7 6.1 <10 
dessert Australia 4926 4.1 0.1 11.5 <10 
 Australia 16183 5.9 1.1 6.8 <10 
mean      5 
soft drinks NZ  2.4 NA NR <10 
 NZ  3 NA 10.2 <10 
 NZ  2.4 NA NR <10 
 NZ  3.5 NA NR <10 
mean      0 
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Food type Country 
of origin 
Lacquer 
area mm2 
pH
 
% fat1 % sugar1 Conc BPA 
µg/kg 
       
European olives Spain 6840 3.6 NA NR <10 
 Spain 30058 6.6 NA NR 23 
mean      14 
NA=not applicable, ND = not detected, NR= no result 
1=as listed on the food label 
 
 
 
BPA was detected at a concentration above the limit of detection in 25 of the 80 samples 
analysed.  Concentrations ranged from <10-29µg/kg except for individual samples of 
tuna, corned beef  and coconut cream that were 109, 98 and 191µg/kg respectively 
(Figure 3.4).  All concentrations detected were below the EU (3000µg/kg) and Japanese 
(2500µg/kg) migratory limits for BPA in food. 
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Figure 3.4: Mean concentration of BPA in different foods packed in lacquered 
cans (µg/kg) 
 
 
 
 
 
 
 3.5 Discussion 
 
Factors influencing concentration of BPA  
 
The area of lacquered surface, pH, sugar, oil/fat content are potentially confounding on 
the concentration of BPA in the can contents (Brotons et al., 1995, Kang et al., 2003).  To 
ascertain the importance of these factors, data sets were considered where three of the 
four variables were constant. 
 
Figure 3.5 shows an apparent relationship between the concentration of BPA measured 
relative to the area of lacquered surface when pH, fat and sugar content were the same.  
Not surprisingly, there was a higher concentration of BPA in the can contents when a 
higher proportion of the can surface was lacquered. 
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Figure 3.5: Concentration of BPA versus area of lacquered surface for foods of  
  similar pH, fat and sugar content. 
 
Contrary to the argument that BPA migration would be facilitated under alkaline 
conditions and, consequently, acidic foods would be less likely to leach BPA from the can 
lacquer than low acid foods, the mean concentration of BPA in tomatoes at pH (4.2-4.4) 
was almost twice that found in peas with a higher pH (6.0-6.4) for samples with 
comparable lacquered surface areas, fat and sugar content.  
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 All the canned fruit samples had low levels of BPA, below the limit of detection.  There 
was no apparent difference between the claimed sugar content and BPA concentration.   
 
The variability and sporadically high concentration of BPA in coconut cream (192, 29, 
<20), corned beef (98, 29, <20) and tuna (109, 27, 26, <20) is difficult to explain but it 
may be related to the fat content and/or storage time.  Each of these samples had >1.5% 
fat and BPA is fat soluble.  These three products were all imported and information on the 
duration of storage time could not be ascertained.  There is no correlation between BPA 
concentration, colour, area of lacquer, fat content or pH for the elevated samples.  
Information on the age and storage conditions of the product was not available but are 
potential factors.  The samples with higher BPA concentration were imported foods from 
potentially hot locations-Thailand and Australia. 
 
Comparison of New Zealand with International data 
 
There is limited data available in the literature for BPA concentration in canned food and 
this is listed in Table 3.6.  The only comprehensive overseas study was for 62 canned 
foods purchased from retail outlets in the UK from January to November 2000 (Goodson 
et al., 2002). 
 
Table 3.7 A compilation of BPA levels in canned foods reported in the current 
and overseas surveys. 
 
Food type BPA concentration range (µg/kg) 
 NZ, 20041 UK, 20022 Japan, 20013,4 
asparagus - - 29.8 
beetroot 13-29 - - 
carrots - 10-42 - 
corn <10-20 16 18.4-95.3 
mushroom <10 - <10-39.5 
peas <10-17 16 - 
tomatoes <10-21 26-27 - 
apricots <10  - 
fruit salad <10 19-38 - 
orange - - <10 
peaches <10 - <10 
pear - - <10 
pineapple <10 - <10 
salmon <20-24 10-18 - 
Other fish <20-109 13-32 - 
soups <10-16 ND-21 - 
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Food type BPA concentration range (µg/kg) 
 NZ, 20041 UK, 20022 Japan, 20013,4 
sauces <10-21 - - 
corned beef <20-98 59-70 - 
other meat <20 16-422 - 
spaghetti <10 ND-38 - 
baked beans <10 9-14 - 
coconut cream <20-192 - - 
dessert  <20 ND-13 - 
milk, condensed milk <20 11-14 21-43 
infant foods-vegetable <10 - - 
infant foods-dessert <10 - - 
soft drinks,cider,lager ND ND - 
European olives 9-23 - - 
Total 25/80 positive 38/62 11/17 
-  = data not available,  1= this survey,  2= Goodson et al.,2002,  3 = Yoshida et al., 2001, 
 4 = Kang and Kondo, 2003. 
 
The levels found in New Zealand foods are low and comparable with international results 
for fruits, vegetables, soups, corned beef, spaghetti, baked beans, condensed milk and soft 
drinks (Goodson et al,. 2002, Yoshida et al.,2001, Kang and Kondo, 2003).  Canned ham, 
that had high levels in the UK study, was not found on New Zealand supermarket shelves 
and levels of BPA in New Zealand meat products that might be comparable, such as 
tongue and luncheon meat, were below the limit of quantitation (LOQ) in the current 
survey.  The high level of BPA found in individual samples of tuna and coconut cream 
have not previously been reported.  The absence of any detectable BPA in canned soft 
drinks is consistent with the findings of Goodson et al. (2002) and migration studies 
reported by Howe et al. (1998).  The lacquered surface of beverage cans are silver 
coloured rather than grey, white or gold suggesting a different lacquer system that may 
account for the non detection of BPA in the limited number of beverages analysed in this 
study.  
 
Estimated dietary exposure to BPA 
 
Aggregated food descriptors from the 1997 National Nutrition Survey (Russell et al., 
1999) were assigned a BPA concentration based on the concentration results determined 
in this survey.  A total of 1046 food descriptors were used.  These foods and 
concentrations were combined with 24 hour dietary recall information for 4399 individual 
consumers for whom body weight information was available, to generate daily exposure 
scenarios for BPA. 
 Since all cans, with the exception of soft drinks, had at least one lacquered surface, there 
was potential for BPA to be present in the can contents.  Where BPA was not detected in 
a sample or a food group, a value of half the limit of detection was assigned, in line with 
international recommendations (WHO, 1995).  The exception was soft drinks where there 
was no evidence of BPA.  Soft drinks were not included in foods contributing to BPA 
exposure. 
 
For foods that had not been analysed in this survey, such as asparagus, plums and 
mackerel, a concentration value for BPA was approximated from similar foods.  For fruits 
and vegetables, a mean of all vegetable results (13 µg/kg) and a mean of all fruit results (5 
µg/kg) was determined and assigned to the foods outside this survey.  For non specified 
canned fish , the mean concentration of BPA for combined tuna and salmon results was 
applied (28 µg/kg). Where a canned food might be included in a recipe, such as canned 
tomatoes in spaghetti bolognaise, a proportion of the ingredient in the recipe was 
approximated.   
 
The mean and percentile dietary exposure estimates derived by combining mean BPA 
levels from the current survey with 24-hour dietary recall information are summarized in 
Table 3.8 and Figure 3.6.  The mean body weight and exposure to BPA for these 4399 
individuals was 74.8 kg and 0.008 µg/kg bw/day respectively.  Assuming this sample of 
individuals is representative of the New Zealand population, the mean per capita exposure 
to BPA from the consumption of canned food is 0.008 µg/kg bw/day and the level of 
exposure for the 97.5th percentile of the population is 0.063 µg/kg bw/day . From these 
scenarios, however, most people (59%) are not exposed to BPA because they do not 
consume canned foods.  The highest level of exposure for one individual was 0.29 µg/kg 
bw/day, well below the t-TDI of 10 µg/kg bw/day. 
 
Exposure was calculated both with and without a contribution of 50% LOQ for soft 
drinks.  The inclusion of soft drinks doubled the mean exposure.  But this is considered an 
over-estimate because we have no evidence that BPA leaches from bottles or cans into 
beverages.  Thus, exposures excluding a contribution from canned or bottled beverages 
beverages, have been presented as the most realistic assessment. 
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 Table 3.8: Mean and percentile dietary exposure estimates for BPA based on   
 concentration data derived from this survey and 24 hr dietary recall 
 information of food consumption for 4399 New Zealand adult consumers 
 (Russell et al., 1999). 
 
 Estimated Dietary Exposure  
 µg/day µg/kg body weight/day 
Mean 0.57 0.0083 
Median 0.00 0.00 
Range 0-25 0-0.29 
95th percentile 3.1 0.041 
97.5th percentile 4.7 0.063 
99th percentile 6.9 0.092 
t-TDI  10 
t-TDI = temporary Tolerable Daily Intake 
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Figure 3.6: Distribution of exposure to BPA (4399 scenarios derived from the food 
consumption information of the 1997 NNS, Russell et al. 1999) 
 
Foods contributing to dietary exposure 
 
Exposure to BPA is mainly through consumption of canned sauces followed by coconut 
cream, corned beef, canned tuna, tomato soup and canned tomatoes (Table 3.8).  Exposure 
to BPA for the individual with the highest BPA exposure scenario (0.28 µg/kg bw/day) 
was from the consumption of coconut cream.  The lowest exposure scenario (above zero) 
was from the consumption of 1.1g of chilli sauce. 
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 Table 3.9: Contribution of foods included in the current study to dietary exposure 
 to BPA. 
 
Food % contribution 
Sauces, canned 30.5 
Coconut cream, canned 9.0 
Beef, corned, canned 7.9 
Tuna, canned 7.8 
Soup, tomato, canned 6.4 
Tomatoes, canned 6.2 
Beetroot, canned 3.8 
Spaghetti, canned 3.6 
Corn, canned 3.3 
Salmon, canned 3.3 
Peaches, canned 3.3 
Beans, baked, canned 3.2 
Fish, other, canned 3.0 
Fruit, other, canned 1.8 
Vegetable, other, canned 1.7 
Fruit salad, canned 1.6 
Pineapple, canned 1.4 
Soup, chicken, canned 1.0 
Apricots, canned 0.8 
Peas, canned 0.3 
Other meat, canned 0.2 
Dessert & dairy, canned 0.1 
Other 0.0 
 
 
Comparison with previous estimates of dietary exposure 
 
The limited comparative exposure estimates for BPA are shown in Table 3.10.  An intake 
of 0.37 μg/kg bw/day BPA has been estimated for a 60 kg adult consuming 1.05 kg of 
canned food per day (SCF, 2002).  This estimate assumes a high level of consumption, the 
97.5th percentile consumer, and a mean contaminant level of 21.2 µg/kg across the 62 
foods reported in the UK study of Goodson et al. (2002).  Therefore it is an overestimate 
of exposure for the average consumer. 
 
A potential daily intake of 6.3µg/day of BPA from food cans has been derived for the US 
consumer, equivalent to 0.105 and 0.084 µg/kg bw/day for a 60 or 75 kg adult 
respectively (NAP, 1999).  This estimate was based on an average migration 
concentration of 0.37µg/kg from extraction studies using food-stimulating solvents, along 
with a factor to account for the proportion of an individual’s daily diet likely to be in 
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 contact with lacquer from a food can (Howe et al., 1998) and a daily food consumption of 
2.89kg.   
 
Table 3.10: Comparison of NZ and overseas exposure estimates for BPA 
 
 NZ 20041 UK, 20021 USA, 19982 
µg/day 4.7 22.2 6.3 
µg/kg bw/day 
for 60kg bw 
0.078 0.37 0.105 
µg/kg bw/day 
for 75kg bw 
0.063 0.30 0.084 
1 97.5th percentile consumer, UK = SCF, 2002 
2 mean consumption, NAP,1999. 
 
From over 4000 exposure scenarios generated in this study there was no individual who 
exceeded the European Commission SCF t-TDI for BPA.  Most individual scenarios 
resulted in zero exposure to BPA from canned food.  The results of this survey suggest 
that at the current level of understanding, the concentrations of BPA identified in canned 
foods are unlikely to be of concern to adult health, and there is no reason for consumers to 
change their consumption patterns as a result of these findings.  This health implication is 
limited to adults until consumption information for other population groups is available. 
 
This survey provides the first data on the concentration of BPA in New Zealand canned 
foods.  The resulting estimate of exposure to BPA from canned foods is considered the 
most robust of any international estimates available at this time because it is derived from 
concentration values for individual foods, in combination with over 4000 individual 
exposure scenarios from 24-hour dietary records.  
 
3.5 Summary 
 
Exposure to bisphenol A (BPA) from the consumption of canned and bottled food has 
been determined for New Zealand adults. Eighty different canned foods purchased from 
retail outlets in Christchurch, New Zealand between November 2003 and February 2004 
were analysed for BPA concentration by gas chromatography/mass spectrometry.  BPA 
was detected in all foods analysed except soft drinks at concentrations ranging from <10- 
29µg/kg, except for individual samples of tuna, corned beef and coconut cream that were 
109, 98 and 191µg/kg respectively.  The limit of detection, based on the variability of 
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 duplicate results, was <10µg/kg for foods of <1% fat content and <20 µg/kg for foods 
containing >1% fat.  Mean concentration data was combined with 24-hour dietary recall 
information for 4399 individual consumers. Mean and maximum exposures were 0.008 
and 0.29 µg/kg bw/day respectively, well below the t-TDI of 10µg/kg bw/day given by 
the European Commission in 2002. The results of this survey suggest that the levels of 
BPA identified in canned foods are unlikely to be of concern to adult health, and there is 
no reason for consumers to change their consumption patterns as a result of these 
findings.   
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Chapter 4 
 
 
The role of gut microflora on the 
bioavailability of isoflavones 
 
 
4.1 Introduction 
 
Only 0.5-1% of ingested isoflavones are measured in serum (Chapter 2.2).  Gut microflora 
have been implicated as having a role in the bioavailability of isoflavones from soy 
containing foods (Hendrich et al., 1998, Rowland et al., 1999, Lampe et al., 1998).  This 
chapter includes an extensive review of the physiology of the human gut, the identity and 
distribution of gut microflora, and microfloral metabolism of isoflavones.  With this 
background, the hypothesis that gut microflora activity accounts for the difference 
between estimated and measured serum levels from dietary intake of isoflavones is tested 
through experimental studies of the degradation of soy isoflavones by the gut microflora 
of 9 New Zealanders.  
 
4.1.1 Physiology of the Human Gut and its Microflora 
 
The chemical and physical nature of the gastrointestinal tract is diverse, thus creating 
myriad environments that select microflora populations by their habitat requirements 
(Tannock, 1995) (Figure 4.1).  The stomach has a pH of approximately 2.0 (Tannock, 
1995, Drasar and Barrow, 1985), and therefore acts as a barrier to microbes entering via 
the mouth. The chyme leaving the stomach is neutralized by bile and pancreatic 
secretions. The small intestine is subdivided into the duodenum (approximately 0.25 m), 
jejunum (approximately 2.5 m), and ileum (approximately 3.5 m) with the majority of 
digestion and absorption occurring in the jejunum (Johnson and McCormack, 1994).  
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 Food takes 3 to 6 hours to move through the small intestine, depending on its consistency 
(Xu et al.,1995).  The large intestine (colon) is 1.5 to 1.8 m long (Spence and Mason, 
1992) and digestive residue transit time is at least 12 hours before elimination through the 
rectum and anus (Lamb et al., 1991).  The transition of structural and functional 
characteristics through the different intestinal regions result in ecologic changes in gut 
microflora that favor colonization by particular microflora communities (Drasar and 
Barrow, 1985). 
 
transverse colon 
Ileum –3.5m 
proximal colon 
rectum 
duodenum 
jejunum –2.5m 
descending colon 
stomach 
oesophagus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Schematic diagram of the human gastrointestinal tract.  Adapted from  
  Shaw IC, Is it safe to eat? Springer, Berlin (2004) by permission of the  
  author. 
 
Studies on faecal bacteria show that once the flora are established in an individual they 
change little, even in response to dietary change (Drasar and Barrow, 1985, Simon and 
Gorbach, 1984, 1986, Carman et al.,1993, Edwards, 1994, Nord and Kager, 1984, 
Hentges,1980).   Despite the apparent consistency of an individual’s microfloral 
population, dietary change may induce significant changes in microfloral metabolic 
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 activity  (Rowland, 1986, Simon and Gorbach, 1984, 1986, Carman et al.,1993, Edwards, 
1994, Hentges,1980).  The influence of diet on the metabolism of isoflavones has been 
observed (Kelly et al.,1993, Setchell et al., 1984, Lampe et al., 1998).   
 
Intestinal bacteria can be divided into three groups: (1) lactic acid bacteria comprising 
Bifidobacterium, Lactobacillus, and Streptococcus; (2) the obligate anaerobes including 
Bacteroidaceae (encompassing the genus Bacteroides), Eubacterium, Veillonella, and 
Clostridium; (3) the aerobes (most of which are facultative anaerobes) including 
Staphylococcus, Bacillus, Corynebacterium, Pseudomonas and yeasts, and 
Enterobacteriaceae (including pathogenic genera such as Escherichia, Klebsiella, and 
Enterobacter) (Mitsuoka et al., 1992). 
 
4.1.2 Distribution of the gut microflora 
 
Despite there being inter-individual variability in gut microfloral populations, a general 
pattern of microfloral colonization can be observed along the gastrointestinal tract in 
humans. Consolidated data from numerous works are summarized in Table 4.1 (Drasar 
and Barrow, 1985, Hawkesworth et al.,1971, Simon and Gorbach, 1984,1986, Orrhage 
and Nord,2000, Mitsuoka, 1992, Bernhardt and Knoke,1989, Thadepalli et al.,1979, 
Goldin,1990).  
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Table 4.1: Distribution of major microflora in the human gastrointestinal tract. 
(Drasar and Barrow, 1985, Hawkesworth et al.,1971, Simon and Gorbach, 
1984, 1986,Orrhage and Nord, 2000, Mitsuoka, 1992, Bernhardt and 
Knoke, 1989, Thadepalli et al.,1979, Goldin, 1990).(compiled by N. 
Turner). 
 
Stomach Log count of bacteria (CFU/ml or CFU/g) 
 Microorganisms Count     1     2     3     4     5     6     7     8     9    10    11   12 
Total count 0-104              
Streptococcus 0-103              
Enterococcus Rare              
Staphylococcus 0-102              
Enterobacteria 0-102              
Yeasts 0-102              
Facultative 
anaerobes 
Lactobacillus 0-103              
Bifidobacterium 0-102              
Bacteroides Rare              
Fusobacterium 0-102              
Eubacterium Rare              
Veillonella 0-102              
Clostridium Rare              
Peptostreptococcus 0-103              
Obligate 
anaerobes 
Prevotella 0-102              
 
Duodenum/Jejunum. Log count of bacteria (CFU/ml or CFU/g) 
 Microorganisms Count    1      2     3     4     5     6     7     8     9    10   11   12 
Total count 0-105              
Streptococcus 0-104              
Enterococcus 0-102              
Staphylococcus 0-103              
Enterobacteria 0-103              
Yeasts 0-102              
Facultative 
anaerobes 
Lactobacillus 0-104              
Bifidobacterium 0-104              
Bacteroides 0-103              
Fusobacterium 0-103              
Eubacterium Rare              
Veillonella 0-103              
Clostridium Rare              
Peptostreptococcus 0-103              
Obligate 
anaerobes 
Prevotella 102-104              
 
Ileum (lower small intestine) Log count of bacteria (CFU/ml or CFU/g) 
 Microorganisms Count    1      2     3     4     5     6     7     8     9    10   11   12 
Total count 104-108              
Streptococcus 102-104              
Enterococcus 102-104              
Staphylococcus 102-105              
Enterobacteria 102-107              
Yeasts 102-104              
Facultative 
anaerobes 
Lactobacillus 0-105              
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Bifidobacterium 103-109              
Bacteroides 103-107              
Fusobacterium 103-104              
Eubacterium Rare              
Veillonella 0-104              
Clostridium 0-104              
Peptostreptococcus 102-106              
Obligate 
anaerobes 
Prevotella 103-104              
 
Colon Log count of bacteria (CFU/ml or CFU/g) 
 Microorganisms Count    1      2     3     4     5     6     7     8     9    10   11   12 
Total count 1010-1012              
Streptococcus 103-105              
Enterococcus 105-1010              
Staphylococcus 104-106              
Enterobacteria 104-1010              
Yeasts 0-105              
Facultative 
anaerobes 
Lactobacillus 106-108              
Bifidobacterium 107-1011              
Bacteroides 108-1012              
Fusobacterium 106-108              
Eubacterium 109-1012              
Veillonella 103-106              
Clostridium 0-109              
Peptostreptococcus 1010-1012              
Obligate 
anaerobes 
Prevotella 104-105              
 
 
The micro-organisms of the stomach are a reflection of the oral flora that are able to 
survive the acidic environment (Drasar and Barrow, 1985).  They are mainly gram-
positive facultative anaerobes such as Streptococcus, Staphylococcus, and Lactobacillus 
(Goldin, 1990).  The duodenal flora also reflect swallowed bacteria and those that 
survived the stomach’s acidic conditions (McDonald, 1984).  The duodenum is a region in 
constant change.  The low pH of the upper intestinal contents owing to gastric acid is 
adjusted to pH 6 to 7 by the alkaline bile and pancreatic juices.  However pH is a strong 
enough influence that only acid-tolerant bacteria grow (Tannock, 1995, Gorbach and 
Goldin, 1992).  Bile and pancreatic fluids also provide sources of nutrients. The flow rate 
of the intestinal contents, which is at its maximum at the top of the small intestine, selects 
for limited establishment of microflora able to best survive in the transient environment 
(Tannock, 1995, Drasar and Barrow,1985).  The predominant duodenal flora are gram-
positive facultative anaerobes.  Coliforms such as E coli and Klebsiella are also present at 
a low count, but these are probably transients (Thadepalli et al.,1979, Goldin, 1990). 
 
 The jejunal flora is similar to that of the duodenum in that it is dominated by the transient 
Lactobacillus and Streptococcus (Tannock, 1995).  Although the total bacterial numbers 
may reach 105/mL of intestinal contents, sterility in this area is not unheard of (Justesen et 
al., 1984a,b).  As with the duodenum, strict anaerobes may also be found in low numbers 
(Gorbach and Goldin, 1992). 
 
The ileum has a great variability in microfloral distribution as it represents a transition in 
microflora from the jejunum to colon. The upper region has similar microflora to the 
jejunum, but increasing distance from the jejunum coincides with a general increase in 
bacterial numbers; by the end of the small intestine, therefore, the bacterial species are 
similar to the colon, just in smaller numbers (McDonald, 1984).  The most common 
genera found in the distal ileum are Bifidobacterium and Bacteroides (Orrhage and Nord, 
2000, Goldin, 1990).  Lactobacillus, Streptococcus (including Enterococcus), 
Clostridium, and members of the Enterobacteriaceae (such as Escherichia, Enterobacter, 
Klebsiella, Salmonella, Serratia, Shigella, and Yersinia) are also prominent (Tannock, 
1995, Orrhage and Nord, 2000).  Low oxygen tension favors growth of obligate 
anaerobes; however 50% of bacteria present may still be facultative anaerobes (Simon and 
Gorbach, 1986, McDonald,1984). 
 
The colon has a large bacterial population (Gorbach and Goldin, 1992), is more anaerobic 
and has a much reduced flow rate than the small intestine. The total concentration of 
bacteria in the colonic contents (1011–1012 colony-forming units [cfu]/mL) approaches the 
theoretic limit that can fit into a given mass (Gorbach and Goldin, 1992).  Greater than 
400 species have been isolated from this region, with the obligate outnumbering 
facultative anaerobes by 1000:1 (Nord and Kager, 1984).  Bacteroides, Bifidobacterium, 
and Eubacterium dominate the obligate anaerobes; however, the Enterobacteria and 
Enterococcus are still present in high numbers (Orrhage and Nord, 2000).  The main 
method for analyzing the colonic flora has been through studies of the feces in which 
nearly one-third of faecal dry weight consists of viable bacteria (Simon and Gorbach, 
1984).  Opinions on the validity of using feces as an indicator of colon microflora differ 
(Drasar and Barrow, 1985, Moore and Moore, 1995, Kasper,1998). 
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4.1.3 Metabolism of isoflavones by microflora 
 
4.1.3.1 Releasing the aglycone 
 
The isoflavones genistein and daidzein (Figure 4.2) often occur in nature as glycosides 
(Goldin, 1990).  The first step in their metabolism is loss of the sugar to release the 
aglycone (Figure 4.3) (Scalbert and Williamson, 2000, Xu et al., 1995, Rowland et al., 
1999, Kim et al., 1998).  Although a portion of this metabolism may be attributed to 
nonbacterial enzymes, in the intestinal tract, this is minor in comparison with the activity 
of gut microflora (Davenport, 1982).  
 
Figure 4.2 Glucoside conjugated, and unconjugated (aglycone), structures of soy 
isoflavones 
 
Following removal of the sugar, the aglycone may be metabolized further or absorbed to 
undergo first pass hepatic metabolism (Scalbert and Williamson, 2000, Xu et al., 1995, 
Kim et al., 1998).  These metabolic steps will significantly alter bioavailability 
(glycosides are poorly absorbed) and bioactivity (many of the microfloral and mammalian 
metabolites are pharmacologically inactive) (Hur et al., 2000, Xu et al., 1995, Joannou et 
al., 1995). 
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Figure 4.3: Two-step process of isoflavone metabolism from food (drawn by 
N.Turner). 
 
Numerous experiments have demonstrated a significant rise in genistein and daidzein in 
the plasma after controlled feeding of isoflavones (usually as a glycoside-containing soy 
protein) to volunteers (Xu et al., 1995, Gooderham et al., 1996, King and Bursill, 1998, 
Rowland et al., 2000, Setchell et al., 2001, Watanabe and Adlercreutz,1998,  Xu et 
al.,1994).  These support liberation of the aglycone prior to absorption. Glycosidases are 
important enzymes in the metabolic release of flavonoid aglycones.  It is very well known 
that gut microflora produce glycosidases and are the most important source of these 
enzymes in the intestine (Hawkesworth et al., 1971, Rowland, 1986, Davenport, 1982).  
Hawksworth et al., (1971) reported the activities of enzymes produced by mammalian 
microflora.  Of the five enzymes investigated, β-glucosidase and β-glucuronidase are most 
important in hydrolysis of glycosylated flavonoids. The β-glucuronidase is important 
when flavonoid glucuronides are excreted in bile during enterohepatic circulation 
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 (Setchell et al., 2001).  Figure 4.4 shows the activities of each enzyme for the principal 
species of gut bacteria. 
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Figure 4.4: Mean glycosidase activities of the principle species of human gut 
bacteria (Hawkesworth et al., 1971)  
 
Clearly, the enterococci (faecal streptococci) display the highest activity of β-glucosidase.  
Because these bacteria predominate in the small intestine, this has obvious implications 
for deglycosylation and uptake of aglycones in this region. The Lactobacillus, 
Bacteroides, and Bifidobacterium also have strong β-glucosidase activity.  Enterobacteria, 
Clostridium, and Bacteroides have strong β-glucuronidase activity that is likely to be 
important in metabolism of enterohepatically recycled flavonoids (Kim et al., 1998, 
Tannock, 2000).  Four strains of Bifidobacterium demonstrated β-glucosidase by 
hydrolyzing isoflavones in soy milk (Tsangalis et al., 2002). 
 
There is evidence that deglycosylation by gut microflora readily occurs.  Indeed, genistein 
appears in plasma irrespective of whether it is consumed as the glycosylated form 
(genistin) or the aglycone (genistein).  However, free isoflavones (e.g., genistein) reach 
peak plasma levels before the corresponding glycosylated form (e.g., genistin) (Setchell et 
al., 2001).  The presence of the sugar moiety therefore delays rather than inhibits 
bioavailability. 
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 Following absorption of the aglycone, liver first pass phase II metabolism results in 
glucuronidation (Scalbert and Williamson, 2000).  The resulting glucuronides are excreted 
in bile (Drasar and Barrow, 1985, Griffiths and Hackett, 1977), and gut microfloral β-
glucuronidase may re-release the aglycone for reabsorption and further enterohepatic 
circulation, thus prolonging the pharmacologic activity of the isoflavones (Figure 4.5) 
(Drasar and Barrow, 1985). 
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Figure 4.5: Schematic representation of the importance of gut microfloral   
  metabolism on the pharmacologic activity of isoflavones (drawn by  
  N.Turner). 
 
 
4.1.3.2 Degradation and Bioavailability of the Aglycone 
 
The gut microflora have an important role in the metabolism of isoflavone aglycones. 
Experiments involving administration of antibiotics to humans showed decreased 
excretion of bacterially produced phytoestrogen metabolites, and experiments with germ-
free rats demonstrated a complete absence of excreted isoflavone metabolites (Rowland et 
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 al., 1999).  Infants on soy formula during the first 4 months of life (when gut bacteria are 
minimal) form only small amounts of the daidzein metabolite equol (Setchell et al., 1997). 
 
The metabolic products might be more or less bioactive than their parents.  Studies on the 
microbial metabolism of isoflavones have shown that an important metabolite of genistein 
is the non-estrogenic p-ethyl phenol (Wiseman, 1999, Watanabe and Adlercreutz, 1998).  
This is an example of gut microfloral deactivation (Figure 4.2). The major daidzein 
metabolites are o-desmethylangolensin (o-DMA) and equol (7-hydroxyisoflavan) 
(Rowland et al., 2000).  The latter is more estrogenic than daidzein, (Rowland et al., 
1999, Markiewicz et al., 1993) and is an example of gut microfloral metabolic activation 
(Figure 4.2). o-DMA is weakly estrogenic and may even be hormonally inert (Rowland et 
al., 1999, Joannou et al., 1995). 
 
Only a small proportion (1–25%) of whole dietary phytoestrogens are excreted in urine 
(Wiseman et al.,2004). Therefore, they are either not absorbed from the gut, absorbed and 
released in bile followed by faecal excretion, or metabolized by gut microflora or in the 
liver (Scalbert and Williamson, 2000).  The amounts of intact free aglycones in faeces are 
low (Watanabe and Adlercreutz, 1998); thus direct elimination via the faeces is not likely.  
Indeed, in a few studies Xu et al. showed total faecal excretion of isoflavones from their 
subjects was only 1 to 2% of the ingested amount (Xu et al., 1994, 1995).  Therefore 
>75% of dietary isoflavones must be metabolized beyond deglycosylation.  The gut 
microflora are likely to be important in this process, which would account for the low 
bioavailability of pharmacologically active isoflavones from food. 
 
There have been several attempts to study the bioavailability of isoflavones from soy. 
Generally these studies have involved administration of a soy-based meal to human 
volunteers, followed by plasma, urine, and faecal sampling to determine isoflavones and 
their metabolites. Most studies discovered that there were inter-individual variations of 
isoflavone metabolism that might be attributed to gut microfloral differences (Kelly et al., 
1993, Setchell et al., 1984, Lampe et al., 1998, Rowland et al., 2000, Wiseman et al., 
2004, Zheng et al.,2003,2004).  The other, less significant factor affecting bioavailability 
is the food matrix (Gorbach and Goldin, 1992), the effect of which may be determined by 
gender (Lampe et al., 1998).  The inter-individual differences in isoflavone metabolism 
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 signify that a food such as soy may be considered functional for one person, but may not 
exert the same extent of functionality in another. 
 
4.1.3.3 Region of absorption. 
 
Little is known about where the phytoestrogens and their metabolites are absorbed along 
the intestine.  There is a perception that isoflavone glycosides and the free aglycones are 
metabolized and absorbed in the colon because this is where there are a very great number 
of microflora (Scalbert and Williamson, 2000, Wiseman, 1999, King and Bursill, 1998, 
Setchell et al., 2001).  However, this is unlikely, because very little absorption of anything 
but water, electrolytes, short chain fatty acids, vitamins, and some trace nutrients occurs 
in the colon (Spence and Mason, 1992, Davenport, 1982, Levitan and Wilson, 1974).  
Additionally, few enzymes, if any, are produced by the epithelial cells of the large 
intestine, and the absorptive villi structures are absent (Spence and Mason, 1992). 
 
The physiology of the human digestive tract points to metabolism and absorption of 
isoflavones primarily taking place in the jejunum, which, along with the duodenum, is the 
principle area of absorption of hydrolyzed compounds (Anderson and Garner, 2000, 
Hawkesworth et al., 1971, Rowland, 1986).  This is supported in human studies in which 
a short time (0.25–1.5 h) between dose and plasma detection of isoflavones was recorded 
(the time would be much longer if absorption occurred in the colon) (Xu et al, 1995, 
Rowland et al., 1999, King and Bursill, 1998, Setchell et al., 2001, Morton et al., 1997).  
One cannot discount the fact that the soy meals administered in these studies could have 
contained low amounts of unconjugated isoflavones, which may account for some of the 
early detection (Arai et al., 2000).  The aglycones likely accounted for less than 5% of the 
total isoflavones (Wang and Murphy, 1994), however, which does not explain peak 
plasma levels being approached within the expected transit time along the small intestine 
(Xu et al., 1995, King and Bursill, 1998, Xu et al., 1994).  Additionally, enterohepatic 
circulation in the small intestine (including the microflora-rich ileum) increases the 
residence time of the compounds and can be misleading by influencing the isoflavone 
plasma peak and half-life length (plasma peaks, which, by their timing, have been 
attributed to colon absorption are more likely the result of isoflavone plasma 
accumulation from recirculation). 
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 4.1.3.4 Microflora involved 
 
There is evidence that faecal bacteria extensively metabolize isoflavones (Xu et al, 1995, 
Hendrich et al., 1998, Zhang et al., 1999), and there have been attempts to identify the 
specific microbes that may be responsible. In one study a strain of E coli and an 
unidentified gram-positive bacteria were identified that could both convert daidzin and 
genistin glycosides to their respective aglycones (Hur et al., 2000).  The unidentified 
strain further metabolized the aglycones to dihydrodaidzein and dihydrogenistein, but a 
final metabolite for daidzein (equol) was not detected. There were other unidentified 
metabolically active bacteria in their experiments, but they were not pursued. Indeed, 
incubation of daidzein with a culture of crude faecal bacteria from which these species 
had been isolated resulted in the generation of equol, thus suggesting that several species 
could be involved at different stages of the metabolic pathway. A study using quercetin 
supported this hypothesis (Schnieder et al., 1999).  More detailed work showed that 
strains of Bacteroides, Eubacterium, and Fusobacterium efficiently cleaved the sugar 
group from daidzein (Kim et al., 1998).  Following this, phenolic acids were principally 
produced by another strain of Bacteroides. Ring fission is important in reduction of 
bioactivity of isoflavones, and was shown to be carried out by Streptococcus spp., 
Lactobacillus spp., Bifidobacterium spp., and Bacteroides spp. All of these microflora 
inhabit the jejunum (Table 4.1). At this time, however, it is not obvious which microbe (or 
microbes) is principally responsible for the degradation of isoflavones in the small 
intestine. 
 
 
4.2 Degradation of isoflavones by faecal microflora 
 
There have been a number of reports where gut microflora have been exposed to 
isoflavones.  Using faecal matter as a source of the total gut microbial population from 
one individual, Xu et al., (1995) traced the rate of genistein and daidzein degradation 
separately from an initial concentration of 120 μmol/l.  Further work established average 
half-lives for genistein and daidzein (in combination, initial concentration 1180 μmol/L) 
of 8.9 h and 15.7 h respectively (n=14) and demonstrated differences between individuals 
(Zhang et al., 1999).  Hendrich and co-workers (1998) reported relatively consistent rates 
of degradation of isoflavones by microflora from faecal samples of 15-20 subjects based 
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 on measurements of activity at day 0 and at day 300.  On the basis of this consistency, 
they suggested relatively stable human gut microfloral differences in the ability to degrade 
isoflavones.  In further work, the same research group found subjects grouped into three 
phenotypes for daidzein and two phenotypes for genistein degradation based on the rate of 
disappearance of the isoflavones in faecal isoflavone incubations (Zheng et al., 2003).  In 
addition subjects with a rapid gut transit time (GTT) and slow faecal degradation had 
higher urinary levels of genistein, indicating that gut transit time and faecal degradation 
rate impact on the bioavailability of genistein, although this was not evidenced for 
daidzein (Zheng et al., 2004).  Wiseman et al., (2004) report 13 ± 12% and 30 ± 20% 
conversion of daidzein for consumers on a low (0.54  ± 0.58 mg total isoflavones/day) 
and high (104  ± 24 mg total isoflavones/day) soy diet respectively after 72 hours 
incubation. 
 
To test the hypothesis that gut microflora activity accounts for the difference between 
estimated and measured serum levels from dietary intake of isoflavones a number of 
experiments were undertaken using aliquots of fresh human faecal samples incubated with 
genistein, daidzein or a mixture of the two isoflavones.  Isoflavone concentrations, 
approximately 60 µmol/l for the individual isoflavones and 120 µmol/l for the isoflavones 
in combination, were measured, in the first instance by thin layer chromatography, and 
subsequently, by HPLC using methodology based on Xu et al., (1995).  Details of the 
methodology are given in Chapter 8.4. 
 
4.2.1 Cultural differences 
 
The initial goal was to obtain preliminary information on genistein and daidzein 
degradation from individuals with different diets.  Therefore, three cultural groups were 
targeted: Chinese (15-20 years) moved to New Zealand recently from China, New 
Zealand Maori and European New Zealanders.  Informed consent and faecal samples 
were obtained from nine individuals comprising 6 European (1 vegetarian, 5 omnivores) 
and 3 Maori New Zealanders.  Attempts to obtain samples from Chinese students were 
unsuccessful, ascribed to the sensitive nature of the sample in the Chinese culture.  The 
assistance given and participation by all subjects is most gratefully acknowledged and 
respected. 
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An aliquot of homogenised, centrifuged faecal supernatant in growth broth was spiked 
with genistein (58µmol/l) and daidzein (39 µmol/l) and incubated at 37 °C (See Chapter 
8.4 for details).  1ml aliquots were extracted and analysed by thin layer chromatography at 
time = 0, 5 and 24 hours and visualised under UV light (265nm) (Figure 4.6, Table 4.2).  
No difference was observed between the time 0 and 5 hour samples.  After 24 hours, 
extracts from 6 of the 9 subjects showed decreased intensity of genistein with 4 of these 
subjects also showing a decrease in the daidzein intensity (but no evidence of the 
estrogenic metabolite, equol).  Of the 6 ‘degraders’ one was Maori (self claimed), one was 
a vegetarian, and 4 were European New Zealanders consuming a typical Western diet.   
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Figure 4.6: Thin layer chromatographic results for standard solutions (genistein, 
equol , daidzein) above and of faecal extracts from 9 New Zealand 
subjects following 24 hours incubation with daidzein (39µmol/l) and 
genistein (58 µmol/l).  The duration of incubation supports the 
unidentified band being p-ethylphenol (a metabolite of genistein) rather 
than O-desmethylangolensin (a metabolite of daidzein).  
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 Table 4.2: Thin layer chromatographic results of faecal extracts from 9 New 
Zealand subjects following 24 hours incubation with daidzein 
(39µmol/l) and genistein (58 µmol/l). 
 
Extract Rf  Intensity Change 
from time 0 
Identification 
Sterility control (no bugs) 0.56 +++  daidzein 
 0.64 +++  genistein 
Positive control (E.Coli) 0.54 +++  daidzein 
 0.62 +++  genistein 
Subject 1  NZ European 0.54 +++ r daidzein 
  (vegetarian) 0.64 ++ a genistein 
Subject 2 NZ Maori 0.54 +++ r daidzein 
 0.62 +++ r genistein 
Subject 3 NZ Maori 0.54 +++ r daidzein 
 0.62 +++ r genistein 
Subject 4 NZ Maori 0.54 ++ a daidzein 
 0.64 ++ a genistein 
Subject 5  NZ European 0.56 + a daidzein 
 0.65 + a genistein 
Subject 6  NZ European 0.54 +++ r daidzein 
 0.64 +++ r genistein 
Subject 7  NZ European 0.56 ++ a daidzein 
 0.67 + a genistein 
Subject 8  NZ European 0.56 ++ a daidzein 
 0.65 + a genistein 
Subject 9  NZ European 0.54 +++ r daidzein 
 0.65 ++ a genistein 
 
Following these preliminary results, intra- and inter- individual differences in the ability 
to degrade isoflavones was quantified using high-pressure liquid chromatography 
(HPLC). 
 
4.2.2 Quality control 
 
Three control experiments were conducted to ensure validity of the extraction and 
detection methodologies.  To assess reproducibility, some samples were set up in 
triplicate using faecal supernatant from Subject A in the three isoflavone conditions (each 
alone and mixed), and sampled over 72 h.  Secondly, to assess efficiency of the Maxi-
Clean cartridge extraction method, a solution of genistein and daidzein (59.8 and 
64.5μmol/L respectively) was processed through prepared cartridges and the products 
collected at various points in the wash and elution process to be analysed by HPLC.  
Finally, the HPLC regime was calibrated against isoflavone standards. 
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 The mean extraction recovery was 67% ± 12 (1 SD) and 64% ± 13 for genistein (n = 34) 
and daidzein (n = 31), respectively.  Losses were not accounted for by the water rinses or 
80% methanol elution and therefore most likely to be associated with lack of, or 
irreversible, absorption onto the cartridge.  The HPLC response to the standards of 
genistein and daidzein was linear (R2 =1.00) over the concentration range analysed (0-128 
μmol/l).  
 
4.2.2.1 Reproducibility 
 
The reproducibility of degradative characteristics of triplicate faecal samples is shown in 
Figure 4.7.  Whilst two of the replicates were similar, the third replicate was different with 
variability ascribed to a combination of analytical and microbial components.  The 
negative degradation for daidzein (mixed with genistein) is indicative of analytical 
variability in the order of ±15% since the isoflavones cannot be synthesized by the 
microbes.  The greater variability observed for 72 compared with 24 hours of incubation 
suggests a microbial component to the variability since more lifecycles give a greater 
chance for the microbial populations from 2 sub-samples to diverge.  The limited 
reproducibility at longer incubation times means that differences observed in subsequent 
studies are preliminary only. 
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Figure 4.7: Reproducibility of degradation of  isoflavones relative to time 0 for 
three replicates of a faecal sample (1,2,3) incubated up to 72 hours. 
Genistein 59.8, daidzein 64.5 and total mixed isoflavones at 124.3 µmol/l.   
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 4.2.3 Intra-individual variation 
 
In four out of five faecal samples taken over a 15 week period, the gut microflora in the 
faeces of Subject A showed degradation ability towards the isoflavones (Figure 4.8).  In 
each case genistein and daidzein were added individually and together. 
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Figure 4.8: Total percentage change in concentration of isoflavones relative to 
time 0 h due to degradation by faecal microflora from Subject A in 5 
experiments over 15 weeks.  ‘Mix’ indicates where daidzein and genistein 
were present in combination.  In all cases the initial concentration of 
isoflavone was 60 μmol/L (total 120 μmol/L when mixed), and 
experiments were concluded at 72 h.  Exceptions are denoted with an (*) 
where the experiment was concluded at 28 h, and (^) where the starting 
concentration was 30 μmol/L (60 μmol/L mixed). 
 
Little (within error) or no degradation of any isoflavone combination was observed at 
week 7, although samples from other subjects did show degradation and were therefore a 
positive control.  Despite the experiment concluding within a shorter timeframe of 
incubation (28 h), much of the isoflavones were completely degraded in the week 14 
sample, where initial concentrations equaled 30 μmol/L (total of 60 μmol/L in mixtures) – 
half the concentration of the other trials.  For the remaining three trials, microflora from 
Subject A consistently degraded genistein alone within 30 h, but showed variable 
degradation ability for daidzein alone (30 and 90% where experiment allowed to run for 
72 h, degradation had not occurred after 28 h).  When present in an isoflavone mixture, 
little to no degradation of daidzein was seen, and degradation of genistein was up to 65% 
only where the experiment was allowed to run to 72 h. 
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 4.2.4 Inter-individual variation 
 
The results in Figure 4.9 show the change in isoflavone concentration relative to time 0 h 
for the 5 NZ European subjects.  The experiment was concluded at 30 h (genistein), and 
72 h for daidzein, genistein/mix (in combination with daidzein) and daidzein/mix (in 
combination with genistein), except where 100% degradation was detected beforehand. 
 
The results demonstrate both the ability for each individual’s faecal gut microflora to 
degrade isoflavones, and differences between individuals in the extent of degradation for 
faecal samples collected at one time point.  Other than Subject A, who showed no 
isoflavone degradation ability in this trial, all subjects completely metabolised genistein 
within 24 h and daidzein to variable extents (100% detected at 36 h and 60 h for Subjects 
B and D respectively).  In the mixtures, significant degradation of genistein was only 
observed in Subject C, and no daidzein metabolism was detected in the microflora of any 
participant. 
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Figure 4.9: Percentage change in concentration of isoflavones relative to time 0 
due to degradation by faecal microflora from 5 NZ European subjects. 
Genistein 59.8, daidzein 64.5 and total mixed isoflavones at 124.3 µmol/l.   
 
4.2.5 Response at varying isoflavone concentration 
 
The ability of the faecal microflora from 3 of the 4 subjects, to degrade both genistein and 
daidzein when added individually (at approx 60µmol/l), but not when presented as a 
mixture (at a total isoflavone concentration of 120 µmol/l), raised the question of whether 
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 isoflavone degradation was concentration dependent.  Figure 4.10 shows the maximum % 
degradation of the isoflavones (up to 72 hours) at varying isoflavone concentrations, for 
subject A.  Isoflavones were added individually and in combination at varying isoflavone 
concentrations.  Initial concentrations were 30, 60, 90, 120 and 150 µmol/l.  For the 
mixtures, this represents the total starting concentration of the isoflavones combined (half 
of each of genistein and daidzein).  There is a tailing off of degradation from a combined 
isoflavone concentration of 90µmol/l upwards, suggesting that higher isoflavone may be 
toxic to the microflora or that the microflora had reached maximum activity (had eaten 
enough isoflavone).  Thus the reduction in isoflavones concentration at 60 µmol/l 
genistein and daidzein compared with at 120 µmol/l for 3 of the 4 subjects (Figure 4.8) 
was confirmed. 
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Figure 4.10:  Percentage reduction of isoflavones at increasing isoflavone 
 concentration in the microflora substrate, Subject A. 
Chapter 4 142 
  
 Chapter 4 143 
  
 
Genistein
-100.00
-80.00
-60.00
-40.00
-20.00
0.00
0 10 20 30 40 50 60 70 80
Time (hrs)
Pe
rc
en
ta
ge
 c
ha
ng
e
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Effect of isoflavone concentration on rate of degradation  Starting 
(time 0 h) concentrations of isoflavone : 30 (♦), 60 (?), 90 (▲), 120 (x) 
and 150 (?) μmol/l.  
 
The rate at which isoflavone concentration changed with varying substrate levels is shown 
in Figure 4.11.  A linear trend-line was selected as the best representation across all 
results.  The coefficient of determination (r-squared) ranged between 0.64-1.00 (excluding 
2-point graphs) with a mean and median of 0.86.  This indicated that the linear trend-line 
was a reasonable estimate of the true pattern. Clearly the rate of change in isoflavone 
concentration (implying degradation) decreased with increasing isoflavone concentration.   
 
The positive trend line for daidzein, when present in a mixture at the highest total 
concentration (150 µmol/l), is a result of low isoflavone recovery and is considered 
indicative of nil degradation. 
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 4.2.6 Effect of Pre-exposure 
 
In one instance 4 ml faecal supernatant from Subject A was grown in the presence of 
genistein at a final concentration of 60 μmol/l in micro-aerophilic conditions at 37 ˚C 
(referred to as tube A).  After 30 h, 1 ml was removed and inoculated into a fresh tube of 
growth medium and genistein to give a total of 5 ml at 60 μmol/l genistein (tube B).  An 
appropriate amount of genistein was added to the original tube (A) to achieve a 
concentration of 60 μmol/l (C).  The tubes were then re-incubated and samples analysed 
over the following 18 hours. 
 
The time taken for complete degradation of genistein was approximately halved for a pre-
exposed sample of faecal microflora (Figure 4.12). 
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Figure 4.12: Impact of pre-exposure on the degradation rate of genistein by faecal 
microflora. (♦= original faecal culture (A), ? = 1ml of original culture 
inoculated into fresh genistein/medium (B), ?= original culture re-
inoculated with genistein. 
 
 
4.3 Discussion 
 
The use of faecal material as a source of gut microflora is a pragmatic approach 
increasingly being used (Xu et al., 1995, Setchell et al., 1984, Zhang et al., 1999, Zheng 
et al., 2003, 2004, Wiseman et al., 2004, Simons et al.,2005).  Ideally, microflora would 
be obtained from the small intestine where the majority of absorption is likely to occur.  
Relative proportions, rather than species diversity, of microflora change along the 
gastrointestinal tract (Table 4.1).  Faecal material is therefore likely to oversample small 
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 intestinal flora compared with the small intestine.  The pH of the BHI broth used to 
incubate the microflora is at the upper end of the pH range for the small intestine (6-7.5, 
Boudinot, 2004) and it is possible that these studies may not represent the in vivo small 
intestine environment.  The limited reproducibility achieved in these experiments means 
that results for incubations beyond 24 hours are preliminary only. 
 
Subject A consumed a typical omnivorous diet with an estimated isoflavone intake of 1.0 
mg/day genistein and 0.8 mg/day daidzein (Table 2.2.4b).  Faecal incubations for this 
subject demonstrated considerable unpredictability in gut microfloral degradation ability 
when sampled 6 times over 3 months, despite no intentional soy consumption during this 
time.  In 4 experiments where degradation was observed and quantified, genistein was 
metabolised to completion within 28 hours when present alone, but the rate and extent of 
metabolism of the daidzein and both isoflavones in mixture was variable.  In one 
experiment, degradation of isoflavones (singularly or in combination) did not occur.  This 
variability within an individual was also observed for one of the other European New 
Zealand subjects and is at variance with opinions of others (Hendrich et al., 1998, Zheng 
et al. 2003, Wiseman et al., 2004).  Zheng and co-workers (2003) found phenotypes were 
maintained when measured 10 months apart.  Wiseman and colleagues (2004) reported 
similar plasma concentrations between mid-point and end-point samplings of a 10 week 
isoflavone feeding trial. It is appreciated that the results presented here are preliminary yet 
there is no evidence that the methodology failed as simultaneous incubations for other 
subjects showed degradation.  No other investigators have reported more than duplicate 
studies. Further work involving more subjects is needed to confirm the overall pattern of 
metabolic ability with time in New Zealand Europeans, but the results, at least for Subject 
A, contradict the ‘stable-microflora metabolism’ conclusions.  
 
A qualitative comparison of the isoflavone metabolic activity of the microflora from 9 
New Zealanders comprising 3 Maori, and 6 European New Zealander (of which 1 was a 
vegetarian) showed that 6 subjects were ‘degraders’.  Quantitative studies with faecal 
samples from 5 of the European subjects showed remarkable differences in both absolute 
ability and rate of degradation. Comparing the degradation ability of genistein across all 
subjects, 4 out of 5 were able to completely degrade genistein within 24 h when present 
alone at a starting concentration of 60 μmol/l.  Coupling this amount with 65 μmol/l 
daidzein, effectively doubling the total isoflavone concentration, basically eliminated all 
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 degradation of genistein in 3 out of 4 of the genistein-degraders.  A similar result was 
seen with daidzein, with 4 out of 5 subjects initially able to metabolise the compound to 
some extent when it was present alone, but none able to metabolise in mixture.  This 
result suggested that there might be a concentration at which the isoflavones become 
inhibitory to the microflora, and that this point of inhibition was more dependent on the 
total concentration of isoflavones than the presence of either compound.  Compromised 
metabolic activity of the microflora at high levels of isoflavone was supported by the 
absence of non-isoflavone metabolic products in the HPLC chromatograms, such as those 
from the growth medium.   
Inter-individual differences in microbial degradation of isoflavones are consistent with the 
wide variation in plasma and urinary concentrations of isoflavones reported by other 
workers (Arai et al., 2000, Uehara et al., 2000, Wiseman et al.,2004).  For example 
plasma levels for genistein and daidzein ranged from 5.0-2513 nmol/l and 1.7-861 nmol/l 
respectively for mean (± SD) intakes of 86.5 (± 47.0) and 57.4 (± 31.4) µmol/day (Uehara 
et al., 2000).  In the work undertaken by Wiseman and co-workers (2004), plasma levels 
of genistein and daidzein were highly variable 691 (± 690 nmol/l) and 369 ± 456 nmol/l 
respectively for 13 subjects who each consumed the same amount of isoflavones, namely 
56 mg genistein and 43 mg daidzein.  
 
Setchell et al., (1984) reported the conversion of daidzein to equol by faecal microflora 
from studies of one individual.   In controlled diet studies Rowland and co-workers (2000) 
found subjects fell into 2 categories, good (64% of subjects) and poor (36% of subjects) 
equol excretors, on the basis of urinary excretion.  Based on relative retention times in the 
HPLC traces, equol was detected as a metabolite product in incubations from 2/5 of our 
subjects (40%).  Microflora from two of our individuals were able to degrade daidzein 
with no evidence of equol production.  Therefore the inter-individual variation in the rate 
and/or ability to degrade daidzein, by the microflora from our subjects, is not explained by 
the ability to produce equol. 
 
The most likely reasons for gut bacteria to metabolise isoflavones are; the provision of 
nutrients for energy, their use in the construction of other compounds needed by the cell, 
because they are toxic to the cell or that they are co-metabolised in the process of another 
reaction.  On the basis of the results obtained it was hypothesised that as the total 
isoflavone concentration approached 120 µmol/l, the rate of degradation would decrease 
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 and no degradation would be seen at this concentration.  However, in the experiments 
designed to show this, degradation of at least 40% was observed in all isoflavone 
combinations except for the daidzein portion of the 120 μmol/L mixed samples.  Though 
the data are limited, a picture emerges (Figure 4.8) that suggests the rate of degradation 
decreases, and hence bioavailability increases, at increasing isoflavone concentration. 
However, this is not supported by % transfer of genistein and daidzein to urine at different 
intakes (Table 4.3) and requires confirmation. 
 
Table 4.3: Recovery of isoflavones in urine as a percentage of intake  
 
Isoflavone Intake (μmol/day) % recovery in 
urine 
Genistein 2061 8 
 1292 7 
 1123 18 
Daidzein 1701 15 
 842 21 
 1033 36 
 1 = Wiseman et al., 2004, 2=Rowland et al., 2000,  3=Watanabe et al., 1998. 
 
With the majority of digestion and absorption occurring in the proximal small intestine, 
microbial activities with significance to bioavailability of isoflavones are most relevant 
within the 3-6 h period it takes for food to pass through this region (Spence and Mason, 
1992).  Results from the studies described in this chapter, showed a delay of around 18 
hour before degradation was significantly detected, suggestive of an incubation lag period 
necessary for an in vitro minority population of bacteria to grow to high levels before 
activity becomes recognizeable.  This initial delay was much reduced (50% degraded in 
6h or less) when faecal microflora had been pre-exposed to genistein.  While 
acknowledging likely in vitro selection factors in this experiment, it is speculated that in 
the natural gut habitat microflora have the ability to metabolise genistein within the time 
needed for food to pass through the upper small intestine, where absorption is at its peak 
(Spence and Mason, 1992).  This is because the gut acts as a continuous culture with 
continuous exposure to estrogenic compounds.  On the other hand, it appears unlikely that 
daidzein will be degraded in significant amounts within this period due to its much slower 
(and sometimes absent) metabolism.  This suggests that daidzein is more bioavailable, 
consistent with the higher proportions of daidzein found in urine compared with genistein 
(Table 4.3).  
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 4.3 Summary 
 
Maximal absorption of bioactive food components is likely to be in the proximal small 
intestine (duodenum, jejunum).  This region of the gastrointestinal tract harbors 
microflora dominated by lactic acid bacteria, Streptococcus, Lactobacillus, and 
Bifidobacterium, with the latter group only present if anaerobicity is sufficient.  Other 
human-associated genera are also present in varying population sizes. Thus there are a 
wide range of bacteria that may potentially be involved in the degradation and 
bioavailability of isoflavones.  The identity of the species involved is not well understood. 
 
Intestinal bacteria express several glycosidase enzymes, with Enterococcus 
(Streptococcus) demonstrating particularly high amounts of β-glucosidase activity, 
followed by Lactobacillus, Bacteroides, and Bifidobacterium. Clearly, small intestinal 
microflora have ample capacity to hydrolyze any glycosidated isoflavones ingested by the 
host, releasing the bioactive aglycone for absorption or further metabolism. 
Enterobacteria, Clostridium, and Bacteroides, all significantly present in the ileum, show 
strong β-glucuronidase expression. These organisms are important in hydrolyzing inactive 
aglycone glucuronides released in the bile via enterohepatic circulation, similarly making 
the aglycone bioavailable to host and microbes alike. 
 
The role of gut microflora in the bioavailability of the active constituents genistein and 
daidzein is highly variable between individuals, and possibly within an individual and at 
least at the present time, unpredictable.  These findings have important implications for 
the promotion and prescription of soy foods and supplements for disease prevention and 
health benefits (such as an alternative to HRT) since the bioavailable dose is highly 
variable.  
 
The low rate of degradation of daidzein by gut microflora found in this study and 
elsewhere (Wiseman et al., 2004) coupled with a transit time of 3-6 hours through the 
upper intestine, mean it is difficult to accept degradation of the aglycone form by gut 
microflora as an explanation for the difference between estimated and measured plasma 
levels from dietary intake of isoflavones (Chapter 2).
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Chapter 5 
 
 
 
The establishment and validation of the 
yeast assay for estrogenicity 
 
 
5.1 Introduction 
 
The “yeast” assay is a “gene expression” assay for measuring the estrogenicity of 
compounds that can interact with the human estrogen receptor (hER). Yeast cells do not 
normally contain an estrogen receptor, however the DNA sequence of the human ERα has 
been stably integrated into the main chromosome of yeast (Saccharomyces cerevisiae) by 
the Genetics Department at Glaxo.  In 1996, Routledge and Sumpter published 
methodology for an assay based on this modified yeast (Routledge and Sumpter, 1996).  
The schematics of this assay are shown in Figure 5.1 
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 Figure 5.1: Schematic for the basis of the yeast assay using yeast transfected with 
the human estrogen receptor (ERα). 
Yeast cells contain expression plasmids for the reporter gene lac-Z.  This gene codes for 
the expression of β-galactosidase enzyme, that cleaves a dye added to the assay medium. 
The binding of a compound to the estrogen receptor results in gene transcription, that 
causes expression of the reporter gene lac-Z, and production of the enzyme β-
galactosidase.  The enzyme is secreted into the medium, where it metabolizes the 
chromogenic dye, chlorophenol red-β-D-galactopyranoside (CPRG), which is normally 
yellow, into a red product. The absorbance of the red colour is measured at 540nm.  
Estrogenicity is quantified relative to the absorbance obtained from the endogenous 
hormone 17β-estradiol. 
 
The assay has been used to measure the estrogenicity of a wide range of compounds 
including: surfactants and their primary degradation products, the synthetic plasticiser 
bisphenol A, insecticides, herbicides, flavonoids and isoflavones (Arnold et al., 1996, 
Breinholt and Larsen, 1998, Connor et al., 1996, De Boever et al., 2001, Routledge and 
Sumpter, 1996).  Environmental applications have included the estrogenicity of 
compounds in water and wastewater (Murk et al., 2002; Garcia-Reyero et al., 2001) and 
sediments (Legler et al., 2002). 
 
In this work, the yeast assay was established and validated, in conjunction with fellow 
PhD student, Anna McCarthy (Chemistry Dept., University of Canterbury) with the aim 
of using it to measure the transfer of estrogenic compounds across the human placenta 
(Chapter 6). 
 
5.2 Establishment of assay 
 
5.2.1 Importation of the yeast 
 
Since the yeast is genetically modified, importation required that New Zealand biosecurity 
regulations were met.  Communications with ERMA (Environmental Risk Management 
Agency) were pursued until authority was gained to import the strain under an ERMA 
approval code NOC000705, for NOC99011, covering the importation into containment, 
for research purposes, genetically modified Saccharomyces cerevisiae laboratory strains 
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 that contain fragments of DNA cloned from other species.  The yeast were imported into 
ESR’s containment facility under MAF permit #2002015009.    
On arrival, the 5 yeast slopes were grown at 32º for 3 days whence 1ml 30% sterile 
glycerol was added and aliquots taken for storage at –80º C. 
5.2.2 Establishment of the assay 
 
Assays were undertaken using standard solutions and following the protocols in Chapter 
8.5.  A total of 12 assay runs were undertaken before reproducibility and appropriate 
concentration ranges for the standards of interest were achieved.  The reason for the 
variability and unpredictability of the results was found to be largely due to an excess of 
yeast cells being added to the growth medium.  In our hands, the assay uses less than the 
amount specified with the assay instructions (250µl rather than 0.5-2.0 ml).  With a 
chemist’s approach, measured volumes of 24 hr yeast culture were added to the assay 
medium rather than a volume based on cell count.   
 
The growth of the yeast culture was measured over a period of 24 hours, to determine the 
growth phase of the yeast. A cell count was also performed to verify that the amount of 
cells in the 24h culture.  From Figure 5.2 it is seen that at 24 hours the cells are in a 
stationary phase of growth.   
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Figure 5.2:  Growth of hER yeast over 24 hours measured by cell count (CFU/ml)  
  and absorbance at 640nm  
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 Since the estrogenic potency is different for different compounds, varying concentrations 
of the starting solutions were required to give a spread of absorbance readings across the 
serial dilutions of the test compounds.  Standard solutions of 17β-estradiol (54.48 µg/l), 
genistein (278 mg/l) and bisphenol A (349 mg/l) resulted in a gradation of colour change 
across the plate (Figure 5.3). 
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17β-estradiol 
 
Figure 5.2: Colour changes observed from the yeast assay for starting   
  concentrations of 17β-estradiol (54.48 µg/l: 10-0.005nM across the  
  plate), genistein (278 mg/l: 51-0.03µM across the plate) and   
  bisphenol A (349 mg/l:76-0.04µM across the plate)   
 
 
5.3 Validation 
 
Replicate ‘S’ curves were obtained for standard solutions of 17β-estradiol (n=8), genistein 
(n=6) and bisphenol A (n=4) Figures 5.4a and 5.4b.  A single standard curve was 
achieved for nonylphenol but because this compound creeps on the well plate, with the 
risk of contaminating other samples, replicates were not pursued.  Data points were fitted 
to a computer generated line fit using the software package ‘SigmaPlot”.  From this line, 
EC50 values were determined where EC50 is the concentration of compound required to 
induce 50% of maximum estrogenic effect.   
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Figure 5.4a Standard curves for estradiol for six different assay experiments 
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Figure 5.4b: Standard curves for bisphenol A and genistein from four different  
  experiments 
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 The assay is based on a biological system and whilst absolute values vary from one assay 
to another, depending for example on the number of yeast cells to begin with, the relative 
responses to different chemicals are comparable.  The EC50 is the concentration of 
compound that gives half the maximum estrogenicity for that compound.  By taking a 
concentration value at a common point on the standard curve, it is possible to measure 
relative estrogenicity of one compound to another.  The variability of EC50 values 
(derived from SigmaPlot) and relative estrogenicities of estradiol, genistein and bisphenol 
A, as measured by the yeast assay, are shown in Table 5.1. 
 
Table 5.1: Reproducibility of estrogenicity and relative estrogenicity for estradiol,  
 genistein and bisphenol A using the yeast assay (EC50 per well= nM) 
 
EC 50 bisphenol A EC 50 genistein 
Assay # 
EC 50 
estradiol 
EC 50 
bisphenol A EC 50 estradiol 
EC 50 
genistein EC 50 estradiol 
3 0.125     
7 0.261     
8 0.228   519 2276
9    239  
13 0.252   489 1940
14 0.248 3176 12806   
16 0.412 5219 12667 1150 2791
18 0.240 2618 10908 422 1758
20 0.396 5310 13409 1058 2672
mean 0.270 4081 12448 646 2192
STD 0.093 1386 1076 369 448
STD 
  (% of mean) 34 34 9 57 20
 
 
Whilst the variability of one standard deviation from the mean EC 50 ranges from  34 to 57 
% between assays, the relative estrogenicity of genistein and bisphenol A to estradiol is 
less variable (9 and 20%).   
 
 
A comparison between the EC50  for 17β-estradiol from this work and published results is 
shown in Table 5.2.  There is good agreement between this work and results obtained by 
Tyler et al.,(2000), Beresford et al., (2000) and De Boever et al., (2001). 
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 Table 5.2: Comparison of EC50  values for 17β-estradiol 
 
EC50 17β-estradiol Reference 
2.7 ± 0.93 x 10 –10 M This work 
2.1 ± 0.35 x 10 –10 M Tyler et al., 2000 
2.2 ±0.22 x 10 –10 M Beresford et al., 2000 
1.44-10.78 x 10 –10 M De Boever et al., 2001 
2.3 ± 0.41 x 10 –11 M Breinholt and Larsen, 1998 
 
 
5.4 Limit of detection 
 
Because the estrogenic potency of the xenoestrogens genistein and bisphenol A is in the 
order of 10,000 times lower than for 17β- estradiol when measured by the yeast assay, 
concentrations of starting solutions of genistein and bisphenol A have to be in the order of 
10,000 times higher than17β- estradiol to detect a measureable colour change in the assay.  
This means that test solutions need to be at a concentration of approximately 300 mg/l for 
estrogenicity to be detected.  Whilst this is possible for standard solutions, it will be 
difficult to obtain extracts of environmental or food samples that are sufficiently 
concentrated.  This is likely to limit the usefulness of the assay for environmental 
samples.  The assay, is however, a useful method for comparing estrogenic potency of 
pure compounds.  
 
5.5 Summary 
 
The yeast assay employs a yeast strain that includes the human estrogen receptor.  
Binding of an estrogenic compound to the receptor results in the activation of a gene that 
encodes for an enzyme that can cause a measureable colour change of a dye.  Thus the 
assay is based on “gene expression”.  The assay has a reproducibility of 10-20% for 
potencies measured relative to a standard compound.  The assay is useful for test 
compounds to be prepared at a starting concentration in the order of 300 mg/l. 
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Chapter 6 
 
 
 
Xenoestrogen exposure during pregnancy 
-use of a placental model to study in utero 
exposure 
 
 
6.1 Introduction 
 
6.1.1 The DES Story 
 
DES (Figure 1.1), is a potent estrogenic compound synthesized by Dodds and colleagues 
in 1938, that was prescribed to women in America and Europe to prevent miscarriage and 
other pregnancy complications (Toppari et al.,1996, CDC, 2004).  Between 1938 and 
1971 as many as 4 million women in the United States and 400,000 women in Europe 
were given DES.  Although studies by Dieckmann and co-workers in 1953 demonstrated 
that DES was not effective for either of these therapies (Dieckmann et al., 1953) it 
continued to be prescribed (CDC, 2004).  Then in 1971 Herbst and colleagues published a 
scientific paper in The Lancet that linked the occurrence of rare cervical and vaginal 
cancers in a small group of young women he was treating to the use of DES by the 
mothers of these patients (Herbst et al., 1971).  This finding lead to a warning from the 
U.S. Food and Drug Administration about potential harmful effects of prescribing DES to 
pregnant women.  The paper by Herbst et al. (1971) was pivotal in that it was the first 
example of transplacental carcinogenesis in humans.  In other words, a chemical is 
transferred from the maternal circulation, across the placenta, into the fetal circulation and 
causes a change resulting in cancer some years after birth.  In the case of DES and vaginal 
cancer, this was usually 15 to 30 years after exposure in utero (McLachlan et al., 2001). 
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 Although the consequences of DES exposure in utero seem less severe for boys than girls, 
some concerns have been raised.  The sons of women who took DES during pregnancy 
are three times more likely to have genital structural abnormalities than men without such 
exposure (Cosgrove et al., 1977).  Men with in utero exposure also have sperm and semen 
abnormalities (but without an increased risk of infertility or sexual dysfunction) (Wilcox 
et al., 1995).  Although individual studies of a link between maternal exposure to DES 
and an increased incidence of testicular cancer are variable (Henderson et al., 1988), a 
meta analysis of studies suggested a 2-fold increased risk of testicular cancer in the sons 
of mothers prescribed DES (Toppari  et al., 1996).   
 
The DES story continues with possible third generational effects.  Alerted by two case 
reports, Klip et al., (2002) undertook a cohort study of 16,284 Dutch women with a 
diagnosis of fertility problems.  The prevalence ratio of hypospadias in the 205 sons of 
women who were exposed to DES in utero compared with the remaining 8729 sons was 
21:3.  Although the absolute risk is small (2% of exposed mothers of boys), the evidence 
of placental transfer of an estrogenic compound affecting not just one, but two, 
subsequent generations is novel, significant and of concern. 
 
Whilst recognizing that DES is not a dietary source of xenoestrogens, the work with DES 
is important because it provides evidence of placental transfer of a xenoestrogen from 
mother to fetus. 
 
6.1.2 Evidence of in utero effects from environmental chemicals 
 
Some pesticides used in agriculture, including DDT, dieldrin, endosulphan and synthetic 
pyrethroids have been shown to be estrogenic (Go et al., 1999, Jorgensen et al., 2000, 
Soto et al., 1995).  Weidner and colleagues (1998) reported a significantly increased risk 
of cryptorchidism, but not hypospadias in the sons of women working in gardening.  The 
subjects were Danish, the adjusted odds ratio= 1.67; 95% confidence interval 1.14-2.47 
(Weidner et al., 1998).  The risks were not increased in sons of men working in farming 
or gardening.  The implication is that in utero exposure to agricultural chemicals resulted 
in the small increased risk of cryptorchidism.  In a more recent study, maternal exposure 
to environmental pollutants at levels currently encountered in New York City have been 
associated with reduced fetal development (lower birth weights, body lengths and head 
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 circumference) in the babies of exposed mothers (Perera et al., 2003).  Swan and 
colleagues (2005) found an association between the concentration of four phthalate 
metabolites in maternal urine and anogenital distance (AGI), penis size and incomplete 
testicular descent in the sons of these women.  A comparison of boys with prenatal 
phthalate concentrations in the highest quartile to those in the lowest quartile showed odds 
ratios of  10.2, 4.7, 3.8 and 7.3.  The median concentrations of phthalate metabolites 
associated with the shorter AGI and incomplete testicular descent were within the range 
found for American women, based on nation-wide sampling. Phthalates are anti-
androgenic, potentially interfering with the production of testosterone, rather than 
estrogenic but this work provides strong  evidence of a link between prenatal exposure to 
an EDC and human male reproductive development. 
6.1.3 Evidence for placental transfer of genistein and bisphenol A  
 
The results reported by Herbst et al. (1971) have stimulated three decades of research into 
the understanding of hormones, our chemical environment and embryonic development 
(McLachlan et al. 2001).  Included in this body of work are the following animal studies 
of placental transfer of the xenoestrogens genistein and BPA after maternal exposure.  
Genistein and BPA were selected as xenoestrogens of particular interest because of their 
contribution to estrogenicity from the diet (Chapter 2, Figures 2.1 and 2.13) and because 
they represent naturally occurring and synthetic compounds respectively.  
 
6.1.3.1 Bisphenol A  
 
In 1999 Miyakoda and co-workers found that BPA orally administered at a dose of 10 
mg/kg transfers from maternal rat to the fetus (Miyakoda et al., 1999).  The concentration 
of BPA in maternal blood plasma and fetal organs peaked at approximately 34 and 11 µg/l 
respectively within 1 hour of administration.  Placental transfer of BPA has also been 
reported following a single subcutaneous dose of BPA administered to pregnant mice and 
monkeys (Uchida et al., 2002).  These results suggest that BPA passes easily through the 
placental barrier in a number of species.   
 
Limited reports from animal studies of the effect of in utero exposure to BPA give mixed 
results.  Prenatal exposure to a dose of bisphenol A comparable to levels found in the 
environment was found to lead to increased growth and early sexual maturity in female 
Chapter 6 159 
  
 mice (Howdeshell et al., 1999).  On the other hand, Yoshino and co-workers (2002) 
concluded that exposure of female rats to BPA at concentrations up to 120 mg/kg/day 
during pregnancy and lactation does not result in any morphological abnormalities in the 
accessory sex organs (testis, epididymis, prostate and seminal vesicles) or 
spermatogenesis of male offspring.  This means that even if BPA is crossing the placental 
barrier, it is not leading to abnormalities in the male rat reproductive outcomes examined.  
 
Naciff and co-workers (2002) found that transplacental exposure of rats to the synthetic  
estrogen, 17 α-ethynyl estradiol, the natural phytoestrogen, genistein, and to bisphenol A, 
changes the gene expression profile of uterus and ovarian tissue in the fetuses of the 
exposed mothers, evidence that these estrogenic compounds cross the placenta in rats and 
have a biochemical effect.  
 
6.1.3.2 Genistein  
 
There is surprisingly little information available on placental transfer of genistein. 
 
High levels of phytoestrogens, including genistein, in chord and amniotic fluid samples of 
healthy Japanese infants relative to maternal plasma levels indicated ready placental 
transfer of genistein and other phytoestrogens (Adlercreutz et al., 1999). 
 
Doerge and colleagues (2001) measured the concentration of genistein (conjugated and 
unconjugated) in maternal and offspring serum and brain following oral administration of 
genistein (20, 34 and 75 mg/kg bw) to pregnant female rats.  Genistein concentrations 
were lower in fetal serum compared to maternal serum and unlike maternal serum, 
concentrations did not increase dose dependently.  They found that a greater proportion of 
genistein was present in fetal serum in the unconjugated form.  The concentration of the 
unconjugated genistein in the fetal serum ranged for 7-30% of the concentration in the 
maternal serum, showing that up to one third of the bioactive form of genistein crosses the 
rat placenta.  
 
A warning “Don’t eat soya if you’re pregnant” was printed in NewScientist, 15 February 
2003 (Jones, 2003).  This article featured a study reporting the development of sex organs 
and sexual behaviour of rats exposed to genistein-supplemented diets during early 
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 development (Wisniewski et al 2003).  To determine if exposure to genistein at gestation 
and lactation at doses common in human diets, alters masculinization, the scientists 
examined the development of external genitalia, testes, wolffian ducts and sexual 
behaviour in male rats exposed to genistein-supplemented diets during early development.  
Exposure to genistein resulted in temporary, prepubertal morphological abnormalities and 
long-term dysfunction in reproductive behaviour, in which adult males exposed to 
genistein were less likely to mount and ejaculate.  Also, males exposed to genistein had 
lower testosterone concentrations in adulthood.  This work also demonstrated placental 
transfer of genistein in rats. 
6.1.4 Sexual differentiation 
 
An early mammalian embryo has the potential to develop either male or female 
reproductive tracts with sexual differentiation in humans occurring at 5-8 weeks of 
gestation.  At this time the SRY gene on the Y chromosome produces an enzyme that 
stimulates development of the testis.  SRY is the acronym for Sex-determining Region of 
the Y chromosome.  In the absence of this enzyme ovaries develop. Once testes have 
formed they secrete a peptide (anti-Mullerian hormone), which causes regression of the 
potential female reproductive tract, and formation of testosterone.  Testosterone in turn 
stimulates development of the male reproductive tract (Tortora and Grabowski, 2003).  
 
Things can go wrong.  If a genotypic male fails to make testosterone, it will not 
masculinize and will develop as a phenotypic female (but with testes).  Conversely, if a 
genotypic female is exposed to sufficient testosterone she will be masculinized (but will 
have ovaries).  The effect may be partial.  Other organ systems such as the brain, liver and 
muscles are also “imprinted” during development and hence may be targets for 
xenoestrogens that perturb the normal endocrine profile at various stages of life.  The 
greatest concern about environmental hormone disruptors arises from the possibility of 
irreversible effects of short term exposure at a critical period of life (WHO 2002a, 2002). 
 
A number of genes are involved in the process of sex determination and differentiation 
and in a recent review article MacLaughlin and Donahoe (2004) discuss how mutations in 
these genes can lead to sexual abnormalities such as male pseudohermaphroditism.  Since 
these are the types of effects observed in wildlife after exposure to xenoestrogens, it 
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 seems highly conceivable to the author that compounds that alter expression of these 
genes at the critical period of differentiation could lead to sexual abnormalities.   
6.1.5 Development of endocrine organs 
 
Different parts of the endocrine organs develop at the following times:- pituitary (3 
weeks), thyroid (4 weeks), pancreas and thymus (5 weeks) and pineal (7 weeks) (Tortora 
and Grabowski, 2003).  Homeostasis of the endocrine system is established during fetal 
development and an abnormal environment, such as exposure to xenoestrogens, at this 
stage of life can result in permanent misprogramming (WHO, 2002a, COT, 2003). 
6.1.6 Circulating levels of estradiol 
 
The normal circulating levels of estradiol for a female are shown in Table 6.1.  Estradiol 
originates from the maternal ovaries in the non-pregnant female and for the for the first 5-
6 weeks of gestation, after which time production of estradiol switches to the placenta 
(Tortora and Grabowski, 2003).  The serum concentration of estradiol varies from about 
0.020 to 0.350 µg/l during the menstrual cycle.   
 
Table 6.1: Normal circulating levels of estradiol for a female (Greespan and 
Gardner, 2001,  Beard and Nathanielsz, 1984)  
 
Time period Serum concentration 
 µg/l nM 
1-5 years 0.005-0.010 0.018-0.037 
6-9 years 0.005-0.060 0.018-0.220 
10-11 years 0.005-0.300 0.018-1.100 
14-16 years 0.020-0.068 0.073-0.250 
Early follicular 0.020-0.100 0.073-0.357 
Preovulatory and luteal 0.100-0.350 0.367-1.285 
Post menopausal 0.010-0.030 0.037-0.110 
Pregnant 0.100-30 0.367-110 
 
In the pregnant female, estradiol rises to about 30 µg/l as shown in Table 6.2.  At the time 
of sexual differentiation (5-8 weeks), which is reasonably a critical time for exposure 
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 effects from environmental hormones the circulating level of estradiol in maternal serum 
increases from approximately 0.45 to 4.0 µg/l (Beard and Nathanielsz, 1984). 
 
Table 6.2: Changes in serum concentration of estradiol during pregnancy 
(modified from Beard and Nathanielsz, 1984)  
 
Gestational age (weeks) Serum concentration (µg/l) 
1 0.05 
5 0.45 
8 4.0 
16 5.0 
24 10.0 
40 30.0 
 
6.1.7 The Placental Model 
 
Dual perfusion (i.e. separate maternal and fetal circulations) of a human placenta ex vivo 
is a technique whereby a placenta is obtained from a consenting mother immediately after 
delivery and solutions (perfusates) that maintain the placental tissue are circulated through 
a fetal lobe and a maternal lobe of the placenta.  A schematic of the model is shown in 
Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Schematic diagram of the ex vivo human placental perfusion model. 
 
The use of human placental perfusions is an alternative or adjunct to animal testing and is 
preferable for two reasons.  Firstly, because it is human based the outputs better reflect a 
human physiological response.  Since the placental structure shows great interspecies 
variation (Leiser and Kaufmann, 1994), there are limitations in extrapolating placental 
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 transfer data from animal studies to humans (Ala-Kokko et al., 2000).  Secondly, it avoids 
the ethical and financial difficulties associated with animal testing.  One of the major 
disadvantages of an isolated organ perfusion is that absolute physiological conditions are 
not attainable.  Also, the viability of the perfused tissue is limited. 
 
The ex vivo human placental perfusion model was designed originally for the study of 
placental physiological features and has been applied to the transfer of electrolytes, amino 
acids, lipids and metabolites (eg Dancis et al.,1981, Schneider et al., 1979, Dancis et al., 
1974, 1976 ).  More recently it is used to study drug transport (eg. Shiverick et al., 2002, 
Heikkinen et al.,2001, Herman et al., 2000) and aspects of the biochemistry of obstetrics 
(eg Huleihel et al.,2003) with the transfer of allergens being a more unusual application 
(Loibichler et al., 2002).  No-one to our knowledge is, or has, applied the model more 
widely to fetal exposure to environmental chemicals (Mitchell, personal communication). 
 
In this chapter, potential fetal exposure to estrogenic compounds was investigated using 
ex vivo human placental perfusion.  In the first instance, endogenous release of 
estrogenicity was determined in samples taken from both the maternal and fetal sides of 
the placenta over 4 hours.  The background estrogenicity of these samples was measured 
using the yeast assay.  Secondly, the endogenous hormone 17β-estradiol was added to the 
perfusate solution and samples collected and measured as for the blank perfusate. Thirdly, 
genistein was added to the perfusate, samples collected and analysed by HPLC. Details of 
the methodology are given in Chapter 8.6.  
 
All perfusions were undertaken in collaboration with Mi-kyung, Iris Shin, Liggins 
Institute, University of Auckland, in fulfillment of her work for a Master’s thesis (Shin, 
2004).  Analysis of the perfusates solutions was undertaken at ESR, Christchurch Science 
Centre, by the author. 
 
6.2 Viability of placentas during perfusion  
 
Biochemical and physical validation data for four perfusions are shown in Tables 6.3 and 
6.4 with comparative data from Cannell et al., (1988) (Shin, 2004).   
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Table 6.3: Physical and biochemical perfusion validation data with comparative 
data from Cannell et al.,1988. 
 
 Experimental data from 
our studies 
Comparative data1  
 mean SEM n mean SEM n 
Placental weight (g) 487 46 4 581 51 5 
Weight of perfused mass (g) 18.6 0.16 4 21.7 6.0 5 
Glucose consumption 
(mmol/kg/hr) 
5.8 1.2 4 7.8 1.5 5 
Lactate production 
(mmol/kg/hr) 
7.1 1.6 4 8.5 1.4 5 
hCG production (i.u./kg/hr) 2310 870 3 4860 3000 4 
Fetal arterial pressure (mean 
mm Hg) 
<40  4 <40  5 
Average leakage (ml/hr) <2  4 <2  5 
 
 
Table 6.4: pH, pressure and flow rate parameters for perfusions. 
 
 
 
pH PCO2 (kPa) PO2 (kPa) Pa (mmHg) Flow rate 
(ml/min) 
Maternal 7.48 ± 0.16 1.87 ± 0.54 28.88 ± 2.8 25.12 ± 7.62 10 
Fetal 7.43 ± 0.21 1.06 ± 0.25 24.48 ± 1.58 35.2 ±4.01 4 
 
 
The physical viability criteria for a successful perfusion was a pressure of less than 40 
mmHg in the fetal circuit (to minimize shear stress ), less than 2ml/hr leakage from the 
fetal to the maternal circuit, pH maintained between 7.2-7.4 and visual bleaching as the 
perfusion continued (Miller et al., 1985, Cannell et al.,1988).  Perfusions were rejected if 
these parameters were not matched.  The average leakage of 2 ml/hr indicated that the 
respective circuits were intact and separate.  For unsuccessful perfusions, the leakage was 
>10 ml/hr and these perfusions were discarded.  Slightly higher pressures (up to 45 
mmHg in the fetal artery) and leakages rates (up to 3 ml/hr) were tolerated in the 4th hour 
of perfusion. 
 
Glucose consumption, lactate production and secretion of human chorionic ganadotrophin 
(hCG) into the maternal circulation showed that the placentas were intact and viable.  
Glucose consumption steadily declined in both the maternal and fetal compartments over 
the 4 hr duration of the perfusion.  Lactate concentration in the maternal arterial 
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perfusates increased from 0.7 to 5.0 mmol/l over the 4 hours.  The production of hCG 
over the 4 hours of perfusion was indicative of cellular metabolic activity.  Stable PO2 and 
PCO2  values were maintained on both sides throughout the dual perfusions.  
 
 
6.3 Endogenous estrogenicity 
 
Because the placenta produces estradiol endogenously it was important to measure 
estrogenicity produced by the placenta and to determine the placental transfer of any 
estrogenicity produced, using the model system. 
 
Two placentas were successfully perfused with perfusion medium and samples taken from 
both the maternal and fetal sides at time 0, 0.5, 1,2, 3 and 4 hours.  The samples were 
assayed using the yeast assay and are shown in Figure 6.2 A,B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 A,B: Estrogenicity of maternal and fetal samples following blank 
perfusions.  
 
The assay showed an increasing amount of estrogenicity in both the maternal and fetal 
perfusate samples with time for the two placentas.  This demonstrates that an endogenous 
estrogenic compound, or compounds, are being eluted from the placenta.   
 
The blank perfusate solutions were subsequently re-analysed, following 6 months storage 
at -18˚C.  The results obtained are shown in Figure 6.3 A,B. 
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Figure 6.3 A,B: Estrogenicity of maternal and fetal samples following blank 
perfusions re-analysed after 6 months storage at -18˚C.  
 
The apparent decrease in estrogenicity between the two assays is due to the difference in 
relative response to estradiol.  This is seen both in the standard curves obtained (Figure 
6.4) and the absorbance readings at 610 nm that are an indicator of cell growth.   
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Figure 6.4: Standard curves for estradiol obtained from two different assays 6 
months apart. 
 
When the initial blank perfusion results are adjusted for the difference in response to 
estradiol between the two assays, much closer agreement between the two perfusions is 
observed (Figure 6.5 A,B). 
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Figure 6.5: Initial blank perfusate assay results (04/08/03) adjusted for 
difference in response to estradiol (10/02/04).  
 
 
 
The blank perfusates solutions developed estrogenicity within 0.5 hr that reached a 
plateau after 2 hours at a corrected absorbance (540nm) of about 0.25 in the perfusate 
solutions.  The similarity of concentration in both the maternal and fetal sides suggests 
ready transfer, or equal production, on both sides of the placentae.  The estrogenicity seen 
in the blank perfusion samples most probably does not reflect a physiologic condition 
since the substrates for placental estrogen synthesis (dehydroepiandrostendione and 
androstenedione) were not included in the perfusates solutions.  However, the blank 
perfusions provide a baseline level of estrogenicity for the estradiol perfusions. 
 
6.4 Placental transfer of 17β-estradiol 
 
Three fresh placentae were perfused with 17β-estradiol at a concentration of 1µg/l.  This 
concentration was selected as close to the circulating level in early pregnancy (Table 6.2) 
during the period of sexual differentiation and development of endocrine organs.  This 
may well be a critical period for exposure to xenoestrogens.  This concentration was also 
within the operating range of the yeast assay.  Varying numbers of maternal and fetal 
samples were obtained, depending on the performance of the placenta, and analysed in 
duplicate for estrogenicity using the yeast assay in the same way as for the blank 
perfusions.  The difference in estrogenicity between the maternal side and the fetal side is 
clearly seen in Figures 6.6 and 6.10.   
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Figure 6.6: Yeast assay plate of perfusates from estradiol-perfused placenta 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 : Duplicate yeast assay results of estradiol perfused placenta 1  
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Figure 6.8: Duplicate yeast assay results of estradiol perfused placenta 2  
Estradiol perfusion 1
Plate 1
-0.25
0.25
0.75
1.25
0 min 1 hr 2 hr 3 hr 4 hr
Duration of perfusion (hrs)
A
bs
 5
40
-A
bs
 5
40
bl
an
k
maternal
fetal
Estradiol perfusion 1
Plate 3
-0.25
0.25
0.75
1.25
0 min 1 hr 2 hr 3 hr 4 hr
Duration of perfusion (hrs)
A
bs
 5
40
-A
bs
 5
40
bl
an
k maternal
fetal
Estradiol perfusion 2
Plate 1
-0.25
25
0.75
1.25
0 hr 2 hr
Duration of perfusion (hrs)
A
bs
 5
40
-A
bs
 
54
0 
bl
an
k
0.
1 hr
maternal
fetal
Estradiol perfusion 2
Plate 4
-0.25
0.75
1.25
0.25
0 hr 1 hr 2 hr
Duration of perfusion (hrs)
A
bs
 5
40
-A
bs
 
54
0 
bl
an
k
maternal
fetal
Estradiol std
Maternal 0-4 hrs
Fetal 0-4 hrs
Blank
Maternal serial dilution
Estradiol std
 Chapter 6 170 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Duplicate yeast assay results of estradiol perfused placenta 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 : Mean of estradiol perfusions 1 and 3. 
 
 
Two perfusions of estradiol were successfully achieved and the results from these were 
combined and are shown in Figure 6.10.  The third perfusion (Figure 6.8) leaked and 
therefore these results were excluded.  From Figure 6.10 it is apparent that estrogenicity 
on the maternal side of the placentae was maintained for the 3-4 hours of the perfusion.  
There was no observable decrease in the level of estrogenicity on the maternal side nor a 
corresponding increase on the fetal side of the placentae.  The implication of this finding 
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 is that the placenta provides an effective barrier against in utero exposure to the 
endogenous hormone 17β-estradiol.  
6.5 Placental transfer of genistein 
 
Three placentae were perfused with genistein at a concentration of 0.200 mg/l.  This is 
about twice the mean serum level of 0.110 mg/l reported for Japanese women but well 
within the range of 0.001-0.680 mg/l reported in that study (Uehar et al., 2000).  
Therefore it represents a realistic human exposure. 
 
The concentration of genistein in the maternal and fetal perfusates samples was 
determined by HPLC.  Details of the methodology are described in Chapter 8.6.5.  The 
results are shown in Table 6.5 and Figure 6.11.  
 
Table 6.5: Concentration of genistein in maternal and fetal samples of three 
perfused placentae (mg/l). 
 
 Perfusion 1 Perfusion 2 Perfusion 3  mean 
Hours M F F/M  M F F/M M F F/M F/M±sd 
0 0.161 0.001*   0.57 0.01 0.02 0.56 0.01 0.02 0.01 ±0.006 
1 0.093 0.003 0.03  0.65 0.06 0.09 0.45 0.02 0.04 0.05±0.03 
2 0.085 0.008 0.09  0.47 0.07 0.15 0.28 0.07 0.25 0.16±0.08 
3 0.066 0.007 0.11     0.23 0.08 0.35 0.23±0.17 
 
* = limit of detection, F= fetal perfusates, M = maternal perfusate 
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Figure 6.11: Concentration of genistein in maternal and fetal samples from three 
genistein perfusions, A,B,C. 
 
The concentration results for the maternal samples of the perfusions undertaken on 
23/04/04 and 06/05/04 are higher than is possible if spiked at 0.2 mg/l.  Inspection of the 
HPLC chromatograms confirms the numbers shown in the graphs.  The most likely 
explanation is that the latter perfusions were spiked at a higher concentration than 0.2 
mg/l.    
 
A small amount of genistein was detected in the fetal samples indicating that some 
placental transfer was occurring.  Since the flow rate and volume of perfusates is greater 
on the maternal side (10 ml/min, 200ml) compared with the fetal side (3 ml/min, 100ml) it 
is expected that the concentrations on the two sides of the model are unequal. The 
percentage transplacental transfer from the maternal to the fetal side may be calculated:  
 
 % TPT =   Fc x Fv  x 100 
  (Fc x Fv ) + (Mc x Mv ) 
 
Where: Fc  = concentration in fetal perfusate sample at time x min, F v = volume of fetal 
perfusate, : Mc  = concentration in maternal perfusate sample at time x min, M v = volume 
of maternal perfusate, (Henderson et al., 1992 ). 
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The % transplacental transfer of genistein for each of the 3 perfusions is shown in Table 
6.6. 
Table 6.6: Maternal to fetal transplacental transfer of genistein (%) 
 
Hours Perfusion 1 Perfusion 2 Perfusion 3 mean 
0 0.3 0.9 0.9 0.7 ± 0.3 
1 1.6 4.4 2.2 2.7 ± 1.5 
2 4.5 6.9 11.1 7.5 ± 3.3 
3 5.0  14.8 9.9 ± 6.9 
 
 
6.6 Discussion 
 
Application of the yeast assay with the placental model, demonstrates a barrier provided 
by the placenta for in utero exposure to estrogenicity from the endogenous hormone, 17β-
estradiol.  As far as the author is aware, this is the first application of the placental model 
to the study of transfer of estrogenic compounds from mother to the developing fetus.  
Although perfusions were undertaken at only one estradiol concentration, and serum 
estradiol concentrations span two orders of magnitude during pregnancy (0.1-30µg/l), the 
perfusion concentration was selected to approximate maternal serum levels when sexual 
differentiation and endocrine development of the fetus is occurring.  This stage of 
pregnancy is likely to be a critical period of in utero exposure to hormonal compounds 
and the maternal serum concentration at this time is therefore an appropriate and 
interesting concentration to use for initial studies.   
 
The yeast assay is designed to assess relative estrogenicity rather than for quantitation of 
absolute concentrations (because of the non linear, sigmoid nature of the standard curve).  
Therefore whilst the yeast assay will measure combined estrogenicity from different 
compounds, relative to a reference compound, it lacks precision to allow quantitation of 
placental transfer parameters.  A more specific analysis is required. 
 
The mean % transplacental transfer of genistein at 2 hours of perfusion (7.5 ± 3.3) is 
similar to the transfer of the antidepressant drugs, amitriptyline (8.2%) and nortriptyline 
(6.5%) (Heikkinen et al., 2001) and the antibiotic drug acyclovir (10.2 %) (Henderson et 
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 al., 1992).  The transfer of genistein is less than for nicotine where about 19% of nicotine 
added to the maternal perfusates was transferred to the fetal perfusates and the 
fetal/maternal concentration ratio reached 1.0 (Rama Sastry et al., 1998).  The mean 
transfer of genistein in the three perfusions was about one third of that measured by 
Henderson and colleagues (1992) for the fully diffusible marker, antipyrine. 
 
Myllynen and Vähäkangas (2003) performed 6 perfusions with the drug diazepam at 2 
and 0.2 mg/l, and the reference compound antipyrine that readily transfers across the 
placenta.  At 2 hours the fetal-maternal ratio for diazepam was 0.48 and 0.55 (for 2.0 and 
0.2 mg/l respectively) and 1.02 for antipyrine.  Our studies show much less placental 
transfer for genistein, with a mean fetal-maternal ratio of 0.16 ± 0.08 at 2 hours (Table 
6.5).  This suggests that the placenta limits but does not completely inhibit transfer of 
genistein at dietary levels.  Interestingly, there is some variance between this result and  
the findings of Adlercreutz et al., 1999 who reported “ready transfer” of genistein from 
Japanese mothers to neonates on the basis of chord and amniotic fluid analysis 
(Adlercreutz et al., 1999).  They reported a median concentration of total isoflavonoids in 
the amniotic fluid of 7 subjects as 34nM compared with a median maternal chord plasma 
concentration of 147 nM.  Thus the level in the amniotic fluid was 23% of the level in the 
chord plasma.  The results reported by Adlercreutz and co-workers were for a full term 
pregnancy when the fetal metabolism is much more developed than at the period when 
exposure may be the most critical, namely 5-8 weeks.  A similar lack of correlation 
between in vivo and placental perfusion data has been reported for diazepam (Myllynen 
and Vähäkangas, 2003).  The placental model is a simplification of an in vivo system as it 
does not allow for fetal metabolism.  This is an advantage for unravelling placental 
transfer versus fetal metabolic effects but a disadvantage for understanding the role of the 
placenta in regulating fetal exposure.  It means that placental perfusion results need to be 
one of a number of methods used for investigating in utero exposure.  
 
The three genistein perfusions show some variability in degree of barrier provided by 
individual placentas and hence the need for replicates.  There is an apparent increase in 
concentration of genistein in the fetal samples with the corresponding decrease in 
concentration in the maternal samples for the perfusion 3.  However, a placental barrier 
was maintained in each perfusion with the fetal to maternal concentration ratio reaching a 
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 maximum of 0.35 and the maximum transfer being 15%.  These results suggest an in 
utero exposure to genistein of between 5-15% of the mother’s serum level.  
 
There was a 40% decrease in genistein concentration in two perfusions 1 and 3 over the 
three hours of perfusion with a lower increase in concentration on the fetal side suggesting 
that genistein is being metabolized in the maternal circuit. 
 
Due to the difficulty of obtaining placentas, it was not possible to undertake perfusions 
with bisphenol A.  This would provide a most useful comparison of placental transfer of 
an endogenous estrogenic compound (17 β-estradiol) with a naturally occurring 
(genistein) and a synthetic estrogenic compound (bisphenol A). 
 
Exposure to xenoestrogens at critical periods of development is a priority for research into 
the human health effects of EDCs.  Since sexual differentiation and reproductive 
development occurs at 5-8 weeks gestation, and is permanently influenced by hormones, 
placental transfer of xenoestrogens is an important area of study.  Although dual 
perfusions of human placenta are challenging to perform because of the difficulty in 
obtaining suitable placentae and the delicate nature of the tissue that is prone to leakages, 
this technique is an interesting way of gaining a better understanding of relative placental 
transfers of xenoestrogens from mother to fetus. 
 
6.7 Summary 
 
Seven dual perfusions were successfully undertaken. 
 
A small amount of estrogenicity is produced by the human placenta in the model system 
and this transfers freely between the maternal and fetal sides. 
 
Estradiol added to the maternal perfusate is maintained over 4 hours of perfusion, with 
little transfer to the fetal side. 
 
A small amount of genistein, in the order of 5-15% is transferred from the maternal to 
fetal sides of the placenta using the dual perfusion model.  This is similar to the transfer of 
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 a number of drugs (amitriptyline, nortriptyline and acyclovir) but less than for the 
reference compound antipyrene, the drug diazepam, and nicotine.  The results suggest that 
the placenta limits transfer of genistein at dietary levels in the human system.  A possible 
discrepancy with in vivo data means that this placental transfer model must be considered 
with caution.   
 
The placental model provides an interesting tool for assessing the relative transfer of 
xenoestrogens across the placenta to add to our knowledge of fetal/in utero exposure to 
these compounds at an important life stage.  Further studies of other xenoestrogens will 
provide a basis for comparison. 
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Chapter 7 
 
 
 
A preliminary genomic approach to 
investigating the health effects of 
xenoestrogens  
 
 
7.1 Introduction 
 
A range of adverse human health effects that have been associated with endocrine 
disrupting chemicals, of which xenoestrogens are a subset, are described in Chapter 1.3.2 
including: 
• Enhancement of carcinogenesis (breast, uterus, ovary, prostate, testis) 
• Elevated carcinogenic potential in the 2nd generation (vagina, breast, uterus, 
prostate, testis) 
• Reproductive dysfunction (spermatogenesis, sexual cycle, endometriosis, fertility) 
• Developmental disorders of sexual organs (reproductive organ malformation, 
hypoplasia) 
• Precocious puberty 
• Immune toxicity (lowered resistance to infection) 
• Neurotoxicity in the 2nd generation (growth retardation, impairment of 
intelligence, emotional instability (WHO, 2002a, Shirai and Asamoto, 2003, 
emcom, 2004). 
 
The assessment of dietary exposure to xenoestrogens (Chapter 2) implicates a possible 
pharmacological effect of dietary xenoestrogens for adult males. Of the adverse effects 
above, those that might plausibly result from male dietary exposure are enhancement of 
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 prostate and testicular cancer, reproductive dysfunction, and immune toxicity.  Causal 
associations, measured as a difference in odds ratios between case and control subjects, 
are relatively attainable. An example is the significantly increased risk of cryptorchidism 
found in the sons of women working in gardening (adjusted odds ratio=1.67, 95% 
confidence interval 1.14-2.47 (Weidner et al, 1998)).  This study analysed the incidence 
of 6177 cases of cryptorchidism in Denmark during the period 1983-1992 with 23,273 
control subjects against risk factors including parental occupation.  An adjusted odds ratio 
greater than 1.0 suggests a positive association between two variables.  The greater the 
number, the stronger the association.  However, proving that exposure to a chemical in 
food causes a chronic health effect, such as prostate or testicular cancer, is notoriously 
difficult because of the delay between exposure and detection of the disease state. 
 
Emerging “omics” technologies offer an exciting opportunity to substantiate cause and 
effect of environmental hazards that are mitigated by altered gene expressions. 
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Figure 7.1: Schematic of the connection between exposure, gene expression 
and health outcome  
 
Using mini or microarrays it is possible to simultaneously screen the expression of 
thousands of genes.  This methodology has been applied to the identification of estrogen 
Chapter 7 178 
  
 responsive genes in breast cancer cell lines  (Coser et al., 2003, Inoue et al., 2002,  
Hayashi S-I, 2004, Soulez and Parker 2001, Terasaka et al., 2004) but not yet of either 
prostate or testicular cell lines or tissues.  If indeed, exposure to xenoestrogens leads to 
breast, prostate and testicular cancers via ligand binding to the estrogen receptor, and a 
transcriptional pathway, it follows that the resulting gene, enzyme or protein expression 
profiles would be different for cells of these types that are exposed compared with non-
exposed cells.  The relative response, either ‘up’ or ‘down’ regulation, of the genes, 
enzymes and proteins involved is measureable using ‘-omic’ technologies.  Moreover, if 
different xenoestrogens act by the same mechanism and are additive, (Silva et al., 2002) 
gene expression profiles for different xenoestrogens will be the same.  This has not yet 
been demonstrated.  An understanding of how gene expression is altered by 
xenoestrogens at a cellular level, mapped against emerging information on the progression 
of hormone cancers will provide knowledge about the etiology of these cancers and 
guidance for therapeutic and intervention strategies.   
 
7.1.1 Evidence for a role of xenoestrogens in prostate cancer 
 
There are racial differences in susceptibility to prostate cancer, with the incidence being 
rare in Asians, higher in Caucasians and higher still in African-American males (Crisp et 
al., 1998).  A racial difference in prostate cancer incidence is suggestive in New Zealand 
with the incidence rate, based on cancer registrations, for Maori men approximately half 
that of the total New Zealand male population (65 and 117 per 100,000, age standardized, 
respectively) (NZHIS, 2004).  Racial differences are likely to be a combination of genetic 
(Carter et al., 1993), age related and environmental factors. The rate of prostate cancer 
incidence increases with age as the ratio of estrogen to testosterone increases (Ho, 2004), 
consistent with an association between estrogenic compounds and prostate cancer.  A 
comparison of prostate cancer incidence rates between migrants and residents of the 
country of origin, supports a role of environmental or lifestyle factors in prostate cancer 
incidence (Doll and Peto, 1981). 
 
Two recent epidemiological studies report a higher incidence of prostate cancer in 
agricultural workers.  The incidence of prostate cancer among commercial agricultural 
workers was 40% higher than predicted on the basis of state age-adjusted incidence rates 
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 for a cohort of 55,332 male Americans in the Agricultural Health Cohort Study (Alavanja 
et al., 2003).  Chlorinated pesticides (aldrin, chlordane, DDT, 2,4,5-T were significantly 
associated with the increased incidence of prostate cancer.  Additional follow-up studies 
for this cohort are anticipated to further strengthen the association between farming and 
prostate cancer risk.  In a case-control study undertaken in Italy, a 40% increased risk of 
prostate cancer was associated with agricultural workers (Settimi et al., 2003).  Major 
components of pesticides associated with an increased risk of prostate cancer included 
organochlorines, specifically DDT and combined treatments of dicofol and tetradifon.  
The mechanism of action for prostate cancer remains to be elucidated but an endocrine 
pathway is one possibility.   
 
Various associations between hormone levels and prostate cancer incidences give a 
confusing picture for a role for estrogenic compounds in the aetiology of prostate cancer.  
For example, African-Americans, who have the highest incidence of prostate cancer in the 
USA, also have significantly higher levels of serum estrogens, even at a young age, when 
compared with their Caucasian-American peers (de Jong, 1991, Ho, 2004 and references 
therein).  Consistent with high serum estrogen levels being a risk factor for prostate 
cancer, lower circulating estrogen and testosterone levels have been noted in Japanese 
men who have a low rate of prostate cancer compared with higher risk Caucasian-Dutch 
men (de Jong et al., 1991).  Conversely, levels of soy-derived estrogenic compounds in 
the prostatic fluid of Asian men, with higher soy consumption (but lower prostate cancer 
incidence), are up to 17 times higher than Western men (Morton et al., 1997), evidence 
that diet may influence circulating ‘estrogenicity’ levels.  Further, the ability to produce 
equol (a metabolite of the isoflavone daidzein) is closely associated with a lower 
incidence of prostate cancer (Akaza et al., 2004).  The protective and/or risk nature of 
circulating estrogens remains to be clarified.  
 
There are at least two plausible theories to explain the mechanism of action of estrogenic 
compounds and prostate cancer (Ho 2004).  The first theory is that cancer results from 
DNA damage, either directly via estrogen metabolite-DNA adducts or indirectly via the 
formation of reactive oxygen species. An alternative theory is that cancer results from 
enhanced cell proliferation via ER binding.  There are two ER subtypes in humans, ERα 
and ER-β, and estrogenic ligands bind with different affinities to the two receptors 
(Kuiper et al., 1997).  Both subtypes have been identified in normal human prostate cells 
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 although the localization of the two subtypes differs (Latil et al., 2001, Leav et al., 2001).  
ER-β but not ER-α is strongly expressed in normal prostate cells (Lau et al., 2000).  ER-β 
is thought to exert anti-proliferative effects in the normal prostate, thus being cancer 
protective (Zhu et al, 2004, Cheng et al., 2004).  Expression of ERβ is lost as prostate 
cancer progresses (Latil et al., 2001, Lau et al., 2000), possibly by a DNA methylation 
pathway (Lau et al., Zhu et al., 2004). 
 
Although ER β is more highly expressed in normal human prostate cells than ER-α , 
studies with ER-α and ER-β knock-out mice suggest that ER-α may be the dominant 
receptor mediating prostate development (Prins et al., 2001). At a genomic level, Cancel-
Tassin and co-workers (2003) looked at polymorphisms of the human ER- α gene in 
healthy and prostate cancer cases.  Their findings implicated variants of a GGGA 
polymorphism of the ER-α gene with an increased risk of developing prostate cancer.   
 
Interestingly, estrogen therapy, is one treatment regime for prostate cancer. Charles 
Huggins pioneered the use of the synthetic xenoestrogen, diethylstilbestrol, for the 
treatment of advanced prostate cancer in the early 1940s. This treatment was subsequently 
discontinued because of adverse effects including feminization and heart failure (Huggins, 
1941).  With increasing health costs and improved cardiovascular care there is renewed 
interest in estrogen therapy for prostate cancer treatment (Oh, 2002, Messina, 2003).  
Estrogen analogs are also being synthesized as potential drugs for prostate therapy 
(Mobley JA et al., 2004).  Estrogenic drugs could plausibly treat prostate cancer by up-
regulating expression, and hence antiproliferative effects, of ER-β that diminishes in 
cancer cells.  However, experiments undertaken by Mobley and co-workers  (2004) 
suggest that the estrogen analogue that they tested induced apoptosis through a non ER 
mechanism, even though it bound preferentially to ER-β.  The protective association of 
equol (Akaza et al., 2004) may be by the same mechanism as the estrogen analogue 
synthesized by Mobley and co-workers or by maintaining expression of ER-β.   
 
7.1.2 Evidence for a role of xenoestrogens in testicular cancer 
 
Cryptorchidism (undescended testes) is a known risk factor for testicular cancer. The 
significantly increased risk of cryptorchidism found in the sons of women working in 
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 gardening (Weidner et al, 1998) implicates pesticide, and therefore possibly 
xenoestrogen, and a possible prenatal etiology with this condition (Moss et al., 1986, 
Henderson et al, 1988).  Although individual studies of a link between maternal exposure 
to the synthetic estrogen, diethylstilbestrol, and an increase in the incidence of testicular 
cancer are variable (Henderson et al., 1988), a meta analysis of studies reported an overall 
increase of approximately twofold (Toppari et al., 1996).  
 
The type of testicular cancer found in humans is very rare in laboratory animals and the 
lack of suitable animal model systems has limited the scope to prove a link between 
exposure to estrogenic chemicals and testicular cancer.  There is limited data from animal 
studies that in utero exposure to a high level of estrogen may increase the risk of 
developing testicular cancer and that exposure of rabbits in utero and/or in infancy to 
octylphenol, p,p’-DDT/DDE or zeranol leads to pretesticular cancer cells (ICPS, 2002). 
 
There have been a few reports of ER gene expression in human testicular cells that begin 
to provide a mechanistic link between exposure to estrogenic compounds and testicular 
cancer.  ER-β and co-regulator mRNA levels have been compared in matched samples of 
human testicular tumors and adjacent normal tissues (Hirvonen-Santti et al., 2003).  These 
results showed that expression of ER-β and one of the cofactors was down regulated in 
the cancerous compared with the normal tissue, suggesting that these genes may play a 
role in testicular tumorigenesis.   
 
Gaskell et al., (2003) detected expression of ER-β but not ER-α in human fetal testis cells 
at 12-19 weeks gestation and suggested that estrogenic compounds may influence the 
genesis and progression of testicular cancers through their interaction with ER- β 
following in utero exposure to estrogenic compounds.  
 
Pais et al., (2003) compared the localization of ER-α and ER-β receptors in normal and 
testicular germ cell cancers.  ER-β, but not ER-α, was expressed in normal and testicular 
germ cell cancer cells suggesting that estrogenic effects on the testis are mediated only via 
the ER-β subtype.  ER-β expression was down regulated in two forms of testicular cancer 
but remained high in endodermal sinus tumors and teratomas.  The differences in ER-β 
expression levels in different testicular germ cell tumors may reflect divergent pathways 
of these neoplasms from a common precursor (Pais et al., 2003). 
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 7.1.3 Additivity of estrogenicity 
 
There is evidence for additive estrogenicity of low concentrations of various 
xenoestrogens from the work published by Payne et al., (2000), Silva et al., (2002), 
Rajapakse et al., (2002), Rajapakse et al., (2004) and Gaido et al., (2003).  Silva and 
colleagues (2002) combined eight xenoestrogens including hydroxylated PCBs, 
benzophenones, parabenes, bisphenol A and genistein  at concentrations below individual 
No Observable Effect Levels in proportion to their individual potencies.  This finding 
suggests a similar mechanistic pathway.  Whether different xenoestrogens, in particular 
endogenous versus natural versus synthetic, alter gene and transcript expression in the 
same or different ways in human prostate and testicular cells remains to be elucidated. 
 
7.2 Cell culture 
 
As the first step of a genomic approach to testing the hypothesis that endogenous, 
naturally occurring and synthetic estrogenic compounds alter gene transcript expressions 
in the same way in prostate and testicular human cells, cell culture capability was 
developed under the guidance of Professor John Masters, at the Prostate Cancer Research 
Centre, University College London, UK.  Time and budget constraints limited the amount 
of experimental work that could be achieved. 
7.2.1 Growth curves  
 
Prostate and testicular cell lines were targeted for study because these are male cells and 
males were signaled to be a higher risk priority than females from the risk assessment 
described in Chapter 2.  Four human cancer cell lines, including DU 145 (prostate), SuSa 
(testicular), 833K (testicular), and HT29 (colon) were grown over 5 days (Chapter. 8.7.3).  
Five plates were prepared for each cell line and cell growth was measured in a different 
plate on days 1-5 using the colourimetric assay developed by Skehan et al., (1990).  In 
this assay, cell growth is measured as cell protein, visualized by binding to a dye, 
sulforhodamine, and measuring absorbance at 540nm on a 96 well plate reader.  Mean 
absorbance values were calculated for each column on the plate. The growth curves, 
Figure 7.1, show that each cell line grew exponentially over days 2-4 following a lag 
phase, especially evident for the solutions with low cell counts.  A stationery growth 
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 phase was reached by day 4 for the higher cell counts for all cell lines.  The 833K cells 
were particularly prone to contamination leading to cessation of growth.  The variability 
in cell growth was greatest for SuSa cells (Table 7.1). 
 
Table 7.1: Variability of cell growth for DU 145, SuSa, 833K and HT 29 cell lines  
 (%CV) 
Cell Line DU 145 SuSa 833K HT29 
Day 1 3.6-15.8 2.5-69.4 2.9-9.7 5.5-35.1 
Day 2 2.4-19.7 3.6-59.7 1.3-15.5 2.0-27.9 
Day 3 2.5-18.2 3.1-39.3 2.3-9.4 5.7-22.7 
Day 4 2.7-12.5 2.7-59.8 4.1-16.1 0.7-12.2 
Day 5 0.9-10.5 0.6-61.4 NR 0.4-17.5 
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Figure 7.1a:  Growth curves for a prostate (DU145) and testicular (SuSa) cell lines with 
  varying initial levels of inoculation.   
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Figure 7.1b:  Growth curves for a testicular (833K) and colon (HT 29) cell  
   lines with varying initial levels of inoculation.   
 
 
7.2.2 Impact of estrogenic compounds on cell growth 
 
Information from the growth curves was used as a basis for designing dose response  
experiments.  To gain an understanding of how selected estrogenic compounds might 
affect the growth of the cell lines of interest, duplicate dose-response experiments were 
carried out.  Details of the methodology are described in Chapter 8.7.4, but in principle, 
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 aliquots of cell culture were exposed to varying amounts of test compound and cell 
growth was measured after 3 days incubation.  The human breast cancer cell line MCF-7 
was included in these experiments as a positive control.  Cell growth was determined by 
the SRB assay on day 3 and the results are shown in Figures 7.2 a-e. 
 
The reproducibility of duplicate dose response experiments was not good but not 
unexpected.  This was partly attributable to greater variability of replicates for Du 145, 
833K and HT29 compared with the growth experiments (Table 7.2).  An apparent 
decrease in cell numbers with increasing concentration of estrogenic compound across the 
plate is not real.  There was a systematic error with the experimental setup because the 
control columns containing ethanol only, on either side of the plates were not consistent.  
Decreasing cell numbers were in the same direction as the addition of culture across the 
plate and therefore it seems likely that the 200µL aliquots of culture medium contained 
decreasing numbers of cells as aliquots were added across the plate. 
 
A control column containing only culture and medium was included in the second dose 
response experiment.  Comparison of cell growth for this column with the adjacent 
column containing ethanol, but no estrogenic compounds, shows that the ethanol itself is 
not toxic to the cells and the technique of adding a test reagent in ethanol and allowing 
this to evaporate, is practical and avoids the problem of solvent toxicity.   
 
With one exception (HT29, DR 1), cell growth following exposure to an estrogenic 
compound, was within the range observed for the control wells across concentration range 
10-5 to 10-12 M.  There is no consistent evidence of toxicity across this concentration 
range.  Human serum concentrations of 17β- estradiol, genistein and BPA are in the order 
of 10-10M, 4x10-7M and 10-8 M respectively (Greenspan and Gardner, 2001, Uehar et al., 
2000, Takeuchi et al, 2002).  These concentrations are mid range of the dose response 
experiments and therefore appropriate doses for future cell exposure experiments. 
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 Figure 7a: Dose response curve of prostate cells (DU145 to BPA, genistein 
  and 17β-estradiol 
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Figure 7b: Dose response curve of testicular cells (SuSa) to BPA, 
genistein and 17β-estradiol 
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Figure 7c :Dose response curve of testicular cells (833K) to BPA, genistein 
  and 17β-estradiol 
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 Figure 7d:Dose response curve of colon cells (HT 29) to BPA, genistein  
   and 17β-estradiol 
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 Figure 7 e: Dose response curve of breast cells (MCF-7) to BPA,   
  genistein and 17β-estradiol 
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 Table 7.2: Variability of cell growth of DU 145, SuSa, 833K, HT 29 and MCF-7 cell 
 lines following exposure to 17β- estradiol (E2), the naturally occurring 
 xenoestrogen genistein and the synthetic xenoestrogen BPA. (%CV). 
 
 Experiment DU 145 SuSa 833K HT29 MCF-7 
E2 1 3.2-14.7 4.6-16.5 2.8-40.6 1.8-47.5 2.2-23.7 
 2 3.9-25.1 3.7-40.2 3.2-2.6.3 3.9-25.2 3.6-46.7 
Genistein 1 4.1-12.9 4.6-15.7 3.7-32.6 1.6-53.7 2.2-64.6 
 2 3.0-26.8 4.5-37.3 3.9-24.3 4.7-18.8 4.0-38.1 
BPA 1 2.6-19.4 1.0-26.4 1.0-30.4 4.3-45.2 2.2-48.2 
 2 4.7-14.8 1.1-27.8 1.9-49.2 1.6-21.5 4.2-61.9 
 
 
7.3 Genomic analysis 
 
Ideally target cell lines that had been exposed to estrogenic compounds would be screened 
for effect on the expression of a wide range of genes using DNA microarray techniques.  
A number of investigators have taken this approach to develop a library of estrogen 
responsive genes using breast and sertoli cell lines (Coser et al., 2003, Inoue et al., 2002, 
Soulez and Parker 2001, Tabuchi et al., 2002, Terasaka et al., 2004).   However it was 
considered prudent to first confirm that the cells had absorbed the test compounds by 
measuring expression of ER-α and ER-β gene transcripts using real-time quantitative 
reverse transcription-PCR (Q, RT-PCR) (Latil et al, 2001, Lau, 2000, Pais et al., 2003). 
7.3.1 Exposure of cells to estrogenic compounds 
 
Five human cancer cell lines including prostate (DU 145), testicular (SuSa, 833K), colon 
(HT29) and breast (MCF-7) were exposed, in larger T-80 vessels, to either 17β-estradiol, 
genistein, bisphenol A or a combination of genistein and bisphenol A at concentrations 
approximating serum concentrations (1.8 x 10 –10 M, 3.1 x 10 –6 M, 1.2 x 10-7M).  Details 
are given in Chapter 8.7.6.  Control cells that were not exposed were also maintained for 
each cell line.  
 
Of the 25 cultures, 6 became contaminated with fungi.  The 833K cells grown in the 
presence of BPA, both alone and in combination with genistein, did not grow, suggesting 
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 that the this level of exposure was in fact toxic to the cells.  Alternative control cells of 
HT 29 and SuSa were extracted and dispatched to New Zealand.  Time and budget 
constraints precluded a repeat of this exposure but a useful set of exposed cells was 
achieved. 
 
7.4 Discussion 
 
The epidemiological data, the change in expression of ER-β with the progression of 
prostate cancer, the results of experiments with knock-out mice and the use of estrogen 
therapy for prostate cancer treatment support a role of ER mediated responses in human 
prostate cancer. Therefore naturally occurring and synthetic xenoestrogens that bind to, 
and influence the expression of ER-α and ER-β, are highly likely to be implicated, either 
as beneficial or risk factors in prostate cancer.   
 
Both animal and human studies suggest that in utero exposure to estrogenic compounds 
may influence the genesis and progression of testicular carcinogenesis through interaction 
with ER-β.  
 
There is no evidence to confirm similar, or different, effects of endogenous and naturally 
occurring or synthetic xenoestrogens, on the expression of ER subtypes in human prostate 
or testicular cells.  
 
 
7.5 Summary 
 
Cell culture capability was developed by maintaining and exposing five different human 
cancer cell lines to three test estrogenic compounds.  These cell lines reached exponential 
growth in 3 days following inoculation at 35,000 cells/ml.  There was no consistent 
evidence of toxicity of 17β- estradiol, genistein and BPA over the concentration range 10-
5  to 10-12 M.  The levels found in human serum are about mid range and therefore this 
level of exposure is unlikely to adversely affect cell growth.  Analysis for changes in 
expression of ER-α and ER-β receptors following exposure is yet to be completed. 
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Chapter 8 
 
 
Experimental 
 
A quote: 
 
“The work of science is to substitute facts for appearances, and demonstration for 
appearances” 
-John Ruskin, The Stones of Venice. 
 
8.2 Experimental details relating to Chapter 2 
 
8.2.1 Food consumption 
 
The 1997 National Nutrition Survey (Russell et al., 1999) was a key source of food 
consumption for selected foods.  The data collected during this survey include 24-hour 
dietary recall records for a cross section of 4636 New Zealand residents. These data are 
the best source of information on the type and quantity of foods consumed in New 
Zealand.  However, the database has limitations, including the fact that it is restricted to 
people 15 years and older, and food descriptions are not consistently applied throughout 
the data collection. For instance, a composite food such as ‘sandwich’ may in some 
instances be included with no further details, in other instances the same food may be 
expressed in terms of its component items (bread, margarine, lettuce, salami, etc). 
8.2.2 Serum levels of xenoestrogens 
 
An estimate of theoretical serum levels of xenoestrogens corresponding to estimated 
dietary intakes was made by assuming average serum volumes of 3.3, 2.5 and 2.9l for 
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 males, females and young males respectively based on: blood masses of 7.5% and 7.0% 
of body weight for men and women; serum volume equates to approximately 55% of 
blood volume (Lentner, 1984) and; body weights of 80, 65, and 70 kg for New Zealand 
males, females and young males (Russell et al.,1999).  It was assumed there was 100% 
absorption as described by Shaw and McCully (2002) and that all estrogenicity was 
associated with the serum component of blood. Allowance for factors influencing serum 
levels was then made by calculating the ratio of actual serum (or plasma) level to actual 
serum level, based on published data.   
 
Example: 
Genistein female intake = 23400 µg/day, measured serum level = 110µg/l 
  Serum volume =2.5l 
theoretical serum level = 23400/2.5 = 9350 µg/l 
measured (or actual) : theoretical serum level: 
A:T = 110/ 9350 ≈0.01    
Serum is plasma minus blood clotting factors and has been used interchangeably with 
plasma in this thesis. 
 
8.3 Experimental details relating to Chapter 3 
8.3.1 Materials 
 
BPA (>99%) and BPA- d 16 were obtained from Sigma-Aldrich. BPA –d16 was converted 
to PBA-d14 by dissolution in aqueous sodium hydroxide and reprecipitation by acidifying 
with dilute sulphuric acid as described by Goodson et al., (2002).  This BPA-d14 was used 
as an internal standard.  Acetonitrile, trimethylpentane and acetic anhydride were Analar 
grade, obtained from BDH. 
8.3.2 Extraction  
 
Sample extraction and analysis for BPA was based on the methodology of Goodson et al., 
(2002).  All extraction glassware was rinsed with ethanol and acetone before use. The 
total contents of each can were homogenized in a solvent rinsed, glass Waring blender.     
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 Sample pH was determined on a separate aliquot of the homogenized sample.  Duplicate 
20.0 ±0.05 g sub-samples of homogenized sample were weighed into 100 ml Schott 
bottles.  One sample was stored at 4°C as a backup. An accurately known quantity of 
BPA-d 14 (100µl) was added as an internal standard.  The sample was then extracted with 
20 ml acetonitrile by shaking on a mechanical shaker for 10-15 mins.  For samples 
containing more than 1% fat (based on label claims), 20ml trimethylpentane (TMP) was 
also added. This was found to be more effective than heptane as used by Goodson et al., 
(2002).  The acetonitrlie portion of the extract was filtered through Whatman No.1 filter 
paper into a conical flask. The filter cake (and TMP) was re-extracted with a second 20 ml 
aliquot of acetonitrile. The combined acetonitrile extracts were dried with sodium 
sulphate (~30g), transferred to a 250ml round bottomed flask, reduced in volume to 5-10 
mls by rotary evaporation and diluted to 50 ml with de-ionised water. The extract was 
derivatised by adding 10ml of 72% w/v potassium carbonate and 10 ml methanol with 
gentle swirling before the addition of 10 ml acetic anhydride.  The solution was left to 
stand for 15 minutes, swirled, left for another 15 minutes and then transferred to a 100ml 
separating funnel for extraction with 5 ml heptane.  A portion of the heptane layer was 
transferred to a vial for GCMS analysis.  For the analysis of soft drinks, a 50 ml aliquot of 
degassed sample was derivatised directly.   
 
8.3.3 GCMS analysis 
 
Samples were analyzed on a Shimadzu QP2010 GCMS with an Electron impact analyzer; 
column, J&W DB5ms, 30m x 0.25mm id, 0.25micron film thickness; carrier gas, zero 
grade helium at a flow rate of 0.76 ml/min; injector, splitless and temperature 
programmed 120º(2mins) to 280º (5 mins) at 10ºC/min. BPA diacetyl m/z 228, 213; 
BPA-d14 m/z 224 ions were monitored.  Primary quantitation was measured on the 228 
ion, with confirmation on the 213 ion.  Standard solutions (5ml) of BPA, including BPA-
d14, were derivatised in the same way as sample extracts. Quantitative results were 
obtained by comparing the ratio of sample response to internal standard response with the 
ratio of external standard response to internal standard response.  
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 8.4 Experimental details relating to Chapter 4 
 
8.4.1 Materials and Chemicals  
 
Genistein (≥98% pure) and daidzein (≥98% pure) were purchased from Sigma (St Louis, 
MO).  Stock solutions were prepared in HPLC grade methanol at concentrations of 1.49 
mmol/L and 1.34 mmol/L respectively.  Standards were made for each isoflavone to 
produce a concentration series from 7 to 120 μmol/L.  Brain Heart Infusion (BHI) Broth 
(Difco) was prepared according to the manufacturer’s instructions with water treated by 
the Elix™ system (Millipore, Molsheim, France).  Maxi-Clean C18 cartridges (300 mg, 
50 μm particle size, 6 nm pore size) were supplied by Alltech. Anaerobic packets were 
Oxoid AnaeroGenTM . 
 
8.4.2 Subjects 
 
Informed consent and faecal samples were initially obtained from nine healthy individuals 
comprising 6 European and 3 Maori New Zealanders.  Ethnicity was on a self-claim basis. 
It was not deemed necessary to consult an ethical committee due to the non-invasive 
nature of the study.  The main subject who participated in all experiments was a European 
New Zealand female (referred to as Subject A), 47 y of age with a Body-Mass Index 
(BMI) of 25 kg/m2.  European subjects who participated in further aspects of the study 
included 1 female (Subject B) and 3 males (C-E), between 31-50 y of age.  Four of the 
participants followed an average omnivorous Western diet with no intentional soy food 
consumption, the other participant was a vegetarian male who occasionally consumed soy 
products (Subject E). 
 
8.4.3 Collection and preparation of faecal samples 
 
Fresh, aseptically collected faecal samples were processed within 3 hours.  A 5% faecal 
slurry was made in a whirlpak bag with BHI broth as the diluent, homogenised in a 
Bagmixer® (Interscience, St Nom, France) for 30 s, and centrifuged at 1660 x g for 2 
min.  Four ml aliquots of faecal slurry supernatant were pipetted into sterile tubes 
containing the appropriate isoflavone preparation.   
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 8.4.4 Preparation, inoculation and incubation of faecal samples 
 
To measure response at varying isoflavone concentrations (using a sample from Subject A 
only), three series of tubes were prepared in triplicate containing genistein alone, daidzein 
alone, and a mixture of genistein and daidzein to final concentrations of 30, 60, 90, 120 
and 150 μmol/L of total isoflavone in 5 ml.  Controls consisted of tubes containing mixed 
isoflavones (15 μmol/L of each of genistein and daidzein) in BHI broth (no inoculum), 
and tubes with faecal supernatant only (4:1 with BHI). All tubes were incubated at 37˚C 
with anaerobic packets to create micro-aerobic conditions.  Where inter-individual 
variation was studied (all 5 subjects), the faecal preparation method did not change but the 
final concentrations of isoflavone used in each tube was 59.8 μmol/L genistein, 64.5 
μmol/L daidzein, and 124.3 μmol/L total isoflavones in the mixed solutions.  Each 
subject/isoflavone combination was sampled 4 times over 72 h.  To assess intra-individual 
variation with time, the results over 15 weeks from several repetitions of the experiment 
on Subject A were compared. 
 
8.4.5 Extraction of isoflavones from inoculated faecal samples 
 
Isolation of isoflavones was modelled on the method described in Xu et al., (1995).   
Samples were quickly vortex mixed and 1 ml passed very slowly through a pre-prepared 
Maxi-Clean (MCC) C18 cartridge.  The MCC was ideally pre-wetted with 1 ml 100% 
methanol, followed by 2 ml water, twice.  Once the sample was pushed through the MCC 
to waste, two rinsing steps followed, each consisting of 2 ml water.  The isoflavones were 
then eluted with 2 ml 80% methanol, reduced in volume by rotary evaporation and made 
up to 2 ml in volumetric tubes, with 80% methanol, for analysis by thin layer or high 
pressure liquid chromatography (HPLC). 
 
8.4.6 Thin layer and HPLC protocols 
 
Thin layer chromatography was performed on silica gel plates in a solvent of toluene: 
ethyl acetate: formic acid (5:4:1).  Bands were visualized under UV light (265nm).  
  
HPLC analysis was performed on a Waters WISP 712 coupled with a Waters 600 
multisolvent delivery system and Waters Lambda-Max 481 spectrophotometer.  
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 Separation was achieved on a Spheri-5 MPLC ODS (Brownlee; Applied Biosystems, 
Melbourne, Australia) C-18 column (4.6 x 220 mm, 5 μm particle size) protected by a RP-
18 ODS NewGuard (PerkinElmer, Melbourne, Australia) pre-filter column.  
Methanol/water was used as the mobile phase, employing a gradient of 40% to 65% 
methanol over 30 min at a flow rate of 1 ml/min.  Detection was by UV absorbance at 260 
nm.  The linearity of response was confirmed for genistein over the concentration range 0-
130 µmol/l and for daidzein 0-120µmol/l 
8.4.7 Effect of pre-exposure to genistein 
 
In one instance 4 ml faecal supernatant from Subject A was grown in the presence of 
genistein at a final concentration of 59.8 μmol/l in micro-aerophilic conditions at 37 ˚C 
(referred to as tube A1).  After 30 h, 1 ml was removed and inoculated into a fresh tube of 
BHI and genistein to give a total of 5 ml at 59.8 μmol/l genistein (tube B).  An appropriate 
amount of genistein was added to the original tube (A1) to achieve a concentration of 59.8 
μmol/l (A2).  The tubes were then re-incubated and samples analysed over the following 
18 h. 
 
8.5 Experimental details relating to Chapter 5 
 
8.5.1 Materials and chemicals 
 
The following reagents, with catalogue numbers in parenthesis, were obtained from 
Sigma: KH2PO4, [P-5655]; (NH4)2SO4, [A-2939]; KOH, [P-1767]; MgSO4, [M-2643]; L-
leucine, [L-8912]; L-histidine, [H-6034], adenine, [A-2786]; L-argenine.HCl, [A-6969]; 
L-methionine, [M-2893]; L-tyrosine, [T-8566]; L-isoleucine, [I-7403]; L-lysine.HCl, [L-
8662]; L-phenylalanine, [P-5482]; L-glutamic acid, [G-5638]; L-valine, [V-0513]; L-
serine, [S-4311]; thiamine.HCl, [T-1270]; pyridoxine, [P-5669]; D-pantothenic acid, [P-
2250]; d-biotin, [B-4639]; D-(+)-glucose, [G-7021], L-aspartic acid, [A-4534]; L-
threonine, [T-8441]; 17β-estradiol, >98%, [E-8875].  
 
The following reagents, with catalogue numbers in parenthesis, were obtained from 
Aldrich: Fe2(SO4)3, [30,771-8], Inositol, [1 665-2]; CuSO4, [20,917-1].  Chlorophenolred-
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 β-D galactopyranoside (CPRG), was obtained from Roche, [884 308].  Nunc [260860], 
96-well flat-bottom microplates were obtained from Invitrogen. 
8.5.2 Preparation and storage of minimal medium and medium components 
 
Minimal medium, vitamin, D-(+)-glucose, aspartic acid, threonine, copper sulphate, 
growth medium and CPRG solutions were prepared according to the following protocol 
supplied by Beresford and Sumpter (personal communication, 2002) with minor 
modifications as indicated. 
 
Minimal medium and medium components prepared in glassware contaminated with an 
estrogenic chemical will lead to elevated background expression.  Glassware, spatulas, 
stirring bars, etc., were scrupulously cleaned, and not had prior contact with steroids.  
Glassware, spatulas, stirring bars were rinsed twice with absolute ethanol, and left to dry.   
 
Minimal Medium (PH 7.1) 
13.61 g KH2PO4, 1.98g (NH4)2SO4, 4.2g KOH pellets, 0.2 g MgSO4, 1 ml Fe2(SO4)3 
solution (40mg/50 ml H2O), 50 mg L-leucine, 50 mg L-histidine, 50 mg adenine, 20 mg 
L-arginine-HCl, 20 mg L-methionine, 30 mg L-tyrosine, 30 mg L-isoleucine, 30 mg L-
lysine-HCl, 25 mg L-phenylalanine, 100 mg L-glutamic acid, 150 mg L-valine, and 375 
mg L-serine were added to 1 L double-distilled water and placed on heated stirrer to 
dissolve.  Aliquots (45 ml) were dispensed into glass bottles,sterilised at 121oC for 10 
min, and stored at room temperature (up to 3 months). 
 
D-(+)-Glucose 
A 20% w/v solution was prepared, sterilised in 20 ml aliquots at 121oC for 10 min. and 
stored at room temperature. 
 
L-Aspartic Acid 
A stock solution of 4 mg/ml was prepared, sterilised in 20 ml aliquots at 121oC for 10 min 
and stored at room temperature. 
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 Vitamin Solution 
8 mg thiamine, 8 mg pyridoxine, 8 mg panthothenic acid, 40 mg inositol, and 20 ml biotin 
solution (2 mg/100 ml H2O) were added to 180 ml double-distilled water.  The solution 
was sterilised by filtering through a 0.2-μm pore size disposable filter, in a laminar air 
flow cabinet, filtered into sterile glass bottles in 10 ml aliquots and 
stored at 4oC. 
 
L-Threonine 
A solution of 24 mg/ml was prepared, sterilised in 10 ml aliquots at 121oC for 10 min and 
stored at 4oC. 
 
Copper (II) Sulfate 
A 20mM solution was prepared and sterilised by filtering through a 0.2-μm pore size 
filter, in a laminar flow cabinet.  The solution was filtered into sterile glass bottles in 5 ml 
aliquots and stored at room temperature. 
 
Cholorophenol red-βD-galactopyranoside (CPRG) 
A stock solution of 10 mg/ml was prepared, sterilised by filtering through a 0.2-μm pore 
size filter into sterile glass bottles, in a laminar flow cabinet and stored at 4oC. 
 
8.5.3 Preparation and storage of yeast stocks 
 
Yeast was prepared and stored according to the following protocol supplied by Beresford 
and Sumpter (personal communication, 2002) with minor modifications as indicated. 
All yeast work was carried out in a type II laminar flow cabinet. 
 
8.5.3.1 Short term storage (-20°C) of 10x concentrated yeast stock culture 
 
Day 1 
Growth medium was prepared by adding 5 ml glucose solution, 1.25 ml L-aspartic acid 
solution, 0.5 ml vitamin, 0.4 ml L-threonine solution, and 125 μl copper (II) sulphate 
solution to 45 ml minimal medium.  The solution was transfered to a sterile conical flask 
Chapter 8 201 
  
 (final volume of approximately 50 ml) and seeded with a 125 μl aliquot of 10X 
concentrated yeast stock from a cryogenic vial stored at –20oC.  This was incubated at 
28oC for approximately 24 hour on an orbital shaker, or until turbid.  (Yeast from a 
cryovial stored at –80oC was also be used. 
 
Day 2 
Growth medium was transfered to two conical flasks (each with a final volume of 
approximately 50 ml). Yeast (1ml) from the 24-h culture was added to each flask and 
incubated at 28oC for approximately 24 hour on an orbital shaker, or until turbid. 
 
Day 3 
Each 24-h culture was transferred to a sterile 50-ml centrifuge tube.  Cultures were 
centrifuged at room temperature (not 4oC as specified) for 10 min at 2,000 g.  The 
supernatant was decanted, and each culture resuspended in 5 ml of minimal medium with 
15% glycerol (add 8 ml sterile glycerol to 45 ml minimal medium).  Aliquots (5ml) of the 
10X concentrated stock culture was transferred to 1.2-ml sterile cryovials and stored at –
20oC for a maximum of 4 months. 
8.5.4 Assay procedure 
 
All preparations of assay solutions and assay plates were carried out in a laminar flow 
cabinet to minimize microbiological contamination of the yeast cultures. 
 
Day 0 
Growth medium was prepared and seeded with yeast in the same way as for the -20°C 
yeast storage (8.5.3.1).   
 
Day 1 
100µl of test chemical solutions of the appropriate concentrations in ethanol were pipetted 
into the first column of a selected row of a 96 well plate. 50µl ethanol was pipetted into 
all other wells of the row.  The test chemical was serially diluted across the row by 
pipetting 50µl aliquots into successive wells.  10μl of each concentration was transferred 
to a second row, and allowed to evaporate. 17β-Estradiol (over the concentration range 
Chapter 8 202 
  
 0.0049 to 10nM per well) was used as a positive control, and ethanol used as a negative 
(or blank). 
 
For each assay, a fresh bottle of growth solution (50ml) was seeded with 250μl of a 24h 
yeast culture (optical density at 640nm of 2.5), from Day 0 and 0.5 ml CPRG. 200μl 
aliquots of this assay medium was added to each well, the plates were sealed with 
autoclave tape and shaken in a fixed wavelength plate reader (BIO-TEK EL312) for 2 
minutes. The plates were incubated for about 48h at 30°C, until a colour degradation from 
red to yellow was observed across the estradiol standard. The red colour denoting 
estrogenicity was measured at 540nm and 610nm. 610nm measures the turbidity of the 
medium, hence the growth rate of the yeast. The Beresford/Sumpter protocol stated 
measurement of turbidity at 620nm, however, we measured turbidity at 610nm because of 
the availability of this fixed wavelength filter.  The negative controls appeared a pale 
orange colour due to background β-galactosidase activity.  The absorbance at 540nm was 
therefore corrected by applying; A540-(A610-blankA610). 
 
Corrected value = A540 – (A610 –blank A610 ). 
 
Concentrations of the test chemicals, 17-β estradiol, bisphenol A and genistein were 
adjusted until a ‘S’ curve was achieved on analysis with SigmaPlot 2000: estradiol (54.48 
µg/l), bisphenol A (349 mg/l) and genistein (278 mg/l).  Absorbance values were entered 
into an excel spreadsheet for the calculation of ‘corrected values’ that were presented 
graphically using SigmaPlot.  An example spreadsheet is shown in Appendix 3.  EC50 
values, the concentration of test chemical required to induce 50% of maximum estrogenic 
effect, were calculated from the line fit generated in SigmaPlot. 
 
 
8.6 Experimental details relating to Chapter 6 
 
 
Perfusions were undertaken by Mi-kyung Iris Shin, University of Auckland as part of a 
Master’s thesis (Shin, 2004). 
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8.6.1 Tissue collection 
 
Placentas were obtained from healthy women undergoing elective caesarean section at 
term at the National Women’s Hospital, Auckland, New Zealand.  Samples were collected 
between July 2003 and May 2004 with informed consent and ethics approval. Placentas 
were obtained within 5 min of delivery and transported immediately to the laboratory. 
 
8.6.2 Dual perfusion technique 
 
The perfusion procedure was based on the method of Cannell et al., 1988.  Perfusates 
were prepared from tissue culture medium 199 (Irvine Scientific California), with added 
sodium bicarbonate pH 7.4 containing 5% polyvinylpyrolidone 40 (BDH laboratories), 
0.1% bovine serum albumin (Sigma), 48µg/ml gentamicin (Sigma) and 20 IU/ml heparin 
(Sigma).  The medium was gassed with 95% oxygen and 5% carbon dioxide (BOC gases, 
Auckland) in a 37˚ C water bath in the chamber.  The perfusate was freshly prepared for 
each perfusion.  Stock solutions of 17β-estradiol and genistein (Sigma Aldrich) were 
prepared in ethanol (99%) and stored at -20˚.  
 
Dual perfusions were undertaken in a 5% humidified compartment at 37˚ C by selecting a 
suitable lobule and cannulating a fetal vein and artery with 18 gauge infusion needles 
within 10 minutes of delivery.  Once fetal arterial flow was started (1 ml/min), the 
corresponding cotyledon on the maternal side was identified and perfused by placing 
butterfly needles into the appropriate intervillous space 0.5cm below the maternal surface.  
Perfusate volumes of 100 and 200 ml were used on the fetal and maternal sides 
respectively.  Flow rates on the fetal and maternal sides were adjusted 3 and 10 ml/min 
respectively, whilst maintaining fetal arterial pressure at less than 40mmHg.  The system 
was equilibrated for 20 mins.  Tygon tubing 1/8 inch (i.d) in the maternal circuit and 1/16 
inch (i.d) in the fetal circuit was used for the perfusion circuits.  Pressure in both circuits 
was monitored with an aneroid sphygmomanometer connected to the fetal and maternal 
artery respectively.  After equilibration, the maternal and fetal reservoirs were changed for 
fresh perfusates.  Test compounds were included in the maternal perfusate only.  Samples 
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 were taken for metabolic viability and estrogenicity or concentration analysis at fixed 
intervals (usually hourly) using a disposable plastic syringe. 
 
8.6.3 Viability of perfusions 
 
Physical markers of integrity and biochemical markers of metabolic viability were 
undertaken as described by Cannell et al., (1986, 1988).  Physical parameters included 
placental weight, fetal arterial pressure and leakage.  Oxygen and carbon dioxide 
saturation, electrolytes (sodium and potassium), glucose consumption, lactate production 
and human chorionic ganadotrophin (hCG) analyses were undertaken by the chemical 
pathology laboratory at National Women’s Hospital. 
 
8.6.4 Estrogenicity in maternal and fetal perfusates 
 
Blank perfusions and perfusions of 17β-estradiol (1µg/l) were measured for estrogenicity, 
as received, using the yeast assay as described in Chapter 8.5.  A comparison of 
estrogenicity between maternal and fetal samples at equivalent sampling times was made 
from respective absorbance readings at 540 nm corrected for difference in turbidity (as a 
measure of cell growth) by subtracting the value for absorbance at 610nm. (i.e. Abs 540-
Abs 610).  
 
8.6.5 Analysis of genistein in perfusates. 
 
Genistein was extracted from fetal and maternal perfusate samples by methodology 
developed for the gut microfloral work described in Chapter 8.4.5.  In this instance, a 
maxi-clean C-18 cartridge was pre-wetted with 3ml of methanol (99.9%, Mallinckrodt) 
followed by 3 ml water.  Perfusate solution (1 ml) was dripped through the cartridge 
followed by 3 ml water.  Genistein was eluted with 80% methanol in water (1 ml) and 
analyzed by HPLC.   
 
HPLC analysis was performed on a Shimadzu SCL-10A liquid chromatograph coupled 
with a Shimadzu SPD-M10A diode array detector.  Separation was achieved on an 
Applied Biosystems RP-18 (Brownlee; Applied Biosystems, Melbourne, Australia) C-18 
column (4.6 x 100 mm) protected by a RP-18 (3.2 x 15 mm) guard column (Brownlee; 
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 Applied Biosystems, Melbourne, Australia).  Methanol/water (50:50) was used as the 
mobile phase at a flow rate of 1.5 ml/min.  Detection was by UV absorbance at 260 nm.   
 
8.6.6 Recovery of genistein from spiked perfusates solution 
 
A blank perfusate solution, spiked with genistein at a concentration of 220µg/l was 
analysed with each HPLC run.  Recovery of genistein was 86.4 and 95.5% for the two 
analytical runs.  The results were not adjusted for recovery of genistein. 
 
 
8.7 Experimental details relating to Chapter 7 
 
8.7.1 Materials and chemicals 
 
RPMI media was Gibco, available from Invitrogen (Ref. 31870-025).  Genistein, 
bisphenol A,  TCA (Trichloroacetic acid,T6399) and sulfohodamine (S1402-5G) were 
obtained from Sigma..  Tris(hydroxymethyl)methylamine was BDH (103156X).  
 
8.7.2 Cell lines and cell culture 
 
Human cancer cell lines including prostate (DU 145), testicular (SuSa and 833K) colon 
(HT29) and breast (MCF-7) were kindly supplied by Professor John Masters, Director, 
Cancer Research Laboratory, University College, London. All these cell lines are 
adherent.  Cell culture media was prepared by adding 40mls Foetal Bovine Serum and 
5ml L-Glutamine to 500mls RPMI 1640 media. Cells were maintained in 5ml media in 
T25 flasks, incubated at 32°C. 
 
8.7.3 Measurement of cell growth curves 
 
Growth media was aspirated from the T25 incubation flask of growing cells, the cells 
released with trypsin (1ml) and resuspended in 10 fresh media.  A 0.2ml sample of this 
culture was stained with trpan blue (0.2 ml of 1% solution) and cells were counted on a 
haemocytometer.  Varying amounts of this culture was diluted to 10ml with media to give 
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 cell counts ranging from 0-15,000 cells per 200µl.  Up to 12 different dilutions were 
prepared for each cell line.  Eight replicate aliquots (200µl) of each dilution was added to 
one column of a 96 well plate (12 columns).  Five plates were prepared for each cell line.  
The plates were incubated at 32°C.  cell growth was measured each day, for 5 days, using 
the SRB assay. 
8.7.4 Dose response of cells to estrogenic compounds 
 
Standard solutions of the endogenous hormone 17β- estradiol, the naturally occurring 
xenoestrogen genistein and the synthetic xenoestrogen bisphenol A were prepared in 
ethanol (1.9 x 10 –3 M, 1.5 x 10 –3 M and 2.4 x 10-3 M respectively) and serially diluted 
over the concentration range of 10-4 to 10-11 M.  Aliquots (20 µL) of individual standards 
were added to Nunc flat bottomed 96 well plates (1 plate per compound per cell line) and 
left to evaporate before the addition of 200 µL of sufficient cell culture medium to 
achieve exponential growth at day 3 (72 hrs).  This time would allow for multiple cell 
cycles to mimic chronic exposure as in the human situation.  From the previous growth 
curve data, a cell density of 7000 cells/200µL was selected as optimal. Cells were 
incubated at 32°C for 3 days.  Cell growth was determined by the SRB assay. 
8.7.5 Sulfohodamine (SRB) assay 
 
This assay developed by Skehan et al., (1990) measures cell growth as cell protein, 
visualized by binding to the dye SRB.  100µl of a 30% (w/v) aqueous solution of 
trichloroacetic acid (TCA) was added to each well in a 96 well plate and allowed to fix for 
at least 20 mins.  Flicking and blotting onto paper removed the TCA.  Cells were washed 
carefully 4-5 times with tap water.  100µl of a 0.4% solution of SRB (in 1% acetic acid) 
was added to each well and allowed to stain for at least 20 mins.  The stain was removed 
by flicking and the cells washed 5 times with 1% acetic acid.  Cells were left to dry 
overnight in a fume hood.  The stain was then solubilised with 100µl 10mM 
tris(hydroxmethyl)methylamine base for 20 mins.  Plates were tapped to mix and 
absorbance measured at 540nm on a Perkin Elmer Wallac Victor 1420 multilabel counter 
with “Workout” software.  Absorbance was linear up to a value of 2.0. 
8.7.6 Exposure of cells and transport to New Zealand. 
 
8.7.6.1 Exposure of cells to estrogenic compounds 
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 On the basis of dose response results, cells were exposed at concentrations approximating 
serum levels.  The following volumes of standard solutions diluted in ethanol were added 
to T80 flasks.  Flasks were left open in laminar flow cabinet until the ethanol had 
evapourated.  The cells of a T25 flask were released with trypsin, media was added 
(15ml) and the contents transferred to the T80 flasks.  For HT29, DU145 and SuSa the 
T25s were confluent before transfer to the T80.  For 833K and MCF-7 the t25s were 
about 50% confluent.  Flasks were incubated at 32°C for 3 days. 
 
Table 8.7.1: Level of exposure of  HT29, DU145, SuSa, MCF-7 and 833K cell lines to 
 17β-estradiol, genistein , BPA and genistein + BPA. 
 
 Conc 
(M) 
Dilution 
factor 
Volume 
added (ml) 
Volume of 
media (ml) 
Final conc. 
(M) 
Estradiol 1.86 x 10-3 10-5 1.5 15 1.8 x 10-9 
Genistein 1.54 x 10-3 2 x 10-3 0.6 15 3.1 x 10-6 
BPA 2.42 x 10-3 10-3 0.75 15 1.2 x 10-7 
Genistein + BPA 1.54 x 10-3 
2.42 x 10-3 
2 x 10-3 
10-3 
0.6 
0.75 
15 
15 
3.1 x 10-6 
1.2 x 10-7 
Control 0 0 0 15 0 
 
 
8.7.6.2 Preparation of cells for transportation 
 
Flasks were examined under the microscope.  Cells in four of the 20 exposure scenarios 
showed fungal contamination and were abandoned.  Media from the remaining flasks was 
aspirated off and the flasks washed with 3 x 3ml fresh media (without FBS or L-
Glutamine).  Cells were scraped from the flasks (to minimize lysing of cell walls), 
transferred to a centrifuge tube with media (7 ml) and centrifuged  (1000rpm , 5 min.).  
The supernatant was discarded and the plug resuspended in media (1ml).  Aliquots 
(0.5ml) were transferred to 2 cryovials, centrifuged (1000rpm, 5 min), the media 
discarded and the cryovials snap-frozen in liquid nitrogen.  Vials were labeled and stored 
at -80°C until dispatch to New Zealand on dry ice and subsequent storage at -80°C until 
analysis.
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Chapter 9 
 
 
 
Overall discussion on dietary 
xenoestrogens. 
 
The question is, could xenoestrogens from the diet affect human health?  Are they likely 
to have a long-term effect at a population level?  The new information generated in this 
thesis will be considered in light of the published literature in the hope of answering these 
questions. 
 
International interest in EDCs, of which xenoestrogens are a major subset, continues, 
albeit less in the lime-light of the popular press.  Whilst effects on wildlife are apparent 
the effects of low-level exposure and adverse human health effects remain  suggestive but 
not proven.  Current concern at a government level over the possible effects of EDCs is 
however, reflected in the millions of dollars allocated by European and American 
agencies to support research on EDCs, for example $23 M by the European Union in 2003 
(Lorenz, 2003).  Clearly governments are concerned about the effects of these chemicals 
on their populations.  This research is wide ranging and includes, for example, food safety 
issues of phytoestrogens, the screening of many thousands of chemicals for endocrine 
effects, how these chemicals interact with one another and how they influence gene 
expression.  It is likely that these large government-funded programmes will shed 
significant light on the issue. 
 
Xenoestrogens are foreign to the body but mimic the action of estrogens, hormones that 
promote the development and maintenance of female sex characteristics.  Whilst 
recognizing that there are various mechanisms by which environmental compounds might 
influence the level and balance of sex hormones in the body, this thesis focuses on dietary 
xenoestrogens that are known to bind and activate ER via the classic genomic pathway of 
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 ligand-dependent activation of the estrogen receptors (ERα and ERβ) leading to a 
conformational change in DNA, transcription to mRNA and altered expression of specific 
genes (Gruber et al., 2002), as a basis for the selection of xenoestrogens from food, so that 
potential additive effects can be discussed. A common mechanism of action is a 
requirement for additivity of effect from exposure to a mixture of chemicals (Rudel, 1997, 
van den Berg, 2000). 
 
Many compounds with in vitro estrogenic activity have been detected in a wide range of 
foods.  Hence all humans will be exposed to xenoestrogens through their diet.  Naturally 
occurring xenoestrogens include the isoflavones (genistein and daidzein), the lignan 
metabolites (enterolactone and enterodiol), coumestrol, and the flavonoids (apigenin, 
isoliquiritigenin, kaempferol, luteolin, naringenin, phloretin and quercetin).  Synthetic 
compounds that have been shown to have estrogenic activity, and have been found in 
foods, include pesticides (DDT and metabolites, dieldrin, endosulphan and synthetic 
pyrethroids) and industrial chemicals (PCBs, alkyl phenols, BPA and BHA).  Although 
public perception may perceive synthetic chemicals to be more risky than natural 
chemicals, the real risk of the synthetic chemicals can only be determined in context of 
the total risk of xenoestrogens from food. 
 
The extensive collation undertaken in this thesis, of existing data on concentrations of 
these compounds in food, consumption information for each food for different population 
groups, reported serum levels and relative estrogenicity information from the literature 
underpins the most comprehensive exposure assessment and ranking currently available in 
the international literature (Chapter 2).  Risk, expressed as estrogenicity relative to normal 
circulating levels of endogenous estrogens, has been calculated for this level of exposure 
for four population groups, with discussion around an additional group, pubescent boys.  
Drawing extensively on pre-existing data, the current assessment has created new 
knowledge of data gaps, a more comprehensive ranking of contributing xenoestrogens and 
an estimate of the total level of risk from exposure to estrogenic compounds across the 
diet, taking into account, factors influencing human serum levels.   
 
Any risk assessment has attendant uncertainties (Covell and Merkhofer, 1996) and the 
uncertainties and biases for even a small number of aggregated chemical components can 
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 be substantial (USEPA, 2000).  In the present example uncertainties relate to each 
component of the assessment, namely the concentration data, food consumption 
information, estrogenic potency and serum data. In each case, the risk assessment has 
been derived from hard (measured) data. However, data for some xenoestrogens are more 
robust (less uncertain) than for other xenoestrogens. A qualitative assignment of the 
robustness of data for one xenoestrogen compared with another indicates that the least 
robust data in the risk assessment is due to the lack of appropriate serum information for 
the sub-populations under study, including data on serum levels for coumestrol, luteolin, 
apigenin, isoliquiritigenin, zearalenone, endosulfan, synthetic pyrethroids and alkyl 
phenols.  In the absence of more appropriate data, extrapolations from one population to 
another were assumed to accommodate these data gaps. This may be erroneous.  These 
compounds could have been excluded from the assessment, however this would have 
presented a very incomplete picture of major contributors and major data gaps.   
 
The risk assessment shows that estrogenicity from the diet is coming primarily from the 
naturally occurring isoflavones (genistein and daidzein) and flavonoids (particularly 
isoliquiritigenin), the contaminant mycotoxin, zearalenone, with minor contributions from 
nonyl phenol, a pesticide excipient and industrial surfactant, and the synthetic compound 
BPA.  The relative contribution of each xenoestrogen is not only a function of potency 
relative to estradiol (Sharpe and Skakkebaek, 2003, vom Saal and Hughes, 2005) but also 
of intake and those factors that influence the A:T ratio, namely absorption, metabolism 
and excretion.  Hence genistein and zearalenone contribute similarly despite the 10,000 
times difference in intake. The contribution from estrogenic pesticides and PCBs is 
negligible because of low levels of exposure combined with low potency, yet these 
chemicals have been the targets of numerous epidemiological studies of potential impacts 
of EDCs on human health (Alavanja et al., 2003, Bhatia et al., 2005, Buck et al., 1999, 
Cooper et al., 2005, Fuortes et al., 1997, Hoyer et al., 1998, ICPS, 2002, , Rignell-
Hydbom et al., 2005, Settimi et al., 2003 Sturgeon et al., 1998, and Windham et al., 
2005). Some of these studies were very reasonably targeting historical exposure (Bhatia et 
al., 2005, Cooper et al., 2005, Krstevska-Konstantinova et al., 2001) but the results 
presented in this thesis suggest that future studies might consider the inclusion of 
isoflavones, isoliquiritigenin, zearalenone, nonyl phenol and BPA as potential causative 
agents for estrogenic effects.  
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 Exposure to the naturally occurring isoflavones, genistein and daidzein for omnivorous 
adults comes largely from foods containing soy ingredients, such as bread and processed 
meats, and for males, from beer. For a vegetarian female, 80-90% of isoflavone intake is 
attributable to genistein from the consumption of soy milk.  Soy production in the USA 
has increased 48% between 1971 and 1996 (Shaw, 2004) and some of this will be going 
into the human diet.  The increasing use of soy as a component of processed foods such as 
prepared meats and bread, means that exposure to estrogenic compounds in the diet, 
hence potential risk, will increase in the future.  The safety of this increasing use of soy as 
a food ingredient has been the topic of press articles last year, both in New Zealand (Allan 
2004) and the United Kingdom (Barnett, 2004) and warrants further study.  Once again, 
this is a controversial area because Asian people consume much higher levels of soy than 
those on a Western diet (Table 2.2.4, Uehar et al., 2000) with no apparent disadvantage, 
and with lower rates of the “hormonal” breast and prostate cancers (IARC, 2004).   
 
Any estrogenic risk from the naturally occurring phytoestrogens (including both 
isoflavones and flavonoids) needs to be considered in context with the claimed benefits of 
these compounds whether that benefit is via an estrogenic or non-estrogenic mechanism.  
The safety of dietary supplements and food additives containing phytoestrogen extracts 
does warrant concern because the risks may be concentrated and the benefits of the whole 
foods from which they are derived, compromised.  Professor Helferich’s group at the 
University of Illinois will hopefully shed light on this topic (IFT, 2004). 
   
The contribution of zearalenone to total estrogenicity is due to its high estrogenic potency 
relative to other xenoestrogens and an occurrence of about 7% in corn based foods.  The 
estrogenicity of zearalenone has been confirmed by 5 authors (Hobson et al., 1977, IEH 
2000, Kiang et al., 1978, Soto et al.,1995, Welshons et al., 1990) using either receptor 
binding, cell proliferation and in vitro assays and is therefore robust.  Currently there is a 
marked paucity of data on human serum levels of zearalenone and no information of 
serum levels relative to dietary intake.  One report (Pillay et al., 2002) of serum levels of 
zearalenone for 132 South African female subjects is 1000 times higher than might be 
estimated for a Western type dietary intake.  Given the relatively high estrogenic potency 
of zearalenone, one would expect that if the serum level found in the South African 
women is also found in post-menopausal women and/or African men, then a human health 
effect would be apparent in these population groups.  In the absence of more data, the 
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 current estimate assumes all ingested zearalenone is bioavailable (but not accumulated).  
Given the contribution of zearalenone to total estrogenicity, clearly more information on 
dietary exposure, serum levels and metabolic pathways of this toxin is a priority area for 
research.   
 
The industrial surfactant or pesticide excipient, nonyl-phenol, is estimated to contribute 
about 5% to total estrogenicity in the current assessment, although there is a high degree 
of uncertainty associated with this estimate.  The concentration data was for German 
foods (Guenther et al., 2002) and most likely does not reflect use in the country of 
consumption (New Zealand). In addition the serum level used to derive the A:T ratio was 
based on data for Malaysian women (Tan and Mohd, 2003).  Nonyl phenol is used in 
some pesticide preparations in New Zealand (Alan Cliffe, Nufarm, personal 
communication, October 2002) but the extent and frequency of use, and discharge into the 
New Zealand environment is not known and is a priority data gap.  So too is the wider 
issue of including the potential effect of “non-active” agents that are used in industrial 
preparations.  In the EU, the use of nonyl phenol is restricted in order to protect the 
environment (EU, 2003).  Evidence from the work in this thesis supports such initiatives. 
 
The synthetic estrogenic compound, BPA, is estimated to contribute about 3% to the total 
daily intake of estrogenicity from the diet.  This estimate is based on a comprehensive 
survey of BPA, in canned foods available to the New Zealand consumer (Chapter 3).  
Although levels of BPA were generally low, there were a few foods with sporadically 
high levels that contributed to exposure.  The foods with sometimes elevated 
concentration of BPA were imported samples of tuna, corned beef and coconut cream 
from Thailand (tuna and coconut cream) and Australia.  The reason for the elevated levels 
of BPA may be related to fat content, because BPA is fat soluble, but is more likely to be 
a factor of processing (Goodson et al., 2004).  The exposure estimates using concentration 
information generated from this study with consumption information from the New 
Zealand National Nutrition Survey (1997) has provided a robust exposure assessment 
(Thomson and Grounds, 2005).  Since the mean and maximum exposures (0.008 and 
0.29µg/kg bw/day respectively), are below the current temporary Tolerable Daily Intake 
of 10 µg/kg bw/day given by the European Commission in 2002 it would appear that the 
levels of BPA identified in canned foods are unlikely to be of concern to adult health and 
there is no reason for consumers to change their consumption patterns as a result of these 
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 findings.  The international guideline is based on a three-generational rat study (SCF, 
2002) where reductions in body and organ weights were observed following exposure to 
BPA.  The questionable relevance of these endpoints for human health is one of the 
reasons that the TDI remains temporary.  This TDI also considers exposure to BPA alone 
and not as one of several compounds contributing to total estrogenicity.  It will be 
important to revise the temporary TDI for BPA as further information is available, as 
most recently recommended by vom Saal and Hughes (2005).  
 
The daily intake of BPA for a New Zealand woman of 0-17.9, mean 0.46, µg/day 
(Chapter 3) spans the range of intakes for Japanese pregnant women of <0.3-7.9 µg/day 
reported by Fujimaki and colleagues (2004). For the same sub-population  (but different 
individuals) Takeuchi et al., (2004) reported higher serum levels of BPA (1.05 ng/ml 
compared 0.71 ng/ml, p<0.05) for normal weight women with ovarian disease (polycystic 
ovary syndrome) compared with a healthy control group. Assuming equivalent dietary 
intakes between the two groups of Japanese women, the level of exposure of New 
Zealand women to BPA is approximately equivalent to the subjects in the Japanese study 
and may be associated with polycystic ovary syndrome.  Because the difference in BPA 
serum levels between normal and subjects with  polycystic ovary syndrome was not 
observed for obese women (Takeuchi et al., (2004), it is important that the association is 
substantiated by independent confirmation.  
 
There is evidence of additivity of effect of low doses of xenoestrogens based on 
experiments using the yeast assay, (Payne et al., 2000, Silva et al., 2002, Rajapakse et al., 
2002) cell proliferation (Rajapakse et al., 2004) and gene expression assays (Gaido et al., 
(2003).  However, additivity of xenoestrogens is neither guaranteed nor predictable 
because the effect in combination may be different to the effect of the compound when 
present as a single compound (Gaido et al., 2003, Rajapakse et al., 2004) and because the 
effect may vary in different target cells (Gaido et al., 2003).   Each of the combinations 
cited above uses a different selection of xenoestrogens and each system is in vitro, not 
accounting for endocrine effects of a complete organ let alone a whole animal.  The risk 
assessment (Chapter 2) ranks the estrogenic contribution of dietary  xenoestrogens for a 
Western diet providing a sound basis for selecting which compounds, in what proportions, 
to combine in future additivity studies.  
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 If the xenoestrogen effect is additive, the conservative, precautionary approach taken in 
this study suggests that combined xenoestrogens from the diet, when compared with 
endogenous levels of estradiol, might almost double the circulating levels of estrogenicity 
for all males and for post menopausal women consuming an average diet.  This is not an 
insignificant increase and could plausibly have a pharmacological effect.   For a 
reproductive female it is hard to see how an extra 3% of estrogenicity from the diet could 
have an effect because a woman’s body is physiologically adapted to major cyclic 
fluctuations of estrogen levels during the menstrual cycle.  The contribution of 
estrogenicity from food is small in comparison to the amount of naturally circulating 
estrogen during the month.  But at menopause this changes as she becomes hormonally 
more male and estrogen levels are much reduced (Greenspan and Gardner, 2001). 
Therefore the dose at menopause may be pharmacologically significant.   
 
Perhaps the most at-risk group is pre-pubescent males, because changes in circulating 
estrogen activity might change the course of their sexual development.  Clearly estrogen 
plays a key role in the growth associated with puberty (MacGillvray, 2004). There are no 
New Zealand food consumption data for this group, and therefore it was not possible to 
include them in our model.  However, Australian data (ABS, 1999) indicates the pre-
pubescent males (8-11 years) eat a similar range of food to adult males (25-44 years) and 
in similar quantity (10% less across the diet).  Their much lower body weights (mean 34.6 
kg against a mean of 82.4 kg for an adult male) mean that their xenoestrogen dose on an 
intake per body weight basis would be approximately twice that for adult males (i.e. 12-16 
ng/l).  Whether this additional estrogenicity from exogenous sources disturbs pubertal 
development remains plausible but speculative (Tielmann et al., 2002). 
 
Serum levels of the naturally occurring isoflavones genistein and daidzein are much lower 
than estimated from dietary intake (Chapter 2.2.4).  Gut microflora clearly have a role in 
the bioavailability, hence dose, of these phytoestogens (Chapter 4).  Some microflora can 
metabolise the conjugated isoflavone to the less polar aglycone but the identity of the 
organisms and the mechanism of metabolism of the aglycone is not known.  Although it is 
preferable to undertake degradation studies with microflora from the small intestine, 
where the majority of absorption is likely to occur, this was not achievable.  Therefore gut 
microflora were sourced from human faecal material to study the microbial degradation of 
genistein and daidzein, a pragmatic approach also taken by other investigators (Xu et 
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 al.,1995, Setchell et al., 1984).  The variability in the ability of faecal gut microflora to 
degrade genistein and daidzein, and hence influence available dose, applies to both 
claimed benefits and possible risks from dietary exposure to these phytoestrogens.  Within 
and between individual variability is particularly interesting in the context of the 
promotion of the consumption of soy as a functional food.  On the basis of experimental 
work undertaken as part of this thesis, the bioavailability of dietary sources of isoflavones 
is highly unpredictable and therefore the dose to target organs must be highly variable, 
and so too the beneficial effect.  How can health claims be substantiated?   
 
In utero exposure to xenoestrogens has been implicated in neurobehavioural and testicular 
dysgenesis syndrome (including cryptorchidism, hypospadias, testis cancer and low sperm 
count) effects (Sharpe and Skakkebaek, 1993, 2003, Shirai and Asamoto, 2003, O’Connor 
and Chapin, 2003).  Implicit in an in utero effect is transfer from the mother to the fetus.  
The risk assessment undertaken within this thesis shows that assuming additivity, the 
combined contribution of estrogenicity from dietary xenoestrogens is very low, (0.02-
0.2%) compared with the very high levels of endogenous estradiol during pregnancy (10-
30,000 ng/l, Beard and Nathanielsz, 1984). This substantiates the view that it seems 
unlikely that altered human exposure to weak estrogenic compounds can account for the 
possible increasing incidence of male reproductive tract disorders (Sharpe and 
Skakkebaek 2003).   
 
However, three generational effects of exposure to the estrogenic drug DES (Klip et al., 
2002), causal associations between exposure and health risks from epidemiological 
studies (Weidner et al., 1998, Perera et al., 2003), combined with evidence for the 
placental transfer of both naturally occurring (Adlercreutz et al., 1999) and synthetic 
xenoestrogens (Miyakoda et al., 1999, Uchida et al., 2002) from animal studies, 
substantiate the potential for effects from in utero exposure to xenoestrogens. 
 
Despite limitations, the ex vivo dual perfusion placental model is a challenging but safe, 
ethically acceptable, appropriate technique for modelling the placental transfer of 
xenobiotics in humans (Ala-Kokko et al., 2000).  Evidence from the studies presented 
(Chapter 6) shows that the placenta limits the transfer of estradiol from maternal to fetal 
compartments and suggest that about 10% of the naturally occurring phytoestrogen, 
genistein, transfers from the maternal to fetal compartments when perfused as an 
individual chemical in a human placenta.  In comparison with some drug transfers 
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 (Myllynen and Vähäkangas, 2003, Rama Sastry et al., 1998) this result demonstrates that 
the placenta has a limiting effect on placental transfer.  Subsequent studies with a 
synthetic xenoestrogen and xenoestrogens in combination with endogenous 17β-estradiol 
will help to resolve the discriminatory function of the placenta, hence transfer of 
xenoestrogens from mother to fetus and fetal “dose”. 
 
North and colleagues (2000) suggested the increased incidence of hypospadias in sons of 
women consuming vegetarian diets during pregnancy might be attributable to increased 
exposure to phytoestrogens for the vegetarian mothers.  The present risk assessment 
shows that vegetarian females are indeed exposed to a higher level of estrogenicity from 
the diet than omnivorous females by a factor of approximately two.  Most of this  
difference is attributable to increased exposure to zearalenone from a higher consumption 
of mixed grain bread by the vegetarian mothers. Whether this is of any significance to 
fetal development is simply not known.  
 
Research on in utero exposure supports the debate on “You are what your mother ate”, 
that your health as an adult may be determined to some extent by imprinting that occurs 
from maternal exposure.  The impact of this exposure on the developing fetus surely 
warrants further study, especially at the critical periods of sexual differentiation and 
development of the endocrine system (around 8-12 weeks gestation).  Such research 
aligns with the international prioritization of the identification of the life stages that are 
most vulnerable to the effects of endocrine disrupting compounds.    
 
The final component of this thesis introduces the concept of a genomic approach to 
explore the mechanistic link between exposure to xenoestrogens and human health effect.  
This “is” the future.  Emerging “omics” technologies (genomics, proteomics, 
metabolomics, toxicogenomics) offer exciting opportunities to substantiate cause and 
effect, at a biochemical level, of hazards that are mitigated by altering gene expressions 
such as the classical pathway of estrogens.  In this way it will be possible to identify key 
candidate genes (and proteins) that are up or down regulated by which dietary 
xenoestrogens in which target tissues.  When these are known, susceptibility of 
individuals to exposure to xenoestrogens will be predictable on the basis of whether the 
individual expresses the relevant genes, i.e. the person’s genotype.  An example of 
progress in this area is the work achieved by Professor Wittliff, University of Louisville 
(Personal communication, March 2004), who has identified 200 estrogen responsive 
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 genes from breast cancer patients and the grouping of breast cancer patients based on 
these gene expressions.  It is a logical step to determine how, or indeed if, the expression 
of these genes is altered by exposure to xenoestrogens.  From the risk assessment, Chapter 
2, health effects on males are considered a priority area and prostate cancer, male 
infertility and sexual differentiation in utero are target health outcomes for genomic 
methodologies.   
 
In addition to classical genomic actions, estrogens can act through non-genomic or 
membrane-initiated signaling pathways via a membrane form of ER (mER).  
Xenoestrogen actions via nongenomic pathways are largely unstudied but in a recent 
publication Wozniak et al., (2005) report on in vitro studies with a pituitary tumor cell 
line, selected for expression of high levels of membrane ER-α.  Low concentrations of 
estradiol, BPA, coumestrol, DDE, DES, dieldrin, endosulfan and nonylphenol (10-8 to 10–
12 M) mediated membrane initiated intracellular Ca++ increases resulting in secretion of 
prolactin. No Ca ++ changes occurred in cells deficient in mER-α, demonstrating a ER 
mechanism. Overstimulation, inappropriate stimulation (for developmental stage or 
reproductive cycle stage), or inhibition of prolactin secretion can lead to a variety of 
disruptions of normal reproductive function (Wozniak et al., 2005). The serum levels 
derived for a young male for BPA, coumestrol, DDE, endosulfan and nonyl phenol 
(Chapter 2) are 10-6,  10-7,  10-6,  10-8 to 10-9and  10-5 M respectively, well above the 
concentration at which the greatest changes in intracellular Ca++ were observed.    
 
Whilst there are yet no definitive causal associations between exposure to xenoestrogens 
in the diet and human health, there clearly remains evidence for concern.  Further exciting 
research awaits on: 
•  the role of gut microflora on the bioavailability of phytoestrogens and how 
this may be influenced by diet 
• quantification and the significance of in utero exposure to both naturally 
occurring and synthetic xenoestrogens at dietary levels  
• the additivity of xenoestrogens using genomic technologies and 
combinations at environmental levels, derived from this work 
• exploration of genomic effects of dietary xenoestrogens in selected tissues, 
in the first instance targeting male health issues
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Appendices 
 Appendix 1:  Intake estimates 
 
Estimated intake of apigenin   
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
celery 108 2.9 2.9 5 2.9 0.313 0.313 0.540 0.313 100 100 100 100
 
 
Estimated intake of coumestrol-upper 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 
24+ 
F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Alfalfa sprouts1 46.8 0.47 0.19 0.36 0.36 0.022 0.009 0.017 0.017 67.6 45.8 61.6 61.6
Alfalfa tablets2 1285    0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0
Alfalfa and kelp2 847 0.01 0.01 0.01 0.01 0.008 0.008 0.008 0.008 26.0 43.6 30.9 30.9
kala chana seeds1,  61.3 0.01 0.01 0.01 0.01 0.001 0.001 0.001 0.001 1.9 3.2 2.2 2.2
split peas1  81.1 0.01 0.01 0.01 0.01 0.001 0.001 0.001 0.001 2.5 4.2 3.0 3.0
lima beans1 14.8 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 0.5 0.8 0.5 0.5
pinto beans1 36.1 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 1.1 1.9 1.3 1.3
soyabean sprouts1 12.10 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 0.4 0.6 0.4 0.4
     total 0.033 0.019 0.027 0.027 100 100.0 100.0 100.0
 
 
Estimated intake of coumestrol-lower 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 
24+ 
F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Alfalfa sprouts1 46.8 0.47 0.19 0.36 0.36 0.022 0.009 0.017 0.017 68.1 46.3 62.1 62.1
Alfalfa tablets2 48.9    0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0
Alfalfa and kelp2 847 0.01 0.01 0.01 0.01 0.008 0.008 0.008 0.008 26.2 44.1 31.2 31.2
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 kala chana seeds1,  61.3 0.01 0.01 0.01 0.01 0.001 0.001 0.001 0.001 1.9 3.2 2.3 2.3
split peas1  81.1 0.01 0.01 0.01 0.01 0.001 0.001 0.001 0.001 2.5 4.2 3.0 3.0
lima beans1 0 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0
pinto beans1 36.1 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 1.1 1.9 1.3 1.3
soyabean sprouts1 4.50 0.01 0.01 0.01 0.01 0.000 0.000 0.000 0.000 0.1 0.2 0.2 0.2
     total 0.032 0.019 0.027 0.027 100 100.0 100.0 100.0
 
 
Estimated intake of diadzein-upper 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc total 
(mg/kg)  YM 24+ M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Ham 1.7 3.54 5.98 3.06 0 0.006 0.010 0.005 0.000 0.41 0.64 0.53 0.00
Saveloys 2.1 7.03 2.24 0.82 0 0.015 0.005 0.002 0.000 1.00 0.29 0.18 0.00
Sausages 4.2 28.04 19.23 9.5 0 0.118 0.081 0.040 0.000 7.99 5.06 4.09 0.00
Luncheon 3.2 1.16 2.87 1.21 0 0.004 0.009 0.004 0.000 0.25 0.58 0.40 0.00
Pies, savoury 6.8 38.58 38.58 16 0 0.092 0.092 0.038 0.000 6.23 5.75 3.90 0.00
Milk, soy 84.8  0.88 2.54 2.13 52.8 0.075 0.215 0.181 4.477 5.07 13.50 18.50 86.44
Milk, cow 0.33  365 235 173 160 0.120 0.078 0.057 0.053 8.18 4.86 5.85 1.02
Bread (soy component) 4.5 189 197 140 140 0.847 0.883 0.628 0.628 57.52 55.35 64.30 12.12
Beer 0.63 312 354 35 35 0.197 0.223 0.022 0.022 13.34 13.97 2.26 0.43
Total       1.47 1.60 0.98 5.18 100 100 100 100
 
Estimated intake of diadzein-lower 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc total 
(mg/kg)  YM 24+ M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Ham 1.7 3.54 5.98 3.06 0 0.006 0.010 0.005 0.000 0.6 0.9 0.7 0.0 
Saveloys 0.5 7.03 2.24 0.82 0 0.004 0.001 0.000 0.000 0.4 0.1 0.1 0.0 
Sausages 0.8 28.04 19.23 9.5 0 0.022 0.015 0.008 0.000 2.3 1.4 1.0 0.0 
Luncheon 2.4 1.16 2.87 1.21 0 0.003 0.007 0.003 0.000 0.3 0.6 0.4 0.0 
Pies, savoury 0.8 38.58 38.58 16 0 0.031 0.031 0.013 0.000 3.2 2.9 1.7 0.0 
Milk, soy 62.2 0.88 2.54 2.13 52.8 0.055 0.158 0.132 3.284 5.6 14.6 17.2 84.4
Milk, cow 0.25 365 235 173 160 0.091 0.059 0.043 0.040 9.3 5.4 5.6 1.0 
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 Bread (soy component) 4 189 197 140 140 0.756 0.788 0.560 0.560 77.8 73.4 73.3 14.5
Beer 0.02 312 354 35 35 0.006 0.007 0.001 0.001 0.6 0.7 0.1 0.0 
Total       0.97 1.08 0.77 3.88 100 100 100 100
 
 
Estimated intake of enterodiol 
 Consumption Intake (mg/day) %intake 
 
Conc 
total 
(mg/kg)  YM 24+ M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Apples 0.01  50 39.3 32.1 25.7 0.0005 0.0004 0.0003 0.0003 0.3 0.3 0.3 0.1 
Bananas 0.14  35.7 25 21.4 25.7 0.0050 0.0035 0.0030 0.0036 3.1 2.4 3.0 1.6 
Bean, kidney 0.812  15 12.9 10.7 19.3 0.0122 0.0105 0.0087 0.0157 7.5 7.1 8.6 6.9 
Beets 0.26  3.2 2.9 3.9 3.9 0.0008 0.0008 0.0010 0.0010 0.5 0.5 1.0 0.4 
Bread or rolls,dark 0.23  51.4 52.5 30 125.7 0.0118 0.0121 0.0069 0.0289 7.3 8.2 6.9 12.7 
Broccoli 0.65  4.4 5.1 4.6 10.2 0.0029 0.0033 0.0030 0.0066 1.8 2.2 3.0 2.9 
Carrots 0.62  20.9 35.4 18.6 30.2 0.0130 0.0219 0.0115 0.0187 8.0 14.9 11.5 8.3 
Cauliflower, brussel 
sprouts 0.77  4.4 5.1 4.6 10.2 0.0034 0.0039 0.0035 0.0079 2.1 2.7 3.5 3.5 
Celery 0.14  2.9 2.9 5 2.9 0.0004 0.0004 0.0007 0.0004 0.3 0.3 0.7 0.2 
Rolled oats 0.125  3.6 3.6 3.6 12.1 0.0005 0.0005 0.0005 0.0015 0.3 0.3 0.4 0.7 
Coleslaw 0.282  17.9 22.1 27.1 15.2 0.0050 0.0062 0.0076 0.0043 3.1 4.2 7.6 1.9 
Cucumber 0.11  6.4 5.7 6.4 8.6 0.0007 0.0006 0.0007 0.0009 0.4 0.4 0.7 0.4 
Green beans 0.56  11.4 16.1 11.4 5.7 0.0064 0.0090 0.0064 0.0032 3.9 6.1 6.3 1.4 
Green pepper 0.33  2.9 2.9 2.9 2.9 0.0010 0.0010 0.0010 0.0010 0.6 0.6 1.0 0.4 
Mushrooms 0.13  1.8 1.8 1.8 5.3 0.0002 0.0002 0.0002 0.0007 0.1 0.2 0.2 0.3 
Onions 1.01  2.9 2.9 2.9 6.4 0.0029 0.0029 0.0029 0.0065 1.8 2.0 2.9 2.8 
Oranges 0.12  15.7 15 10.7 16.4 0.0019 0.0018 0.0013 0.0020 1.2 1.2 1.3 0.9 
Peanuts, peanut butter 0.56  5.8 4.6 4.6 80.5 0.0032 0.0026 0.0026 0.0451 2.0 1.7 2.6 19.9 
Pears 0.69  7.1 5.7 4.3 7.1 0.0049 0.0039 0.0030 0.0049 3.0 2.7 2.9 2.2 
Pizza 0.035  17.9 16.1 14.3 0 0.0006 0.0006 0.0005 0.0000 0.4 0.4 0.5 0.0 
Potatoes, fried 0.5  25.7 17.9 5.7 0 0.0129 0.0090 0.0029 0.0000 7.9 6.1 2.8 0.0 
Potato, other 0.5  126.4 88.6 48.6 111.1 0.0632 0.0443 0.0243 0.0556 39.1 30.0 24.1 24.5 
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 Potato, sweet 0.55  4.5 4.5 4.6 21.6 0.0025 0.0025 0.0025 0.0119 1.5 1.7 2.5 5.2 
Salad, lettuce 0.55  3.6 3.4 3.2 2.9 0.0020 0.0019 0.0018 0.0016 1.2 1.3 1.7 0.7 
Spaghetti and pasta 
with tomato sauce 0.036  7.1 5.7 4.3 4.3 0.0003 0.0002 0.0002 0.0002 0.2 0.1 0.2 0.1 
Tomatoes 0.1  37.1 37.5 37.5 45.7 0.0037 0.0038 0.0038 0.0046 2.3 2.5 3.7 2.0 
Total       0.1618 0.1477 0.1007 0.2268 100 100 100 100.0 
 
 
Estimated intake of enterolactone 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg)  YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Apples 0.34  50 39.3 32.1 25.7 0.017 0.013 0.011 0.0087 6.4 6.4 4.8 5.7 
Bananas 0.55  35.7 25 21.4 25.7 0.020 0.014 0.012 0.0141 7.4 7.4 4.9 6.2 
Bean, kidney 1.155  15 12.9 10.7 19.3 0.017 0.015 0.012 0.0223 6.6 6.6 5.3 6.5 
Beets 1.09  3.2 2.9 3.9 3.9 0.003 0.003 0.004 0.0043 1.3 1.3 1.1 2.2 
Bread or rolls,dark 0.648  51.4 52.5 30 125.7 0.033 0.034 0.019 0.0815 12.6 12.6 12.2 10.2 
Broccoli 1.61  4.4 5.1 4.6 10.2 0.007 0.008 0.007 0.0164 2.7 2.7 2.9 3.9 
Carrots 2.84  20.9 35.4 18.6 30.2 0.059 0.101 0.053 0.0858 22.5 22.5 36.0 27.8 
Cauliflower, brussel 
sprouts 0.68  4.4 5.1 4.6 10.2 0.003 0.003 0.003 0.0069 1.1 1.1 1.2 1.6 
Celery 0.17  2.9 2.9 5 2.9 0.000 0.000 0.001 0.0005 0.2 0.2 0.2 0.4 
Rolled oats 0.351  3.6 3.6 3.6 12.1 0.001 0.001 0.001 0.0042 0.5 0.5 0.5 0.7 
Coleslaw 0.249  17.9 22.1 27.1 15.2 0.004 0.006 0.007 0.0038 1.7 1.7 2.0 3.5 
Cucumber 0.18  6.4 5.7 6.4 8.6 0.001 0.001 0.001 0.0015 0.4 0.4 0.4 0.6 
Green beans 0.4  11.4 16.1 11.4 5.7 0.005 0.006 0.005 0.0023 1.7 1.7 2.3 2.4 
Green pepper 1.62  2.9 2.9 2.9 2.9 0.005 0.005 0.005 0.0047 1.8 1.8 1.7 2.5 
Mushrooms 0.43  1.8 1.8 1.8 5.3 0.001 0.001 0.001 0.0023 0.3 0.3 0.3 0.4 
Onions 0.11  2.9 2.9 2.9 6.4 0.000 0.000 0.000 0.0007 0.1 0.1 0.1 0.2 
Oranges 0.27  15.7 15 10.7 16.4 0.004 0.004 0.003 0.0044 1.6 1.6 1.4 1.5 
Peanuts, peanut butter 1.05  5.8 4.6 4.6 80.5 0.006 0.005 0.005 0.0845 2.3 2.3 1.7 2.5 
Pears 1.12  7.1 5.7 4.3 7.1 0.008 0.006 0.005 0.0080 3.0 3.0 2.3 2.5 
Pizza 0.038  17.9 16.1 14.3 0 0.001 0.001 0.001 0.0000 0.3 0.3 0.2 0.3 
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 Potatoes, fried 0.33  25.7 17.9 5.7 0 0.008 0.006 0.002 0.0000 3.2 3.2 2.1 1.0 
Potato, other 0.33  126.4 88.6 48.6 111.1 0.042 0.029 0.016 0.0367 15.8 15.8 10.5 8.4 
Potato, sweet 2.4  4.5 4.5 4.6 21.6 0.011 0.011 0.011 0.0518 4.1 4.1 3.9 5.8 
Salad, lettuce 0.425  3.6 3.4 3.2 2.9 0.002 0.001 0.001 0.0012 0.6 0.6 0.5 0.7 
Spaghetti and pasta 
with tomato sauce 0.039  7.1 5.7 4.3 4.3 0.000 0.000 0.000 0.0002 0.1 0.1 0.1 0.1 
Tomatoes 0.11  37.1 37.5 37.5 45.7 0.004 0.004 0.004 0.0050 1.5 1.5 1.5 2.2 
Total       0.264 0.280 0.190 0.452 100.0 100.0 100.0 100.0
  
 
 
Estimated intake of genistein-upper concentrations 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
Ham 4.2 3.54 5.98 3.06 0 0.015 0.025 0.013 0.000 0.6 0.9 0.9 0.0 
Saveloys 5.4 7.03 2.24 0.82 0 0.038 0.012 0.004 0.000 1.5 0.5 0.3 0.0 
Sausages 10.8 28.04 19.23 9.5 0 0.303 0.208 0.103 0.000 12.4 7.8 7.3 0.0 
Luncheon 8.1 1.16 2.87 1.21 0 0.009 0.023 0.010 0.000 0.4 0.9 0.7 0.0 
Pies, savoury 17.5 38.58 38.58 16 0 0.236 0.236 0.098 0.000 9.6 8.9 7.0 0.0 
Milk, soy 110 0.88 2.54 2.13 52.8 0.097 0.279 0.234 5.808 3.9 10.5 16.6 86.0 
Bread (soy component) 6.3 189 197 140 140 1.191 1.242 0.882 0.882 48.6 46.6 62.7 13.1 
Beer 1.8 312 354 35 35 0.562 0.637 0.063 0.063 22.9 23.9 4.5 0.9 
Total      2.45 2.66 1.41 6.75  100.0 100.0 100.0
 
 
 
 
 
Estimated intake of genistein-lower concentrations 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
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 Ham 4.2 3.54 5.98 3.06 0 0.015 0.025 0.013 0.000 1.1 1.7 1.3 0.0 
Saveloys 1.3 7.03 2.24 0.82 0 0.009 0.003 0.001 0.000 0.7 0.2 0.1 0.0 
Sausages 2.2 28.04 19.23 9.5 0 0.061 0.042 0.021 0.000 4.4 2.8 2.0 0.0 
Luncheon 6.1 1.16 2.87 1.21 0 0.007 0.017 0.007 0.000 0.5 1.2 0.7 0.0 
Pies, savoury 1.9 38.58 38.58 16 0 0.075 0.075 0.031 0.000 5.4 5.0 3.0 0.0 
Milk, soy 39.0 0.88 2.54 2.13 52.8 0.034 0.099 0.083 2.059 2.5 6.6 8.1 70.4 
Bread (soy component) 6.2 189 197 140 140 1.168 1.217 0.865 0.865 84.4 81.5 84.6 29.6 
Beer 0.0 312 354 35 35 0.014 0.016 0.002 0.002 1.0 1.1 0.2 0.1 
Total      1.38 1.49 1.02 2.93 100.0 100.0 100.0 100.0
 
 
Estimated intake of isoliquiritigenin  
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
Licorice 9600 0.24 0.24 0.24 0.24 2.304 2.304 2.304 2.304 100.0 100.0 100.0 100.0
 
 
Estimated intake of keampferol 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
broccoli 72 8.8 10.2 19.5 10.2 0.634 0.734 1.404 0.734 35.0 21.0 28.0 24.6 
endive 46 0.001 0.001 0.001 0.001 0.000 0.000 0.000 0.000 0.0 0.0 0.0 0.0 
leek 30 1 1 0.67 0.67 0.030 0.030 0.020 0.020 1.7 0.9 0.4 0.7 
strawberry 12 1.47 1.47 1.64 1.64 0.018 0.018 0.020 0.020 1.0 0.5 0.4 0.7 
Tea1 14 80.7 194.3 255 158 1.130 2.720 3.570 2.212 62.4 77.7 71.2 74.1 
      1.81 3.50 5.01 2.99 100.0 100.0 100.0 100.0
 
Estimated intake of luteolin 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
celery 22 2.9 2.9 5 2.9 0.064 0.064 0.110 0.064 66.7 66.7 77.5 66.7 
 254 
 Red pepper 11 2.9 2.9 2.9 2.9 0.032 0.032 0.032 0.032 33.3 33.3 22.5 33.3 
      0.096 0.096 0.142 0.096 100.0 100.0 100.0 100.0 
 
 
Estimated intake of naringenin 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
Grapefruit 480 2.9 2.9 1.8 1.8 1.392 1.392 0.864 0.864 48.8 48.8 47.4 47.4 
Grapefruit juice 384 3.8 3.8 2.5 2.5 1.459 1.459 0.960 0.960 51.2 51.2 52.6 52.6 
      2.85 2.85 1.82 1.82 100.0 100.0 100.0 100.0 
 
 
Estimated intake of nonylphenols 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
mayonnaise 5 0.44 0.44 0.44 0.44 0.002 0.002 0.002 0.002 0.0 0.1 0.1 0.1
sugar 6.8 13.7 13.7 13.7 13.7 0.093 0.093 0.093 0.093 2.0 2.6 3.1 2.7
tuna 8.1 0.7 0.7 0.7 0 0.006 0.006 0.006 0.000 0.1 0.2 0.2 0.0
butter 14.4 18.9 15.9 10.3 12 0.272 0.229 0.148 0.173 5.8 6.4 4.9 5.0
lard 10.2 5.2 5.2 5.2 5.2 0.053 0.053 0.053 0.053 1.1 1.5 1.8 1.5
spinach 1.3 1.3 1.3 1.3 1.3 0.002 0.002 0.002 0.002 0.0 0.0 0.1 0.0
milk chocolate 14.1 2.9 2.9 1.8 2.8 0.041 0.041 0.025 0.039 0.9 1.1 0.8 1.1
egg 1.5 16.5 21.8 13.8 22.7 0.025 0.033 0.021 0.034 0.5 0.9 0.7 1.0
pineapple 2.6 2.1 3.6 3.6 4.3 0.005 0.009 0.009 0.011 0.1 0.3 0.3 0.3
fresh cheese 7.5 29.9 20 18.9 32.9 0.224 0.150 0.142 0.247 4.8 4.2 4.7 7.1
pasta 1 11.4 11.4 8.6 27.9 0.011 0.011 0.009 0.028 0.2 0.3 0.3 0.8
apples 19.4 114.3 67.1 57.1 75 2.217 1.302 1.108 1.455 47.2 36.3 36.8 41.7
chicken meat 3.8 35.4 35.4 27.5 0 0.135 0.135 0.105 0.000 2.9 3.7 3.5 0.0
tea 0.1 80.7 194 255 158 0.008 0.019 0.026 0.016 0.2 0.5 0.8 0.5
potatoes 0.6 130 93.2 51.1 111.1 0.078 0.056 0.031 0.067 1.7 1.6 1.0 1.9
tomatoes 18.5 37.1 37.5 37.5 40 0.686 0.694 0.694 0.740 14.6 19.3 23.0 21.2
whole milk 1.1 399 256 190 200 0.439 0.282 0.209 0.220 9.4 7.8 6.9 6.3
wholemeal bread 1.6 51.4 52.5 30 125.7 0.082 0.084 0.048 0.201 1.8 2.3 1.6 5.8
 255 
 beer 0.5 186 271 19.3 28.6 0.093 0.136 0.010 0.014 2.0 3.8 0.3 0.4
coffee(brewed) 0.3 128 241 278 220 0.038 0.072 0.083 0.066 0.8 2.0 2.8 1.9
orange juice 0.1 50 35 25.7 21.4 0.005 0.004 0.003 0.002 0.1 0.1 0.1 0.1
freshwater fish 2020 0.08 0.08 0.08 0 0.162 0.162 0.162 0.000 3.4 4.5 5.4 0.0
water 0.029 547 541 877 886 0.016 0.016 0.025 0.026 0.3 0.4 0.8 0.7
  4.69 3.59 3.01 3.49 100 100 100 100
 
Estimated intake of PCBs 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(ng/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
Beef Meat 58.7 26.4 25.7 15.7 0 1.55 1.51 0.92 0 1.7 1.8 1.6 0.0
Sheep meat 67.6 40 64.3 23.6 0 2.71 4.35 1.60 0 3.0 5.2 2.8 0.0
Pork meat 535.9 18.6 16.4 12.1 0 9.97 8.79 6.48 0 11.1 10.5 11.2 0.0
Beef fat 638.6 3.5 3.4 2.1 0 2.23 2.17 1.32 0 2.5 2.6 2.3 0.0
Sheep fat 198.3 6.2 10.0 3.7 0 1.23 1.98 0.73 0 1.4 2.4 1.3 0.0
Pork fat 194.9 4.6 4.1 3.0 0 0.90 0.79 0.58 0 1.0 0.9 1.0 0.0
Liver 1041 2.5 2.1 1.8 0 0.26 0.22 0.19 0 0.3 0.3 0.3 0.0
Processed meats 117.5 23.6 22.9 13.6 0 2.77 2.69 1.60 0 3.1 3.2 2.8 0.0
Milk 14.9 365 235.4 172.9 160 5.43 3.51 2.57 2.38 6.1 4.2 4.5 5.4
Butter 514.1 18.9 15.9 10.3 12 9.72 8.17 5.30 6.17 10.8 9.8 9.2 14.0
Cheese 237.5 29.9 20 18.9 32.9 7.10 4.75 4.49 7.81 7.9 5.7 7.8 17.7
Ice 
cream/yoghurt 83.6 33.9 20.9 17.1 40.3 2.83 1.75 1.43 3.37 3.2 2.1 2.5 7.6
New Zealand fish 552.8 11.2 16.3 6.9 0 6.19 9.01 3.81 0.00 6.9 10.8 6.6 0.0
Imported tinned 
fish 2371.4 5.1 5.4 5 0 12.09 12.81 11.86 0.00 13.5 15.3 20.5 0.0
Shellfish 231.7 5 5 5 0 1.16 1.16 1.16 0.00 1.3 1.4 2.0 0.0
Poultry 27.0 20 20 14.3 0 0.54 0.54 0.39 0.00 0.6 0.6 0.7 0.0
Eggs 141.9 16.5 21.8 13.9 22.7 2.34 3.09 1.97 3.22 2.6 3.7 3.4 7.3
Bread 43.2 189.8 152.8 105.4 205.7 8.20 6.60 4.55 8.88 9.1 7.9 7.9 20.1
Cereals 70.1 24.5 18.9 16.4 48.2 1.72 1.32 1.15 3.38 1.9 1.6 2.0 7.7
Potatoes 52.1 155.7 111.1 56.8 111.1 8.11 5.79 2.96 5.79 9.0 6.9 5.1 13.1
Snack foods 161.9 14.6 14.6 14.6 14.6 2.36 2.36 2.36 2.36 2.6 2.8 4.1 5.4
Vegetable 
fats/oils 37.9 10.3 10.3 10.3 19.2 0.39 0.39 0.39 0.73 0.4 0.5 0.7 1.6
 256 
              
Daily intake 
(ng/day)     0 89.80 83.74 57.81 44.09 100 100 100 100
 
 
Estimated intake of phloretin 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+M 24+ F VF YM 24+M 24+ F VF 
apples 40 50 39.3 32.1 25.7 2.000 1.572 1.284 1.028 29.3 42.9 40.6 21.8
Apple juice1 75 64.3 27.9 25 49.3 4.823 2.093 1.875 3.698 70.7 57.1 59.4 78.2
      6.82 3.66 3.16 4.7 100.0 100.0 100.0 100.0
 
 
Estimated intake of quercetin-upper 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
apples 36 50 39.3 32.1 25.7 1.800 1.415 1.156 0.925 25.5 10.1 8.5 9.7 
Apple juice1 2.8 64.3 27.9 25 49.3 0.180 0.078 0.070 0.138 2.5 0.6 0.5 1.4 
apricot 25 30 26.1 26.4 69.2 0.750 0.653 0.660 1.730 10.6 4.7 4.9 18.1 
Broad beans 20 0.35 0.35 0.35 0.35 0.007 0.007 0.007 0.007 0.1 0.1 0.1 0.1 
broccoli 30 4.4 5.1 4.6 10.2 0.132 0.153 0.138 0.306 1.9 1.1 1.0 3.2 
grape 15.0 2.4 2.4 2.4 2.4 0.036 0.036 0.036 0.036 0.5 0.3 0.3 0.4 
Green beans 39 11.4 16.1 11.4 5.7 0.445 0.628 0.445 0.222 6.3 4.5 3.3 2.3 
Green pepper 18 2.9 2.9 2.9 2.9 0.052 0.052 0.052 0.052 0.7 0.4 0.4 0.5 
lettuce 14 3.6 3.4 3.2 2.9 0.050 0.048 0.045 0.041 0.7 0.3 0.3 0.4 
onion 347 2.9 2.9 2.9 6.4 1.006 1.006 1.006 2.221 14.2 7.2 7.4 23.3 
Orange juice 5.7 27.1 19.3 15 21.4 0.154 0.110 0.086 0.122 2.2 0.8 0.6 1.3 
pear 6.4 7.1 5.7 4.3 7.1 0.045 0.036 0.028 0.045 0.6 0.3 0.2 0.5 
plum 9 2.3 2.3 2.3 2.3 0.021 0.021 0.021 0.021 0.3 0.1 0.2 0.2 
Red wine 11 8.6 19.3 12.1 11.4 0.095 0.212 0.133 0.125 1.3 1.5 1.0 1.3 
strawberry 8.6 1.47 1.47 1.64 1.64 0.013 0.013 0.014 0.014 0.2 0.1 0.1 0.1 
Tea1 20 103 463.5 472.8 158 2.060 9.270 9.456 3.150 29.1 66.3 69.6 33.0 
 257 
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tomato 8 27.1 28.2 28.9 27.1 0.217 0.226 0.231 0.217 3.1 1.6 1.7 2.3 
Tomato juice1 13 0.7 0.7 0.7 12.9 0.009 0.009 0.009 0.168 0.1 0.1 0.1 1.8 
      6.86 8.85 9.77 9.54 100.0 100.0 100.0 100.0
 
  
Estimated intake of quercetin-lower 
 Consumption (g/day) Intake (mg/day) %intake 
 
Conc 
(mg/kg) YM 24+M 24+ F VF YM 24+ M 24+ F VF YM 24+ M 24+ F VF 
apples 36 50 39.3 32.1 25.7 1.800 1.415 1.156 0.925 27.0 16.4 12.0 9.8 
Apple juice1 2.8 64.3 27.9 25 49.3 0.180 0.078 0.070 0.138 2.7 0.9 0.7 1.5 
apricot 25 30 26.1 26.4 69.2 0.750 0.653 0.660 1.730 11.2 7.6 6.9 18.4 
Broad beans 20 0.35 0.35 0.35 0.35 0.007 0.007 0.007 0.007 0.1 0.1 0.1 0.1 
broccoli 30 4.4 5.1 4.6 10.2 0.264 0.306 0.585 0.306 4.0 3.5 6.1 3.2 
grape 12.0 2.4 2.4 2.4 2.4 0.029 0.029 0.029 0.029 0.4 0.3 0.3 0.3 
Green beans 29 11.4 16.1 11.4 5.7 0.331 0.467 0.331 0.165 5.0 5.4 3.4 1.8 
Green pepper 18 2.9 2.9 2.9 2.9 0.052 0.052 0.052 0.052 0.8 0.6 0.5 0.6 
lettuce 14 3.6 3.4 3.2 2.9 0.050 0.048 0.045 0.041 0.8 0.6 0.5 0.4 
onion 347 2.9 2.9 2.9 6.4 1.006 1.006 1.006 2.221 15.1 11.7 10.5 23.6 
Orange juice 3.4 27.1 19.3 15 21.4 0.092 0.066 0.051 0.073 1.4 0.8 0.5 0.8 
pear 6.4 7.1 5.7 4.3 7.1 0.045 0.036 0.028 0.045 0.7 0.4 0.3 0.5 
plum 9 2.3 2.3 2.3 2.3 0.021 0.021 0.021 0.021 0.3 0.2 0.2 0.2 
Red wine 11 8.6 19.3 12.1 11.4 0.095 0.212 0.133 0.125 1.4 2.5 1.4 1.3 
strawberry 8.6 1.47 1.47 1.64 1.64 0.013 0.013 0.014 0.014 0.2 0.1 0.1 0.1 
Tea1 20 103 463.5 472.8 158 1.614 3.886 5.100 3.150 24.2 45.0 53.1 33.4 
tomato 8 27.1 28.2 28.9 27.1 0.142 0.157 0.186 0.217 2.1 1.8 1.9 2.3 
Tomato juice1 13 0.7 0.7 0.7 12.9 0.186 0.186 0.139 0.168 2.8 2.2 1.4 1.8 
      6.68 8.64 9.61 9.43 100.0 100.0 100.0 100.0
 
 Appendix 2: Simulated typical diets for the 1997/1998 Total Diet Survey 
 
Table A1: Summary of weights of foods consumed (Brinsdon S, Nicolson R, Mackay S, 1999) 
ID Food 19-24 
male 
25+  
male 
25+ 
female 
19-40 
female 
lacto-ovo 
vegetarian 
4-6  
child 
1-3 
child 
  Total grams (or millilitres) for the 14 day diet 
A Grains  
1 Bran cereal 20 20 20 85 10 10
2 Cornflakes 61 40 60 60 50 50
3 Muesli 30 25 25 90 25 25
4 Rolled Oats 50 50 50 170 30 25
5 Wheatbix 182 150 75 270 100 75
6 Cake plain 481 380 355 200 210 150
7 Chocolate biscuit 280 250 175 108 240 195
8 Cracker biscuit 296 270 135 230 85 55
9 Sweet biscuit 140 155 85 90 210 145
10 Flour, white 75 80 75 145 45 40
11 Noodles, instant 30 30 60 100 50 40
12 Rice, white 60 100 60 270 50 40
13 Spaghetti, dried 80 80 60 330 50 40
14 Mixed grain bread 400 350 240 870 280 160
15 Wheatmeal bread 320 385 180 890 180 110
16 White bread 1937 1405 1055 1120 1160 665
17 Spaghetti in sauce 100 80 60 60 70 35
B Dairy Products  
18 Butter, salted 265 223 144 168 129 86
19 Cheese 418 280 265 460 185 145
20 Dairy dessert 160 110 60 150 150 80
21 Ice cream 270 160 140 170 155 135
22 Milk, trim 520 685 790 1150 600 350
23 Milk, standard 4590 2610 1630 1090 6100 5465
24 Yoghurt 205 133 100 395 350 190
C Oils  
25 Olive oil 22 9 19 80 9 8
26 Margarine 174 146 87 124 67 44
27 Salad/Cooking Oil 27 18 25 65 11 6
D Chicken, Eggs, Fish and Meat  
28 Bacon 60 70 50 0 35 20
29 Beef mince 190 180 110 0 50 40
30 Beef rump steak 180 180 110 0 55 20
31 Chicken 170 180 140 0 55 35
32 Egg 231 305 194 318 185 170
33 Fish, terakihi 70 120 60 0 30 20
34 Lamb, mutton leg 190 180 130 0 55 25
35 Lamb mutton 
shoulder 
370 360 200 0 80 50
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ID Food 19-24 
male 
25+  
male 
25+ 
female 
19-40 
female 
lacto-ovo 
vegetarian 
4-6  
child 
1-3 
child 
36 Luncheon 150 140 105 0 55 35
37 Pork pieces 200 160 120 0 37 35
38 Sausages, beef 180 180 85 0 50 30
39 Salmon, canned 72 75 70 0 25 25
40 Soup, chicken 200 200 180 0 80 100
E Vegetables  
41 Beans 160 225 160 80 95 90
42 Broccoli, cauliflower 123 143 130 143 60 45
43 Cabbage 250 310 380 213 115 70
44 Capsicum 40 40 40 40 15 10
45 Carrots 293 495 260 423 155 120
46 Celery 40 40 70 40 30 25
47 Courgette 30 30 30 60 20 15
48 Cucumber 90 80 90 120 20 20
49 Kumara 63 63 65 303 40 40
50 Lettuce 50 47 45 40 12 10
51 Mushrooms 25 25 25 75 10 10
52 Onions 40 40 40 90 15 12
53 Peas 258 395 325 348 140 120
54 Potato, boiled 1240 860 440 560 415 265
55 Potato, baked 530 380 240 896 230 130
56 Potato crisps 50 65 35 100 45 35
57 Pumpkin 70 80 65 110 105 135
58 Silverbeet 160 145 155 30 35 35
59 Tomato 180 195 255 320 65 65
60 Baked beans 210 180 150 270 35 35
61 Beetroot 45 40 55 45 25 25
62 Corn 73 73 80 200 45 40
63 Pasta sauce 70 50 50 80 60 40
64 Tomato sauce 70 80 70 60 80 70
65 Tomatoes in juice 200 200 150 180 80 80
F Fruits  
66 Juice, apple based 900 390 350 690 260 130
67 Apple 700 550 450 360 250 170
68 Bananas 500 350 300 360 200 200
69 Kiwifruit 100 100 100 200 70 60
70 Orange 220 210 150 230 140 130
71 Orange juice 380 270 210 300 200 160
72 Pears 100 80 60 100 90 60
73 Nectarines 130 110 110 230 60 60
74 Apricots, stewed 420 365 370 600 240 200
75 Dates 20 20 15 70 15 10
76 Peaches, canned 230 190 225 240 130 120
77 Pineapple, canned 30 50 50 60 30 30
78 Raisins/Sultanas 25 15 20 50 20 10
G Spreads and Sweets  
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ID Food 19-24 
male 
25+  
male 
25+ 
female 
19-40 
female 
lacto-ovo 
vegetarian 
4-6  
child 
1-3 
child 
79 Mints, confectionery 30 20 20 20 20 20
80 Chocolate 40 40 25 40 25 25
81 Honey 10 15 10 15 7 7
82 Jam 45 48 65 58 15 10
83 Marmalade 25 17 25 20 5 5
84 Yeast extract 17 17 22 17 15 15
85 Jelly 300 300 300 150 220 180
H Alcohol  
86 Beer, draught 1600 1900 120 200 0 0
87 Beer, lager 1002 1900 150 200 0 0
88 Wine, red 120 270 170 160 0 0
89 Wine, white 150 220 300 330 0 0
I Take-Aways  
90 Chicken nuggets 110 100 60 0 45 30
91 Chinese dish 200 150 120 0 80 40
92 Fish in batter 145 180 60 0 40 25
93 Hamburger 270 225 225 0 150 60
94 Meat pie 160 160 120 0 120 40
95 Pizza 250 225 200 0 100 80
96 Hot potato chips 360 250 80 0 50 30
J Nuts  
97 Peanut butter 45 35 40 85 17 10
98 Peanuts 36 30 24 76 7 0
K Beverages  
99 Lemonade 484 360 120 234 400 240
100 Coke 925 655 225 225 100 100
101 Milo - made up 440 440 440 660 520 450
102 Coffee brewed 1790 3370 3900 3080 0 0
103 Breakfast drink 420 300 350 150 1200 920
104 Tea infused 1130 2720 3570 2205 0 0
105 Drinking water* 7653 7580 12281 12410 9073 6035
L Additional meat and shellfish  
106 Lamb's liver 35 30 25 0 20 10
107 Mussels 35 35 35 0 0 0
108 Oysters 35 35 35 0 0 0
M Vegetarian additions  
109 Hummus 0 0 0 295 0 0
110 Soya milk 0 0 0 740 0 0
111 Tofu 0 0 0 265 0 0
O Children’s Foods/Snacks  
112 Cheese flav snacks 0 0 0 0 90 55
113 Fish fingers 0 0 0 0 40 20
114 Tortilla chips 0 0 0 0 45 30
* This is additional drinking water and does not include that used in making up 
drinks. 
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Appendix 3: An example Excel spreadsheet used for processing yeast assay data  
 
Run #20 Estradiol std @ 54.48µg/L             
well conc (ng/L) 2724 1362 681 340 170 85.1 42.6 21.3 10.6 5.32 2.66 1.33  
well conc (nM) 10
1
5 2.5 1.25 0.625 0.3125
5
0.156 0.0781
7
0.0391
8
0.0195
9
0.0098 0.0049  
48 hrs Well   # 2 3 4 6 10 11 12  
Plate #1               
540nm row B 2.941 3 2.87 2.653 2.326 1.845 1.426 1.185 1.147 1.133 1.094 1.056  
610nm 1.407 1.436 1.425 1.305 1.235 1.147 1.054 0.979 1.007 1.016 0.993 0.96  
abs 540- 2.512333 2.542333 2.423333 2.326333 2.06933 1.67633 1.35033 1.18433 1.11833 1.09533 1.07933 1.07433  
(abs 610-abs 610 bl)              
blank610nm 1.03 1.027 0.98 0.975 0.946 1.008 0.964 0.983 0.924 0.98 0.944 0.979 0.97833 
               
540nm row E 3 2.849 2.87 2.627 2.333 1.936 1.535 1.298 1.168 1.132 1.003 1.034  
610nm 1.426 1.386 1.379 1.333 1.241 1.191 1.081 1 1.012 1.014 0.914 0.947  
abs 540- 2.552333 2.441333 2.469333 2.272333 2.07033 1.72333 1.43233 1.27633 1.13433 1.09633 1.06733 1.06533  
(abs 610-abs 610 bl)              
blank610nm 1.03 1.027 0.98 0.975 0.946 1.008 0.964 0.983 0.924 0.98 0.944 0.979 0.97833 
Plate #2               
540nm row B 2.941 2.893 2.709 2.569 2.154 1.823 1.401 1.259 1.106 1.046 1.065 1.015  
610nm 1.392 1.324 1.329 1.261 1.192 1.076 0.999 0.954 0.935 0.918 0.97 0.938  
abs 540- 2.575833 2.595833 2.406833 2.334833 1.98883 1.77383 1.42883 1.33183 1.19783 1.15483 1.12183 1.10383  
(abs 610-abs 610 bl)              
blank610nm 1.062 1.041 1.045 1.012 1.055 1.028 0.958 1.016 1.015 1.036 1.026 1.028 1.02683 
               
540nm row E 2.849 2.615 2.653 2.499 2.258 1.888 1.517 1.299 1.094 1.074 0.997 1.008  
610nm 1.317 1.251 1.251 1.246 1.184 1.116 1.026 0.987 0.915 0.945 0.904 0.918  
abs 540- 2.558833 2.390833 2.428833 2.279833 2.10083 1.79883 1.51783 1.33883 1.20583 1.15583 1.11983 1.11683  
(abs 610-abs 610 bl)              
blank610nm 1.062 1.041 1.045 1.012 1.055 1.028 0.958 1.016 1.015 1.036 1.026 1.028 1.02683 
               
 Cont’d              
estradiol nmoles 48 hrs             
 plate #1 B plate #1 E plate #2 B plate #2 E mean SE  1/[S] 1/mean  Y50 1.81996  
0.0049 1.074333 1.065333 1.1038 1.116833 1.09008 0.02426 204.082 0.91736     
0.0098 1.079333 1.067333 1.1218 1.119833 1.09708 0.02787 102.041 0.91151 [Equation]   
0.0195 1.095333 1.096333 1.1548 1.155833 1.12558 0.03436 51.2821 0.88843 f=y0+a/(1+exp(-(x-x0)/b))  
0.0391 1.118333 1.134333 1.1978 1.205833 1.16408 0.0442 25.5754 0.85905     
0.0781 1.184333 1.276333 1.3318 1.338833 1.28283 0.07137 12.8041 0.77952 R = 0.99865381Rsqr = 0.99730943Adj Rsqr = 0.996
0.156 1.350333 1.432333 1.4288 1.517833 1.43233 0.06843 6.41026 0.69816     
0.3125 1.676333 1.723333 1.7738 1.798833 1.74308 0.05446 3.2 0.5737 Coefficient Std. Error t P 
0.625 2.069333 2.070333 1.9888 2.100833 2.05733 0.04795 1.6 0.48607 a 40.2287 324.849 0.123
1.25 2.326333 2.272333 2.3348 2.279833 2.30333 0.0318 0.8 0.43415 b 0.5176 0.1148 4.507
2.5 2.423333 2.469333 2.4068 2.428833 2.43208 0.02653 0.4 0.41117 x0 -1.7182 4.9505 -0.347
5 2.542333 2.441333 2.5958 2.390833 2.49258 0.0933 0.2 0.40119 y0 -37.743 324.841 -0.116
10 2.512333 2.552333 2.5758 2.558833 2.54983 0.02689 0.1 0.39218 EC50 0.396 1.81988 
 
 263 
